docId	isConfirmed	chrom	start	end	offset	varId	inDb	patType	hgvsProt	hgvsCoding	hgvsRna	comment	rsIds	protId	texts	rsIdsMentioned	dbSnpStarts	dbSnpEnds	geneSymbol	geneType	entrezId	geneStarts	geneEnds	seqType	mutPatNames	mutStarts	mutEnds	mutSnippets	geneSnippets	dbSnpSnippets
23199084	confirmed					23199084		sub		NM_007294.3:c.2457C>T|NM_007300.3:c.2457C>T|NM_007297.3:c.2457C>T	NM_007294.3:c.2688C>T|NM_007300.3:c.2688C>T|NM_007297.3:c.2737C>T		rs80357669|rs80357669|na		 2457C>T|2457C>T				BRCA1	entrez	672			dna	859G>A|859G>A	23323,44380	23331,44388	Eighteen BRCA1 mutations, including the most common c.5266dupC, c.181T>G, c.4065_4068del4 (BIC: 4184del4) and c.2338C>T (BIC:<<< 2457C>T>>>), were found at least 3 times and comprised 66% of all BRCA1 mutations.|  5382insC     c.4478del4     4706del4      c.181T>G     300T>G     c.9098dupA     9326insA      c.4065_4068del4     4184del4            c.2338C>T    <<< 2457C>T>>>            Czech     c.181T>G     300T>G     c.7913_7917del5     8141del5      c.5266dupC     5382insC     c.8537_8538del2     8765delAG      c.3700_		
23199084	confirmed					23199084		sub		NM_007294.3:c.5467G>A|NM_007297.3:c.5467G>A	NM_007294.3:c.5698G>A|NM_007297.3:c.5747G>A		rs80357212|na		c.5467G>A| c.5467G>A				BRCA1	entrez	672			dna	c.123T>A|c.123T>A	26451,44904	26461,44914	98dupA [104].  ### Greece  In the Greek population four BRCA1 mutations (c.5526dupC, c.5212G>A (BIC: 5331G>A/G1738R), c.5251C>T (BIC: 5370C>T/R1751X),<<< c.5467G>A>>> (BIC: 5586G>A), account for 54% of all mutations detected in BRCA1/2 genes and for 73% of the BRCA1 mutations positive families, whereas the rest are|   c.68_69delAG     185delAG            Greek     c.5266dupC     5382insC            c.5212G>A     5331G>A            c.5251C>T     5370C>T           <<< c.5467G>A>>>     5586G>A            Cypriot           c.8755delG     8984delG      Danish     c.2475delC     2594delC     c.6373delA     6601delA      c.3319G>T  		
23199084	confirmed					23199084		sub		NM_007300.3:c.5569G>T	NM_007300.3:c.5800G>T		rs80356942		c.5569G>T				BRCA1	entrez	672			dna	c.123T>A	33074	33084	6384del2 (BIC: 6503delTT), c.3853dupA (BIC: 4081insA) and<<< c.5569G>T>>> (BIC: 5797G>T)).		
23199084	confirmed					23199084		sub		NM_000059.3:c.5569G>T	NM_000059.3:c.5795G>T		rs80358778		c.5569G>T				BRCA2	entrez	675			dna	c.123T>A	33074	33084	6384del2 (BIC: 6503delTT), c.3853dupA (BIC: 4081insA) and<<< c.5569G>T>>> (BIC: 5797G>T)).		
23199084	confirmed					23199084		dup		NM_007294.3:c.1292dupT|NM_007300.3:c.1292dupT	NM_007294.3:c.1523dupT|NM_007300.3:c.1523dupT		rs80357346|rs80357346		 c.1292dupT|c.1292dupT				BRCA1	entrez	672			dna	c.123dupA|c.123dupA	21308,44046	21319,44057	BRCA1 c.2193del5 (BIC: 2312del5), and<<< c.1292dupT>>> (BIC: 1411insT) mutations were also commonly found [92, 94].  In the south-west of Holland two founder mutations: 3.8-kb deletion of BRCA1 exon 13, a|132delC      Dutch     c.2685_2686delAA     2804delAA     c.5351dupA     5579insA      c.2193del5     2312del5     c.6275_6276delTT     6503delTT     <<< c.1292dupT>>>     1411insT            exon 13 deletion (3,8-kb)            exon 22 deletion (510-bp)            German     exon 17 deletion     c.1813dupA     2041		
23199084	confirmed					23199084		del		NM_007299.3:c.3604delA|NM_007297.3:c.3604delA	NM_007299.3:c.3797delA|NM_007297.3:c.3884delA		na		 3604delA|3604delA				BRCA1	entrez	672			dna	6174delT|6174delT	32627,46149	32636,46158	The most common BRCA1 mutations are c.4097-2A>G (BIC: 4216-2A>G), c.3485delA (BIC:<<< 3604delA>>>), c.3626delT (BIC: 3745delT), c.4327C>T (BIC: 4446C>T), c.2684del2 (BIC: 2803delAA) and c.5251C>T (BIC: 5370C>T).|eletion            exon 13 duplication (ins6kbEx13)            Finnish     c.4097-2A>G     4216-2A>G     c.771_775del5     999del5      c.3485delA    <<< 3604delA>>>     c.7480C>T     7708C>T      c.3626delT     3745delT     c.8327T>G     8555T>G      c.4327C>T     4446C>T     c.9118-2A>G     9346-2A>G      c.2684		
23199084	confirmed					23199084		del		NM_000059.3:c.3604delA	NM_000059.3:c.3830delA		na		 3604delA|3604delA				BRCA2	entrez	675			dna	6174delT|6174delT	32627,46149	32636,46158	The most common BRCA1 mutations are c.4097-2A>G (BIC: 4216-2A>G), c.3485delA (BIC:<<< 3604delA>>>), c.3626delT (BIC: 3745delT), c.4327C>T (BIC: 4446C>T), c.2684del2 (BIC: 2803delAA) and c.5251C>T (BIC: 5370C>T).|eletion            exon 13 duplication (ins6kbEx13)            Finnish     c.4097-2A>G     4216-2A>G     c.771_775del5     999del5      c.3485delA    <<< 3604delA>>>     c.7480C>T     7708C>T      c.3626delT     3745delT     c.8327T>G     8555T>G      c.4327C>T     4446C>T     c.9118-2A>G     9346-2A>G      c.2684		
23199084	confirmed					23199084		del		NM_007297.3:c.5149delC	NM_007297.3:c.5429delC		na		5149delC				BRCA1	entrez	672			dna	6174delT	16221	16230	e specific to the France, but the analysis of its haplotype is less conclusive and needs further confirmation [6].  The BRCA1 c.5030_5033delCTAA (BIC:<<< 5149delC>>>TAA) [76] and c.3839_3843delinsAGGC (BIC: 3958delCTCAGinsAGGC) [77] mutations were reported in at least three independent families from France.  Well-		
23199084	notConfirmed							sub		c.5370C>T					5370C>T| 5370C>T				BRCA1	entrez	672			dna	859G>A|859G>A|859G>A|859G>A	26434,32740,44885,46375	26442,32748,44893,46383	s, including c.9098dupA [104].  ### Greece  In the Greek population four BRCA1 mutations (c.5526dupC, c.5212G>A (BIC: 5331G>A/G1738R), c.5251C>T (BIC:<<< 5370C>T>>>/R1751X), c.5467G>A (BIC: 5586G>A), account for 54% of all mutations detected in BRCA1/2 genes and for 73% of the BRCA1 mutations positive families, w|>G (BIC: 4216-2A>G), c.3485delA (BIC: 3604delA), c.3626delT (BIC: 3745delT), c.4327C>T (BIC: 4446C>T), c.2684del2 (BIC: 2803delAA) and c.5251C>T (BIC:<<< 5370C>T>>>).|elT     6174delT      c.68_69delAG     185delAG            Greek     c.5266dupC     5382insC            c.5212G>A     5331G>A            c.5251C>T    <<< 5370C>T>>>            c.5467G>A     5586G>A            Cypriot           c.8755delG     8984delG      Danish     c.2475delC     2594delC     c.6373delA     6601|>G     8555T>G      c.4327C>T     4446C>T     c.9118-2A>G     9346-2A>G      c.2684del2     2803delAA     c.9117+1G>A     9345+1G>A      c.5251C>T    <<< 5370C>T>>>            c.4096+3A>G     IVS11+3A>G            Iceland           c.771_775del5     999del5      British     c.2681_2682delAA (Scotland)     2800del		
23199084	confirmed					23199084		sub		NM_000059.3:c.8754+1_8754G>A	NM_000059.3:c.8980+1_8980G>A		rs397508006		c.8754+1G>A| c.8754+1G>A				BRCA2	entrez	675			dna	c.123+2A>T|c.123+2A>T	12629,42474	12641,42486	The most prevalent BRCA2 mutations are c.8363G>A (BIC: 8591G>A/W2788X),<<< c.8754+1G>A>>> (BIC: IVS21-1G>A) and c.3860delA (BIC: 4088delA), representing 9%, 7% and 6% of the BRCA2 mutation families respectively (Rappaport, personal communi|6delT     6174delT      c.5266dupC     5382insC            Austrian     c.181T>G     300T>G     c.8363G>A     8591G>A      c.5266dupC     5382insC    <<< c.8754+1G>A>>>     IVS21-1G>A      c.1687C>T     1806C>T     c.3860delA     4088delA      c.3016_3019del4     3135del4            c.2676_2679del4     2795del4      		
23199084	confirmed					23199084		sub		NM_007294.3:c.211A>G|NM_007300.3:c.211A>G|NM_007299.3:c.211A>G|NM_007298.3:c.211A>G	NM_007294.3:c.442A>G|NM_007300.3:c.442A>G|NM_007299.3:c.404A>G|NM_007298.3:c.229A>G		rs80357382|rs80357382|rs80357382|rs80357382		 c.211A>G|c.211A>G				BRCA1	entrez	672			dna	c.123T>A|c.123T>A|c.123T>A	17626,18157,43349	17635,18166,43358	nd geographic distribution.  A compilation of BRCA test results from different laboratories shows that five mutations in the BRCA1 gene (c.68_69delAG,<<< c.211A>G>>> (BIC: 330A>G), c.5117G>A (BIC: 5236G>A), c.5123C>A (BIC: 5242C>A), c.470_471delCT (BIC: 589_590delCT) account for 46.6% of BRCA1 mutations and four m| al., [80] have reviewed the frequency of BRCA1 and BRCA2 recurrent mutations reported in seven geographic areas of Spain.  The founder mutation BRCA1<<< c.211A>G>>>, that leads to aberrant splicing of the transcript, originates from North Western Spain (Galicia) and accounts up to 50% of all mutations in this region [81].|3600del11            c.5128G>T     5247G>T            Spanish     c.68_69delAG     185delAG     c.2808_2811del4 (Castilla-Leon)     3036_3039del4     <<< c.211A>G>>> (Galicia)     330A>G     c.6629_6630delAA     c.6857delAA      c.5117G>A     5236G>A     c.9026_9030del5     9254-9258del5      c.5123C>A     5242C>A		
23199084	notConfirmed							del		c.8984G>None					 8984delG|8984delG				BRCA2	entrez	675			dna	6174delT|6174delT	27216,44970	27225,44979	The BRCA2 c.8755delG (BIC:<<< 8984delG>>>) mutation was reported in three unrelated families and could represent Cypriot founder mutation [107, 108].  ### Denmark  BRCA1 and BRCA2 small scale|382insC            c.5212G>A     5331G>A            c.5251C>T     5370C>T            c.5467G>A     5586G>A            Cypriot           c.8755delG    <<< 8984delG>>>      Danish     c.2475delC     2594delC     c.6373delA     6601delA      c.3319G>T     3438G>T     c.1310_1013del4     1538del4      c.5266dupC     5		
23199084	confirmed					23199084		del		NM_000059.3:c.6275_6276delTT	NM_000059.3:c.6501_6502delTT		rs11571658		c.6275_6276delTT| c.6275_6276delTT				BRCA2	entrez	675			dna	c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT	20511,21864,34702,34846,43812,44010,46539	20528,21881,34719,34863,43829,44027,46556	r mutations (three BRCA1 c.212+3A> (BIC: IVS5+3A>G), c.2359dupG (BIC: 2478insG), c.3661G>T (BIC: 3780G>T) and three BRCA2 c.516+1G>A (BIC: IVS6+1G>A),<<< c.6275_6276delTT>>> (BIC: 6503_6504delTT), c.8904delC (BIC: 9132delC) alterations), which accounted for nearly 60% of all mutations identified. BRCA1 c.212+3A>G was prev|Together with another Dutch BRCA2 founder mutation<<< c.6275_6276delTT>>> (BIC: 6503delTT), c.5351dupA accounts for 62% of hereditary breast/ovarian families [94, 95].  Slightly outdated (as of year 2002) list of published |f the total mutations detected, and almost one-quarter were accounted by just two founder mutations (BRCA1 c.2681_2682delAA (BIC: 2800delAA) and BRCA2<<< c.6275_6276delTT>>> (BIC: 6503delTT) [149].|BRCA2<<< c.6275_6276delTT>>> has been found elsewhere in the UK as well as in Dutch, Swedish, Danish and Belgian families (BIC database).  In the North-west of England two reccur|uguese           c.156_157insAlu     384insAlu      Belgian     c.212+3A>G     IVS5+3A>G     c.516+1G>A     IVS6+1G>A      c.2359dupG     2478insG    <<< c.6275_6276delTT>>>     6503_6504delTT      c.3661G>T     3780G>T     c.8904delC     9132delC      Dutch     c.2685_2686delAA     2804delAA     c.5351dupA     5579insA  |G>T     3780G>T     c.8904delC     9132delC      Dutch     c.2685_2686delAA     2804delAA     c.5351dupA     5579insA      c.2193del5     2312del5    <<< c.6275_6276delTT>>>     6503delTT      c.1292dupT     1411insT            exon 13 deletion (3,8-kb)            exon 22 deletion (510-bp)            German     exon 17 de|      c.4096+3A>G     IVS11+3A>G            Iceland           c.771_775del5     999del5      British     c.2681_2682delAA (Scotland)     2800delAA    <<< c.6275_6276delTT>>> (Scotland)     6503delTT      c.4065_4068del4 (North-West)     4184del4     c.1929delG (North-West)     2157delG      exon 13 duplication (ins6kbEx13		
23199084	notConfirmed							del		c.3829T>None					3829delT| 3829delT				BRCA1	entrez	672			dna	6174delT|6174delT	27625,45189	27634,45198	including BRCA1 c.5266dupC. The most common BRCA1 mutations were c.2475delC (BIC: 2594delC), c.3319G>T (BIC: 3438G>T), c.5266dupC and c.3710delT (BIC:<<< 3829delT>>>), which accounted 16%, 9%, 8% and 5% of BRCA1 positive families, respectively [109, 110, 111]. The c.2475delC BRCA1 mutation was also reported in Swe|6601delA      c.3319G>T     3438G>T     c.1310_1013del4     1538del4      c.5266dupC     5382insC     c.6486_6489del4     6714del4      c.3710delT    <<< 3829delT>>>     c.3847_3848delGT     4075delGT      exons 3-16 deletion            Swedish     c.3171_3175dup     3171ins5     c.4258delG     4486delG      c.247		
23199084	confirmed					23199084		sub		NM_007300.3:c.5331G>A	NM_007300.3:c.5562G>A		rs571834423		 5331G>A				BRCA1	entrez	672			dna	859G>A|859G>A	26401,44852	26409,44860	 one third carried BRCA2 mutations, including c.9098dupA [104].  ### Greece  In the Greek population four BRCA1 mutations (c.5526dupC, c.5212G>A (BIC:<<< 5331G>A>>>/G1738R), c.5251C>T (BIC: 5370C>T/R1751X), c.5467G>A (BIC: 5586G>A), account for 54% of all mutations detected in BRCA1/2 genes and for 73% of the BRC|  c.181T>G     300T>G     c.5946delT     6174delT      c.68_69delAG     185delAG            Greek     c.5266dupC     5382insC            c.5212G>A    <<< 5331G>A>>>            c.5251C>T     5370C>T            c.5467G>A     5586G>A            Cypriot           c.8755delG     8984delG      Danish     c.2475delC    		
23199084	confirmed					23199084		sub		NM_000059.3:c.5331G>A	NM_000059.3:c.5557G>A		na		 5331G>A				BRCA2	entrez	675			dna	859G>A|859G>A	26401,44852	26409,44860	 one third carried BRCA2 mutations, including c.9098dupA [104].  ### Greece  In the Greek population four BRCA1 mutations (c.5526dupC, c.5212G>A (BIC:<<< 5331G>A>>>/G1738R), c.5251C>T (BIC: 5370C>T/R1751X), c.5467G>A (BIC: 5586G>A), account for 54% of all mutations detected in BRCA1/2 genes and for 73% of the BRC|  c.181T>G     300T>G     c.5946delT     6174delT      c.68_69delAG     185delAG            Greek     c.5266dupC     5382insC            c.5212G>A    <<< 5331G>A>>>            c.5251C>T     5370C>T            c.5467G>A     5586G>A            Cypriot           c.8755delG     8984delG      Danish     c.2475delC    		
23199084	notConfirmed							sub		c.8555T>G					 8555T>G|8555T>G				BRCA2	entrez	675			dna	859G>A|859G>A	32959,46231	32967,46239	ost recurrent mutation in BRCA2 is the Icelandic founder mutation c.771_775del5 (BIC: 999del5), three other (c.7480C>T (BIC: 7708C>T), c.8327T>G (BIC:<<< 8555T>G>>>), c.9118-2A>G (BIC: 9346-2A>G) and following (c. 6384del2 (BIC: 6503delTT), c.3853dupA (BIC: 4081insA) and c.5569G>T (BIC: 5797G>T)).|2A>G     4216-2A>G     c.771_775del5     999del5      c.3485delA     3604delA     c.7480C>T     7708C>T      c.3626delT     3745delT     c.8327T>G    <<< 8555T>G>>>      c.4327C>T     4446C>T     c.9118-2A>G     9346-2A>G      c.2684del2     2803delAA     c.9117+1G>A     9345+1G>A      c.5251C>T     5370C>T      		
23199084	confirmed					23199084		dup		NM_007294.3:c.5266dupC	NM_007294.3:c.5497dupC		rs397509247		 c.5266dupC|c.5266dupC				BRCA1	entrez	672			dna	c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA	9011,9261,9657,9944,10298,11316,11673,12929,23249,23427,23846,24142,24255,24512,25751,26068,27490,27593,28539,32754,36036,36217,36905,37611,37785,38546,40039,40314,40439,42347,42446,42744,44216,44467,44646,44803,45112,46770,46918,47003,47053,47131	9022,9272,9668,9955,10309,11327,11684,12940,23260,23438,23857,24153,24266,24523,25762,26079,27501,27604,28550,32765,36047,36228,36916,37622,37796,38557,40050,40325,40450,42358,42457,42755,44227,44478,44657,44814,45123,46781,46929,47014,47064,47142	The most well characterized three founder mutations are two in BRCA1 gene c.68_69delAG (BIC: 185delAG) and<<< c.5266dupC>>> (BIC: 5382insC) and one in BRCA2 c.5946delT (BIC: 6174delT) [31, 32, 33].|these three founder mutations alone is now part of routine clinical practice for Ashkenazi Jewish individuals.  These 3 mutations (BRCA1 c.68_69delAG,<<< c.5266dupC>>> and BRCA2 c.5946delT) account for 98–99% of identified mutations and are carried by about 2.6% (1/40) of the Ashkenazi Jewish population (1%, 0.13% and 1.52% respectively) [34, 35, 36].|The average risk of breast cancer by the age of 70 years is similar for carriers of the BRCA1 c.68_69delAG and<<< c.5266dupC>>> mutations (64% and 67% respectively), however is much lower for the c.5946delT mutation (43%).|varian cancer lifetime risk is respectively of 14%, 33% and 20% in carriers, respectively [6, 37, 38].  It is worth noting that BRCA1 c.68_69delAG and<<< c.5266dupC>>> are not found exclusively in Ashkenazi patients.|s with frequencies similar to those in Ashkenazi populations [3], suggesting a common ancient ancestor or two independent mutational events [39].  The<<< c.5266dupC>>> mutation in BRCA1 exon 20 is the second most frequently reported mutation in the BIC database, being very prevalent in Central and Eastern Europe.|A common ancestor for<<< c.5266dupC>>> mutation families reported from Europe, Brazil and North America is evident [46, 56, 57].  ### Austria  In Austria the ratio of BRCA1 mutations to BRCA2 mutations is 2:1 (Rappaport, personal communication).|There were initial reports for several apparently founder BRCA1 mutations in Austria [58, 59], although they (c.181T>G (BIC: 300T>G/C61G),<<< c.5266dupC>>>, c.1687C>T (BIC: 1806C>T)) represent common mutations prevalent in other European countries.|onal communication).  ### Slovenia  In Slovenia five highly recurrent specific mutations were identified: four in the BRCA1 gene (c.1687C>T, c.181T>G,<<< c.5266dupC>>>, c.181T> (BIC: 300T>A)) and one in the BRCA2 gene (c.7806-2A>G (BIC: IVS16-2A>G) [43, 61, 62]. Respectively, they accounted for 26%, 18%, 13% and 11% of BRCA1 mutations and 56% of BRCA2 mutations.|Eighteen BRCA1 mutations, including the most common<<< c.5266dupC>>>, c.181T>G, c.4065_4068del4 (BIC: 4184del4) and c.2338C>T (BIC: 2457C>T), were found at least 3 times and comprised 66% of all BRCA1 mutations.|The 2 most common BRCA1<<< c.5266dupC>>> and c.181T>G mutations, also prevalent in other populations, accounted for 38% of BRCA1 mutations [4, 99].| (BIC: 9326insA) were associated with common alleles, suggesting a possible founder effect [99].  ### Czech Republic  Five mutations (BRCA1: c.181T>G,<<< c.5266dupC>>>, c.3700_3704del5 (BIC: 3819del5), and BRCA2: c.7913_7917del5 (BIC: 8141del5) and c.8537_8538del2 (BIC: 8765delAG)) represented 52% of all mutations detected in one study population [52].|There is evident strong Slavic founder effect, particularly for two BRCA1 mutations (c.181T>G and<<< c.5266dupC>>>) also regarded as founder mutations in Poland and some other Slavic countries [100].|The single BRCA1<<< c.5266dupC>>> mutation was detected in 51.4% of BRCA1 mutation positive women in one study from Prague area [51].|Three BRCA1 Czech founder mutations (c.181T>G, c.3700_3704del5, and<<< c.5266dupC>>>) account for approximately 9%, 13% and 44% of the BRCA1 mutations identified, respectively [51, 52].  BRCA1 mutations appears to be about 2 times mor|ational spectrum in this population.  ### Hungary  In Hungarian patients from high-risk breast/ovarian cancer families, common BRCA1 founder mutations<<< c.5266dupC>>>, c.181T>G and c.68_69delAG accounted for 80% of all BRCA1 mutations and c.9098dupA (BIC: 9326insA) with c.5946delT accounted for 50% of all BRCA2 mutations [42, 103].|Breast cancer patients were more likely to carry the<<< c.5266dupC>>> mutation whereas ovarian patients were more likely to carry either the c.68_69delAG or the c.181T>G mutation [103].|enmark  BRCA1 and BRCA2 small scale mutations in Denmark are a mixture of Scandinavian founder mutations and other European mutations, including BRCA1<<< c.5266dupC>>>. The most common BRCA1 mutations were c.2475delC (BIC: 2594delC), c.3319G>T (BIC: 3438G>T), c.5266dupC and c.3710delT (BIC: 3829delT), which accounte|s and other European mutations, including BRCA1 c.5266dupC. The most common BRCA1 mutations were c.2475delC (BIC: 2594delC), c.3319G>T (BIC: 3438G>T),<<< c.5266dupC>>> and c.3710delT (BIC: 3829delT), which accounted 16%, 9%, 8% and 5% of BRCA1 positive families, respectively [109, 110, 111]. The c.2475delC BRCA1 mut|Altogether 7 common BRCA1/2 mutations (excluding<<< c.5266dupC>>> ) accounts for around 35% of carriers [4].  LGRs in BRCA1 and BRCA2 are common in East Denmark and account for 9.2% (15/163) of the disease causing mutations.|The<<< c.5266dupC>>> is also found relatively frequently.  The most recurrent mutation in BRCA2 is the Icelandic founder mutation c.771_775del5 (BIC: 999del5), three othe|he founder effect [153].  ### Poland  There is strong founder effect in Polish population for BRCA1 gene mutations. In Poland 3 most common mutations <<<(c.5266dupC>>>, c.181T>G and c.4035delA (BIC: 4154delA) accounted for 91% (111/122) BRCA1 mutations detected and for 86% of all detected mutations in BRCA1/2 genes [40, 100].|The BRCA1<<< c.5266dupC>>>, c.181T>G and c.4035delA accounted for about 56%, 25% and 10% of all BRCA1 mutations, respectively.|In North- Eastern Poland two common mutations <<<(c.5266dupC>>> and c.181T>G) accounted for more than half (up to 70%) of all BRCA-mutated families and no c.4035delA was identified [156], what is in accordance with other studies [157].|nd its necessary to extend analysis, including LGR, among patients negative for BRCA1/2 founder mutations.  ### Latvia  In Latvia two BRCA1 mutations <<<(c.5266dupC>>> and c.4035delA) made up more than 80% of all mutations BRCA1 identified [50, 158].|The 4154delA mutation is the second most abundant BRCA1 gene mutation after the<<< c.5266dupC>>> in Latvia [50] and is especially common for patients of Baltic (Latvian and Lithuanian) origin.|BRCA1 c.4035delA and<<< c.5266dupC>>> attributes to 86% (53% and 33% respectively) of detected BRCA1 mutations [53, 54, 160].| this mutation in Lithuania.  ### Estonia  Newly published data from Estonia about BRCA1/2 mutations structure showed significant involvement of BRCA1<<< c.5266dupC>>> and to a lesser extent BRCA1 c.4035delA [162], what could be also expected projecting data from adjacent countries.  ### Belarus  Only one small stud|s.  ### Belarus  Only one small study in West Belarus for targeted BRCA1 mutations identified similar spectrum of 3 common mutations as in Poland, and<<< c.5266dupC>>> accounted here for 73% of all BRCA1 mutations [49].  ### Russia  In Russia the most common BRCA1 gene mutation in c.5266dupC, comprising around 90% of all BRCA1 mutations [41, 163, 164, 165, 166, 167].|tations as in Poland, and c.5266dupC accounted here for 73% of all BRCA1 mutations [49].  ### Russia  In Russia the most common BRCA1 gene mutation in<<< c.5266dupC>>>, comprising around 90% of all BRCA1 mutations [41, 163, 164, 165, 166, 167].| BRCA2 mutation      --- --- ---      HGVS     BIC     HGVS     BIC      Ashkenazi Jews     c.68_69delAG     185delAG     c.5946delT     6174delT     <<< c.5266dupC>>>     5382insC            Austrian     c.181T>G     300T>G     c.8363G>A     8591G>A      c.5266dupC     5382insC     c.8754+1G>A     IVS21-1G>A      c|delAG     185delAG     c.5946delT     6174delT      c.5266dupC     5382insC            Austrian     c.181T>G     300T>G     c.8363G>A     8591G>A     <<< c.5266dupC>>>     5382insC     c.8754+1G>A     IVS21-1G>A      c.1687C>T     1806C>T     c.3860delA     4088delA      c.3016_3019del4     3135del4            c.267|        c.2676_2679del4     2795del4            Slovenian     c.1687C>T     1806C>T     c.7806-2A>G     IVS16-2A>G      c.181T>G     300T>G           <<< c.5266dupC>>>     5382insC            c.181T>A     300T>A            Italian (Tuscany)     c.3228_3229delAG     3347delAG     c.8537_8538delAG  (Sardinia)     8765|insT            exon 13 deletion (3,8-kb)            exon 22 deletion (510-bp)            German     exon 17 deletion     c.1813dupA     2041insA     <<< c.5266dupC>>>     5382insC     c.4478del4     4706del4      c.181T>G     300T>G     c.9098dupA     9326insA      c.4065_4068del4     4184del4            c.2338C>T |insA      c.4065_4068del4     4184del4            c.2338C>T     2457C>T            Czech     c.181T>G     300T>G     c.7913_7917del5     8141del5     <<< c.5266dupC>>>     5382insC     c.8537_8538del2     8765delAG      c.3700_3704del5     3819del5            exons 1–17 deletion            exons 5–14 deletion       |c.8537_8538del2     8765delAG      c.3700_3704del5     3819del5            exons 1–17 deletion            exons 5–14 deletion            Hungarian    <<< c.5266dupC>>>     5382insC     c.9098dupA     9326insA      c.181T>G     300T>G     c.5946delT     6174delT      c.68_69delAG     185delAG            Greek     c.5|dupC     5382insC     c.9098dupA     9326insA      c.181T>G     300T>G     c.5946delT     6174delT      c.68_69delAG     185delAG            Greek    <<< c.5266dupC>>>     5382insC            c.5212G>A     5331G>A            c.5251C>T     5370C>T            c.5467G>A     5586G>A            Cypriot           c.8755de|delG     8984delG      Danish     c.2475delC     2594delC     c.6373delA     6601delA      c.3319G>T     3438G>T     c.1310_1013del4     1538del4     <<< c.5266dupC>>>     5382insC     c.6486_6489del4     6714del4      c.3710delT     3829delT     c.3847_3848delGT     4075delGT      exons 3-16 deletion            Swe|4184del4     c.1929delG (North-West)     2157delG      exon 13 duplication (ins6kbEx13)            Irish     c.427G>T     546G>T            Polish    <<< c.5266dupC>>>     5382insC            c.181T>G     300T>G            c.4035delA     4154delA            Latvian     c.4035delA     4154delA            c.5266dupC  |   c.5266dupC     5382insC            c.181T>G     300T>G            c.4035delA     4154delA            Latvian     c.4035delA     4154delA           <<< c.5266dupC>>>     5382insC            Lithuanian     c.4035delA     4154delA            c.5266dupC     5382insC            Belarusian     c.5266dupC     5382insC  |154delA            Latvian     c.4035delA     4154delA            c.5266dupC     5382insC            Lithuanian     c.4035delA     4154delA           <<< c.5266dupC>>>     5382insC            Belarusian     c.5266dupC     5382insC            c.181T>G     300T>G            Russian     c.5266dupC     5382insC            Apparently true founder mutations are written in italic.|delA            c.5266dupC     5382insC            Lithuanian     c.4035delA     4154delA            c.5266dupC     5382insC            Belarusian    <<< c.5266dupC>>>     5382insC            c.181T>G     300T>G            Russian     c.5266dupC     5382insC            Apparently true founder mutations are written in italic.|   4154delA            c.5266dupC     5382insC            Belarusian     c.5266dupC     5382insC            c.181T>G     300T>G            Russian    <<< c.5266dupC>>>     5382insC            Apparently true founder mutations are written in italic.		
23199084	confirmed					23199084		del		NM_000059.3:c.8755delG	NM_000059.3:c.8981delG		na		 c.8755delG|c.8755delG				BRCA2	entrez	675			dna	c.123delT|c.123delT	27199,44955	27210,44966	The BRCA2<<< c.8755delG>>> (BIC: 8984delG) mutation was reported in three unrelated families and could represent Cypriot founder mutation [107, 108].  ### Denmark  BRCA1 and BR|.5266dupC     5382insC            c.5212G>A     5331G>A            c.5251C>T     5370C>T            c.5467G>A     5586G>A            Cypriot          <<< c.8755delG>>>     8984delG      Danish     c.2475delC     2594delC     c.6373delA     6601delA      c.3319G>T     3438G>T     c.1310_1013del4     1538del4      c.5		
23199084	notConfirmed							del		c.4075G>None					 4075delG|4075delG				BRCA1	entrez	672			dna	6174delT|6174delT|6174delT|6174delT	28092,31621,45223,45694	28101,31630,45232,45703	st common BRCA2 mutations were c.6373delA (BIC: 6601delA), c.1310_1013del4 (BIC: 1538del4), c.6486_6489del4 (BIC: 6714del4) and c.3847_3848delGT (BIC:<<< 4075delG>>>T), found in 11%, 10%, 9% and 5% of BRCA2 positive families, respectively [111].|3297G>T), c.4745delA (BIC: 4864delA), c.2351del7 (BIC: 2470del7), c.3084del11 (BIC: 3203del11) and BRCA2 c.2808del4 (BIC: 3036del4), c.3847delGT (BIC:<<< 4075delG>>>T)), account for about 60% BRCA1/2 carriers in Norway [128].|T     c.1310_1013del4     1538del4      c.5266dupC     5382insC     c.6486_6489del4     6714del4      c.3710delT     3829delT     c.3847_3848delGT    <<< 4075delG>>>T      exons 3-16 deletion            Swedish     c.3171_3175dup     3171ins5     c.4258delG     4486delG      c.2475delC     2594delC            c.10|plication (ins6kbEx13)            Norwegian     c.1556delA     1675delA     c.2808del4     3036del4      c.3228delAG     3347delAG     c.3847delGT    <<< 4075delG>>>T      c.697delGT     816delGT            c.1016dupA     1135insA            c.3178G>T     3297G>T            c.4745delA     4864delA            c.235		
23199084	confirmed					23199084		sub		NM_007294.3:c.1687C>T|NM_007300.3:c.1687C>T	NM_007294.3:c.1918C>T|NM_007300.3:c.1918C>T		rs80356898|rs80356898		 c.1687C>T|c.1687C>T				BRCA1	entrez	672			dna	c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A	11685,11923,12908,29946,30674,42506,42655,45419	11695,11933,12918,29956,30684,42516,42665,45429	There were initial reports for several apparently founder BRCA1 mutations in Austria [58, 59], although they (c.181T>G (BIC: 300T>G/C61G), c.5266dupC,<<< c.1687C>T>>> (BIC: 1806C>T)) represent common mutations prevalent in other European countries.|Of note,<<< c.1687C>T>>> is also frequent in Slovenia [43] and Sweden (BIC database).|vely (Rappaport, personal communication).  ### Slovenia  In Slovenia five highly recurrent specific mutations were identified: four in the BRCA1 gene <<<(c.1687C>T>>>, c.181T>G, c.5266dupC, c.181T> (BIC: 300T>A)) and one in the BRCA2 gene (c.7806-2A>G (BIC: IVS16-2A>G) [43, 61, 62]. Respectively, they accounted for 26%, 18%, 13% and 11% of BRCA1 mutations and 56% of BRCA2 mutations.|Another BRCA1 mutation,<<< c.1687C>T>>>, occurs primarily in southern Sweden as well as other European countries (BIC database).|n Sweden, six mutations, including the most common BRCA1 c.3171_3175dup, four other common Scandinavian BCRA1 mutations (c.1082_1092del11, c.2475delC,<<< c.1687C>T>>>, c.1016dupA (BIC: 1135insA)) and one BRCA2 mutation (c.4258delG) accounted for approximately 75% of all BRCA1/2 mutations [124].|pC     5382insC            Austrian     c.181T>G     300T>G     c.8363G>A     8591G>A      c.5266dupC     5382insC     c.8754+1G>A     IVS21-1G>A     <<< c.1687C>T>>>     1806C>T     c.3860delA     4088delA      c.3016_3019del4     3135del4            c.2676_2679del4     2795del4            Slovenian     c.1687C>T |  c.1687C>T     1806C>T     c.3860delA     4088delA      c.3016_3019del4     3135del4            c.2676_2679del4     2795del4            Slovenian    <<< c.1687C>T>>>     1806C>T     c.7806-2A>G     IVS16-2A>G      c.181T>G     300T>G            c.5266dupC     5382insC            c.181T>A     300T>A            Ital| Swedish     c.3171_3175dup     3171ins5     c.4258delG     4486delG      c.2475delC     2594delC            c.1082_1092del11     1201del11           <<< c.1687C>T>>>     1806C>T            c.3626delT (Northern)     3745delT            c.1016dupA     1135insA            exon 13 duplication (ins6kbEx13)            N		
23199084	confirmed					23199084		sub		NM_007297.3:c.4097-2_4097A>G	NM_007297.3:c.4377-2_4377A>G		na		 c.4097-2A>G				BRCA1	entrez	672			dna	c.123+2A>T|c.123+2A>T	32580,46073	32592,46085	The most common BRCA1 mutations are<<< c.4097-2A>G>>> (BIC: 4216-2A>G), c.3485delA (BIC: 3604delA), c.3626delT (BIC: 3745delT), c.4327C>T (BIC: 4446C>T), c.2684del2 (BIC: 2803delAA) and c.5251C>T (BIC: 5370C>T).|A>C     120A>C            c.5075-2A>C     IVS17-2A>C            exons 1-13 deletion            exon 13 duplication (ins6kbEx13)            Finnish    <<< c.4097-2A>G>>>     4216-2A>G     c.771_775del5     999del5      c.3485delA     3604delA     c.7480C>T     7708C>T      c.3626delT     3745delT     c.8327T>G     855		
23199084	confirmed					23199084		del		NM_000059.3:c.9310_9311delAA	NM_000059.3:c.9536_9537delAA		rs80359756		 c.9310_9311delAA|c.9310_9311delAA				BRCA2	entrez	675			dna	c.123_125delAT|c.123_125delAT	17916,43512	17933,43529	utations and four mutations in BRCA2 (c.2808_2811del4 (BIC: 3036_3039del4), c.6629_6630delAA (BIC: c.6857delAA), c.9026_9030del5 (BIC: 9254-9258del5),<<< c.9310_9311delAA>>> (BIC: 9538delAA)) account for 56.6% of the BRCA2 mutations [79].  Diez et al., [80] have reviewed the frequency of BRCA1 and BRCA2 recurrent mutation|licia)     330A>G     c.6629_6630delAA     c.6857delAA      c.5117G>A     5236G>A     c.9026_9030del5     9254-9258del5      c.5123C>A     5242C>A    <<< c.9310_9311delAA>>>     9538delAA      c.470_471delCT     589_590delCT     c.5146_5149del4     374delTATG      c.5153-1G>A     5272-1G>A            Portuguese           		
23199084	confirmed					23199084		sub		NM_007298.3:c.3297G>T	NM_007298.3:c.3315G>T		na		3297G>T| 3297G>T				BRCA1	entrez	672			dna	859G>A|859G>A	31470,45793	31478,45801	 the fourth is from the south-east [127].  These four founder mutations together with other six most frequent BRCA1/2 mutations (BRCA1 c.3178G>T (BIC:<<< 3297G>T>>>), c.4745delA (BIC: 4864delA), c.2351del7 (BIC: 2470del7), c.3084del11 (BIC: 3203del11) and BRCA2 c.2808del4 (BIC: 3036del4), c.3847delGT (BIC: 4075delGT)), account for about 60% BRCA1/2 carriers in Norway [128].|      c.3228delAG     3347delAG     c.3847delGT     4075delGT      c.697delGT     816delGT            c.1016dupA     1135insA            c.3178G>T    <<< 3297G>T>>>            c.4745delA     4864delA            c.2351del7     2470del7            c.3084del11     3203del11            c.1A>C     120A>C            c.		
23199084	confirmed					23199084		sub		NM_007294.3:c.5128G>T|NM_007297.3:c.5128G>T	NM_007294.3:c.5359G>T|NM_007297.3:c.5408G>T		rs397509229|na		 c.5128G>T|c.5128G>T				BRCA1	entrez	672			dna	c.123T>A|c.123T>A|c.123T>A	15615,16043,43219	15625,16053,43229	The c.3481_3491del11 (BIC: 3600del11) in exon 11 accounts for 37% and the nonsense mutation<<< c.5128G>T>>> (BIC: 5247G>T/Gly1710X) in exon 18 for 15% of all BRCA1/2 mutations in that region (overall 52%) [4, 75].  The haplotype analysis of the families car|The BRCA1 mutation<<< c.5128G>T>>> would appear to be specific to the France, but the analysis of its haplotype is less conclusive and needs further confirmation [6].  The BRCA1 c.5030|   5083del19            Italian (North-East)     c.5062_5064delGTT     5181_5183delGTT            French     c.3481_3491del11     3600del11           <<< c.5128G>T>>>     5247G>T            Spanish     c.68_69delAG     185delAG     c.2808_2811del4 (Castilla-Leon)     3036_3039del4      c.211A>G (Galicia)     330A>G		
23199084	confirmed					23199084		del		NM_007294.3:c.4035delA|NM_007300.3:c.4035delA|NM_007297.3:c.4035delA	NM_007294.3:c.4266delA|NM_007300.3:c.4266delA|NM_007297.3:c.4315delA		rs80357711|rs80357711|na		c.4035delA| c.4035delA				BRCA1	entrez	672			dna	c.123delT|c.123delT|c.123delT|c.123delT|c.123delT|c.123delT|c.123delT|c.123delT|c.123delT|c.123delT|c.123delT	36061,36242,37007,37626,38531,39139,40079,40583,46836,46883,46968	36072,36253,37018,37637,38542,39150,40090,40594,46847,46894,46979	 ### Poland  There is strong founder effect in Polish population for BRCA1 gene mutations. In Poland 3 most common mutations (c.5266dupC, c.181T>G and<<< c.4035delA>>> (BIC: 4154delA) accounted for 91% (111/122) BRCA1 mutations detected and for 86% of all detected mutations in BRCA1/2 genes [40, 100].|The BRCA1 c.5266dupC, c.181T>G and<<< c.4035delA>>> accounted for about 56%, 25% and 10% of all BRCA1 mutations, respectively.|In North- Eastern Poland two common mutations (c.5266dupC and c.181T>G) accounted for more than half (up to 70%) of all BRCA-mutated families and no<<< c.4035delA>>> was identified [156], what is in accordance with other studies [157].|y to extend analysis, including LGR, among patients negative for BRCA1/2 founder mutations.  ### Latvia  In Latvia two BRCA1 mutations (c.5266dupC and<<< c.4035delA>>>) made up more than 80% of all mutations BRCA1 identified [50, 158].|BRCA1<<< c.4035delA>>> and c.5266dupC attributes to 86% (53% and 33% respectively) of detected BRCA1 mutations [53, 54, 160].|CA1 amplicons by HRM analysis now is the innitial procedure for breast/ovarian cancer patients in our hospital.  The most frequently observed is BRCA1<<< c.4035delA>>> mutation, which is more frequent in families of Baltic (Lithuanian) origin rather than Slavic [53, 54, 161], and was detected in 16.3% (7/43) of unrelated ovarian cancer patients unselected for family history in one study [159].|a  Newly published data from Estonia about BRCA1/2 mutations structure showed significant involvement of BRCA1 c.5266dupC and to a lesser extent BRCA1<<< c.4035delA>>> [162], what could be also expected projecting data from adjacent countries.  ### Belarus  Only one small study in West Belarus for targeted BRCA1 mut|Other less common mutations found in Western Russia are<<< c.4035delA>>>, c.181T>G, and c.68_69delAG. In Siberian region of Russia there is seen preponderance of individual BRCA2 gene mutations [164].  ### Other countries |lication (ins6kbEx13)            Irish     c.427G>T     546G>T            Polish     c.5266dupC     5382insC            c.181T>G     300T>G           <<< c.4035delA>>>     4154delA            Latvian     c.4035delA     4154delA            c.5266dupC     5382insC            Lithuanian     c.4035delA     4154delA     |7G>T     546G>T            Polish     c.5266dupC     5382insC            c.181T>G     300T>G            c.4035delA     4154delA            Latvian    <<< c.4035delA>>>     4154delA            c.5266dupC     5382insC            Lithuanian     c.4035delA     4154delA            c.5266dupC     5382insC            Belar| 300T>G            c.4035delA     4154delA            Latvian     c.4035delA     4154delA            c.5266dupC     5382insC            Lithuanian    <<< c.4035delA>>>     4154delA            c.5266dupC     5382insC            Belarusian     c.5266dupC     5382insC            c.181T>G     300T>G            Russian     c.5266dupC     5382insC            Apparently true founder mutations are written in italic.		
23199084	confirmed					23199084		sub		NM_007294.3:c.5117G>A|NM_007297.3:c.5117G>A	NM_007294.3:c.5348G>A|NM_007297.3:c.5397G>A		rs80356860|rs397509246		 c.5117G>A|c.5117G>A				BRCA1	entrez	672			dna	c.123T>A|c.123T>A	17650,43421	17660,43431	on.  A compilation of BRCA test results from different laboratories shows that five mutations in the BRCA1 gene (c.68_69delAG, c.211A>G (BIC: 330A>G),<<< c.5117G>A>>> (BIC: 5236G>A), c.5123C>A (BIC: 5242C>A), c.470_471delCT (BIC: 589_590delCT) account for 46.6% of BRCA1 mutations and four mutations in BRCA2 (c.2808|9delAG     185delAG     c.2808_2811del4 (Castilla-Leon)     3036_3039del4      c.211A>G (Galicia)     330A>G     c.6629_6630delAA     c.6857delAA     <<< c.5117G>A>>>     5236G>A     c.9026_9030del5     9254-9258del5      c.5123C>A     5242C>A     c.9310_9311delAA     9538delAA      c.470_471delCT     589_590delCT 		
23199084	confirmed					23199084		del		NM_000059.3:c.8537_8538delAG	NM_000059.3:c.8763_8764delAG		rs80359716		 c.8537_8538delAG|c.8537_8538delAG				BRCA2	entrez	675			dna	c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT	14227,16794,17092,42867	14244,16811,17109,42884	 of BRCA1/2 mutations to breast cancer predisposition has been reported for populations from the Northern part of the island [67], where founder BRCA2<<< c.8537_8538delAG>>> (BIC: 8765delAG) mutation comprises 28% for BRCA1/2 positive families [68, 69].|, c.962G>A (BIC: 1081G>A), c.2834_2836delinsC (BIC: 2953delGTA/insC) and 3 BRCA2 mutations (c.3170_3174del5 (BIC: 3398del5), c.5857G>T (BIC: 6085G>T),<<< c.8537_8538delAG>>> (BIC: 8765delAG)) are now routinely included in early onset breast/ovarian cancer screening assays and represent up to 84% of the total BRCA1/2 mutations in the French-Canadian population in Quebec [78].|Among these, the most common founder mutations are BRCA1 c.4327C>T and BRCA2<<< c.8537_8538delAG>>> and c.3170_3174del5, which are found in 1.7% of women affected by breast cancer diagnosed before age 41 and in 1.3% of women with ovarian cancer [6].|81T>G     300T>G            c.5266dupC     5382insC            c.181T>A     300T>A            Italian (Tuscany)     c.3228_3229delAG     3347delAG    <<< c.8537_8538delAG>>>  (Sardinia)     8765delAG      c.3285delA     3404delA            c.1380dupA     1499insA            c.5062_5064del3     5181delGTT            Italia		
23199084	confirmed					23199084		sub		NM_000059.3:c.8363G>A	NM_000059.3:c.8589G>A		rs80359080		c.8363G>A| c.8363G>A				BRCA2	entrez	675			dna	c.123T>A|c.123T>A	12596,42419	12606,42429	The most prevalent BRCA2 mutations are<<< c.8363G>A>>> (BIC: 8591G>A/W2788X), c.8754+1G>A (BIC: IVS21-1G>A) and c.3860delA (BIC: 4088delA), representing 9%, 7% and 6% of the BRCA2 mutation families respec| Ashkenazi Jews     c.68_69delAG     185delAG     c.5946delT     6174delT      c.5266dupC     5382insC            Austrian     c.181T>G     300T>G    <<< c.8363G>A>>>     8591G>A      c.5266dupC     5382insC     c.8754+1G>A     IVS21-1G>A      c.1687C>T     1806C>T     c.3860delA     4088delA      c.3016_3019del4  		
23199084	confirmed					23199084		sub		NM_000059.3:c.7480C>T	NM_000059.3:c.7706C>T		rs80358972		 c.7480C>T|c.7480C>T				BRCA2	entrez	675			dna	c.123T>A|c.123T>A|c.123T>A	32917,33222,46162	32927,33232,46172	s also found relatively frequently.  The most recurrent mutation in BRCA2 is the Icelandic founder mutation c.771_775del5 (BIC: 999del5), three other <<<(c.7480C>T>>> (BIC: 7708C>T), c.8327T>G (BIC: 8555T>G), c.9118-2A>G (BIC: 9346-2A>G) and following (c. 6384del2 (BIC: 6503delTT), c.3853dupA (BIC: 4081insA) and c.5569G>T (BIC: 5797G>T)).|Some mutations are unique to the Finns, such as c.4096+3A>G (BIC: IVS11+3A>G) in BRCA1 and c.9117+1G>A (BIC: 9345+1G>A),<<< c.7480C>T>>>, c.8327T>G in BRCA2 genes.  The mutation spectrum in Eastern part slightly differs from those observed in the Northern and Southern parts of the coun|      exon 13 duplication (ins6kbEx13)            Finnish     c.4097-2A>G     4216-2A>G     c.771_775del5     999del5      c.3485delA     3604delA    <<< c.7480C>T>>>     7708C>T      c.3626delT     3745delT     c.8327T>G     8555T>G      c.4327C>T     4446C>T     c.9118-2A>G     9346-2A>G      c.2684del2     2803d		
23199084	confirmed					23199084		sub		NM_007294.3:c.5857G>T	NM_007294.3:c.6088G>T		na		c.5857G>T				BRCA1	entrez	672			dna	c.123T>A	16768	16778	759del4 (BIC: 3875delGTCT), c.962G>A (BIC: 1081G>A), c.2834_2836delinsC (BIC: 2953delGTA/insC) and 3 BRCA2 mutations (c.3170_3174del5 (BIC: 3398del5),<<< c.5857G>T>>> (BIC: 6085G>T), c.8537_8538delAG (BIC: 8765delAG)) are now routinely included in early onset breast/ovarian cancer screening assays and represent up to 84% of the total BRCA1/2 mutations in the French-Canadian population in Quebec [78].		
23199084	confirmed					23199084		sub		NM_000059.3:c.5857G>T	NM_000059.3:c.6083G>T		rs80358814		c.5857G>T				BRCA2	entrez	675			dna	c.123T>A	16768	16778	759del4 (BIC: 3875delGTCT), c.962G>A (BIC: 1081G>A), c.2834_2836delinsC (BIC: 2953delGTA/insC) and 3 BRCA2 mutations (c.3170_3174del5 (BIC: 3398del5),<<< c.5857G>T>>> (BIC: 6085G>T), c.8537_8538delAG (BIC: 8765delAG)) are now routinely included in early onset breast/ovarian cancer screening assays and represent up to 84% of the total BRCA1/2 mutations in the French-Canadian population in Quebec [78].		
23199084	confirmed					23199084		del		NM_007294.3:c.2681_2682delAA|NM_007300.3:c.2681_2682delAA	NM_007294.3:c.2912_2913delAA|NM_007300.3:c.2912_2913delAA		rs80357971|rs80357971		c.2681_2682delAA| c.2681_2682delAA				BRCA1	entrez	672			dna	c.123_125delAT|c.123_125delAT|c.123_125delAT	34658,34753,46493	34675,34770,46510	ve in each gene) accounted for almost half of the total mutations detected, and almost one-quarter were accounted by just two founder mutations (BRCA1<<< c.2681_2682delAA>>> (BIC: 2800delAA) and BRCA2 c.6275_6276delTT (BIC: 6503delTT) [149].|The BRCA1<<< c.2681_2682delAA>>>, probably originated from the West-Central Scotland or Ireland [150].|    9345+1G>A      c.5251C>T     5370C>T            c.4096+3A>G     IVS11+3A>G            Iceland           c.771_775del5     999del5      British    <<< c.2681_2682delAA>>> (Scotland)     2800delAA     c.6275_6276delTT (Scotland)     6503delTT      c.4065_4068del4 (North-West)     4184del4     c.1929delG (North-West)    		
23199084	confirmed					23199084		del		NM_007294.3:c.2803delA|NM_007300.3:c.2803delA	NM_007294.3:c.3034delA|NM_007300.3:c.3034delA		na|na		2803delA| 2803delA				BRCA1	entrez	672			dna	6174delT|6174delT	32709,46316	32718,46325	n BRCA1 mutations are c.4097-2A>G (BIC: 4216-2A>G), c.3485delA (BIC: 3604delA), c.3626delT (BIC: 3745delT), c.4327C>T (BIC: 4446C>T), c.2684del2 (BIC:<<< 2803delA>>>A) and c.5251C>T (BIC: 5370C>T).|480C>T     7708C>T      c.3626delT     3745delT     c.8327T>G     8555T>G      c.4327C>T     4446C>T     c.9118-2A>G     9346-2A>G      c.2684del2    <<< 2803delA>>>A     c.9117+1G>A     9345+1G>A      c.5251C>T     5370C>T            c.4096+3A>G     IVS11+3A>G            Iceland           c.771_775del5     999del		
23199084	confirmed					23199084		del		NM_007300.3:c.4843delC	NM_007300.3:c.5074delC		na		4843delC				BRCA1	entrez	672			dna	6174delT	14889	14898	It was also recurrently found at least four times in Sicilia [70, 71]. Another BRCA1 c.4724delC (BIC:<<< 4843delC>>>) mutation could be a possible Sicilian founder mutation, although present evidence is scarce [71, 72, 73].  Using a number of independent approaches,		
23199084	confirmed					23199084		del		NM_000059.3:c.4843delC	NM_000059.3:c.5069delC		na		4843delC				BRCA2	entrez	675			dna	6174delT	14889	14898	It was also recurrently found at least four times in Sicilia [70, 71]. Another BRCA1 c.4724delC (BIC:<<< 4843delC>>>) mutation could be a possible Sicilian founder mutation, although present evidence is scarce [71, 72, 73].  Using a number of independent approaches,		
23199084	notConfirmed							sub		c.2A>C					2A>C				BRCA1	entrez	672			dna	859G>A|859G>A|859G>A|859G>A	31728,31745,45955,45970	31733,31750,45960,45975	BRCA1 c.1A>C (BIC: 120A>C) and c.5075<<<-2A>C>>> (BIC: IVS17-2A>C) mutations are also locally frequent.|BRCA1 c.1A>C (BIC: 120A>C) and c.5075-2A>C (BIC: IVS17<<<-2A>C>>>) mutations are also locally frequent.|        c.4745delA     4864delA            c.2351del7     2470del7            c.3084del11     3203del11            c.1A>C     120A>C            c.5075<<<-2A>C>>>     IVS17-2A>C            exons 1-13 deletion            exon 13 duplication (ins6kbEx13)            Finnish     c.4097-2A>G     4216-2A>G     c.771_|elA     4864delA            c.2351del7     2470del7            c.3084del11     3203del11            c.1A>C     120A>C            c.5075-2A>C     IVS17<<<-2A>C>>>            exons 1-13 deletion            exon 13 duplication (ins6kbEx13)            Finnish     c.4097-2A>G     4216-2A>G     c.771_775del5     999		
23199084	confirmed					23199084		del		NM_007294.3:c.6601delA|NM_007300.3:c.6601delA	NM_007294.3:c.6832delA|NM_007300.3:c.6832delA		na|na		6601delA| 6601delA				BRCA1	entrez	672			dna	6174delT|6174delT	27989,45038	27998,45047	.3319G>T BRCA1 mutation was also reported in Norway (http://www.legeforeningen.no/id/153250.0).  The most common BRCA2 mutations were c.6373delA (BIC:<<< 6601delA>>>), c.1310_1013del4 (BIC: 1538del4), c.6486_6489del4 (BIC: 6714del4) and c.3847_3848delGT (BIC: 4075delGT), found in 11%, 10%, 9% and 5% of BRCA2 positive families, respectively [111].|70C>T            c.5467G>A     5586G>A            Cypriot           c.8755delG     8984delG      Danish     c.2475delC     2594delC     c.6373delA    <<< 6601delA>>>      c.3319G>T     3438G>T     c.1310_1013del4     1538del4      c.5266dupC     5382insC     c.6486_6489del4     6714del4      c.3710delT     3829del		
23199084	notConfirmed							sub		c.2A>G					2A>G				BRCA2	entrez	675			dna	859G>A|859G>A|859G>A|859G>A|859G>A|859G>A|859G>A|859G>A|859G>A|859G>A|859G>A|859G>A|859G>A	12998,13015,13148,32587,32603,32976,32992,42688,42703,46080,46094,46277,46291	13003,13020,13153,32592,32608,32981,32997,42693,42708,46085,46099,46282,46296	 specific mutations were identified: four in the BRCA1 gene (c.1687C>T, c.181T>G, c.5266dupC, c.181T> (BIC: 300T>A)) and one in the BRCA2 gene (c.7806<<<-2A>G>>> (BIC: IVS16-2A>G) [43, 61, 62]. Respectively, they accounted for 26%, 18%, 13% and 11% of BRCA1 mutations and 56% of BRCA2 mutations.|ns were identified: four in the BRCA1 gene (c.1687C>T, c.181T>G, c.5266dupC, c.181T> (BIC: 300T>A)) and one in the BRCA2 gene (c.7806-2A>G (BIC: IVS16<<<-2A>G>>>) [43, 61, 62]. Respectively, they accounted for 26%, 18%, 13% and 11% of BRCA1 mutations and 56% of BRCA2 mutations.|The c.7806<<<-2A>G>>> in the BRCA2 gene appears to be an unique founder mutation in the Slovenian population, found in 26% (10/38) of all BRCA1/2 mutations harboring families.|The most common BRCA1 mutations are c.4097<<<-2A>G>>> (BIC: 4216-2A>G), c.3485delA (BIC: 3604delA), c.3626delT (BIC: 3745delT), c.4327C>T (BIC: 4446C>T), c.2684del2 (BIC: 2803delAA) and c.5251C>T (BIC: 5370C>T).|The most common BRCA1 mutations are c.4097-2A>G (BIC: 4216<<<-2A>G>>>), c.3485delA (BIC: 3604delA), c.3626delT (BIC: 3745delT), c.4327C>T (BIC: 4446C>T), c.2684del2 (BIC: 2803delAA) and c.5251C>T (BIC: 5370C>T).|ation in BRCA2 is the Icelandic founder mutation c.771_775del5 (BIC: 999del5), three other (c.7480C>T (BIC: 7708C>T), c.8327T>G (BIC: 8555T>G), c.9118<<<-2A>G>>> (BIC: 9346-2A>G) and following (c. 6384del2 (BIC: 6503delTT), c.3853dupA (BIC: 4081insA) and c.5569G>T (BIC: 5797G>T)).|s the Icelandic founder mutation c.771_775del5 (BIC: 999del5), three other (c.7480C>T (BIC: 7708C>T), c.8327T>G (BIC: 8555T>G), c.9118-2A>G (BIC: 9346<<<-2A>G>>>) and following (c. 6384del2 (BIC: 6503delTT), c.3853dupA (BIC: 4081insA) and c.5569G>T (BIC: 5797G>T)).|0delA     4088delA      c.3016_3019del4     3135del4            c.2676_2679del4     2795del4            Slovenian     c.1687C>T     1806C>T     c.7806<<<-2A>G>>>     IVS16-2A>G      c.181T>G     300T>G            c.5266dupC     5382insC            c.181T>A     300T>A            Italian (Tuscany)     c.3228_322|elA      c.3016_3019del4     3135del4            c.2676_2679del4     2795del4            Slovenian     c.1687C>T     1806C>T     c.7806-2A>G     IVS16<<<-2A>G>>>      c.181T>G     300T>G            c.5266dupC     5382insC            c.181T>A     300T>A            Italian (Tuscany)     c.3228_3229delAG     3347| 120A>C            c.5075-2A>C     IVS17-2A>C            exons 1-13 deletion            exon 13 duplication (ins6kbEx13)            Finnish     c.4097<<<-2A>G>>>     4216-2A>G     c.771_775del5     999del5      c.3485delA     3604delA     c.7480C>T     7708C>T      c.3626delT     3745delT     c.8327T>G     855|     c.5075-2A>C     IVS17-2A>C            exons 1-13 deletion            exon 13 duplication (ins6kbEx13)            Finnish     c.4097-2A>G     4216<<<-2A>G>>>     c.771_775del5     999del5      c.3485delA     3604delA     c.7480C>T     7708C>T      c.3626delT     3745delT     c.8327T>G     8555T>G      c.43|l5      c.3485delA     3604delA     c.7480C>T     7708C>T      c.3626delT     3745delT     c.8327T>G     8555T>G      c.4327C>T     4446C>T     c.9118<<<-2A>G>>>     9346-2A>G      c.2684del2     2803delAA     c.9117+1G>A     9345+1G>A      c.5251C>T     5370C>T            c.4096+3A>G     IVS11+3A>G           |delA     3604delA     c.7480C>T     7708C>T      c.3626delT     3745delT     c.8327T>G     8555T>G      c.4327C>T     4446C>T     c.9118-2A>G     9346<<<-2A>G>>>      c.2684del2     2803delAA     c.9117+1G>A     9345+1G>A      c.5251C>T     5370C>T            c.4096+3A>G     IVS11+3A>G            Iceland      		
23199084	confirmed					23199084		dup		NM_000059.3:c.5351dupA	NM_000059.3:c.5577dupA		rs80359509		 c.5351dupA|c.5351dupA				BRCA2	entrez	675			dna	c.123dupA|c.123dupA|c.123dupA	21565,21899,43953	21576,21910,43964	founder mutations: 3.8-kb deletion of BRCA1 exon 13, also known as c.4186-1643_4357+2020del3835 (BIC: del exon 13del3835/IVS12-1643del3835), and BRCA2<<< c.5351dupA>>> (BIC: 5579insA) were found in families from two different geographical areas, and were prevalent respectively in Catholic (West Braband clustering) and Protestant (South Beveland clustering) families, reflecting religious endogamy [95].|Together with another Dutch BRCA2 founder mutation c.6275_6276delTT (BIC: 6503delTT),<<< c.5351dupA>>> accounts for 62% of hereditary breast/ovarian families [94, 95].  Slightly outdated (as of year 2002) list of published and unpublished BRCA1/2 mutat|8insG     c.6275_6276delTT     6503_6504delTT      c.3661G>T     3780G>T     c.8904delC     9132delC      Dutch     c.2685_2686delAA     2804delAA    <<< c.5351dupA>>>     5579insA      c.2193del5     2312del5     c.6275_6276delTT     6503delTT      c.1292dupT     1411insT            exon 13 deletion (3,8-kb)       		
23199084	confirmed					23199084		del		NM_007294.3:c.470_471delCT|NM_007300.3:c.470_471delCT|NM_007299.3:c.470_471delCT|NM_007298.3:c.470_471delCT	NM_007294.3:c.701_702delCT|NM_007300.3:c.701_702delCT|NM_007299.3:c.663_664delCT|NM_007298.3:c.488_489delCT		rs80357887|rs80357887|rs80357887|rs80357887		 c.470_471delCT|c.470_471delCT				BRCA1	entrez	672			dna	c.123_125delAT|c.123_125delAT	17702,43548	17717,43563	nt laboratories shows that five mutations in the BRCA1 gene (c.68_69delAG, c.211A>G (BIC: 330A>G), c.5117G>A (BIC: 5236G>A), c.5123C>A (BIC: 5242C>A),<<< c.470_471delCT>>> (BIC: 589_590delCT) account for 46.6% of BRCA1 mutations and four mutations in BRCA2 (c.2808_2811del4 (BIC: 3036_3039del4), c.6629_6630delAA (BIC: c.|AA     c.6857delAA      c.5117G>A     5236G>A     c.9026_9030del5     9254-9258del5      c.5123C>A     5242C>A     c.9310_9311delAA     9538delAA     <<< c.470_471delCT>>>     589_590delCT     c.5146_5149del4     374delTATG      c.5153-1G>A     5272-1G>A            Portuguese           c.156_157insAlu     384insAlu     		
23199084	notConfirmed							sub		c.4446C>T					4446C>T| 4446C>T				BRCA1	entrez	672			dna	859G>A|859G>A|859G>A	16590,32682,46258	16598,32690,46266	In this region 4 BRCA1 gene mutations (c.4327C>T (BIC:<<< 4446C>T>>>/Arg1443X), c.3756_3759del4 (BIC: 3875delGTCT), c.962G>A (BIC: 1081G>A), c.2834_2836delinsC (BIC: 2953delGTA/insC) and 3 BRCA2 mutations (c.3170_3174d|The most common BRCA1 mutations are c.4097-2A>G (BIC: 4216-2A>G), c.3485delA (BIC: 3604delA), c.3626delT (BIC: 3745delT), c.4327C>T (BIC:<<< 4446C>T>>>), c.2684del2 (BIC: 2803delAA) and c.5251C>T (BIC: 5370C>T).|1_775del5     999del5      c.3485delA     3604delA     c.7480C>T     7708C>T      c.3626delT     3745delT     c.8327T>G     8555T>G      c.4327C>T    <<< 4446C>T>>>     c.9118-2A>G     9346-2A>G      c.2684del2     2803delAA     c.9117+1G>A     9345+1G>A      c.5251C>T     5370C>T            c.4096+3A>G     IVS11		
23199084	confirmed					23199084		sub		NM_007294.3:c.962G>A|NM_007300.3:c.962G>A	NM_007294.3:c.1193G>A|NM_007300.3:c.1193G>A		rs80357292|rs80357292		c.962G>A				BRCA1	entrez	672			dna	c.123T>A	16645	16654	In this region 4 BRCA1 gene mutations (c.4327C>T (BIC: 4446C>T/Arg1443X), c.3756_3759del4 (BIC: 3875delGTCT),<<< c.962G>A>>> (BIC: 1081G>A), c.2834_2836delinsC (BIC: 2953delGTA/insC) and 3 BRCA2 mutations (c.3170_3174del5 (BIC: 3398del5), c.5857G>T (BIC: 6085G>T), c.8537_85		
23199084	confirmed					23199084		del		NM_007300.3:c.6373delA|NM_007297.3:c.6373delA	NM_007300.3:c.6604delA|NM_007297.3:c.6653delA		na|na		 c.6373delA|c.6373delA				BRCA1	entrez	672			dna	c.123delT|c.123delT|c.123delT	27972,28319,45023	27983,28330,45034	tabase) and the c.3319G>T BRCA1 mutation was also reported in Norway (http://www.legeforeningen.no/id/153250.0).  The most common BRCA2 mutations were<<< c.6373delA>>> (BIC: 6601delA), c.1310_1013del4 (BIC: 1538del4), c.6486_6489del4 (BIC: 6714del4) and c.3847_3848delGT (BIC: 4075delGT), found in 11%, 10%, 9% and 5% of BRCA2 positive families, respectively [111].|Two of the recurrent BRCA2 mutations (c.1310_1313del4 and c.6486_6489del4) have also been observed in many other populations, whereas the<<< c.6373delA>>> BRCA2 mutation is less frequent.|.5251C>T     5370C>T            c.5467G>A     5586G>A            Cypriot           c.8755delG     8984delG      Danish     c.2475delC     2594delC    <<< c.6373delA>>>     6601delA      c.3319G>T     3438G>T     c.1310_1013del4     1538del4      c.5266dupC     5382insC     c.6486_6489del4     6714del4      c.3710del		
23199084	confirmed					23199084		del		NM_000059.3:c.6373delA	NM_000059.3:c.6599delA		rs80359578		 c.6373delA|c.6373delA				BRCA2	entrez	675			dna	c.123delT|c.123delT|c.123delT	27972,28319,45023	27983,28330,45034	tabase) and the c.3319G>T BRCA1 mutation was also reported in Norway (http://www.legeforeningen.no/id/153250.0).  The most common BRCA2 mutations were<<< c.6373delA>>> (BIC: 6601delA), c.1310_1013del4 (BIC: 1538del4), c.6486_6489del4 (BIC: 6714del4) and c.3847_3848delGT (BIC: 4075delGT), found in 11%, 10%, 9% and 5% of BRCA2 positive families, respectively [111].|Two of the recurrent BRCA2 mutations (c.1310_1313del4 and c.6486_6489del4) have also been observed in many other populations, whereas the<<< c.6373delA>>> BRCA2 mutation is less frequent.|.5251C>T     5370C>T            c.5467G>A     5586G>A            Cypriot           c.8755delG     8984delG      Danish     c.2475delC     2594delC    <<< c.6373delA>>>     6601delA      c.3319G>T     3438G>T     c.1310_1013del4     1538del4      c.5266dupC     5382insC     c.6486_6489del4     6714del4      c.3710del		
23199084	confirmed					23199084		sub		NM_007294.3:c.181T>G|NM_007300.3:c.181T>G|NM_007299.3:c.181T>G|NM_007298.3:c.181T>G	NM_007294.3:c.412T>G|NM_007300.3:c.412T>G|NM_007299.3:c.374T>G|NM_007298.3:c.199T>G		rs28897672|rs28897672|rs28897672|rs28897672		c.181T>G| c.181T>G				BRCA1	entrez	672			dna	c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A	11644,12919,23261,23442,23836,24129,24481,25763,25939,26170,36048,36229,36920,38206,38672,40595,42395,42713,44273,44409,44703,46805,47088	11653,12928,23270,23451,23845,24138,24490,25772,25948,26179,36057,36238,36929,38215,38681,40604,42404,42722,44282,44418,44712,46814,47097	There were initial reports for several apparently founder BRCA1 mutations in Austria [58, 59], although they <<<(c.181T>G>>> (BIC: 300T>G/C61G), c.5266dupC, c.1687C>T (BIC: 1806C>T)) represent common mutations prevalent in other European countries.|port, personal communication).  ### Slovenia  In Slovenia five highly recurrent specific mutations were identified: four in the BRCA1 gene (c.1687C>T,<<< c.181T>G>>>, c.5266dupC, c.181T> (BIC: 300T>A)) and one in the BRCA2 gene (c.7806-2A>G (BIC: IVS16-2A>G) [43, 61, 62]. Respectively, they accounted for 26%, 18%, 13% and 11% of BRCA1 mutations and 56% of BRCA2 mutations.|Eighteen BRCA1 mutations, including the most common c.5266dupC,<<< c.181T>G>>>, c.4065_4068del4 (BIC: 4184del4) and c.2338C>T (BIC: 2457C>T), were found at least 3 times and comprised 66% of all BRCA1 mutations.|The 2 most common BRCA1 c.5266dupC and<<< c.181T>G>>> mutations, also prevalent in other populations, accounted for 38% of BRCA1 mutations [4, 99].|c.9098dupA (BIC: 9326insA) were associated with common alleles, suggesting a possible founder effect [99].  ### Czech Republic  Five mutations (BRCA1:<<< c.181T>G>>>, c.5266dupC, c.3700_3704del5 (BIC: 3819del5), and BRCA2: c.7913_7917del5 (BIC: 8141del5) and c.8537_8538del2 (BIC: 8765delAG)) represented 52% of all mutations detected in one study population [52].|There is evident strong Slavic founder effect, particularly for two BRCA1 mutations <<<(c.181T>G>>> and c.5266dupC) also regarded as founder mutations in Poland and some other Slavic countries [100].|Three BRCA1 Czech founder mutations <<<(c.181T>G>>>, c.3700_3704del5, and c.5266dupC) account for approximately 9%, 13% and 44% of the BRCA1 mutations identified, respectively [51, 52].  BRCA1 mutation|trum in this population.  ### Hungary  In Hungarian patients from high-risk breast/ovarian cancer families, common BRCA1 founder mutations c.5266dupC,<<< c.181T>G>>> and c.68_69delAG accounted for 80% of all BRCA1 mutations and c.9098dupA (BIC: 9326insA) with c.5946delT accounted for 50% of all BRCA2 mutations [42, 103].|The BRCA1<<< c.181T>G>>> is the most frequent of founder mutations, representing 48% [103].|st cancer patients were more likely to carry the c.5266dupC mutation whereas ovarian patients were more likely to carry either the c.68_69delAG or the<<< c.181T>G>>> mutation [103].|ffect [153].  ### Poland  There is strong founder effect in Polish population for BRCA1 gene mutations. In Poland 3 most common mutations (c.5266dupC,<<< c.181T>G>>> and c.4035delA (BIC: 4154delA) accounted for 91% (111/122) BRCA1 mutations detected and for 86% of all detected mutations in BRCA1/2 genes [40, 100].|The BRCA1 c.5266dupC,<<< c.181T>G>>> and c.4035delA accounted for about 56%, 25% and 10% of all BRCA1 mutations, respectively.|In North- Eastern Poland two common mutations (c.5266dupC and<<< c.181T>G>>>) accounted for more than half (up to 70%) of all BRCA-mutated families and no c.4035delA was identified [156], what is in accordance with other studies [157].|The BRCA1<<< c.181T>G>>> is the third recurrent mutation in Latvia, but is not very commonly found.|Two other mutations, BRCA1<<< c.181T>G>>> and recently proved to be pathogenious c.5258G>C (BIC: 5377G>C/R1753T) were also found in more than one family; together with two founder mutations t|Other less common mutations found in Western Russia are c.4035delA,<<< c.181T>G>>>, and c.68_69delAG. In Siberian region of Russia there is seen preponderance of individual BRCA2 gene mutations [164].  ### Other countries  In some c|IC     HGVS     BIC      Ashkenazi Jews     c.68_69delAG     185delAG     c.5946delT     6174delT      c.5266dupC     5382insC            Austrian    <<< c.181T>G>>>     300T>G     c.8363G>A     8591G>A      c.5266dupC     5382insC     c.8754+1G>A     IVS21-1G>A      c.1687C>T     1806C>T     c.3860delA     4088de|.3016_3019del4     3135del4            c.2676_2679del4     2795del4            Slovenian     c.1687C>T     1806C>T     c.7806-2A>G     IVS16-2A>G     <<< c.181T>G>>>     300T>G            c.5266dupC     5382insC            c.181T>A     300T>A            Italian (Tuscany)     c.3228_3229delAG     3347delAG     c.85| 22 deletion (510-bp)            German     exon 17 deletion     c.1813dupA     2041insA      c.5266dupC     5382insC     c.4478del4     4706del4     <<< c.181T>G>>>     300T>G     c.9098dupA     9326insA      c.4065_4068del4     4184del4            c.2338C>T     2457C>T            Czech     c.181T>G     300T>G   | 4706del4      c.181T>G     300T>G     c.9098dupA     9326insA      c.4065_4068del4     4184del4            c.2338C>T     2457C>T            Czech    <<< c.181T>G>>>     300T>G     c.7913_7917del5     8141del5      c.5266dupC     5382insC     c.8537_8538del2     8765delAG      c.3700_3704del5     3819del5         |19del5            exons 1–17 deletion            exons 5–14 deletion            Hungarian     c.5266dupC     5382insC     c.9098dupA     9326insA     <<< c.181T>G>>>     300T>G     c.5946delT     6174delT      c.68_69delAG     185delAG            Greek     c.5266dupC     5382insC            c.5212G>A     5331G>A  |)     2157delG      exon 13 duplication (ins6kbEx13)            Irish     c.427G>T     546G>T            Polish     c.5266dupC     5382insC           <<< c.181T>G>>>     300T>G            c.4035delA     4154delA            Latvian     c.4035delA     4154delA            c.5266dupC     5382insC            Lithuanian|insC            Lithuanian     c.4035delA     4154delA            c.5266dupC     5382insC            Belarusian     c.5266dupC     5382insC           <<< c.181T>G>>>     300T>G            Russian     c.5266dupC     5382insC            Apparently true founder mutations are written in italic.		
23199084	confirmed					23199084		sub		NM_007294.3:c.181T>A|NM_007300.3:c.181T>A|NM_007299.3:c.181T>A|NM_007298.3:c.181T>A	NM_007294.3:c.412T>A|NM_007300.3:c.412T>A|NM_007299.3:c.374T>A|NM_007298.3:c.199T>A		rs28897672|rs28897672|rs28897672|rs28897672		 c.181T>A				BRCA1	entrez	672			dna	c.123T>A	42779	42788	4            Slovenian     c.1687C>T     1806C>T     c.7806-2A>G     IVS16-2A>G      c.181T>G     300T>G            c.5266dupC     5382insC           <<< c.181T>A>>>     300T>A            Italian (Tuscany)     c.3228_3229delAG     3347delAG     c.8537_8538delAG  (Sardinia)     8765delAG      c.3285delA     3404del		
23199084	notConfirmed							sub		c.8591G>A					8591G>A| 8591G>A				BRCA2	entrez	675			dna	859G>A|859G>A	12612,42433	12620,42441	The most prevalent BRCA2 mutations are c.8363G>A (BIC:<<< 8591G>A>>>/W2788X), c.8754+1G>A (BIC: IVS21-1G>A) and c.3860delA (BIC: 4088delA), representing 9%, 7% and 6% of the BRCA2 mutation families respectively (Rappap|s     c.68_69delAG     185delAG     c.5946delT     6174delT      c.5266dupC     5382insC            Austrian     c.181T>G     300T>G     c.8363G>A    <<< 8591G>A>>>      c.5266dupC     5382insC     c.8754+1G>A     IVS21-1G>A      c.1687C>T     1806C>T     c.3860delA     4088delA      c.3016_3019del4     3135del4 		
23199084	confirmed					23199084		sub		NM_007294.3:c.5153-1_5153G>A|NM_007300.3:c.5153-1_5153G>A	NM_007294.3:c.5384-1_5384G>A|NM_007300.3:c.5384-1_5384G>A		rs80357239|na		 c.5153-1G>A|c.5153-1G>A				BRCA1	entrez	672			dna	c.123+2A>T|c.123+2A>T	19240,43620	19252,43632	nd is the second recurrent pathological mutation in the BIC database ranking with a presumable multiple different origins [85, 86].  Splicing mutation<<< c.5153-1G>A>>> (BIC: 5272-1G>A) of BRCA1 and frameshift mutation c.5146_5149del4 (BIC: 5374delTATG) of BRCA2 are also prevalent founder mutations in the Central Spa|54-9258del5      c.5123C>A     5242C>A     c.9310_9311delAA     9538delAA      c.470_471delCT     589_590delCT     c.5146_5149del4     374delTATG     <<< c.5153-1G>A>>>     5272-1G>A            Portuguese           c.156_157insAlu     384insAlu      Belgian     c.212+3A>G     IVS5+3A>G     c.516+1G>A     IVS6+1G>A   		
23199084	confirmed					23199084		sub		NM_007294.3:c.427G>T|NM_007300.3:c.427G>T|NM_007299.3:c.427G>T|NM_007298.3:c.427G>T	NM_007294.3:c.658G>T|NM_007300.3:c.658G>T|NM_007299.3:c.620G>T|NM_007298.3:c.445G>T		rs80356991|rs80356991|rs80356991|rs80356991		c.427G>T| c.427G>T				BRCA1	entrez	672			dna	c.123T>A|c.123T>A	35713,46728	35722,46737	It is distributed mainly in English- speaking countries or in countries with historical links with Britain.  ### Ireland  A single BRCA1<<< c.427G>T>>> (BIC: 546G>T/E143X) mutation accounts for about 22% of all hereditary breast cancer patients from relatively homogenous Irish population and presumab|lTT      c.4065_4068del4 (North-West)     4184del4     c.1929delG (North-West)     2157delG      exon 13 duplication (ins6kbEx13)            Irish    <<< c.427G>T>>>     546G>T            Polish     c.5266dupC     5382insC            c.181T>G     300T>G            c.4035delA     4154delA            Latvian     c.4		
23199084	confirmed					23199084		del		NM_007294.3:c.6857delA	NM_007294.3:c.7088delA		na		 c.6857delA|c.6857delA				BRCA1	entrez	672			dna	c.123delT|c.123delT	17864,43404	17875,43415	lCT (BIC: 589_590delCT) account for 46.6% of BRCA1 mutations and four mutations in BRCA2 (c.2808_2811del4 (BIC: 3036_3039del4), c.6629_6630delAA (BIC:<<< c.6857delA>>>A), c.9026_9030del5 (BIC: 9254-9258del5), c.9310_9311delAA (BIC: 9538delAA)) account for 56.6% of the BRCA2 mutations [79].  Diez et al., [80] have re|panish     c.68_69delAG     185delAG     c.2808_2811del4 (Castilla-Leon)     3036_3039del4      c.211A>G (Galicia)     330A>G     c.6629_6630delAA    <<< c.6857delA>>>A      c.5117G>A     5236G>A     c.9026_9030del5     9254-9258del5      c.5123C>A     5242C>A     c.9310_9311delAA     9538delAA      c.470_471delCT  		
23199084	confirmed					23199084		del		NM_000059.3:c.6857delA	NM_000059.3:c.7083delA		na		 c.6857delA|c.6857delA				BRCA2	entrez	675			dna	c.123delT|c.123delT	17864,43404	17875,43415	lCT (BIC: 589_590delCT) account for 46.6% of BRCA1 mutations and four mutations in BRCA2 (c.2808_2811del4 (BIC: 3036_3039del4), c.6629_6630delAA (BIC:<<< c.6857delA>>>A), c.9026_9030del5 (BIC: 9254-9258del5), c.9310_9311delAA (BIC: 9538delAA)) account for 56.6% of the BRCA2 mutations [79].  Diez et al., [80] have re|panish     c.68_69delAG     185delAG     c.2808_2811del4 (Castilla-Leon)     3036_3039del4      c.211A>G (Galicia)     330A>G     c.6629_6630delAA    <<< c.6857delA>>>A      c.5117G>A     5236G>A     c.9026_9030del5     9254-9258del5      c.5123C>A     5242C>A     c.9310_9311delAA     9538delAA      c.470_471delCT  		
23199084	notConfirmed							del		c.4154A>None					 4154delA|4154delA				BRCA1	entrez	672			dna	6174delT|6174delT|6174delT|6174delT|6174delT	36078,37709,46851,46898,46983	36087,37718,46860,46907,46992	e is strong founder effect in Polish population for BRCA1 gene mutations. In Poland 3 most common mutations (c.5266dupC, c.181T>G and c.4035delA (BIC:<<< 4154delA>>>) accounted for 91% (111/122) BRCA1 mutations detected and for 86% of all detected mutations in BRCA1/2 genes [40, 100].|The<<< 4154delA>>> mutation is the second most abundant BRCA1 gene mutation after the c.5266dupC in Latvia [50] and is especially common for patients of Baltic (Latvian and Lithuanian) origin.|bEx13)            Irish     c.427G>T     546G>T            Polish     c.5266dupC     5382insC            c.181T>G     300T>G            c.4035delA    <<< 4154delA>>>            Latvian     c.4035delA     4154delA            c.5266dupC     5382insC            Lithuanian     c.4035delA     4154delA            c.5266|            Polish     c.5266dupC     5382insC            c.181T>G     300T>G            c.4035delA     4154delA            Latvian     c.4035delA    <<< 4154delA>>>            c.5266dupC     5382insC            Lithuanian     c.4035delA     4154delA            c.5266dupC     5382insC            Belarusian     c.5|    c.4035delA     4154delA            Latvian     c.4035delA     4154delA            c.5266dupC     5382insC            Lithuanian     c.4035delA    <<< 4154delA>>>            c.5266dupC     5382insC            Belarusian     c.5266dupC     5382insC            c.181T>G     300T>G            Russian     c.5266dupC     5382insC            Apparently true founder mutations are written in italic.		
23199084	confirmed					23199084		del		NM_000059.3:c.1929delG	NM_000059.3:c.2155delG		rs80359316		 c.1929delG|c.1929delG				BRCA2	entrez	675			dna	c.123delT|c.123delT	35059,46632	35070,46643	 in Dutch, Swedish, Danish and Belgian families (BIC database).  In the North-west of England two reccurent mutations (BRCA1 c.4065_4068del4 and BRCA2<<< c.1929delG>>> (BIC: 2157delG) accounted for 16% of identified BRCA1 mutations in breast/ovarian cancer families and for 20% of BRCA2 positive male breast cancer fa|British     c.2681_2682delAA (Scotland)     2800delAA     c.6275_6276delTT (Scotland)     6503delTT      c.4065_4068del4 (North-West)     4184del4    <<< c.1929delG>>> (North-West)     2157delG      exon 13 duplication (ins6kbEx13)            Irish     c.427G>T     546G>T            Polish     c.5266dupC     5382ins		
23199084	confirmed					23199084		del		NM_007294.3:c.697delG|NM_007300.3:c.697delG|NM_007299.3:c.697delG|NM_007298.3:c.697delG|NM_007297.3:c.697delG	NM_007294.3:c.928delG|NM_007300.3:c.928delG|NM_007299.3:c.890delG|NM_007298.3:c.715delG|NM_007297.3:c.977delG		na|na|na|na|na		c.697delG| c.697delG				BRCA1	entrez	672			dna	c.123delT|c.123delT	31085,45709	31095,45719	ncer in this region [115, 125].  ### Norway  Four Norwegian founder mutations in BRCA1 gene (c.1556delA (BIC: 1675delA), c.3228delAG (BIC: 3347delAG),<<< c.697delG>>>T (BIC: 816delGT) and c.1016dupA make up 68% of the BRCA1 mutation carriers [126, 127], and these have their own specific geographic distribution.|kbEx13)            Norwegian     c.1556delA     1675delA     c.2808del4     3036del4      c.3228delAG     3347delAG     c.3847delGT     4075delGT     <<< c.697delG>>>T     816delGT            c.1016dupA     1135insA            c.3178G>T     3297G>T            c.4745delA     4864delA            c.2351del7     2470de		
23199084	confirmed					23199084		sub		NM_000059.3:c.9117+1_9117G>A	NM_000059.3:c.9343+1_9343G>A		rs81002802		c.9117+1G>A| c.9117+1G>A				BRCA2	entrez	675			dna	c.123+2A>T|c.123+2A>T	33192,46330	33204,46342	Some mutations are unique to the Finns, such as c.4096+3A>G (BIC: IVS11+3A>G) in BRCA1 and<<< c.9117+1G>A>>> (BIC: 9345+1G>A), c.7480C>T, c.8327T>G in BRCA2 genes.  The mutation spectrum in Eastern part slightly differs from those observed in the Northern an|8C>T      c.3626delT     3745delT     c.8327T>G     8555T>G      c.4327C>T     4446C>T     c.9118-2A>G     9346-2A>G      c.2684del2     2803delAA    <<< c.9117+1G>A>>>     9345+1G>A      c.5251C>T     5370C>T            c.4096+3A>G     IVS11+3A>G            Iceland           c.771_775del5     999del5      British   		
23199084	confirmed					23199084		sub		NM_007300.3:c.5247G>T	NM_007300.3:c.5478G>T		na		5247G>T| 5247G>T				BRCA1	entrez	672			dna	859G>A|859G>A	15631,43233	15639,43241	The c.3481_3491del11 (BIC: 3600del11) in exon 11 accounts for 37% and the nonsense mutation c.5128G>T (BIC:<<< 5247G>T>>>/Gly1710X) in exon 18 for 15% of all BRCA1/2 mutations in that region (overall 52%) [4, 75].  The haplotype analysis of the families carrying the muta|          Italian (North-East)     c.5062_5064delGTT     5181_5183delGTT            French     c.3481_3491del11     3600del11            c.5128G>T    <<< 5247G>T>>>            Spanish     c.68_69delAG     185delAG     c.2808_2811del4 (Castilla-Leon)     3036_3039del4      c.211A>G (Galicia)     330A>G     c.6629_		
23199084	notConfirmed							sub		c.300T>A					 300T>A|300T>A				BRCA2	entrez	675			dna	859G>A|859G>A	12955,42792	12962,42799	Slovenia  In Slovenia five highly recurrent specific mutations were identified: four in the BRCA1 gene (c.1687C>T, c.181T>G, c.5266dupC, c.181T> (BIC:<<< 300T>A>>>)) and one in the BRCA2 gene (c.7806-2A>G (BIC: IVS16-2A>G) [43, 61, 62]. Respectively, they accounted for 26%, 18%, 13% and 11% of BRCA1 mutations and 56% of BRCA2 mutations.|Slovenian     c.1687C>T     1806C>T     c.7806-2A>G     IVS16-2A>G      c.181T>G     300T>G            c.5266dupC     5382insC            c.181T>A    <<< 300T>A>>>            Italian (Tuscany)     c.3228_3229delAG     3347delAG     c.8537_8538delAG  (Sardinia)     8765delAG      c.3285delA     3404delA          		
23199084	confirmed					23199084		del		NM_007294.3:c.4745delA|NM_007297.3:c.4745delA	NM_007294.3:c.4976delA|NM_007297.3:c.5025delA		rs80357907|na		c.4745delA| c.4745delA				BRCA1	entrez	672			dna	c.123delT|c.123delT	31480,45812	31491,45823	h is from the south-east [127].  These four founder mutations together with other six most frequent BRCA1/2 mutations (BRCA1 c.3178G>T (BIC: 3297G>T),<<< c.4745delA>>> (BIC: 4864delA), c.2351del7 (BIC: 2470del7), c.3084del11 (BIC: 3203del11) and BRCA2 c.2808del4 (BIC: 3036del4), c.3847delGT (BIC: 4075delGT)), account for about 60% BRCA1/2 carriers in Norway [128].|   3347delAG     c.3847delGT     4075delGT      c.697delGT     816delGT            c.1016dupA     1135insA            c.3178G>T     3297G>T           <<< c.4745delA>>>     4864delA            c.2351del7     2470del7            c.3084del11     3203del11            c.1A>C     120A>C            c.5075-2A>C     IVS17-2A		
23199084	confirmed					23199084		sub		NM_007297.3:c.5377G>C	NM_007297.3:c.5657G>C		na		 5377G>C				BRCA1	entrez	672			dna	859G>A	38736	38744	Two other mutations, BRCA1 c.181T>G and recently proved to be pathogenious c.5258G>C (BIC:<<< 5377G>C>>>/R1753T) were also found in more than one family; together with two founder mutations they comprise around 90% of BRCA1 gene mutations and around 85% of all BRCA1/2 mutations identified (Janavičius, unpublished data).		
23199084	confirmed					23199084		del		NM_007294.3:c.1556delA|NM_007300.3:c.1556delA|NM_007297.3:c.1556delA	NM_007294.3:c.1787delA|NM_007300.3:c.1787delA|NM_007297.3:c.1836delA		rs80357662|rs80357662|na		c.1556delA| c.1556delA				BRCA1	entrez	672			dna	c.123delT|c.123delT	31027,45591	31038,45602	han 80% of excess number of ovarian cancer after breast cancer in this region [115, 125].  ### Norway  Four Norwegian founder mutations in BRCA1 gene <<<(c.1556delA>>> (BIC: 1675delA), c.3228delAG (BIC: 3347delAG), c.697delGT (BIC: 816delGT) and c.1016dupA make up 68% of the BRCA1 mutation carriers [126, 127], and these have their own specific geographic distribution.|            c.3626delT (Northern)     3745delT            c.1016dupA     1135insA            exon 13 duplication (ins6kbEx13)            Norwegian    <<< c.1556delA>>>     1675delA     c.2808del4     3036del4      c.3228delAG     3347delAG     c.3847delGT     4075delGT      c.697delGT     816delGT            c.1016d		
23199084	confirmed					23199084		sub		NM_007294.3:c.3178G>T|NM_007300.3:c.3178G>T|NM_007297.3:c.3178G>T	NM_007294.3:c.3409G>T|NM_007300.3:c.3409G>T|NM_007297.3:c.3458G>T		rs80357424|rs80357424|rs80357106		c.3178G>T| c.3178G>T				BRCA1	entrez	672			dna	c.123T>A|c.123T>A	31454,45779	31464,45789	e country, while the fourth is from the south-east [127].  These four founder mutations together with other six most frequent BRCA1/2 mutations (BRCA1<<< c.3178G>T>>> (BIC: 3297G>T), c.4745delA (BIC: 4864delA), c.2351del7 (BIC: 2470del7), c.3084del11 (BIC: 3203del11) and BRCA2 c.2808del4 (BIC: 3036del4), c.3847delGT (BIC: 4075delGT)), account for about 60% BRCA1/2 carriers in Norway [128].|4     3036del4      c.3228delAG     3347delAG     c.3847delGT     4075delGT      c.697delGT     816delGT            c.1016dupA     1135insA           <<< c.3178G>T>>>     3297G>T            c.4745delA     4864delA            c.2351del7     2470del7            c.3084del11     3203del11            c.1A>C     120A>C  		
23199084	notConfirmed							sub		c.234T>G					c.234T>G				BRCA1	entrez	672			dna	c.123T>A	28880	28889	etion represents Danish founder mutation, comprising 40% (6/15) of all BRCA1/2 families with LGRs [112].  Recently a pathogenic founder BRCA1 mutation<<< c.234T>G>>> (BIC: 2466T>G/Cys39Gly) was desribed in Greenland (Inuit population), an autonomous country within the Kingdom of Denmark, with a high carrier frequency (1.6%) in this population [113, 114].		
23199084	notConfirmed							sub		c.330A>G					 330A>G|330A>G				BRCA1	entrez	672			dna	859G>A|859G>A	17641,43372	17648,43379	istribution.  A compilation of BRCA test results from different laboratories shows that five mutations in the BRCA1 gene (c.68_69delAG, c.211A>G (BIC:<<< 330A>G>>>), c.5117G>A (BIC: 5236G>A), c.5123C>A (BIC: 5242C>A), c.470_471delCT (BIC: 589_590delCT) account for 46.6% of BRCA1 mutations and four mutations in B|5128G>T     5247G>T            Spanish     c.68_69delAG     185delAG     c.2808_2811del4 (Castilla-Leon)     3036_3039del4      c.211A>G (Galicia)    <<< 330A>G>>>     c.6629_6630delAA     c.6857delAA      c.5117G>A     5236G>A     c.9026_9030del5     9254-9258del5      c.5123C>A     5242C>A     c.9310_9311delAA		
23199084	notConfirmed							sub		c.4096+3A>G					c.4096+3A>G| c.4096+3A>G				BRCA1	entrez	672			dna	c.123+2A>T|c.123+2A>T	33149,46394	33161,46406	Some mutations are unique to the Finns, such as<<< c.4096+3A>G>>> (BIC: IVS11+3A>G) in BRCA1 and c.9117+1G>A (BIC: 9345+1G>A), c.7480C>T, c.8327T>G in BRCA2 genes.  The mutation spectrum in Eastern part slightly dif| c.4327C>T     4446C>T     c.9118-2A>G     9346-2A>G      c.2684del2     2803delAA     c.9117+1G>A     9345+1G>A      c.5251C>T     5370C>T           <<< c.4096+3A>G>>>     IVS11+3A>G            Iceland           c.771_775del5     999del5      British     c.2681_2682delAA (Scotland)     2800delAA     c.6275_6276delTT		
23199084	notConfirmed							sub		c.7708C>T					7708C>T| 7708C>T				BRCA2	entrez	675			dna	859G>A|859G>A	32933,46176	32941,46184	atively frequently.  The most recurrent mutation in BRCA2 is the Icelandic founder mutation c.771_775del5 (BIC: 999del5), three other (c.7480C>T (BIC:<<< 7708C>T>>>), c.8327T>G (BIC: 8555T>G), c.9118-2A>G (BIC: 9346-2A>G) and following (c. 6384del2 (BIC: 6503delTT), c.3853dupA (BIC: 4081insA) and c.5569G>T (BIC: 5797G>T)).|duplication (ins6kbEx13)            Finnish     c.4097-2A>G     4216-2A>G     c.771_775del5     999del5      c.3485delA     3604delA     c.7480C>T    <<< 7708C>T>>>      c.3626delT     3745delT     c.8327T>G     8555T>G      c.4327C>T     4446C>T     c.9118-2A>G     9346-2A>G      c.2684del2     2803delAA     c.9		
23199084	notConfirmed							sub		c.9118-2A>G					 c.9118-2A>G|c.9118-2A>G				BRCA2	entrez	675			dna	c.123+2A>T|c.123+2A>T	32969,46270	32981,46282	ent mutation in BRCA2 is the Icelandic founder mutation c.771_775del5 (BIC: 999del5), three other (c.7480C>T (BIC: 7708C>T), c.8327T>G (BIC: 8555T>G),<<< c.9118-2A>G>>> (BIC: 9346-2A>G) and following (c. 6384del2 (BIC: 6503delTT), c.3853dupA (BIC: 4081insA) and c.5569G>T (BIC: 5797G>T)).|  999del5      c.3485delA     3604delA     c.7480C>T     7708C>T      c.3626delT     3745delT     c.8327T>G     8555T>G      c.4327C>T     4446C>T    <<< c.9118-2A>G>>>     9346-2A>G      c.2684del2     2803delAA     c.9117+1G>A     9345+1G>A      c.5251C>T     5370C>T            c.4096+3A>G     IVS11+3A>G           		
23199084	confirmed					23199084		del		NM_007294.3:c.2475delC|NM_007300.3:c.2475delC|NM_007299.3:c.2475delC|NM_007298.3:c.2475delC	NM_007294.3:c.2706delC|NM_007300.3:c.2706delC|NM_007299.3:c.2668delC|NM_007298.3:c.2493delC		rs80357970|rs80357970|na|na		c.2475delC| c.2475delC				BRCA1	entrez	672			dna	c.123delT|c.123delT|c.123delT|c.123delT|c.123delT|c.123delT	27539,27733,29758,30662,44995,45342	27550,27744,29769,30673,45006,45353	Denmark are a mixture of Scandinavian founder mutations and other European mutations, including BRCA1 c.5266dupC. The most common BRCA1 mutations were<<< c.2475delC>>> (BIC: 2594delC), c.3319G>T (BIC: 3438G>T), c.5266dupC and c.3710delT (BIC: 3829delT), which accounted 16%, 9%, 8% and 5% of BRCA1 positive families, | 3438G>T), c.5266dupC and c.3710delT (BIC: 3829delT), which accounted 16%, 9%, 8% and 5% of BRCA1 positive families, respectively [109, 110, 111]. The<<< c.2475delC>>> BRCA1 mutation was also reported in Sweden, Norway and Western Europe (BIC database) and the c.3319G>T BRCA1 mutation was also reported in Norway (ht|Other common BRCA1 mutations in Sweden,<<< c.2475delC>>> and c.1082_1092del11 (BIC: 1201del11), have been detected primarily in families from southern Sweden [118, 119, 120], Denmark and Norway (BIC database).|n the Western Sweden, six mutations, including the most common BRCA1 c.3171_3175dup, four other common Scandinavian BCRA1 mutations (c.1082_1092del11,<<< c.2475delC>>>, c.1687C>T, c.1016dupA (BIC: 1135insA)) and one BRCA2 mutation (c.4258delG) accounted for approximately 75% of all BRCA1/2 mutations [124].|G>A     5331G>A            c.5251C>T     5370C>T            c.5467G>A     5586G>A            Cypriot           c.8755delG     8984delG      Danish    <<< c.2475delC>>>     2594delC     c.6373delA     6601delA      c.3319G>T     3438G>T     c.1310_1013del4     1538del4      c.5266dupC     5382insC     c.6486_6489del4|29delT     c.3847_3848delGT     4075delGT      exons 3-16 deletion            Swedish     c.3171_3175dup     3171ins5     c.4258delG     4486delG     <<< c.2475delC>>>     2594delC            c.1082_1092del11     1201del11            c.1687C>T     1806C>T            c.3626delT (Northern)     3745delT            c.10		
23199084	confirmed					23199084		dup		NM_007294.3:c.1380dupA|NM_007300.3:c.1380dupA|NM_007297.3:c.1380dupA	NM_007294.3:c.1611dupA|NM_007300.3:c.1611dupA|NM_007297.3:c.1660dupA		rs397508863|rs397508863|na		c.1380dupA| c.1380dupA				BRCA1	entrez	672			dna	c.123dupA|c.123dupA|c.123dupA	13683,13916,42950	13694,13927,42961	emonstrated for few mutations [63, 64, 65, 66].  Four distinct BRCA1 founder mutations (c.3228_3229delAG (BIC: 3347delAG), c.3285delA (BIC: 3404delA),<<< c.1380dupA>>> (BIC: 1499insA), c.5062_5064del3 (BIC: 5181delGTT) accounted for a large fraction (73%) of BRCA1-attributable hereditary breast/ovarian cancer in fam|e fraction (73%) of BRCA1-attributable hereditary breast/ovarian cancer in families originating from Tuscany (Central Italy) area [47, 66].  The BRCA1<<< c.1380dupA>>> mutation was reported in at least 14 families from Tuscany and originated here about 30 generations ago (∼750 years) [65].  In Sardinia, contribution|           Italian (Tuscany)     c.3228_3229delAG     3347delAG     c.8537_8538delAG  (Sardinia)     8765delAG      c.3285delA     3404delA           <<< c.1380dupA>>>     1499insA            c.5062_5064del3     5181delGTT            Italian (Calabria)     c.4964_4982del19     5083del19            Italian (North-Eas		
23199084	notConfirmed							sub		c.7806-2A>G					c.7806-2A>G| c.7806-2A>G				BRCA2	entrez	675			dna	c.123+2A>T|c.123+2A>T|c.123+2A>T	12991,13141,42681	13003,13153,42693	current specific mutations were identified: four in the BRCA1 gene (c.1687C>T, c.181T>G, c.5266dupC, c.181T> (BIC: 300T>A)) and one in the BRCA2 gene <<<(c.7806-2A>G>>> (BIC: IVS16-2A>G) [43, 61, 62]. Respectively, they accounted for 26%, 18%, 13% and 11% of BRCA1 mutations and 56% of BRCA2 mutations.|The<<< c.7806-2A>G>>> in the BRCA2 gene appears to be an unique founder mutation in the Slovenian population, found in 26% (10/38) of all BRCA1/2 mutations harboring families.|  c.3860delA     4088delA      c.3016_3019del4     3135del4            c.2676_2679del4     2795del4            Slovenian     c.1687C>T     1806C>T    <<< c.7806-2A>G>>>     IVS16-2A>G      c.181T>G     300T>G            c.5266dupC     5382insC            c.181T>A     300T>A            Italian (Tuscany)     c.3228_322		
23199084	notConfirmed							del		c.9538A>None					 9538delA|9538delA				BRCA2	entrez	675			dna	6174delT|6174delT	17939,43533	17948,43542	ions in BRCA2 (c.2808_2811del4 (BIC: 3036_3039del4), c.6629_6630delAA (BIC: c.6857delAA), c.9026_9030del5 (BIC: 9254-9258del5), c.9310_9311delAA (BIC:<<< 9538delA>>>A)) account for 56.6% of the BRCA2 mutations [79].  Diez et al., [80] have reviewed the frequency of BRCA1 and BRCA2 recurrent mutations reported in s| c.6629_6630delAA     c.6857delAA      c.5117G>A     5236G>A     c.9026_9030del5     9254-9258del5      c.5123C>A     5242C>A     c.9310_9311delAA    <<< 9538delA>>>A      c.470_471delCT     589_590delCT     c.5146_5149del4     374delTATG      c.5153-1G>A     5272-1G>A            Portuguese           c.156_157insA		
23199084	confirmed					23199084		del		NM_007299.3:c.1675delA|NM_007298.3:c.1675delA	NM_007299.3:c.1868delA|NM_007298.3:c.1693delA		rs80357117|rs80357117		1675delA| 1675delA				BRCA1	entrez	672			dna	6174delT|6174delT	31044,45606	31053,45615	 number of ovarian cancer after breast cancer in this region [115, 125].  ### Norway  Four Norwegian founder mutations in BRCA1 gene (c.1556delA (BIC:<<< 1675delA>>>), c.3228delAG (BIC: 3347delAG), c.697delGT (BIC: 816delGT) and c.1016dupA make up 68% of the BRCA1 mutation carriers [126, 127], and these have their own specific geographic distribution.|626delT (Northern)     3745delT            c.1016dupA     1135insA            exon 13 duplication (ins6kbEx13)            Norwegian     c.1556delA    <<< 1675delA>>>     c.2808del4     3036del4      c.3228delAG     3347delAG     c.3847delGT     4075delGT      c.697delGT     816delGT            c.1016dupA     1135i		
23199084	confirmed					23199084		sub		NM_007297.3:c.5242C>A	NM_007297.3:c.5522C>A		na		5242C>A| 5242C>A				BRCA1	entrez	672			dna	859G>A|859G>A	17692,43500	17700,43508	om different laboratories shows that five mutations in the BRCA1 gene (c.68_69delAG, c.211A>G (BIC: 330A>G), c.5117G>A (BIC: 5236G>A), c.5123C>A (BIC:<<< 5242C>A>>>), c.470_471delCT (BIC: 589_590delCT) account for 46.6% of BRCA1 mutations and four mutations in BRCA2 (c.2808_2811del4 (BIC: 3036_3039del4), c.6629_6|c.211A>G (Galicia)     330A>G     c.6629_6630delAA     c.6857delAA      c.5117G>A     5236G>A     c.9026_9030del5     9254-9258del5      c.5123C>A    <<< 5242C>A>>>     c.9310_9311delAA     9538delAA      c.470_471delCT     589_590delCT     c.5146_5149del4     374delTATG      c.5153-1G>A     5272-1G>A            		
23199084	confirmed					23199084		del		NM_007294.3:c.5030_5033delCTAA	NM_007294.3:c.5261_5264delCTAA		rs80357862		c.5030_5033delCTAA				BRCA1	entrez	672			dna	c.123_125delAT	16196	16215	5128G>T would appear to be specific to the France, but the analysis of its haplotype is less conclusive and needs further confirmation [6].  The BRCA1<<< c.5030_5033delCTAA>>> (BIC: 5149delCTAA) [76] and c.3839_3843delinsAGGC (BIC: 3958delCTCAGinsAGGC) [77] mutations were reported in at least three independent families from		
23199084	confirmed					23199084		sub		NM_007300.3:c.5236G>A	NM_007300.3:c.5467G>A		rs80357291		 5236G>A|5236G>A				BRCA1	entrez	672			dna	859G>A|859G>A	17666,43435	17674,43443	on of BRCA test results from different laboratories shows that five mutations in the BRCA1 gene (c.68_69delAG, c.211A>G (BIC: 330A>G), c.5117G>A (BIC:<<< 5236G>A>>>), c.5123C>A (BIC: 5242C>A), c.470_471delCT (BIC: 589_590delCT) account for 46.6% of BRCA1 mutations and four mutations in BRCA2 (c.2808_2811del4 (BIC|delAG     c.2808_2811del4 (Castilla-Leon)     3036_3039del4      c.211A>G (Galicia)     330A>G     c.6629_6630delAA     c.6857delAA      c.5117G>A    <<< 5236G>A>>>     c.9026_9030del5     9254-9258del5      c.5123C>A     5242C>A     c.9310_9311delAA     9538delAA      c.470_471delCT     589_590delCT     c.5146_5		
23199084	confirmed					23199084		del		NM_000059.3:c.4258delG	NM_000059.3:c.4484delG		rs28897727		 c.4258delG|c.4258delG				BRCA2	entrez	675			dna	c.123delT|c.123delT|c.123delT	30416,30737,45313	30427,30748,45324	5ins6000(dup_ex13) mutation, is quite common in Sweden and is apparently specific to English-speaking and related countries [122].  One BRCA2 mutation<<< c.4258delG>>> (BIC: 4486delG) is found repeatedly in Swedish breast cancer families [120, 123].  In the Western Sweden, six mutations, including the most common BR|_3175dup, four other common Scandinavian BCRA1 mutations (c.1082_1092del11, c.2475delC, c.1687C>T, c.1016dupA (BIC: 1135insA)) and one BRCA2 mutation <<<(c.4258delG>>>) accounted for approximately 75% of all BRCA1/2 mutations [124].|14del4      c.3710delT     3829delT     c.3847_3848delGT     4075delGT      exons 3-16 deletion            Swedish     c.3171_3175dup     3171ins5    <<< c.4258delG>>>     4486delG      c.2475delC     2594delC            c.1082_1092del11     1201del11            c.1687C>T     1806C>T            c.3626delT (Northern)		
23199084	confirmed					23199084		del		NM_007297.3:c.4088delA	NM_007297.3:c.4368delA		na		4088delA| 4088delA				BRCA1	entrez	672			dna	6174delT|6174delT	12680,42547	12689,42556	The most prevalent BRCA2 mutations are c.8363G>A (BIC: 8591G>A/W2788X), c.8754+1G>A (BIC: IVS21-1G>A) and c.3860delA (BIC:<<< 4088delA>>>), representing 9%, 7% and 6% of the BRCA2 mutation families respectively (Rappaport, personal communication).  ### Slovenia  In Slovenia five highly |.181T>G     300T>G     c.8363G>A     8591G>A      c.5266dupC     5382insC     c.8754+1G>A     IVS21-1G>A      c.1687C>T     1806C>T     c.3860delA    <<< 4088delA>>>      c.3016_3019del4     3135del4            c.2676_2679del4     2795del4            Slovenian     c.1687C>T     1806C>T     c.7806-2A>G     IVS16-2A		
23199084	confirmed					23199084		del		NM_000059.3:c.4088delA	NM_000059.3:c.4314delA		na		4088delA| 4088delA				BRCA2	entrez	675			dna	6174delT|6174delT	12680,42547	12689,42556	The most prevalent BRCA2 mutations are c.8363G>A (BIC: 8591G>A/W2788X), c.8754+1G>A (BIC: IVS21-1G>A) and c.3860delA (BIC:<<< 4088delA>>>), representing 9%, 7% and 6% of the BRCA2 mutation families respectively (Rappaport, personal communication).  ### Slovenia  In Slovenia five highly |.181T>G     300T>G     c.8363G>A     8591G>A      c.5266dupC     5382insC     c.8754+1G>A     IVS21-1G>A      c.1687C>T     1806C>T     c.3860delA    <<< 4088delA>>>      c.3016_3019del4     3135del4            c.2676_2679del4     2795del4            Slovenian     c.1687C>T     1806C>T     c.7806-2A>G     IVS16-2A		
23199084	confirmed					23199084		del		NM_007294.3:c.3285delA|NM_007300.3:c.3285delA|NM_007299.3:c.3285delA|NM_007298.3:c.3285delA|NM_007297.3:c.3285delA	NM_007294.3:c.3516delA|NM_007300.3:c.3516delA|NM_007299.3:c.3478delA|NM_007298.3:c.3303delA|NM_007297.3:c.3565delA		rs397509051|rs397509051|na|na|rs80356843		 c.3285delA				BRCA1	entrez	672			dna	c.123delT|c.123delT	13655,42915	13666,42926	al founder effect has been demonstrated for few mutations [63, 64, 65, 66].  Four distinct BRCA1 founder mutations (c.3228_3229delAG (BIC: 3347delAG),<<< c.3285delA>>> (BIC: 3404delA), c.1380dupA (BIC: 1499insA), c.5062_5064del3 (BIC: 5181delGTT) accounted for a large fraction (73%) of BRCA1-attributable hereditary |nsC            c.181T>A     300T>A            Italian (Tuscany)     c.3228_3229delAG     3347delAG     c.8537_8538delAG  (Sardinia)     8765delAG     <<< c.3285delA>>>     3404delA            c.1380dupA     1499insA            c.5062_5064del3     5181delGTT            Italian (Calabria)     c.4964_4982del19     5083		
23199084	confirmed					23199084		sub		NM_007294.3:c.4327C>T|NM_007300.3:c.4327C>T	NM_007294.3:c.4558C>T|NM_007300.3:c.4558C>T		rs41293455|rs41293455		 c.4327C>T|c.4327C>T				BRCA1	entrez	672			dna	c.123T>A|c.123T>A|c.123T>A|c.123T>A	16574,17072,32666,46244	16584,17082,32676,46254	In this region 4 BRCA1 gene mutations <<<(c.4327C>T>>> (BIC: 4446C>T/Arg1443X), c.3756_3759del4 (BIC: 3875delGTCT), c.962G>A (BIC: 1081G>A), c.2834_2836delinsC (BIC: 2953delGTA/insC) and 3 BRCA2 mutations|Among these, the most common founder mutations are BRCA1<<< c.4327C>T>>> and BRCA2 c.8537_8538delAG and c.3170_3174del5, which are found in 1.7% of women affected by breast cancer diagnosed before age 41 and in 1.3% of wom|The most common BRCA1 mutations are c.4097-2A>G (BIC: 4216-2A>G), c.3485delA (BIC: 3604delA), c.3626delT (BIC: 3745delT),<<< c.4327C>T>>> (BIC: 4446C>T), c.2684del2 (BIC: 2803delAA) and c.5251C>T (BIC: 5370C>T).|-2A>G     c.771_775del5     999del5      c.3485delA     3604delA     c.7480C>T     7708C>T      c.3626delT     3745delT     c.8327T>G     8555T>G     <<< c.4327C>T>>>     4446C>T     c.9118-2A>G     9346-2A>G      c.2684del2     2803delAA     c.9117+1G>A     9345+1G>A      c.5251C>T     5370C>T            c.4096+3A		
23199084	confirmed					23199084		sub		NM_000059.3:c.6085G>T	NM_000059.3:c.6311G>T		rs397507828		6085G>T				BRCA2	entrez	675			dna	859G>A	16784	16792	75delGTCT), c.962G>A (BIC: 1081G>A), c.2834_2836delinsC (BIC: 2953delGTA/insC) and 3 BRCA2 mutations (c.3170_3174del5 (BIC: 3398del5), c.5857G>T (BIC:<<< 6085G>T>>>), c.8537_8538delAG (BIC: 8765delAG)) are now routinely included in early onset breast/ovarian cancer screening assays and represent up to 84% of the total BRCA1/2 mutations in the French-Canadian population in Quebec [78].		
23199084	confirmed					23199084		sub		NM_000059.3:c.212+3_212A>G	NM_000059.3:c.438+3_438A>G		rs276174818		 c.212+3A>G|c.212+3A>G				BRCA2	entrez	675			dna	c.123+2A>T|c.123+2A>T	20658,43725	20669,43736	A), c.6275_6276delTT (BIC: 6503_6504delTT), c.8904delC (BIC: 9132delC) alterations), which accounted for nearly 60% of all mutations identified. BRCA1<<< c.212+3A>G>>> was previously reported as Belgian founder mutation [92, 93], later also found in a few German, Dutch and French families [91].|delCT     c.5146_5149del4     374delTATG      c.5153-1G>A     5272-1G>A            Portuguese           c.156_157insAlu     384insAlu      Belgian    <<< c.212+3A>G>>>     IVS5+3A>G     c.516+1G>A     IVS6+1G>A      c.2359dupG     2478insG     c.6275_6276delTT     6503_6504delTT      c.3661G>T     3780G>T     c.8904		
23199084	confirmed					23199084		sub		NM_007294.3:c.5074G>A|NM_007297.3:c.5074G>A	NM_007294.3:c.5305G>A|NM_007297.3:c.5354G>A		rs80187739|rs80357283		c.5074G>A				BRCA1	entrez	672			dna	c.123T>A	33940	33950	 population, 8.5% of consecutive unselected breast cancer cases, 7.9% of ovarian cancer cases and 40% of male breast cancer cases [6, 146].  The BRCA1<<< c.5074G>A>>> (BIC: 5193G>A) is another founder mutation recently identified in Icelandic population, however it is extremely rare and contributes only to 1% of br		
23199084	confirmed					23199084		del		NM_007294.3:c.4864delA|NM_007300.3:c.4864delA	NM_007294.3:c.5095delA|NM_007300.3:c.5095delA		na|rs80357303		 4864delA|4864delA				BRCA1	entrez	672			dna	6174delT|6174delT	31497,45827	31506,45836	th-east [127].  These four founder mutations together with other six most frequent BRCA1/2 mutations (BRCA1 c.3178G>T (BIC: 3297G>T), c.4745delA (BIC:<<< 4864delA>>>), c.2351del7 (BIC: 2470del7), c.3084del11 (BIC: 3203del11) and BRCA2 c.2808del4 (BIC: 3036del4), c.3847delGT (BIC: 4075delGT)), account for about 60% BRCA1/2 carriers in Norway [128].|  c.3847delGT     4075delGT      c.697delGT     816delGT            c.1016dupA     1135insA            c.3178G>T     3297G>T            c.4745delA    <<< 4864delA>>>            c.2351del7     2470del7            c.3084del11     3203del11            c.1A>C     120A>C            c.5075-2A>C     IVS17-2A>C           		
23199084	confirmed					23199084		del		NM_000059.3:c.4864delA	NM_000059.3:c.5090delA		na		 4864delA|4864delA				BRCA2	entrez	675			dna	6174delT|6174delT	31497,45827	31506,45836	th-east [127].  These four founder mutations together with other six most frequent BRCA1/2 mutations (BRCA1 c.3178G>T (BIC: 3297G>T), c.4745delA (BIC:<<< 4864delA>>>), c.2351del7 (BIC: 2470del7), c.3084del11 (BIC: 3203del11) and BRCA2 c.2808del4 (BIC: 3036del4), c.3847delGT (BIC: 4075delGT)), account for about 60% BRCA1/2 carriers in Norway [128].|  c.3847delGT     4075delGT      c.697delGT     816delGT            c.1016dupA     1135insA            c.3178G>T     3297G>T            c.4745delA    <<< 4864delA>>>            c.2351del7     2470del7            c.3084del11     3203del11            c.1A>C     120A>C            c.5075-2A>C     IVS17-2A>C           		
23199084	confirmed					23199084		sub		NM_007294.3:c.546G>T|NM_007300.3:c.546G>T|NM_007299.3:c.546G>T|NM_007298.3:c.546G>T	NM_007294.3:c.777G>T|NM_007300.3:c.777G>T|NM_007299.3:c.739G>T|NM_007298.3:c.564G>T		na|na|na|na		546G>T| 546G>T				BRCA1	entrez	672			dna	859G>A|859G>A	35728,46741	35735,46748	t is distributed mainly in English- speaking countries or in countries with historical links with Britain.  ### Ireland  A single BRCA1 c.427G>T (BIC:<<< 546G>T>>>/E143X) mutation accounts for about 22% of all hereditary breast cancer patients from relatively homogenous Irish population and presumably is due to |65_4068del4 (North-West)     4184del4     c.1929delG (North-West)     2157delG      exon 13 duplication (ins6kbEx13)            Irish     c.427G>T    <<< 546G>T>>>            Polish     c.5266dupC     5382insC            c.181T>G     300T>G            c.4035delA     4154delA            Latvian     c.4035delA    		
23199084	confirmed					23199084		sub		NM_007294.3:c.2338C>T|NM_007300.3:c.2338C>T|NM_007298.3:c.2338C>T	NM_007294.3:c.2569C>T|NM_007300.3:c.2569C>T|NM_007298.3:c.2356C>T		rs80356945|rs80356945|rs137892861		 c.2338C>T|c.2338C>T				BRCA1	entrez	672			dna	c.123T>A|c.123T>A	23307,44366	23317,44376	Eighteen BRCA1 mutations, including the most common c.5266dupC, c.181T>G, c.4065_4068del4 (BIC: 4184del4) and<<< c.2338C>T>>> (BIC: 2457C>T), were found at least 3 times and comprised 66% of all BRCA1 mutations.| c.5266dupC     5382insC     c.4478del4     4706del4      c.181T>G     300T>G     c.9098dupA     9326insA      c.4065_4068del4     4184del4           <<< c.2338C>T>>>     2457C>T            Czech     c.181T>G     300T>G     c.7913_7917del5     8141del5      c.5266dupC     5382insC     c.8537_8538del2     8765delAG 		
23199084	confirmed					23199084		del		NM_007294.3:c.3860delA|NM_007300.3:c.3860delA	NM_007294.3:c.4091delA|NM_007300.3:c.4091delA		na|na		 c.3860delA|c.3860delA				BRCA1	entrez	672			dna	c.123delT|c.123delT	12663,42532	12674,42543	The most prevalent BRCA2 mutations are c.8363G>A (BIC: 8591G>A/W2788X), c.8754+1G>A (BIC: IVS21-1G>A) and<<< c.3860delA>>> (BIC: 4088delA), representing 9%, 7% and 6% of the BRCA2 mutation families respectively (Rappaport, personal communication).  ### Slovenia  In Sloven| Austrian     c.181T>G     300T>G     c.8363G>A     8591G>A      c.5266dupC     5382insC     c.8754+1G>A     IVS21-1G>A      c.1687C>T     1806C>T    <<< c.3860delA>>>     4088delA      c.3016_3019del4     3135del4            c.2676_2679del4     2795del4            Slovenian     c.1687C>T     1806C>T     c.7806-2A>G		
23199084	confirmed					23199084		del		NM_000059.3:c.3860delA	NM_000059.3:c.4086delA		rs80359411		 c.3860delA|c.3860delA				BRCA2	entrez	675			dna	c.123delT|c.123delT	12663,42532	12674,42543	The most prevalent BRCA2 mutations are c.8363G>A (BIC: 8591G>A/W2788X), c.8754+1G>A (BIC: IVS21-1G>A) and<<< c.3860delA>>> (BIC: 4088delA), representing 9%, 7% and 6% of the BRCA2 mutation families respectively (Rappaport, personal communication).  ### Slovenia  In Sloven| Austrian     c.181T>G     300T>G     c.8363G>A     8591G>A      c.5266dupC     5382insC     c.8754+1G>A     IVS21-1G>A      c.1687C>T     1806C>T    <<< c.3860delA>>>     4088delA      c.3016_3019del4     3135del4            c.2676_2679del4     2795del4            Slovenian     c.1687C>T     1806C>T     c.7806-2A>G		
23199084	confirmed					23199084		sub		NM_000059.3:c.8327T>G	NM_000059.3:c.8553T>G		rs397507977		c.8327T>G| c.8327T>G				BRCA2	entrez	675			dna	c.123T>A|c.123T>A|c.123T>A	32943,33233,46217	32953,33243,46227	equently.  The most recurrent mutation in BRCA2 is the Icelandic founder mutation c.771_775del5 (BIC: 999del5), three other (c.7480C>T (BIC: 7708C>T),<<< c.8327T>G>>> (BIC: 8555T>G), c.9118-2A>G (BIC: 9346-2A>G) and following (c. 6384del2 (BIC: 6503delTT), c.3853dupA (BIC: 4081insA) and c.5569G>T (BIC: 5797G>T)).|Some mutations are unique to the Finns, such as c.4096+3A>G (BIC: IVS11+3A>G) in BRCA1 and c.9117+1G>A (BIC: 9345+1G>A), c.7480C>T,<<< c.8327T>G>>> in BRCA2 genes.  The mutation spectrum in Eastern part slightly differs from those observed in the Northern and Southern parts of the country [139]. |sh     c.4097-2A>G     4216-2A>G     c.771_775del5     999del5      c.3485delA     3604delA     c.7480C>T     7708C>T      c.3626delT     3745delT    <<< c.8327T>G>>>     8555T>G      c.4327C>T     4446C>T     c.9118-2A>G     9346-2A>G      c.2684del2     2803delAA     c.9117+1G>A     9345+1G>A      c.5251C>T     5		
23199084	confirmed					23199084		sub		NM_007294.3:c.3661G>T|NM_007300.3:c.3661G>T	NM_007294.3:c.3892G>T|NM_007300.3:c.3892G>T		rs80357310|rs80357310		 c.3661G>T|c.3661G>T				BRCA1	entrez	672			dna	c.123T>A|c.123T>A	20441,43853	20451,43863	91] in a 49 BRCA1/2 positive families found six major recurrent founder mutations (three BRCA1 c.212+3A> (BIC: IVS5+3A>G), c.2359dupG (BIC: 2478insG),<<< c.3661G>T>>> (BIC: 3780G>T) and three BRCA2 c.516+1G>A (BIC: IVS6+1G>A), c.6275_6276delTT (BIC: 6503_6504delTT), c.8904delC (BIC: 9132delC) alterations), which ac|nsAlu      Belgian     c.212+3A>G     IVS5+3A>G     c.516+1G>A     IVS6+1G>A      c.2359dupG     2478insG     c.6275_6276delTT     6503_6504delTT     <<< c.3661G>T>>>     3780G>T     c.8904delC     9132delC      Dutch     c.2685_2686delAA     2804delAA     c.5351dupA     5579insA      c.2193del5     2312del5     c.		
23199084	notConfirmed							dup		c.9098A>AA					 c.9098dupA|c.9098dupA				BRCA1	entrez	672			dna	c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA	23685,25834,26296,44297,44674	23696,25845,26307,44308,44685	Seven distinct mutations accounted for 28% of BRCA2 mutations, and most frequent c.1813dupA (BIC: 2041insA), c.4478del4 (BIC: 4706del4) and<<< c.9098dupA>>> (BIC: 9326insA) were associated with common alleles, suggesting a possible founder effect [99].  ### Czech Republic  Five mutations (BRCA1: c.181T>G,|risk breast/ovarian cancer families, common BRCA1 founder mutations c.5266dupC, c.181T>G and c.68_69delAG accounted for 80% of all BRCA1 mutations and<<< c.9098dupA>>> (BIC: 9326insA) with c.5946delT accounted for 50% of all BRCA2 mutations [42, 103].|Among unselected Hungarian male breast cancer patients, one third carried BRCA2 mutations, including<<< c.9098dupA>>> [104].  ### Greece  In the Greek population four BRCA1 mutations (c.5526dupC, c.5212G>A (BIC: 5331G>A/G1738R), c.5251C>T (BIC: 5370C>T/R1751X), c.546|         German     exon 17 deletion     c.1813dupA     2041insA      c.5266dupC     5382insC     c.4478del4     4706del4      c.181T>G     300T>G    <<< c.9098dupA>>>     9326insA      c.4065_4068del4     4184del4            c.2338C>T     2457C>T            Czech     c.181T>G     300T>G     c.7913_7917del5     8141|G      c.3700_3704del5     3819del5            exons 1–17 deletion            exons 5–14 deletion            Hungarian     c.5266dupC     5382insC    <<< c.9098dupA>>>     9326insA      c.181T>G     300T>G     c.5946delT     6174delT      c.68_69delAG     185delAG            Greek     c.5266dupC     5382insC        		
23199084	confirmed					23199084		dup		NM_007300.3:c.5526dupC	NM_007300.3:c.5757dupC		na		c.5526dupC				BRCA1	entrez	672			dna	c.123dupA|c.123dupA	26373,26732	26384,26743	male breast cancer patients, one third carried BRCA2 mutations, including c.9098dupA [104].  ### Greece  In the Greek population four BRCA1 mutations <<<(c.5526dupC>>>, c.5212G>A (BIC: 5331G>A/G1738R), c.5251C>T (BIC: 5370C>T/R1751X), c.5467G>A (BIC: 5586G>A), account for 54% of all mutations detected in BRCA1/2 gen|amilies, whereas the rest are unique or low- frequency mutations, reflecting the population’s genetic heterogeneity.  The most frequent BRCA1 mutation<<< c.5526dupC>>> accounts for 31% of the BRCA1/2 mutations identified in Greek familial breast/ovarian cancer patients [45, 105].  Previously described as unclassifie		
23199084	notConfirmed							sub		c.5797G>T					5797G>T				BRCA1	entrez	672			dna	859G>A	33090	33098	6384del2 (BIC: 6503delTT), c.3853dupA (BIC: 4081insA) and c.5569G>T (BIC:<<< 5797G>T>>>)).		
23199084	notConfirmed							del		c.2953G>None					2953delG				BRCA2	entrez	675			dna	6174delT	16695	16704	egion 4 BRCA1 gene mutations (c.4327C>T (BIC: 4446C>T/Arg1443X), c.3756_3759del4 (BIC: 3875delGTCT), c.962G>A (BIC: 1081G>A), c.2834_2836delinsC (BIC:<<< 2953delG>>>TA/insC) and 3 BRCA2 mutations (c.3170_3174del5 (BIC: 3398del5), c.5857G>T (BIC: 6085G>T), c.8537_8538delAG (BIC: 8765delAG)) are now routinely includ		
23199084	notConfirmed							sub		c.3438G>T					3438G>T| 3438G>T				BRCA1	entrez	672			dna	859G>A|859G>A	27583,45066	27591,45074	r mutations and other European mutations, including BRCA1 c.5266dupC. The most common BRCA1 mutations were c.2475delC (BIC: 2594delC), c.3319G>T (BIC:<<< 3438G>T>>>), c.5266dupC and c.3710delT (BIC: 3829delT), which accounted 16%, 9%, 8% and 5% of BRCA1 positive families, respectively [109, 110, 111]. The c.2475d|   5586G>A            Cypriot           c.8755delG     8984delG      Danish     c.2475delC     2594delC     c.6373delA     6601delA      c.3319G>T    <<< 3438G>T>>>     c.1310_1013del4     1538del4      c.5266dupC     5382insC     c.6486_6489del4     6714del4      c.3710delT     3829delT     c.3847_3848delGT     		
23199084	notConfirmed							sub		c.1081G>A					 1081G>A				BRCA2	entrez	675			dna	859G>A	16660	16668	In this region 4 BRCA1 gene mutations (c.4327C>T (BIC: 4446C>T/Arg1443X), c.3756_3759del4 (BIC: 3875delGTCT), c.962G>A (BIC:<<< 1081G>A>>>), c.2834_2836delinsC (BIC: 2953delGTA/insC) and 3 BRCA2 mutations (c.3170_3174del5 (BIC: 3398del5), c.5857G>T (BIC: 6085G>T), c.8537_8538delAG (BIC: 		
23199084	confirmed					23199084		del		NM_000059.3:c.6629_6630delAA	NM_000059.3:c.6855_6856delAA		rs80359611		 c.6629_6630delAA|c.6629_6630delAA				BRCA2	entrez	675			dna	c.123_125delAT|c.123_125delAT	17841,43383	17858,43400	: 5242C>A), c.470_471delCT (BIC: 589_590delCT) account for 46.6% of BRCA1 mutations and four mutations in BRCA2 (c.2808_2811del4 (BIC: 3036_3039del4),<<< c.6629_6630delAA>>> (BIC: c.6857delAA), c.9026_9030del5 (BIC: 9254-9258del5), c.9310_9311delAA (BIC: 9538delAA)) account for 56.6% of the BRCA2 mutations [79].  Diez et | 5247G>T            Spanish     c.68_69delAG     185delAG     c.2808_2811del4 (Castilla-Leon)     3036_3039del4      c.211A>G (Galicia)     330A>G    <<< c.6629_6630delAA>>>     c.6857delAA      c.5117G>A     5236G>A     c.9026_9030del5     9254-9258del5      c.5123C>A     5242C>A     c.9310_9311delAA     9538delAA      c		
23199084	notConfirmed							del		c.2800A>None					 2800delA|2800delA				BRCA2	entrez	675			dna	6174delT|6174delT	34681,46525	34690,46534	ted for almost half of the total mutations detected, and almost one-quarter were accounted by just two founder mutations (BRCA1 c.2681_2682delAA (BIC:<<< 2800delA>>>A) and BRCA2 c.6275_6276delTT (BIC: 6503delTT) [149].| 5370C>T            c.4096+3A>G     IVS11+3A>G            Iceland           c.771_775del5     999del5      British     c.2681_2682delAA (Scotland)    <<< 2800delA>>>A     c.6275_6276delTT (Scotland)     6503delTT      c.4065_4068del4 (North-West)     4184del4     c.1929delG (North-West)     2157delG      exon 13 d		
23199084	confirmed					23199084		del		NM_007297.3:c.6503delT	NM_007297.3:c.6783delT		na		6503delT| 6503delT				BRCA1	entrez	672			dna	6174delT|6174delT|6174delT|6174delT|6174delT	21887,33031,34725,44031,46571	21896,33040,34734,44040,46580	Together with another Dutch BRCA2 founder mutation c.6275_6276delTT (BIC:<<< 6503delT>>>T), c.5351dupA accounts for 62% of hereditary breast/ovarian families [94, 95].  Slightly outdated (as of year 2002) list of published and unpublished|6384del2 (BIC:<<< 6503delT>>>T), c.3853dupA (BIC: 4081insA) and c.5569G>T (BIC: 5797G>T)).|etected, and almost one-quarter were accounted by just two founder mutations (BRCA1 c.2681_2682delAA (BIC: 2800delAA) and BRCA2 c.6275_6276delTT (BIC:<<< 6503delT>>>T) [149].|.8904delC     9132delC      Dutch     c.2685_2686delAA     2804delAA     c.5351dupA     5579insA      c.2193del5     2312del5     c.6275_6276delTT    <<< 6503delT>>>T      c.1292dupT     1411insT            exon 13 deletion (3,8-kb)            exon 22 deletion (510-bp)            German     exon 17 deletion     c.|            Iceland           c.771_775del5     999del5      British     c.2681_2682delAA (Scotland)     2800delAA     c.6275_6276delTT (Scotland)    <<< 6503delT>>>T      c.4065_4068del4 (North-West)     4184del4     c.1929delG (North-West)     2157delG      exon 13 duplication (ins6kbEx13)            Irish     c		
23199084	confirmed					23199084		del		NM_007300.3:c.4486delG|NM_007297.3:c.4486delG	NM_007300.3:c.4717delG|NM_007297.3:c.4766delG		na|na		4486delG| 4486delG				BRCA1	entrez	672			dna	6174delT|6174delT	30433,45328	30442,45337	) mutation, is quite common in Sweden and is apparently specific to English-speaking and related countries [122].  One BRCA2 mutation c.4258delG (BIC:<<< 4486delG>>>) is found repeatedly in Swedish breast cancer families [120, 123].  In the Western Sweden, six mutations, including the most common BRCA1 c.3171_3175|710delT     3829delT     c.3847_3848delGT     4075delGT      exons 3-16 deletion            Swedish     c.3171_3175dup     3171ins5     c.4258delG    <<< 4486delG>>>      c.2475delC     2594delC            c.1082_1092del11     1201del11            c.1687C>T     1806C>T            c.3626delT (Northern)     3745delT		
23199084	notConfirmed							del		c.3958C>None					3958delC				BRCA1	entrez	672			dna	6174delT	16271	16280	haplotype is less conclusive and needs further confirmation [6].  The BRCA1 c.5030_5033delCTAA (BIC: 5149delCTAA) [76] and c.3839_3843delinsAGGC (BIC:<<< 3958delC>>>TCAGinsAGGC) [77] mutations were reported in at least three independent families from France.  Well-described founder mutations are identified in Fren		
23199084	notConfirmed							sub		c.1806C>T					 1806C>T|1806C>T				BRCA1	entrez	672			dna	859G>A|859G>A|859G>A|859G>A	11701,42520,42669,45433	11709,42528,42677,45441	al reports for several apparently founder BRCA1 mutations in Austria [58, 59], although they (c.181T>G (BIC: 300T>G/C61G), c.5266dupC, c.1687C>T (BIC:<<< 1806C>T>>>)) represent common mutations prevalent in other European countries.|C            Austrian     c.181T>G     300T>G     c.8363G>A     8591G>A      c.5266dupC     5382insC     c.8754+1G>A     IVS21-1G>A      c.1687C>T    <<< 1806C>T>>>     c.3860delA     4088delA      c.3016_3019del4     3135del4            c.2676_2679del4     2795del4            Slovenian     c.1687C>T     1806C>T |  1806C>T     c.3860delA     4088delA      c.3016_3019del4     3135del4            c.2676_2679del4     2795del4            Slovenian     c.1687C>T    <<< 1806C>T>>>     c.7806-2A>G     IVS16-2A>G      c.181T>G     300T>G            c.5266dupC     5382insC            c.181T>A     300T>A            Italian (Tuscany|.3171_3175dup     3171ins5     c.4258delG     4486delG      c.2475delC     2594delC            c.1082_1092del11     1201del11            c.1687C>T    <<< 1806C>T>>>            c.3626delT (Northern)     3745delT            c.1016dupA     1135insA            exon 13 duplication (ins6kbEx13)            Norwegian    		
23199084	notConfirmed							del		c.5181G>None					 5181delG				BRCA1	entrez	672			dna	6174delT|6174delT	13733,43005	13742,43014	our distinct BRCA1 founder mutations (c.3228_3229delAG (BIC: 3347delAG), c.3285delA (BIC: 3404delA), c.1380dupA (BIC: 1499insA), c.5062_5064del3 (BIC:<<< 5181delG>>>TT) accounted for a large fraction (73%) of BRCA1-attributable hereditary breast/ovarian cancer in families originating from Tuscany (Central Italy) a|347delAG     c.8537_8538delAG  (Sardinia)     8765delAG      c.3285delA     3404delA            c.1380dupA     1499insA            c.5062_5064del3    <<< 5181delG>>>TT            Italian (Calabria)     c.4964_4982del19     5083del19            Italian (North-East)     c.5062_5064delGTT     5181_5183delGTT         		
23199084	confirmed					23199084		sub		NM_000059.3:c.120A>C	NM_000059.3:c.346A>C		na		 120A>C|120A>C				BRCA2	entrez	675			dna	859G>A|859G>A	31709,45930	31716,45937	BRCA1 c.1A>C (BIC:<<< 120A>C>>>) and c.5075-2A>C (BIC: IVS17-2A>C) mutations are also locally frequent.|c.3178G>T     3297G>T            c.4745delA     4864delA            c.2351del7     2470del7            c.3084del11     3203del11            c.1A>C    <<< 120A>C>>>            c.5075-2A>C     IVS17-2A>C            exons 1-13 deletion            exon 13 duplication (ins6kbEx13)            Finnish     c.4097-2A>G  		
23199084	confirmed					23199084		del		NM_007294.3:c.4724delC|NM_007300.3:c.4724delC|NM_007297.3:c.4724delC	NM_007294.3:c.4955delC|NM_007300.3:c.4955delC|NM_007297.3:c.5004delC		rs80357052|na|na		c.4724delC				BRCA1	entrez	672			dna	c.123delT	14872	14883	It was also recurrently found at least four times in Sicilia [70, 71]. Another BRCA1<<< c.4724delC>>> (BIC: 4843delC) mutation could be a possible Sicilian founder mutation, although present evidence is scarce [71, 72, 73].  Using a number of independ		
23199084	confirmed					23199084		sub		NM_007294.3:c.5258G>C	NM_007294.3:c.5489G>C		rs397509246		c.5258G>C				BRCA1	entrez	672			dna	c.123T>A	38720	38730	Two other mutations, BRCA1 c.181T>G and recently proved to be pathogenious<<< c.5258G>C>>> (BIC: 5377G>C/R1753T) were also found in more than one family; together with two founder mutations they comprise around 90% of BRCA1 gene mutations and around 85% of all BRCA1/2 mutations identified (Janavičius, unpublished data).		
23199084	confirmed					23199084		sub		NM_007297.3:c.5586G>A	NM_007297.3:c.5866G>A		na		5586G>A| 5586G>A				BRCA1	entrez	672			dna	859G>A|859G>A	26467,44918	26475,44926	## Greece  In the Greek population four BRCA1 mutations (c.5526dupC, c.5212G>A (BIC: 5331G>A/G1738R), c.5251C>T (BIC: 5370C>T/R1751X), c.5467G>A (BIC:<<< 5586G>A>>>), account for 54% of all mutations detected in BRCA1/2 genes and for 73% of the BRCA1 mutations positive families, whereas the rest are unique or low|G     185delAG            Greek     c.5266dupC     5382insC            c.5212G>A     5331G>A            c.5251C>T     5370C>T            c.5467G>A    <<< 5586G>A>>>            Cypriot           c.8755delG     8984delG      Danish     c.2475delC     2594delC     c.6373delA     6601delA      c.3319G>T     3438G>T  		
23199084	confirmed					23199084		sub		NM_000059.3:c.5586G>A	NM_000059.3:c.5812G>A		na		5586G>A| 5586G>A				BRCA2	entrez	675			dna	859G>A|859G>A	26467,44918	26475,44926	## Greece  In the Greek population four BRCA1 mutations (c.5526dupC, c.5212G>A (BIC: 5331G>A/G1738R), c.5251C>T (BIC: 5370C>T/R1751X), c.5467G>A (BIC:<<< 5586G>A>>>), account for 54% of all mutations detected in BRCA1/2 genes and for 73% of the BRCA1 mutations positive families, whereas the rest are unique or low|G     185delAG            Greek     c.5266dupC     5382insC            c.5212G>A     5331G>A            c.5251C>T     5370C>T            c.5467G>A    <<< 5586G>A>>>            Cypriot           c.8755delG     8984delG      Danish     c.2475delC     2594delC     c.6373delA     6601delA      c.3319G>T     3438G>T  		
23199084	confirmed					23199084		del		NM_007294.3:c.68_69delAG|NM_007300.3:c.68_69delAG|NM_007299.3:c.68_69delAG|NM_007298.3:c.68_69delAG	NM_007294.3:c.299_300delAG|NM_007300.3:c.299_300delAG|NM_007299.3:c.261_262delAG|NM_007298.3:c.86_87delAG		rs386833395|rs386833395|rs386833395|rs386833395		c.68_69delAG| c.68_69delAG				BRCA1	entrez	672			dna	c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT	8978,9247,9640,9927,10008,17612,18409,18687,25776,26150,37135,40609,42288,43264,44756	8991,9260,9653,9940,10021,17625,18422,18700,25789,26163,37148,40622,42301,43277,44769	The most well characterized three founder mutations are two in BRCA1 gene<<< c.68_69delAG>>> (BIC: 185delAG) and c.5266dupC (BIC: 5382insC) and one in BRCA2 c.5946delT (BIC: 6174delT) [31, 32, 33].|Screening for these three founder mutations alone is now part of routine clinical practice for Ashkenazi Jewish individuals.  These 3 mutations (BRCA1<<< c.68_69delAG>>>, c.5266dupC and BRCA2 c.5946delT) account for 98–99% of identified mutations and are carried by about 2.6% (1/40) of the Ashkenazi Jewish population (1%, 0.13% and 1.52% respectively) [34, 35, 36].|The average risk of breast cancer by the age of 70 years is similar for carriers of the BRCA1<<< c.68_69delAG>>> and c.5266dupC mutations (64% and 67% respectively), however is much lower for the c.5946delT mutation (43%).|ding values for ovarian cancer lifetime risk is respectively of 14%, 33% and 20% in carriers, respectively [6, 37, 38].  It is worth noting that BRCA1<<< c.68_69delAG>>> and c.5266dupC are not found exclusively in Ashkenazi patients.|The<<< c.68_69delAG>>> mutation has been found in patients of Spanish ancestry (i.e.| frequencies and geographic distribution.  A compilation of BRCA test results from different laboratories shows that five mutations in the BRCA1 gene <<<(c.68_69delAG>>>, c.211A>G (BIC: 330A>G), c.5117G>A (BIC: 5236G>A), c.5123C>A (BIC: 5242C>A), c.470_471delCT (BIC: 589_590delCT) account for 46.6% of BRCA1 mutations |It was also found in French and British families of Spanish origin [82].  The BRCA1<<< c.68_69delAG>>> and BRCA2 c.9026_9030del5 mutations accounted for the 30.4% (7/23) of the BRCA1 mutations and for the 18.5% (5/27) of the BRCA2 positive families respectively and were specific only to the Mediterranean areas.|Indeed, haplotype studies indicated a common origin of<<< c.68_69delAG>>> mutation in Spanish (Sephardic Jewish) and Ashkenazi Jewish populations [83]. Some data indicate an unique origin of reported BRCA2 exon 23 mutation BRCA2 c.9026_9030del5 in Catalan families (North-East Spain) [84].|population.  ### Hungary  In Hungarian patients from high-risk breast/ovarian cancer families, common BRCA1 founder mutations c.5266dupC, c.181T>G and<<< c.68_69delAG>>> accounted for 80% of all BRCA1 mutations and c.9098dupA (BIC: 9326insA) with c.5946delT accounted for 50% of all BRCA2 mutations [42, 103].|Breast cancer patients were more likely to carry the c.5266dupC mutation whereas ovarian patients were more likely to carry either the<<< c.68_69delAG>>> or the c.181T>G mutation [103].|By adding two other recurring BRCA1 mutations <<<(c.68_69delAG>>> and c.3700_3704del5), the vast majority (87%) of mutation-positive families will be encompassed.|Other less common mutations found in Western Russia are c.4035delA, c.181T>G, and<<< c.68_69delAG>>>. In Siberian region of Russia there is seen preponderance of individual BRCA2 gene mutations [164].  ### Other countries  In some countries, such as | in European populations  Population     BRCA1 mutation     BRCA2 mutation      --- --- ---      HGVS     BIC     HGVS     BIC      Ashkenazi Jews    <<< c.68_69delAG>>>     185delAG     c.5946delT     6174delT      c.5266dupC     5382insC            Austrian     c.181T>G     300T>G     c.8363G>A     8591G>A      c.52|    c.5062_5064delGTT     5181_5183delGTT            French     c.3481_3491del11     3600del11            c.5128G>T     5247G>T            Spanish    <<< c.68_69delAG>>>     185delAG     c.2808_2811del4 (Castilla-Leon)     3036_3039del4      c.211A>G (Galicia)     330A>G     c.6629_6630delAA     c.6857delAA      c.511|s 5–14 deletion            Hungarian     c.5266dupC     5382insC     c.9098dupA     9326insA      c.181T>G     300T>G     c.5946delT     6174delT     <<< c.68_69delAG>>>     185delAG            Greek     c.5266dupC     5382insC            c.5212G>A     5331G>A            c.5251C>T     5370C>T            c.5467G>A     		
23199084	confirmed					23199084		del		NM_007294.3:c.2685_2686delAA|NM_007300.3:c.2685_2686delAA|NM_007299.3:c.2685_2686delAA	NM_007294.3:c.2916_2917delAA|NM_007300.3:c.2916_2917delAA|NM_007299.3:c.2878_2879delAA		rs80357636|rs80357636|na		 c.2685_2686delAA				BRCA1	entrez	672			dna	c.123_125delAT|c.123_125delAT	21060,43918	21077,43935	The BRCA1<<< c.2685_2686delAA>>> (BIC: 2804delAA) founder mutation probably originated approximately 32 generations (∼200 years) ago, was also reported few times in Belgium and accounted for 24% of all BRCA1/2 mutations [92].|  IVS6+1G>A      c.2359dupG     2478insG     c.6275_6276delTT     6503_6504delTT      c.3661G>T     3780G>T     c.8904delC     9132delC      Dutch    <<< c.2685_2686delAA>>>     2804delAA     c.5351dupA     5579insA      c.2193del5     2312del5     c.6275_6276delTT     6503delTT      c.1292dupT     1411insT            exo		
23199084	confirmed					23199084		del		NM_007294.3:c.3228delA|NM_007300.3:c.3228delA	NM_007294.3:c.3459delA|NM_007300.3:c.3459delA		rs397509048|rs397509048		 c.3228delA				BRCA1	entrez	672			dna	c.123delT|c.123delT	31055,45648	31066,45659	ovarian cancer after breast cancer in this region [115, 125].  ### Norway  Four Norwegian founder mutations in BRCA1 gene (c.1556delA (BIC: 1675delA),<<< c.3228delA>>>G (BIC: 3347delAG), c.697delGT (BIC: 816delGT) and c.1016dupA make up 68% of the BRCA1 mutation carriers [126, 127], and these have their own specific geographic distribution.| c.1016dupA     1135insA            exon 13 duplication (ins6kbEx13)            Norwegian     c.1556delA     1675delA     c.2808del4     3036del4     <<< c.3228delA>>>G     3347delAG     c.3847delGT     4075delGT      c.697delGT     816delGT            c.1016dupA     1135insA            c.3178G>T     3297G>T        		
23199084	confirmed					23199084		del		NM_000059.3:c.3228delA	NM_000059.3:c.3454delA		na		 c.3228delA				BRCA2	entrez	675			dna	c.123delT|c.123delT	31055,45648	31066,45659	ovarian cancer after breast cancer in this region [115, 125].  ### Norway  Four Norwegian founder mutations in BRCA1 gene (c.1556delA (BIC: 1675delA),<<< c.3228delA>>>G (BIC: 3347delAG), c.697delGT (BIC: 816delGT) and c.1016dupA make up 68% of the BRCA1 mutation carriers [126, 127], and these have their own specific geographic distribution.| c.1016dupA     1135insA            exon 13 duplication (ins6kbEx13)            Norwegian     c.1556delA     1675delA     c.2808del4     3036del4     <<< c.3228delA>>>G     3347delAG     c.3847delGT     4075delGT      c.697delGT     816delGT            c.1016dupA     1135insA            c.3178G>T     3297G>T        		
23199084	confirmed					23199084		del		NM_000059.3:c.8904delC	NM_000059.3:c.9130delC		rs41293519		 c.8904delC|c.8904delC				BRCA2	entrez	675			dna	c.123delT|c.123delT	20551,43879	20562,43890	 IVS5+3A>G), c.2359dupG (BIC: 2478insG), c.3661G>T (BIC: 3780G>T) and three BRCA2 c.516+1G>A (BIC: IVS6+1G>A), c.6275_6276delTT (BIC: 6503_6504delTT),<<< c.8904delC>>> (BIC: 9132delC) alterations), which accounted for nearly 60% of all mutations identified. BRCA1 c.212+3A>G was previously reported as Belgian founder mutation [92, 93], later also found in a few German, Dutch and French families [91].|12+3A>G     IVS5+3A>G     c.516+1G>A     IVS6+1G>A      c.2359dupG     2478insG     c.6275_6276delTT     6503_6504delTT      c.3661G>T     3780G>T    <<< c.8904delC>>>     9132delC      Dutch     c.2685_2686delAA     2804delAA     c.5351dupA     5579insA      c.2193del5     2312del5     c.6275_6276delTT     6503delT		
23199084	notConfirmed							del		c.2594C>None					2594delC| 2594delC				BRCA1	entrez	672			dna	6174delT|6174delT|6174delT	27556,45010,45357	27565,45019,45366	ture of Scandinavian founder mutations and other European mutations, including BRCA1 c.5266dupC. The most common BRCA1 mutations were c.2475delC (BIC:<<< 2594delC>>>), c.3319G>T (BIC: 3438G>T), c.5266dupC and c.3710delT (BIC: 3829delT), which accounted 16%, 9%, 8% and 5% of BRCA1 positive families, respectively [1|            c.5251C>T     5370C>T            c.5467G>A     5586G>A            Cypriot           c.8755delG     8984delG      Danish     c.2475delC    <<< 2594delC>>>     c.6373delA     6601delA      c.3319G>T     3438G>T     c.1310_1013del4     1538del4      c.5266dupC     5382insC     c.6486_6489del4     6714del4|47_3848delGT     4075delGT      exons 3-16 deletion            Swedish     c.3171_3175dup     3171ins5     c.4258delG     4486delG      c.2475delC    <<< 2594delC>>>            c.1082_1092del11     1201del11            c.1687C>T     1806C>T            c.3626delT (Northern)     3745delT            c.1016dupA     11		
23199084	confirmed					23199084		del		NM_000059.3:c.6174delT	NM_000059.3:c.6400delT		na		 6174delT|6174delT				BRCA2	entrez	675			dna	6174delT|6174delT|6174delT	9072,42333,44742	9081,42342,44751	racterized three founder mutations are two in BRCA1 gene c.68_69delAG (BIC: 185delAG) and c.5266dupC (BIC: 5382insC) and one in BRCA2 c.5946delT (BIC:<<< 6174delT>>>) [31, 32, 33].|1 mutation     BRCA2 mutation      --- --- ---      HGVS     BIC     HGVS     BIC      Ashkenazi Jews     c.68_69delAG     185delAG     c.5946delT    <<< 6174delT>>>      c.5266dupC     5382insC            Austrian     c.181T>G     300T>G     c.8363G>A     8591G>A      c.5266dupC     5382insC     c.8754+1G>A     I|          exons 5–14 deletion            Hungarian     c.5266dupC     5382insC     c.9098dupA     9326insA      c.181T>G     300T>G     c.5946delT    <<< 6174delT>>>      c.68_69delAG     185delAG            Greek     c.5266dupC     5382insC            c.5212G>A     5331G>A            c.5251C>T     5370C>T        		
23199084	confirmed					23199084		del		NM_007294.3:c.3626delT|NM_007300.3:c.3626delT	NM_007294.3:c.3857delT|NM_007300.3:c.3857delT		rs80357571|rs80357571		 c.3626delT|c.3626delT				BRCA1	entrez	672			dna	c.123delT|c.123delT|c.123delT|c.123delT	30072,32638,45452,46189	30083,32649,45463,46200	Yet another BRCA1 mutation<<< c.3626delT>>> (BIC: 3745delT) apparently originates in northern Sweden and Finland [121].  The 6-kb duplication of BRCA1 exon 13, aslo known as ins6kbEx13 (HGVS: c|The most common BRCA1 mutations are c.4097-2A>G (BIC: 4216-2A>G), c.3485delA (BIC: 3604delA),<<< c.3626delT>>> (BIC: 3745delT), c.4327C>T (BIC: 4446C>T), c.2684del2 (BIC: 2803delAA) and c.5251C>T (BIC: 5370C>T).|171ins5     c.4258delG     4486delG      c.2475delC     2594delC            c.1082_1092del11     1201del11            c.1687C>T     1806C>T           <<< c.3626delT>>> (Northern)     3745delT            c.1016dupA     1135insA            exon 13 duplication (ins6kbEx13)            Norwegian     c.1556delA     1675de|ins6kbEx13)            Finnish     c.4097-2A>G     4216-2A>G     c.771_775del5     999del5      c.3485delA     3604delA     c.7480C>T     7708C>T     <<< c.3626delT>>>     3745delT     c.8327T>G     8555T>G      c.4327C>T     4446C>T     c.9118-2A>G     9346-2A>G      c.2684del2     2803delAA     c.9117+1G>A     934		
23199084	confirmed					23199084		del		NM_007294.3:c.3228_3229delAG|NM_007300.3:c.3228_3229delAG	NM_007294.3:c.3459_3460delAG|NM_007300.3:c.3459_3460delAG		rs80357635|rs80357635		c.3228_3229delAG| c.3228_3229delAG				BRCA1	entrez	672			dna	c.123_125delAT|c.123_125delAT	13620,42832	13637,42849	ed families, and significant regional founder effect has been demonstrated for few mutations [63, 64, 65, 66].  Four distinct BRCA1 founder mutations <<<(c.3228_3229delAG>>> (BIC: 3347delAG), c.3285delA (BIC: 3404delA), c.1380dupA (BIC: 1499insA), c.5062_5064del3 (BIC: 5181delGTT) accounted for a large fraction (73%) of B|c.7806-2A>G     IVS16-2A>G      c.181T>G     300T>G            c.5266dupC     5382insC            c.181T>A     300T>A            Italian (Tuscany)    <<< c.3228_3229delAG>>>     3347delAG     c.8537_8538delAG  (Sardinia)     8765delAG      c.3285delA     3404delA            c.1380dupA     1499insA            c.5062_5064de		
23199084	confirmed					23199084		del		NM_000059.3:c.3228_3229delAG	NM_000059.3:c.3454_3455delAG		rs80359378		c.3228_3229delAG| c.3228_3229delAG				BRCA2	entrez	675			dna	c.123_125delAT|c.123_125delAT	13620,42832	13637,42849	ed families, and significant regional founder effect has been demonstrated for few mutations [63, 64, 65, 66].  Four distinct BRCA1 founder mutations <<<(c.3228_3229delAG>>> (BIC: 3347delAG), c.3285delA (BIC: 3404delA), c.1380dupA (BIC: 1499insA), c.5062_5064del3 (BIC: 5181delGTT) accounted for a large fraction (73%) of B|c.7806-2A>G     IVS16-2A>G      c.181T>G     300T>G            c.5266dupC     5382insC            c.181T>A     300T>A            Italian (Tuscany)    <<< c.3228_3229delAG>>>     3347delAG     c.8537_8538delAG  (Sardinia)     8765delAG      c.3285delA     3404delA            c.1380dupA     1499insA            c.5062_5064de		
23199084	confirmed					23199084		del		NM_007294.3:c.3404delA|NM_007300.3:c.3404delA|NM_007297.3:c.3404delA	NM_007294.3:c.3635delA|NM_007300.3:c.3635delA|NM_007297.3:c.3684delA		na|na|na		 3404delA|3404delA				BRCA1	entrez	672			dna	6174delT|6174delT	13672,42930	13681,42939	 has been demonstrated for few mutations [63, 64, 65, 66].  Four distinct BRCA1 founder mutations (c.3228_3229delAG (BIC: 3347delAG), c.3285delA (BIC:<<< 3404delA>>>), c.1380dupA (BIC: 1499insA), c.5062_5064del3 (BIC: 5181delGTT) accounted for a large fraction (73%) of BRCA1-attributable hereditary breast/ovarian |c.181T>A     300T>A            Italian (Tuscany)     c.3228_3229delAG     3347delAG     c.8537_8538delAG  (Sardinia)     8765delAG      c.3285delA    <<< 3404delA>>>            c.1380dupA     1499insA            c.5062_5064del3     5181delGTT            Italian (Calabria)     c.4964_4982del19     5083del19        		
23199084	confirmed					23199084		del		NM_000059.3:c.3404delA	NM_000059.3:c.3630delA		na		 3404delA|3404delA				BRCA2	entrez	675			dna	6174delT|6174delT	13672,42930	13681,42939	 has been demonstrated for few mutations [63, 64, 65, 66].  Four distinct BRCA1 founder mutations (c.3228_3229delAG (BIC: 3347delAG), c.3285delA (BIC:<<< 3404delA>>>), c.1380dupA (BIC: 1499insA), c.5062_5064del3 (BIC: 5181delGTT) accounted for a large fraction (73%) of BRCA1-attributable hereditary breast/ovarian |c.181T>A     300T>A            Italian (Tuscany)     c.3228_3229delAG     3347delAG     c.8537_8538delAG  (Sardinia)     8765delAG      c.3285delA    <<< 3404delA>>>            c.1380dupA     1499insA            c.5062_5064del3     5181delGTT            Italian (Calabria)     c.4964_4982del19     5083del19        		
23199084	confirmed					23199084		del		NM_007294.3:c.5062_5064delGTT	NM_007294.3:c.5293_5295delGTT		rs80358344		 c.5062_5064delGTT|c.5062_5064delGTT				BRCA1	entrez	672			dna	c.123_125delAT|c.123_125delAT|c.123_125delAT	15108,15288,43117	15126,15306,43135	[74] showed that previously reported BRCA1<<< c.5062_5064delGTT>>> (BIC: 5181_5183delGTT/1688Val) variant of unknown significance (VUS) actually is a deleterious mutation with high frequency in North-East Italy [74].|The founder<<< c.5062_5064delGTT>>> mutation accounts for 15% (9/61) of families with small BRCA1 mutations.  ### France  In France geographical clustering in North-Eastern part is evident for two recurrent BRCA1 mutations, suggesting a founder effect.|499insA            c.5062_5064del3     5181delGTT            Italian (Calabria)     c.4964_4982del19     5083del19            Italian (North-East)    <<< c.5062_5064delGTT>>>     5181_5183delGTT            French     c.3481_3491del11     3600del11            c.5128G>T     5247G>T            Spanish     c.68_69delAG     185		
23199084	notConfirmed							del		c.8765A>None					8765delA| 8765delA				BRCA2	entrez	675			dna	6174delT|6174delT|6174delT|6174delT|6174delT	14250,16817,23960,42900,44515	14259,16826,23969,42909,44524	o breast cancer predisposition has been reported for populations from the Northern part of the island [67], where founder BRCA2 c.8537_8538delAG (BIC:<<< 8765delA>>>G) mutation comprises 28% for BRCA1/2 positive families [68, 69].|A), c.2834_2836delinsC (BIC: 2953delGTA/insC) and 3 BRCA2 mutations (c.3170_3174del5 (BIC: 3398del5), c.5857G>T (BIC: 6085G>T), c.8537_8538delAG (BIC:<<< 8765delA>>>G)) are now routinely included in early onset breast/ovarian cancer screening assays and represent up to 84% of the total BRCA1/2 mutations in the French-Canadian population in Quebec [78].|ic  Five mutations (BRCA1: c.181T>G, c.5266dupC, c.3700_3704del5 (BIC: 3819del5), and BRCA2: c.7913_7917del5 (BIC: 8141del5) and c.8537_8538del2 (BIC:<<< 8765delA>>>G)) represented 52% of all mutations detected in one study population [52].|6dupC     5382insC            c.181T>A     300T>A            Italian (Tuscany)     c.3228_3229delAG     3347delAG     c.8537_8538delAG  (Sardinia)    <<< 8765delA>>>G      c.3285delA     3404delA            c.1380dupA     1499insA            c.5062_5064del3     5181delGTT            Italian (Calabria)     c.4964_4|  c.2338C>T     2457C>T            Czech     c.181T>G     300T>G     c.7913_7917del5     8141del5      c.5266dupC     5382insC     c.8537_8538del2    <<< 8765delA>>>G      c.3700_3704del5     3819del5            exons 1–17 deletion            exons 5–14 deletion            Hungarian     c.5266dupC     5382insC    		
23199084	confirmed					23199084		dup		NM_007297.3:c.1813dupA	NM_007297.3:c.2093dupA		na		 c.1813dupA|c.1813dupA				BRCA1	entrez	672			dna	c.123dupA|c.123dupA	23626,44187	23637,44198	Seven distinct mutations accounted for 28% of BRCA2 mutations, and most frequent<<< c.1813dupA>>> (BIC: 2041insA), c.4478del4 (BIC: 4706del4) and c.9098dupA (BIC: 9326insA) were associated with common alleles, suggesting a possible founder effect |elTT      c.1292dupT     1411insT            exon 13 deletion (3,8-kb)            exon 22 deletion (510-bp)            German     exon 17 deletion    <<< c.1813dupA>>>     2041insA      c.5266dupC     5382insC     c.4478del4     4706del4      c.181T>G     300T>G     c.9098dupA     9326insA      c.4065_4068del4     4		
23199084	confirmed					23199084		dup		NM_000059.3:c.1813dupA	NM_000059.3:c.2039dupA		rs80359309		 c.1813dupA|c.1813dupA				BRCA2	entrez	675			dna	c.123dupA|c.123dupA	23626,44187	23637,44198	Seven distinct mutations accounted for 28% of BRCA2 mutations, and most frequent<<< c.1813dupA>>> (BIC: 2041insA), c.4478del4 (BIC: 4706del4) and c.9098dupA (BIC: 9326insA) were associated with common alleles, suggesting a possible founder effect |elTT      c.1292dupT     1411insT            exon 13 deletion (3,8-kb)            exon 22 deletion (510-bp)            German     exon 17 deletion    <<< c.1813dupA>>>     2041insA      c.5266dupC     5382insC     c.4478del4     4706del4      c.181T>G     300T>G     c.9098dupA     9326insA      c.4065_4068del4     4		
23199084	confirmed					23199084		del		NM_000059.3:c.3847_3848delGT	NM_000059.3:c.4073_4074delGT		rs80359405		 c.3847_3848delGT				BRCA2	entrez	675			dna	c.123_125delAT|c.123_125delAT	28069,45202	28086,45219	o/id/153250.0).  The most common BRCA2 mutations were c.6373delA (BIC: 6601delA), c.1310_1013del4 (BIC: 1538del4), c.6486_6489del4 (BIC: 6714del4) and<<< c.3847_3848delGT>>> (BIC: 4075delGT), found in 11%, 10%, 9% and 5% of BRCA2 positive families, respectively [111].| c.3319G>T     3438G>T     c.1310_1013del4     1538del4      c.5266dupC     5382insC     c.6486_6489del4     6714del4      c.3710delT     3829delT    <<< c.3847_3848delGT>>>     4075delGT      exons 3-16 deletion            Swedish     c.3171_3175dup     3171ins5     c.4258delG     4486delG      c.2475delC     2594delC   		
23199084	confirmed					23199084		del		NM_000059.3:c.3847delG	NM_000059.3:c.4073delG		rs397507691		c.3847delG| c.3847delG				BRCA2	entrez	675			dna	c.123delT|c.123delT	31603,45678	31614,45689	1 c.3178G>T (BIC: 3297G>T), c.4745delA (BIC: 4864delA), c.2351del7 (BIC: 2470del7), c.3084del11 (BIC: 3203del11) and BRCA2 c.2808del4 (BIC: 3036del4),<<< c.3847delG>>>T (BIC: 4075delGT)), account for about 60% BRCA1/2 carriers in Norway [128].|      exon 13 duplication (ins6kbEx13)            Norwegian     c.1556delA     1675delA     c.2808del4     3036del4      c.3228delAG     3347delAG    <<< c.3847delG>>>T     4075delGT      c.697delGT     816delGT            c.1016dupA     1135insA            c.3178G>T     3297G>T            c.4745delA     4864delA   		
23199084	confirmed					23199084		sub		NM_007294.3:c.2466T>G|NM_007300.3:c.2466T>G|NM_007299.3:c.2466T>G|NM_007297.3:c.2466T>G	NM_007294.3:c.2697T>G|NM_007300.3:c.2697T>G|NM_007299.3:c.2659T>G|NM_007297.3:c.2746T>G		na|na|na|na		2466T>G				BRCA1	entrez	672			dna	859G>A	28895	28903	s Danish founder mutation, comprising 40% (6/15) of all BRCA1/2 families with LGRs [112].  Recently a pathogenic founder BRCA1 mutation c.234T>G (BIC:<<< 2466T>G>>>/Cys39Gly) was desribed in Greenland (Inuit population), an autonomous country within the Kingdom of Denmark, with a high carrier frequency (1.6%) in this population [113, 114].		
23199084	confirmed					23199084		sub		NM_000059.3:c.2466T>G	NM_000059.3:c.2692T>G		na		2466T>G				BRCA2	entrez	675			dna	859G>A	28895	28903	s Danish founder mutation, comprising 40% (6/15) of all BRCA1/2 families with LGRs [112].  Recently a pathogenic founder BRCA1 mutation c.234T>G (BIC:<<< 2466T>G>>>/Cys39Gly) was desribed in Greenland (Inuit population), an autonomous country within the Kingdom of Denmark, with a high carrier frequency (1.6%) in this population [113, 114].		
23199084	confirmed					23199084		del		NM_007294.3:c.816delG|NM_007300.3:c.816delG	NM_007294.3:c.1047delG|NM_007300.3:c.1047delG		na|na		816delG| 816delG				BRCA1	entrez	672			dna	6174delT|6174delT	31102,45724	31110,45732	on [115, 125].  ### Norway  Four Norwegian founder mutations in BRCA1 gene (c.1556delA (BIC: 1675delA), c.3228delAG (BIC: 3347delAG), c.697delGT (BIC:<<< 816delG>>>T) and c.1016dupA make up 68% of the BRCA1 mutation carriers [126, 127], and these have their own specific geographic distribution.|    Norwegian     c.1556delA     1675delA     c.2808del4     3036del4      c.3228delAG     3347delAG     c.3847delGT     4075delGT      c.697delGT    <<< 816delG>>>T            c.1016dupA     1135insA            c.3178G>T     3297G>T            c.4745delA     4864delA            c.2351del7     2470del7           		
23199084	notConfirmed							dup		c.3853A>AA					c.3853dupA				BRCA1	entrez	672			dna	c.123dupA	33043	33054	6384del2 (BIC: 6503delTT),<<< c.3853dupA>>> (BIC: 4081insA) and c.5569G>T (BIC: 5797G>T)).		
23199084	confirmed					23199084		del		NM_007294.3:c.374delT|NM_007300.3:c.374delT|NM_007299.3:c.374delT|NM_007298.3:c.374delT	NM_007294.3:c.605delT|NM_007300.3:c.605delT|NM_007299.3:c.567delT|NM_007298.3:c.392delT		na|na|na|na		 374delT				BRCA1	entrez	672			dna	6174delT	43604	43612	_9030del5     9254-9258del5      c.5123C>A     5242C>A     c.9310_9311delAA     9538delAA      c.470_471delCT     589_590delCT     c.5146_5149del4    <<< 374delT>>>ATG      c.5153-1G>A     5272-1G>A            Portuguese           c.156_157insAlu     384insAlu      Belgian     c.212+3A>G     IVS5+3A>G     c.516+1		
23199084	confirmed					23199084		sub		NM_007294.3:c.5251C>T	NM_007294.3:c.5482C>T		rs80357123		c.5251C>T| c.5251C>T				BRCA1	entrez	672			dna	c.123T>A|c.123T>A|c.123T>A|c.123T>A	26418,32724,44871,46361	26428,32734,44881,46371	d BRCA2 mutations, including c.9098dupA [104].  ### Greece  In the Greek population four BRCA1 mutations (c.5526dupC, c.5212G>A (BIC: 5331G>A/G1738R),<<< c.5251C>T>>> (BIC: 5370C>T/R1751X), c.5467G>A (BIC: 5586G>A), account for 54% of all mutations detected in BRCA1/2 genes and for 73% of the BRCA1 mutations positi|ns are c.4097-2A>G (BIC: 4216-2A>G), c.3485delA (BIC: 3604delA), c.3626delT (BIC: 3745delT), c.4327C>T (BIC: 4446C>T), c.2684del2 (BIC: 2803delAA) and<<< c.5251C>T>>> (BIC: 5370C>T).|>G     c.5946delT     6174delT      c.68_69delAG     185delAG            Greek     c.5266dupC     5382insC            c.5212G>A     5331G>A           <<< c.5251C>T>>>     5370C>T            c.5467G>A     5586G>A            Cypriot           c.8755delG     8984delG      Danish     c.2475delC     2594delC     c.6373d|lT     c.8327T>G     8555T>G      c.4327C>T     4446C>T     c.9118-2A>G     9346-2A>G      c.2684del2     2803delAA     c.9117+1G>A     9345+1G>A     <<< c.5251C>T>>>     5370C>T            c.4096+3A>G     IVS11+3A>G            Iceland           c.771_775del5     999del5      British     c.2681_2682delAA (Scotland)		
23199084	confirmed					23199084		sub		NM_000059.3:c.516+1_516G>A	NM_000059.3:c.742+1_742G>A		rs397507762		c.516+1G>A| c.516+1G>A				BRCA2	entrez	675			dna	c.123+2A>T|c.123+2A>T|c.123+2A>T	20482,20824,43754	20493,20835,43765	nd six major recurrent founder mutations (three BRCA1 c.212+3A> (BIC: IVS5+3A>G), c.2359dupG (BIC: 2478insG), c.3661G>T (BIC: 3780G>T) and three BRCA2<<< c.516+1G>A>>> (BIC: IVS6+1G>A), c.6275_6276delTT (BIC: 6503_6504delTT), c.8904delC (BIC: 9132delC) alterations), which accounted for nearly 60% of all mutations id|BRCA1 c.2359dupG and BRCA2<<< c.516+1G>A>>> have not yet been reported in other populations.  ### The Netherlands (Holland)  Several founder mutations in BRCA1/2 have been identified in Holland [94], where significant regional and cultural differences exist.| 374delTATG      c.5153-1G>A     5272-1G>A            Portuguese           c.156_157insAlu     384insAlu      Belgian     c.212+3A>G     IVS5+3A>G    <<< c.516+1G>A>>>     IVS6+1G>A      c.2359dupG     2478insG     c.6275_6276delTT     6503_6504delTT      c.3661G>T     3780G>T     c.8904delC     9132delC      Dutch 		
23199084	notConfirmed							sub		c.300T>G					 300T>G				BRCA1	entrez	672			dna	859G>A|859G>A|859G>A|859G>A|859G>A|859G>A|859G>A|859G>A	11659,42408,42726,44286,44422,44716,46818,47101	11666,42415,42733,44293,44429,44723,46825,47108	There were initial reports for several apparently founder BRCA1 mutations in Austria [58, 59], although they (c.181T>G (BIC:<<< 300T>G>>>/C61G), c.5266dupC, c.1687C>T (BIC: 1806C>T)) represent common mutations prevalent in other European countries.|   BIC      Ashkenazi Jews     c.68_69delAG     185delAG     c.5946delT     6174delT      c.5266dupC     5382insC            Austrian     c.181T>G    <<< 300T>G>>>     c.8363G>A     8591G>A      c.5266dupC     5382insC     c.8754+1G>A     IVS21-1G>A      c.1687C>T     1806C>T     c.3860delA     4088delA      c.3|4     3135del4            c.2676_2679del4     2795del4            Slovenian     c.1687C>T     1806C>T     c.7806-2A>G     IVS16-2A>G      c.181T>G    <<< 300T>G>>>            c.5266dupC     5382insC            c.181T>A     300T>A            Italian (Tuscany)     c.3228_3229delAG     3347delAG     c.8537_8538delA|(510-bp)            German     exon 17 deletion     c.1813dupA     2041insA      c.5266dupC     5382insC     c.4478del4     4706del4      c.181T>G    <<< 300T>G>>>     c.9098dupA     9326insA      c.4065_4068del4     4184del4            c.2338C>T     2457C>T            Czech     c.181T>G     300T>G     c.7913_79|  c.181T>G     300T>G     c.9098dupA     9326insA      c.4065_4068del4     4184del4            c.2338C>T     2457C>T            Czech     c.181T>G    <<< 300T>G>>>     c.7913_7917del5     8141del5      c.5266dupC     5382insC     c.8537_8538del2     8765delAG      c.3700_3704del5     3819del5            exons 1–|     exons 1–17 deletion            exons 5–14 deletion            Hungarian     c.5266dupC     5382insC     c.9098dupA     9326insA      c.181T>G    <<< 300T>G>>>     c.5946delT     6174delT      c.68_69delAG     185delAG            Greek     c.5266dupC     5382insC            c.5212G>A     5331G>A            c|G      exon 13 duplication (ins6kbEx13)            Irish     c.427G>T     546G>T            Polish     c.5266dupC     5382insC            c.181T>G    <<< 300T>G>>>            c.4035delA     4154delA            Latvian     c.4035delA     4154delA            c.5266dupC     5382insC            Lithuanian     c.4035|   Lithuanian     c.4035delA     4154delA            c.5266dupC     5382insC            Belarusian     c.5266dupC     5382insC            c.181T>G    <<< 300T>G>>>            Russian     c.5266dupC     5382insC            Apparently true founder mutations are written in italic.		
23199084	confirmed					23199084		del		NM_007297.3:c.5374delT	NM_007297.3:c.5654delT		na		5374delT				BRCA1	entrez	672			dna	6174delT	19324	19333	presumable multiple different origins [85, 86].  Splicing mutation c.5153-1G>A (BIC: 5272-1G>A) of BRCA1 and frameshift mutation c.5146_5149del4 (BIC:<<< 5374delT>>>ATG) of BRCA2 are also prevalent founder mutations in the Central Spain region, accounting for 18.4% and 13.6% of BRCA1 and BRCA2 positive families, respectively [80, 85, 87].		
23199084	confirmed					23199084		del		NM_000059.3:c.5374delT	NM_000059.3:c.5600delT		na		5374delT				BRCA2	entrez	675			dna	6174delT	19324	19333	presumable multiple different origins [85, 86].  Splicing mutation c.5153-1G>A (BIC: 5272-1G>A) of BRCA1 and frameshift mutation c.5146_5149del4 (BIC:<<< 5374delT>>>ATG) of BRCA2 are also prevalent founder mutations in the Central Spain region, accounting for 18.4% and 13.6% of BRCA1 and BRCA2 positive families, respectively [80, 85, 87].		
23199084	confirmed					23199084		dup		NM_007294.3:c.1016dupA|NM_007300.3:c.1016dupA	NM_007294.3:c.1247dupA|NM_007300.3:c.1247dupA		rs80357618|rs80357618		c.1016dupA| c.1016dupA				BRCA1	entrez	672			dna	c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA	30685,31116,31937,45498,45744	30696,31127,31948,45509,45755	ix mutations, including the most common BRCA1 c.3171_3175dup, four other common Scandinavian BCRA1 mutations (c.1082_1092del11, c.2475delC, c.1687C>T,<<< c.1016dupA>>> (BIC: 1135insA)) and one BRCA2 mutation (c.4258delG) accounted for approximately 75% of all BRCA1/2 mutations [124].|  ### Norway  Four Norwegian founder mutations in BRCA1 gene (c.1556delA (BIC: 1675delA), c.3228delAG (BIC: 3347delAG), c.697delGT (BIC: 816delGT) and<<< c.1016dupA>>> make up 68% of the BRCA1 mutation carriers [126, 127], and these have their own specific geographic distribution.|The large deletion of BRCA1 exons 1–13 is frequently found as well as exon 13 duplication (ins6kb13Ex) (http://www.inherited-cancer.com).  The BRCA1<<< c.1016dupA>>> mutation has also been reported in other countries (Italy, Germany, French-Canada), however allelotyping results indicated an independent origin of this mutation.|5delC     2594delC            c.1082_1092del11     1201del11            c.1687C>T     1806C>T            c.3626delT (Northern)     3745delT           <<< c.1016dupA>>>     1135insA            exon 13 duplication (ins6kbEx13)            Norwegian     c.1556delA     1675delA     c.2808del4     3036del4      c.3228delA|1556delA     1675delA     c.2808del4     3036del4      c.3228delAG     3347delAG     c.3847delGT     4075delGT      c.697delGT     816delGT           <<< c.1016dupA>>>     1135insA            c.3178G>T     3297G>T            c.4745delA     4864delA            c.2351del7     2470del7            c.3084del11     3203de		
23199084	confirmed					23199084		dup		NM_000059.3:c.1016dupA	NM_000059.3:c.1242dupA		na		c.1016dupA| c.1016dupA				BRCA2	entrez	675			dna	c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA	30685,31116,31937,45498,45744	30696,31127,31948,45509,45755	ix mutations, including the most common BRCA1 c.3171_3175dup, four other common Scandinavian BCRA1 mutations (c.1082_1092del11, c.2475delC, c.1687C>T,<<< c.1016dupA>>> (BIC: 1135insA)) and one BRCA2 mutation (c.4258delG) accounted for approximately 75% of all BRCA1/2 mutations [124].|  ### Norway  Four Norwegian founder mutations in BRCA1 gene (c.1556delA (BIC: 1675delA), c.3228delAG (BIC: 3347delAG), c.697delGT (BIC: 816delGT) and<<< c.1016dupA>>> make up 68% of the BRCA1 mutation carriers [126, 127], and these have their own specific geographic distribution.|The large deletion of BRCA1 exons 1–13 is frequently found as well as exon 13 duplication (ins6kb13Ex) (http://www.inherited-cancer.com).  The BRCA1<<< c.1016dupA>>> mutation has also been reported in other countries (Italy, Germany, French-Canada), however allelotyping results indicated an independent origin of this mutation.|5delC     2594delC            c.1082_1092del11     1201del11            c.1687C>T     1806C>T            c.3626delT (Northern)     3745delT           <<< c.1016dupA>>>     1135insA            exon 13 duplication (ins6kbEx13)            Norwegian     c.1556delA     1675delA     c.2808del4     3036del4      c.3228delA|1556delA     1675delA     c.2808del4     3036del4      c.3228delAG     3347delAG     c.3847delGT     4075delGT      c.697delGT     816delGT           <<< c.1016dupA>>>     1135insA            c.3178G>T     3297G>T            c.4745delA     4864delA            c.2351del7     2470del7            c.3084del11     3203de		
23199084	confirmed					23199084		del		NM_007297.3:c.5946delT	NM_007297.3:c.6226delT		na		c.5946delT| c.5946delT				BRCA1	entrez	672			dna	c.123delT|c.123delT|c.123delT|c.123delT|c.123delT|c.123delT	9055,9282,9736,25866,42318,44727	9066,9293,9747,25877,42329,44738	The most well characterized three founder mutations are two in BRCA1 gene c.68_69delAG (BIC: 185delAG) and c.5266dupC (BIC: 5382insC) and one in BRCA2<<< c.5946delT>>> (BIC: 6174delT) [31, 32, 33].|utations alone is now part of routine clinical practice for Ashkenazi Jewish individuals.  These 3 mutations (BRCA1 c.68_69delAG, c.5266dupC and BRCA2<<< c.5946delT>>>) account for 98–99% of identified mutations and are carried by about 2.6% (1/40) of the Ashkenazi Jewish population (1%, 0.13% and 1.52% respectively) [34, 35, 36].|e age of 70 years is similar for carriers of the BRCA1 c.68_69delAG and c.5266dupC mutations (64% and 67% respectively), however is much lower for the<<< c.5946delT>>> mutation (43%).|ies, common BRCA1 founder mutations c.5266dupC, c.181T>G and c.68_69delAG accounted for 80% of all BRCA1 mutations and c.9098dupA (BIC: 9326insA) with<<< c.5946delT>>> accounted for 50% of all BRCA2 mutations [42, 103].|lation     BRCA1 mutation     BRCA2 mutation      --- --- ---      HGVS     BIC     HGVS     BIC      Ashkenazi Jews     c.68_69delAG     185delAG    <<< c.5946delT>>>     6174delT      c.5266dupC     5382insC            Austrian     c.181T>G     300T>G     c.8363G>A     8591G>A      c.5266dupC     5382insC     c.87|1–17 deletion            exons 5–14 deletion            Hungarian     c.5266dupC     5382insC     c.9098dupA     9326insA      c.181T>G     300T>G    <<< c.5946delT>>>     6174delT      c.68_69delAG     185delAG            Greek     c.5266dupC     5382insC            c.5212G>A     5331G>A            c.5251C>T     53		
23199084	confirmed					23199084		del		NM_000059.3:c.5946delT	NM_000059.3:c.6172delT		rs80359550		c.5946delT| c.5946delT				BRCA2	entrez	675			dna	c.123delT|c.123delT|c.123delT|c.123delT|c.123delT|c.123delT	9055,9282,9736,25866,42318,44727	9066,9293,9747,25877,42329,44738	The most well characterized three founder mutations are two in BRCA1 gene c.68_69delAG (BIC: 185delAG) and c.5266dupC (BIC: 5382insC) and one in BRCA2<<< c.5946delT>>> (BIC: 6174delT) [31, 32, 33].|utations alone is now part of routine clinical practice for Ashkenazi Jewish individuals.  These 3 mutations (BRCA1 c.68_69delAG, c.5266dupC and BRCA2<<< c.5946delT>>>) account for 98–99% of identified mutations and are carried by about 2.6% (1/40) of the Ashkenazi Jewish population (1%, 0.13% and 1.52% respectively) [34, 35, 36].|e age of 70 years is similar for carriers of the BRCA1 c.68_69delAG and c.5266dupC mutations (64% and 67% respectively), however is much lower for the<<< c.5946delT>>> mutation (43%).|ies, common BRCA1 founder mutations c.5266dupC, c.181T>G and c.68_69delAG accounted for 80% of all BRCA1 mutations and c.9098dupA (BIC: 9326insA) with<<< c.5946delT>>> accounted for 50% of all BRCA2 mutations [42, 103].|lation     BRCA1 mutation     BRCA2 mutation      --- --- ---      HGVS     BIC     HGVS     BIC      Ashkenazi Jews     c.68_69delAG     185delAG    <<< c.5946delT>>>     6174delT      c.5266dupC     5382insC            Austrian     c.181T>G     300T>G     c.8363G>A     8591G>A      c.5266dupC     5382insC     c.87|1–17 deletion            exons 5–14 deletion            Hungarian     c.5266dupC     5382insC     c.9098dupA     9326insA      c.181T>G     300T>G    <<< c.5946delT>>>     6174delT      c.68_69delAG     185delAG            Greek     c.5266dupC     5382insC            c.5212G>A     5331G>A            c.5251C>T     53		
23199084	notConfirmed							ins		c.156None>A					 c.156_157insA|c.156_157insA				BRCA2	entrez	675			dna	c.123_124insGC|c.123_124insGC	19926,43678	19940,43692	cted for family history had pathological mutations; no founder mutation was identified [88].  ### Portugal  An Alu sequence insertion in BRCA2 exon 3 <<<(c.156_157insA>>>lu (BIC: 384insAlu)) is a founder mutation of Portuguese origin and accounts for more than one- fourth of deleterious BRCA1/2 mutations in breast/ovarian cancer families in Northern/Central Portugal.|A     9538delAA      c.470_471delCT     589_590delCT     c.5146_5149del4     374delTATG      c.5153-1G>A     5272-1G>A            Portuguese          <<< c.156_157insA>>>lu     384insAlu      Belgian     c.212+3A>G     IVS5+3A>G     c.516+1G>A     IVS6+1G>A      c.2359dupG     2478insG     c.6275_6276delTT     6503_650		
23199084	confirmed					23199084		sub		NM_007294.3:c.3319G>T|NM_007300.3:c.3319G>T|NM_007299.3:c.3319G>T	NM_007294.3:c.3550G>T|NM_007300.3:c.3550G>T|NM_007299.3:c.3512G>T		rs80357106|rs80357106|rs111791349		 c.3319G>T|c.3319G>T				BRCA1	entrez	672			dna	c.123T>A|c.123T>A|c.123T>A	27567,27837,45052	27577,27847,45062	ndinavian founder mutations and other European mutations, including BRCA1 c.5266dupC. The most common BRCA1 mutations were c.2475delC (BIC: 2594delC),<<< c.3319G>T>>> (BIC: 3438G>T), c.5266dupC and c.3710delT (BIC: 3829delT), which accounted 16%, 9%, 8% and 5% of BRCA1 positive families, respectively [109, 110, 111|ve families, respectively [109, 110, 111]. The c.2475delC BRCA1 mutation was also reported in Sweden, Norway and Western Europe (BIC database) and the<<< c.3319G>T>>> BRCA1 mutation was also reported in Norway (http://www.legeforeningen.no/id/153250.0).  The most common BRCA2 mutations were c.6373delA (BIC: 6601del|   c.5467G>A     5586G>A            Cypriot           c.8755delG     8984delG      Danish     c.2475delC     2594delC     c.6373delA     6601delA     <<< c.3319G>T>>>     3438G>T     c.1310_1013del4     1538del4      c.5266dupC     5382insC     c.6486_6489del4     6714del4      c.3710delT     3829delT     c.3847_38		
23199084	notConfirmed							del		c.3347A>None					 3347delA|3347delA				BRCA1	entrez	672			dna	6174delT|6174delT|6174delT|6174delT	13643,31073,42853,45664	13652,31082,42862,45673	icant regional founder effect has been demonstrated for few mutations [63, 64, 65, 66].  Four distinct BRCA1 founder mutations (c.3228_3229delAG (BIC:<<< 3347delA>>>G), c.3285delA (BIC: 3404delA), c.1380dupA (BIC: 1499insA), c.5062_5064del3 (BIC: 5181delGTT) accounted for a large fraction (73%) of BRCA1-attributab|er breast cancer in this region [115, 125].  ### Norway  Four Norwegian founder mutations in BRCA1 gene (c.1556delA (BIC: 1675delA), c.3228delAG (BIC:<<< 3347delA>>>G), c.697delGT (BIC: 816delGT) and c.1016dupA make up 68% of the BRCA1 mutation carriers [126, 127], and these have their own specific geographic distribution.|-2A>G      c.181T>G     300T>G            c.5266dupC     5382insC            c.181T>A     300T>A            Italian (Tuscany)     c.3228_3229delAG    <<< 3347delA>>>G     c.8537_8538delAG  (Sardinia)     8765delAG      c.3285delA     3404delA            c.1380dupA     1499insA            c.5062_5064del3     5181de|1135insA            exon 13 duplication (ins6kbEx13)            Norwegian     c.1556delA     1675delA     c.2808del4     3036del4      c.3228delAG    <<< 3347delA>>>G     c.3847delGT     4075delGT      c.697delGT     816delGT            c.1016dupA     1135insA            c.3178G>T     3297G>T            c.4745delA		
23199084	confirmed					23199084		sub		NM_007294.3:c.5075-2_5075A>C|NM_007300.3:c.5075-2_5075A>C|NM_007297.3:c.5075-2_5075A>C	NM_007294.3:c.5306-2_5306A>C|NM_007300.3:c.5306-2_5306A>C|NM_007297.3:c.5355-2_5355A>C		na|na|na		 c.5075-2A>C|c.5075-2A>C				BRCA1	entrez	672			dna	c.123+2A>T|c.123+2A>T	31721,45948	31733,45960	BRCA1 c.1A>C (BIC: 120A>C) and<<< c.5075-2A>C>>> (BIC: IVS17-2A>C) mutations are also locally frequent.|G>T            c.4745delA     4864delA            c.2351del7     2470del7            c.3084del11     3203del11            c.1A>C     120A>C           <<< c.5075-2A>C>>>     IVS17-2A>C            exons 1-13 deletion            exon 13 duplication (ins6kbEx13)            Finnish     c.4097-2A>G     4216-2A>G     c.771_		
23199084	confirmed					23199084		dup		NM_007294.3:c.2359dupG|NM_007300.3:c.2359dupG|NM_007299.3:c.2359dupG|NM_007297.3:c.2359dupG	NM_007294.3:c.2590dupG|NM_007300.3:c.2590dupG|NM_007299.3:c.2552dupG|NM_007297.3:c.2639dupG		rs397508964|rs397508964|na|na		c.2359dupG| c.2359dupG				BRCA1	entrez	672			dna	c.123dupA|c.123dupA|c.123dupA	20413,20803,43784	20424,20814,43795	[91] in a 49 BRCA1/2 positive families found six major recurrent founder mutations (three BRCA1 c.212+3A> (BIC: IVS5+3A>G),<<< c.2359dupG>>> (BIC: 2478insG), c.3661G>T (BIC: 3780G>T) and three BRCA2 c.516+1G>A (BIC: IVS6+1G>A), c.6275_6276delTT (BIC: 6503_6504delTT), c.8904delC (BIC: 9132d|BRCA1<<< c.2359dupG>>> and BRCA2 c.516+1G>A have not yet been reported in other populations.  ### The Netherlands (Holland)  Several founder mutations in BRCA1/2 have been identified in Holland [94], where significant regional and cultural differences exist.|   5272-1G>A            Portuguese           c.156_157insAlu     384insAlu      Belgian     c.212+3A>G     IVS5+3A>G     c.516+1G>A     IVS6+1G>A     <<< c.2359dupG>>>     2478insG     c.6275_6276delTT     6503_6504delTT      c.3661G>T     3780G>T     c.8904delC     9132delC      Dutch     c.2685_2686delAA     2804d		
23199084	confirmed					23199084		del		NM_007294.3:c.2804delA|NM_007300.3:c.2804delA|NM_007298.3:c.2804delA	NM_007294.3:c.3035delA|NM_007300.3:c.3035delA|NM_007298.3:c.2822delA		na|na|na		 2804delA|2804delA				BRCA1	entrez	672			dna	6174delT|6174delT	21083,43939	21092,43948	The BRCA1 c.2685_2686delAA (BIC:<<< 2804delA>>>A) founder mutation probably originated approximately 32 generations (∼200 years) ago, was also reported few times in Belgium and accounted for 24% of all BRCA1/2 mutations [92].|59dupG     2478insG     c.6275_6276delTT     6503_6504delTT      c.3661G>T     3780G>T     c.8904delC     9132delC      Dutch     c.2685_2686delAA    <<< 2804delA>>>A     c.5351dupA     5579insA      c.2193del5     2312del5     c.6275_6276delTT     6503delTT      c.1292dupT     1411insT            exon 13 deletion		
23199084	confirmed					23199084		del		NM_000059.3:c.2804delA	NM_000059.3:c.3030delA		na		 2804delA|2804delA				BRCA2	entrez	675			dna	6174delT|6174delT	21083,43939	21092,43948	The BRCA1 c.2685_2686delAA (BIC:<<< 2804delA>>>A) founder mutation probably originated approximately 32 generations (∼200 years) ago, was also reported few times in Belgium and accounted for 24% of all BRCA1/2 mutations [92].|59dupG     2478insG     c.6275_6276delTT     6503_6504delTT      c.3661G>T     3780G>T     c.8904delC     9132delC      Dutch     c.2685_2686delAA    <<< 2804delA>>>A     c.5351dupA     5579insA      c.2193del5     2312del5     c.6275_6276delTT     6503delTT      c.1292dupT     1411insT            exon 13 deletion		
23199084	notConfirmed							del		c.3875G>None					3875delG				BRCA1	entrez	672			dna	6174delT	16631	16640	In this region 4 BRCA1 gene mutations (c.4327C>T (BIC: 4446C>T/Arg1443X), c.3756_3759del4 (BIC:<<< 3875delG>>>TCT), c.962G>A (BIC: 1081G>A), c.2834_2836delinsC (BIC: 2953delGTA/insC) and 3 BRCA2 mutations (c.3170_3174del5 (BIC: 3398del5), c.5857G>T (BIC: 6085G		
23199084	notConfirmed							del		c.2157G>None					 2157delG|2157delG				BRCA2	entrez	675			dna	6174delT|6174delT	35076,46660	35085,46669	h, Danish and Belgian families (BIC database).  In the North-west of England two reccurent mutations (BRCA1 c.4065_4068del4 and BRCA2 c.1929delG (BIC:<<< 2157delG>>>) accounted for 16% of identified BRCA1 mutations in breast/ovarian cancer families and for 20% of BRCA2 positive male breast cancer families, respect| (Scotland)     2800delAA     c.6275_6276delTT (Scotland)     6503delTT      c.4065_4068del4 (North-West)     4184del4     c.1929delG (North-West)    <<< 2157delG>>>      exon 13 duplication (ins6kbEx13)            Irish     c.427G>T     546G>T            Polish     c.5266dupC     5382insC            c.181T>G     		
23199084	confirmed					23199084		sub		NM_007294.3:c.5123C>A|NM_007297.3:c.5123C>A	NM_007294.3:c.5354C>A|NM_007297.3:c.5403C>A		rs28897696|na		 c.5123C>A|c.5123C>A				BRCA1	entrez	672			dna	c.123T>A|c.123T>A	17676,43486	17686,43496	 test results from different laboratories shows that five mutations in the BRCA1 gene (c.68_69delAG, c.211A>G (BIC: 330A>G), c.5117G>A (BIC: 5236G>A),<<< c.5123C>A>>> (BIC: 5242C>A), c.470_471delCT (BIC: 589_590delCT) account for 46.6% of BRCA1 mutations and four mutations in BRCA2 (c.2808_2811del4 (BIC: 3036_3039d|3039del4      c.211A>G (Galicia)     330A>G     c.6629_6630delAA     c.6857delAA      c.5117G>A     5236G>A     c.9026_9030del5     9254-9258del5     <<< c.5123C>A>>>     5242C>A     c.9310_9311delAA     9538delAA      c.470_471delCT     589_590delCT     c.5146_5149del4     374delTATG      c.5153-1G>A     5272-1G>A		
23199084	confirmed					23199084		sub		NM_000059.3:c.5123C>A	NM_000059.3:c.5349C>A		na		 c.5123C>A|c.5123C>A				BRCA2	entrez	675			dna	c.123T>A|c.123T>A	17676,43486	17686,43496	 test results from different laboratories shows that five mutations in the BRCA1 gene (c.68_69delAG, c.211A>G (BIC: 330A>G), c.5117G>A (BIC: 5236G>A),<<< c.5123C>A>>> (BIC: 5242C>A), c.470_471delCT (BIC: 589_590delCT) account for 46.6% of BRCA1 mutations and four mutations in BRCA2 (c.2808_2811del4 (BIC: 3036_3039d|3039del4      c.211A>G (Galicia)     330A>G     c.6629_6630delAA     c.6857delAA      c.5117G>A     5236G>A     c.9026_9030del5     9254-9258del5     <<< c.5123C>A>>>     5242C>A     c.9310_9311delAA     9538delAA      c.470_471delCT     589_590delCT     c.5146_5149del4     374delTATG      c.5153-1G>A     5272-1G>A		
23199084	notConfirmed							sub		c.3780G>T					3780G>T| 3780G>T				BRCA2	entrez	675			dna	859G>A|859G>A	20457,43867	20465,43875	1/2 positive families found six major recurrent founder mutations (three BRCA1 c.212+3A> (BIC: IVS5+3A>G), c.2359dupG (BIC: 2478insG), c.3661G>T (BIC:<<< 3780G>T>>>) and three BRCA2 c.516+1G>A (BIC: IVS6+1G>A), c.6275_6276delTT (BIC: 6503_6504delTT), c.8904delC (BIC: 9132delC) alterations), which accounted for ne|gian     c.212+3A>G     IVS5+3A>G     c.516+1G>A     IVS6+1G>A      c.2359dupG     2478insG     c.6275_6276delTT     6503_6504delTT      c.3661G>T    <<< 3780G>T>>>     c.8904delC     9132delC      Dutch     c.2685_2686delAA     2804delAA     c.5351dupA     5579insA      c.2193del5     2312del5     c.6275_6276del		
23199084	confirmed					23199084		del		NM_007297.3:c.3745delT	NM_007297.3:c.4025delT		na		 3745delT|3745delT				BRCA1	entrez	672			dna	6174delT|6174delT|6174delT|6174delT	30089,32655,45478,46204	30098,32664,45487,46213	Yet another BRCA1 mutation c.3626delT (BIC:<<< 3745delT>>>) apparently originates in northern Sweden and Finland [121].  The 6-kb duplication of BRCA1 exon 13, aslo known as ins6kbEx13 (HGVS: c.4186-1787_4357|The most common BRCA1 mutations are c.4097-2A>G (BIC: 4216-2A>G), c.3485delA (BIC: 3604delA), c.3626delT (BIC:<<< 3745delT>>>), c.4327C>T (BIC: 4446C>T), c.2684del2 (BIC: 2803delAA) and c.5251C>T (BIC: 5370C>T).| 4486delG      c.2475delC     2594delC            c.1082_1092del11     1201del11            c.1687C>T     1806C>T            c.3626delT (Northern)    <<< 3745delT>>>            c.1016dupA     1135insA            exon 13 duplication (ins6kbEx13)            Norwegian     c.1556delA     1675delA     c.2808del4     30|        Finnish     c.4097-2A>G     4216-2A>G     c.771_775del5     999del5      c.3485delA     3604delA     c.7480C>T     7708C>T      c.3626delT    <<< 3745delT>>>     c.8327T>G     8555T>G      c.4327C>T     4446C>T     c.9118-2A>G     9346-2A>G      c.2684del2     2803delAA     c.9117+1G>A     9345+1G>A      c		
23199084	confirmed					23199084		del		NM_007294.3:c.3710delT|NM_007300.3:c.3710delT	NM_007294.3:c.3941delT|NM_007300.3:c.3941delT		rs80357564|rs80357564		c.3710delT| c.3710delT				BRCA1	entrez	672			dna	c.123delT|c.123delT	27608,45174	27619,45185	opean mutations, including BRCA1 c.5266dupC. The most common BRCA1 mutations were c.2475delC (BIC: 2594delC), c.3319G>T (BIC: 3438G>T), c.5266dupC and<<< c.3710delT>>> (BIC: 3829delT), which accounted 16%, 9%, 8% and 5% of BRCA1 positive families, respectively [109, 110, 111]. The c.2475delC BRCA1 mutation was also |c.6373delA     6601delA      c.3319G>T     3438G>T     c.1310_1013del4     1538del4      c.5266dupC     5382insC     c.6486_6489del4     6714del4     <<< c.3710delT>>>     3829delT     c.3847_3848delGT     4075delGT      exons 3-16 deletion            Swedish     c.3171_3175dup     3171ins5     c.4258delG     4486de		
23199084	confirmed					23199084		del		NM_007294.3:c.3485delA|NM_007300.3:c.3485delA|NM_007299.3:c.3485delA|NM_007298.3:c.3485delA	NM_007294.3:c.3716delA|NM_007300.3:c.3716delA|NM_007299.3:c.3678delA|NM_007298.3:c.3503delA		rs80357509|rs80357509|na|na		c.3485delA| c.3485delA				BRCA1	entrez	672			dna	c.123delT|c.123delT	32610,46134	32621,46145	The most common BRCA1 mutations are c.4097-2A>G (BIC: 4216-2A>G),<<< c.3485delA>>> (BIC: 3604delA), c.3626delT (BIC: 3745delT), c.4327C>T (BIC: 4446C>T), c.2684del2 (BIC: 2803delAA) and c.5251C>T (BIC: 5370C>T).|   exons 1-13 deletion            exon 13 duplication (ins6kbEx13)            Finnish     c.4097-2A>G     4216-2A>G     c.771_775del5     999del5     <<< c.3485delA>>>     3604delA     c.7480C>T     7708C>T      c.3626delT     3745delT     c.8327T>G     8555T>G      c.4327C>T     4446C>T     c.9118-2A>G     9346-2A>		
23199084	confirmed					23199084		sub		NM_007294.3:c.1A>C|NM_007300.3:c.1A>C|NM_007299.3:c.1A>C|NM_007298.3:c.1A>C|NM_007297.3:c.1A>C	NM_007294.3:c.232A>C|NM_007300.3:c.232A>C|NM_007299.3:c.194A>C|NM_007298.3:c.19A>C|NM_007297.3:c.281A>C		rs80357287|rs80357287|rs80357287|rs80357287|na		 c.1A>C|c.1A>C				BRCA1	entrez	672			dna	c.123T>A|c.123T>A	31696,45919	31703,45926	BRCA1<<< c.1A>C>>> (BIC: 120A>C) and c.5075-2A>C (BIC: IVS17-2A>C) mutations are also locally frequent.|           c.3178G>T     3297G>T            c.4745delA     4864delA            c.2351del7     2470del7            c.3084del11     3203del11           <<< c.1A>C>>>     120A>C            c.5075-2A>C     IVS17-2A>C            exons 1-13 deletion            exon 13 duplication (ins6kbEx13)            Finnish     c.		
23199084	confirmed					23199084		sub		NM_000059.3:c.1A>C	NM_000059.3:c.227A>C		na		 c.1A>C|c.1A>C				BRCA2	entrez	675			dna	c.123T>A|c.123T>A	31696,45919	31703,45926	BRCA1<<< c.1A>C>>> (BIC: 120A>C) and c.5075-2A>C (BIC: IVS17-2A>C) mutations are also locally frequent.|           c.3178G>T     3297G>T            c.4745delA     4864delA            c.2351del7     2470del7            c.3084del11     3203del11           <<< c.1A>C>>>     120A>C            c.5075-2A>C     IVS17-2A>C            exons 1-13 deletion            exon 13 duplication (ins6kbEx13)            Finnish     c.		
23199084	notConfirmed							del		c.9132C>None					 9132delC|9132delC				BRCA1	entrez	672			dna	6174delT|6174delT	20568,43894	20577,43903	59dupG (BIC: 2478insG), c.3661G>T (BIC: 3780G>T) and three BRCA2 c.516+1G>A (BIC: IVS6+1G>A), c.6275_6276delTT (BIC: 6503_6504delTT), c.8904delC (BIC:<<< 9132delC>>>) alterations), which accounted for nearly 60% of all mutations identified. BRCA1 c.212+3A>G was previously reported as Belgian founder mutation [92, 93], later also found in a few German, Dutch and French families [91].|5+3A>G     c.516+1G>A     IVS6+1G>A      c.2359dupG     2478insG     c.6275_6276delTT     6503_6504delTT      c.3661G>T     3780G>T     c.8904delC    <<< 9132delC>>>      Dutch     c.2685_2686delAA     2804delAA     c.5351dupA     5579insA      c.2193del5     2312del5     c.6275_6276delTT     6503delTT      c.1292		
23199084	confirmed					23199084		sub		NM_007294.3:c.5212G>A	NM_007294.3:c.5443G>A		rs80356937		c.5212G>A| c.5212G>A				BRCA1	entrez	672			dna	c.123T>A|c.123T>A	26385,44838	26395,44848	cancer patients, one third carried BRCA2 mutations, including c.9098dupA [104].  ### Greece  In the Greek population four BRCA1 mutations (c.5526dupC,<<< c.5212G>A>>> (BIC: 5331G>A/G1738R), c.5251C>T (BIC: 5370C>T/R1751X), c.5467G>A (BIC: 5586G>A), account for 54% of all mutations detected in BRCA1/2 genes and for |  9326insA      c.181T>G     300T>G     c.5946delT     6174delT      c.68_69delAG     185delAG            Greek     c.5266dupC     5382insC           <<< c.5212G>A>>>     5331G>A            c.5251C>T     5370C>T            c.5467G>A     5586G>A            Cypriot           c.8755delG     8984delG      Danish     c.		
23199084	confirmed					23199084		sub		NM_007294.3:c.5193G>A	NM_007294.3:c.5424G>A		na		5193G>A				BRCA1	entrez	672			dna	859G>A	33956	33964	% of consecutive unselected breast cancer cases, 7.9% of ovarian cancer cases and 40% of male breast cancer cases [6, 146].  The BRCA1 c.5074G>A (BIC:<<< 5193G>A>>>) is another founder mutation recently identified in Icelandic population, however it is extremely rare and contributes only to 1% of breast/ovarian c		
23199084	notConfirmed							sub		c.1G>A					1G>A				BRCA1	entrez	672			dna	859G>A|859G>A|859G>A|859G>A|859G>A|859G>A	12653,19247,19263,42496,43627,43641	12658,19252,19268,42501,43632,43646	The most prevalent BRCA2 mutations are c.8363G>A (BIC: 8591G>A/W2788X), c.8754+1G>A (BIC: IVS21<<<-1G>A>>>) and c.3860delA (BIC: 4088delA), representing 9%, 7% and 6% of the BRCA2 mutation families respectively (Rappaport, personal communication).  ### Slo|he second recurrent pathological mutation in the BIC database ranking with a presumable multiple different origins [85, 86].  Splicing mutation c.5153<<<-1G>A>>> (BIC: 5272-1G>A) of BRCA1 and frameshift mutation c.5146_5149del4 (BIC: 5374delTATG) of BRCA2 are also prevalent founder mutations in the Central Spa|ent pathological mutation in the BIC database ranking with a presumable multiple different origins [85, 86].  Splicing mutation c.5153-1G>A (BIC: 5272<<<-1G>A>>>) of BRCA1 and frameshift mutation c.5146_5149del4 (BIC: 5374delTATG) of BRCA2 are also prevalent founder mutations in the Central Spain region, accounting for 18.4% and 13.6% of BRCA1 and BRCA2 positive families, respectively [80, 85, 87].|  c.5266dupC     5382insC            Austrian     c.181T>G     300T>G     c.8363G>A     8591G>A      c.5266dupC     5382insC     c.8754+1G>A     IVS21<<<-1G>A>>>      c.1687C>T     1806C>T     c.3860delA     4088delA      c.3016_3019del4     3135del4            c.2676_2679del4     2795del4            Slovenian|del5      c.5123C>A     5242C>A     c.9310_9311delAA     9538delAA      c.470_471delCT     589_590delCT     c.5146_5149del4     374delTATG      c.5153<<<-1G>A>>>     5272-1G>A            Portuguese           c.156_157insAlu     384insAlu      Belgian     c.212+3A>G     IVS5+3A>G     c.516+1G>A     IVS6+1G>A   |23C>A     5242C>A     c.9310_9311delAA     9538delAA      c.470_471delCT     589_590delCT     c.5146_5149del4     374delTATG      c.5153-1G>A     5272<<<-1G>A>>>            Portuguese           c.156_157insAlu     384insAlu      Belgian     c.212+3A>G     IVS5+3A>G     c.516+1G>A     IVS6+1G>A      c.2359dupG 		
23199084	confirmed					23199084		del		NM_007297.3:c.185delA	NM_007297.3:c.465delA		na		 185delA|185delA				BRCA1	entrez	672			dna	6174delT|6174delT|6174delT|6174delT	8997,42305,43281,44773	9005,42313,43289,44781	The most well characterized three founder mutations are two in BRCA1 gene c.68_69delAG (BIC:<<< 185delA>>>G) and c.5266dupC (BIC: 5382insC) and one in BRCA2 c.5946delT (BIC: 6174delT) [31, 32, 33].|lations  Population     BRCA1 mutation     BRCA2 mutation      --- --- ---      HGVS     BIC     HGVS     BIC      Ashkenazi Jews     c.68_69delAG    <<< 185delA>>>G     c.5946delT     6174delT      c.5266dupC     5382insC            Austrian     c.181T>G     300T>G     c.8363G>A     8591G>A      c.5266dupC     5|lGTT     5181_5183delGTT            French     c.3481_3491del11     3600del11            c.5128G>T     5247G>T            Spanish     c.68_69delAG    <<< 185delA>>>G     c.2808_2811del4 (Castilla-Leon)     3036_3039del4      c.211A>G (Galicia)     330A>G     c.6629_6630delAA     c.6857delAA      c.5117G>A     523|          Hungarian     c.5266dupC     5382insC     c.9098dupA     9326insA      c.181T>G     300T>G     c.5946delT     6174delT      c.68_69delAG    <<< 185delA>>>G            Greek     c.5266dupC     5382insC            c.5212G>A     5331G>A            c.5251C>T     5370C>T            c.5467G>A     5586G>A     		
23199084	confirmed					23199084		sub	NP_009225.1:p.Gly1710Stop	NM_007294.3:c.5128G>T	NM_007294.3:c.5359G>T		rs397509229		/Gly1710X				BRCA1	entrez	672			prot	Met1775Arg	15639	15648	The c.3481_3491del11 (BIC: 3600del11) in exon 11 accounts for 37% and the nonsense mutation c.5128G>T (BIC: 5247G>T<<</Gly1710X>>>) in exon 18 for 15% of all BRCA1/2 mutations in that region (overall 52%) [4, 75].  The haplotype analysis of the families carrying the mutation c.34		
23199084	confirmed					23199084		sub	NP_000050.2:p.Trp2788Stop	NM_000059.3:c.8364G>A|NM_000059.3:c.8363G>A	NM_000059.3:c.8590G>A|NM_000059.3:c.8589G>A		rs397507981|rs80359080		/W2788X				BRCA2	entrez	675			prot	M1775R	12620	12627	The most prevalent BRCA2 mutations are c.8363G>A (BIC: 8591G>A<<</W2788X>>>), c.8754+1G>A (BIC: IVS21-1G>A) and c.3860delA (BIC: 4088delA), representing 9%, 7% and 6% of the BRCA2 mutation families respectively (Rappaport, pe		
23199084	confirmed					23199084		sub	NP_009225.1:p.Arg1443Stop|NP_009231.2:p.Arg1443Stop	NM_007294.3:c.4327C>T|NM_007300.3:c.4327C>T	NM_007294.3:c.4558C>T|NM_007300.3:c.4558C>T		rs41293455|rs41293455		/Arg1443X				BRCA1	entrez	672			prot	Met1775Arg	16598	16607	In this region 4 BRCA1 gene mutations (c.4327C>T (BIC: 4446C>T<<</Arg1443X>>>), c.3756_3759del4 (BIC: 3875delGTCT), c.962G>A (BIC: 1081G>A), c.2834_2836delinsC (BIC: 2953delGTA/insC) and 3 BRCA2 mutations (c.3170_3174del5 (BIC:		
23199084	confirmed					23199084		sub	NP_009225.1:p.Arg1751Stop	NM_007294.3:c.5251C>T	NM_007294.3:c.5482C>T		rs80357123		/R1751X				BRCA1	entrez	672			prot	M1775R	26442	26449	ding c.9098dupA [104].  ### Greece  In the Greek population four BRCA1 mutations (c.5526dupC, c.5212G>A (BIC: 5331G>A/G1738R), c.5251C>T (BIC: 5370C>T<<</R1751X>>>), c.5467G>A (BIC: 5586G>A), account for 54% of all mutations detected in BRCA1/2 genes and for 73% of the BRCA1 mutations positive families, whereas 		
23199084	confirmed					23199084		sub	NP_009230.2:p.Cys39Gly|NP_009225.1:p.Cys39Gly|NP_009229.2:p.Cys39Gly|NP_009231.2:p.Cys39Gly	NM_007299.3:c.115T>G|NM_007294.3:c.115T>G|NM_007298.3:c.115T>G|NM_007300.3:c.115T>G	NM_007299.3:c.308T>G|NM_007294.3:c.346T>G|NM_007298.3:c.133T>G|NM_007300.3:c.346T>G		rs80357164|rs80357164|rs80357164|rs80357164		/Cys39Gly				BRCA1	entrez	672			prot	Met1775Arg	28903	28912	 founder mutation, comprising 40% (6/15) of all BRCA1/2 families with LGRs [112].  Recently a pathogenic founder BRCA1 mutation c.234T>G (BIC: 2466T>G<<</Cys39Gly>>>) was desribed in Greenland (Inuit population), an autonomous country within the Kingdom of Denmark, with a high carrier frequency (1.6%) in this population [113, 114].		
23199084	confirmed					23199084		sub	NP_009230.2:p.Glu143Stop|NP_009225.1:p.Glu143Stop|NP_009229.2:p.Glu143Stop|NP_009231.2:p.Glu143Stop	NM_007299.3:c.427G>T|NM_007294.3:c.427G>T|NM_007298.3:c.427G>T|NM_007300.3:c.427G>T	NM_007299.3:c.620G>T|NM_007294.3:c.658G>T|NM_007298.3:c.445G>T|NM_007300.3:c.658G>T		rs80356991|rs80356991|rs80356991|rs80356991		/E143X				BRCA1	entrez	672			prot	M1775R	35735	35741	stributed mainly in English- speaking countries or in countries with historical links with Britain.  ### Ireland  A single BRCA1 c.427G>T (BIC: 546G>T<<</E143X>>>) mutation accounts for about 22% of all hereditary breast cancer patients from relatively homogenous Irish population and presumably is due to the fo		
23199084	confirmed					23199084		sub	NP_009225.1:p.Gly1738Arg	NM_007294.3:c.5212G>C|NM_007294.3:c.5212G>A	NM_007294.3:c.5443G>C|NM_007294.3:c.5443G>A		rs80356937|rs80356937		/G1738R|G1738R				BRCA1	entrez	672			prot	M1775R|M1775R	26409,26917	26416,26924	rd carried BRCA2 mutations, including c.9098dupA [104].  ### Greece  In the Greek population four BRCA1 mutations (c.5526dupC, c.5212G>A (BIC: 5331G>A<<</G1738R>>>), c.5251C>T (BIC: 5370C>T/R1751X), c.5467G>A (BIC: 5586G>A), account for 54% of all mutations detected in BRCA1/2 genes and for 73% of the BRCA1 muta| BRCA1/2 mutations identified in Greek familial breast/ovarian cancer patients [45, 105].  Previously described as unclassified BRCA1 missense variant<<< G1738R>>> was proved to be pathogenic founder mutation in Greece and accounts for about 12% of all carriers with deleterious mutations in BRCA1/2 genes [106]. 		
23199084	confirmed					23199084		sub	NP_009230.2:p.Cys61Gly|NP_009225.1:p.Cys61Gly|NP_009229.2:p.Cys61Gly|NP_009231.2:p.Cys61Gly	NM_007299.3:c.181T>G|NM_007294.3:c.181T>G|NM_007298.3:c.181T>G|NM_007300.3:c.181T>G	NM_007299.3:c.374T>G|NM_007294.3:c.412T>G|NM_007298.3:c.199T>G|NM_007300.3:c.412T>G		rs28897672|rs28897672|rs28897672|rs28897672		/C61G				BRCA1	entrez	672			prot	M1775R	11666	11671	There were initial reports for several apparently founder BRCA1 mutations in Austria [58, 59], although they (c.181T>G (BIC: 300T>G<<</C61G>>>), c.5266dupC, c.1687C>T (BIC: 1806C>T)) represent common mutations prevalent in other European countries.		
23199084	confirmed					23199084		sub	NP_009225.1:p.Arg1753Thr	NM_007294.3:c.5258G>C	NM_007294.3:c.5489G>C		rs397509246		/R1753T				BRCA1	entrez	672			prot	M1775R	38744	38751	Two other mutations, BRCA1 c.181T>G and recently proved to be pathogenious c.5258G>C (BIC: 5377G>C<<</R1753T>>>) were also found in more than one family; together with two founder mutations they comprise around 90% of BRCA1 gene mutations and around 85% of all BRCA1/2 mutations identified (Janavičius, unpublished data).		
23199084	notConfirmed							sub		IVS21-1G>A					IVS21-1G>A				BRCA2	entrez	675			intron	IVS5+3A>G|IVS5+3A>G	12648,42491	12658,42501	The most prevalent BRCA2 mutations are c.8363G>A (BIC: 8591G>A/W2788X), c.8754+1G>A (BIC: <<<IVS21-1G>A>>>) and c.3860delA (BIC: 4088delA), representing 9%, 7% and 6% of the BRCA2 mutation families respectively (Rappaport, personal communication).  ### Slo|T      c.5266dupC     5382insC            Austrian     c.181T>G     300T>G     c.8363G>A     8591G>A      c.5266dupC     5382insC     c.8754+1G>A     <<<IVS21-1G>A>>>      c.1687C>T     1806C>T     c.3860delA     4088delA      c.3016_3019del4     3135del4            c.2676_2679del4     2795del4            Slovenian		
23199084	notConfirmed							sub		IVS5+3A>G					IVS5+3A>G				BRCA1	entrez	672			intron	IVS5+3A>G|IVS5+3A>G	20402,43741	20411,43750	[91] in a 49 BRCA1/2 positive families found six major recurrent founder mutations (three BRCA1 c.212+3A> (BIC: <<<IVS5+3A>G>>>), c.2359dupG (BIC: 2478insG), c.3661G>T (BIC: 3780G>T) and three BRCA2 c.516+1G>A (BIC: IVS6+1G>A), c.6275_6276delTT (BIC: 6503_6504delTT), c.8904del|_5149del4     374delTATG      c.5153-1G>A     5272-1G>A            Portuguese           c.156_157insAlu     384insAlu      Belgian     c.212+3A>G     <<<IVS5+3A>G>>>     c.516+1G>A     IVS6+1G>A      c.2359dupG     2478insG     c.6275_6276delTT     6503_6504delTT      c.3661G>T     3780G>T     c.8904delC     9132d		
23199084	notConfirmed							sub		IVS6+1G>A					IVS6+1G>A				BRCA2	entrez	675			intron	IVS5+3A>G|IVS5+3A>G	20500,43770	20509,43779	rent founder mutations (three BRCA1 c.212+3A> (BIC: IVS5+3A>G), c.2359dupG (BIC: 2478insG), c.3661G>T (BIC: 3780G>T) and three BRCA2 c.516+1G>A (BIC: <<<IVS6+1G>A>>>), c.6275_6276delTT (BIC: 6503_6504delTT), c.8904delC (BIC: 9132delC) alterations), which accounted for nearly 60% of all mutations identified. BRCA1 | c.5153-1G>A     5272-1G>A            Portuguese           c.156_157insAlu     384insAlu      Belgian     c.212+3A>G     IVS5+3A>G     c.516+1G>A     <<<IVS6+1G>A>>>      c.2359dupG     2478insG     c.6275_6276delTT     6503_6504delTT      c.3661G>T     3780G>T     c.8904delC     9132delC      Dutch     c.2685_268		
23199084	notConfirmed							sub		IVS11+3A>G					IVS11+3A>G				BRCA1	entrez	672			intron	IVS5+3A>G|IVS5+3A>G	33168,46411	33178,46421	Some mutations are unique to the Finns, such as c.4096+3A>G (BIC: <<<IVS11+3A>G>>>) in BRCA1 and c.9117+1G>A (BIC: 9345+1G>A), c.7480C>T, c.8327T>G in BRCA2 genes.  The mutation spectrum in Eastern part slightly differs from those o|46C>T     c.9118-2A>G     9346-2A>G      c.2684del2     2803delAA     c.9117+1G>A     9345+1G>A      c.5251C>T     5370C>T            c.4096+3A>G     <<<IVS11+3A>G>>>            Iceland           c.771_775del5     999del5      British     c.2681_2682delAA (Scotland)     2800delAA     c.6275_6276delTT (Scotland)    		
23199084	notConfirmed							sub		IVS17-2A>C					IVS17-2A>C				BRCA1	entrez	672			intron	IVS5+3A>G|IVS5+3A>G	31740,45965	31750,45975	BRCA1 c.1A>C (BIC: 120A>C) and c.5075-2A>C (BIC: <<<IVS17-2A>C>>>) mutations are also locally frequent.|4745delA     4864delA            c.2351del7     2470del7            c.3084del11     3203del11            c.1A>C     120A>C            c.5075-2A>C     <<<IVS17-2A>C>>>            exons 1-13 deletion            exon 13 duplication (ins6kbEx13)            Finnish     c.4097-2A>G     4216-2A>G     c.771_775del5     999		
23199084	notConfirmed							sub		IVS16-2A>G					IVS16-2A>G				BRCA2	entrez	675			intron	IVS5+3A>G|IVS5+3A>G	13010,42698	13020,42708	tations were identified: four in the BRCA1 gene (c.1687C>T, c.181T>G, c.5266dupC, c.181T> (BIC: 300T>A)) and one in the BRCA2 gene (c.7806-2A>G (BIC: <<<IVS16-2A>G>>>) [43, 61, 62]. Respectively, they accounted for 26%, 18%, 13% and 11% of BRCA1 mutations and 56% of BRCA2 mutations.|4088delA      c.3016_3019del4     3135del4            c.2676_2679del4     2795del4            Slovenian     c.1687C>T     1806C>T     c.7806-2A>G     <<<IVS16-2A>G>>>      c.181T>G     300T>G            c.5266dupC     5382insC            c.181T>A     300T>A            Italian (Tuscany)     c.3228_3229delAG     3347		
23199084 All mutations found
23199084	confirmed					23199084		sub		NM_007294.3:c.2457C>T|NM_007300.3:c.2457C>T|NM_007297.3:c.2457C>T	NM_007294.3:c.2688C>T|NM_007300.3:c.2688C>T|NM_007297.3:c.2737C>T		rs80357669|rs80357669|na		 2457C>T|2457C>T				BRCA1	entrez	672			dna	859G>A|859G>A	23541,40706	23549,40714	Eighteen BRCA1 mutations, including the most common c.5266dupC, c.181T>G, c.4065_4068del4 (BIC: 4184del4) and c.2338C>T (BIC:<<< 2457C>T>>>), were found at least 3 times and comprised 66% of all BRCA1 mutations.|dupA c.5946delT  9326insA 6174delT  c.3700_3704del5 exons 1–17 deletion exons 5–14 deletion c.5266dupC c.181T>G c.68_69delAG  5382insC 300T>G 4184del4<<< 2457C>T>>> 300T>G 5382insC 3819del5  5382insC 300T>G 185delAG  406  EPMA Journal (2010) 1:397–412  Table 1 (continued) Population  Greek  Cypriot Danish  Swedis		
23199084	confirmed					23199084		sub		NM_007294.3:c.5467G>A|NM_007297.3:c.5467G>A	NM_007294.3:c.5698G>A|NM_007297.3:c.5747G>A		rs80357212|na		c.5467G>A| c.5467G>A				BRCA1	entrez	672			dna	c.123T>A|c.123T>A	26681,41000	26691,41010	e Greek population four BRCA1 mutations (c.5526dupC, c.5212G>A (BIC: 5331G>A/G1738R), c.5251C>T (BIC:  EPMA Journal (2010) 1:397–412  5370C>T/R1751X),<<< c.5467G>A>>> (BIC: 5586G>A), account for 54% of all mutations detected in BRCA1/2 genes and for 73% of the BRCA1 mutations positive families, whereas the rest are|Danish  Swedish  Norwegian  Finnish  Iceland British  Irish Polish  Latvian  BRCA1 mutation  BRCA2 mutation  HGVS  BIC  c.5266dupC c.5212G>A c.5251C>T<<< c.5467G>A>>>  5382insC 5331G>A 5370C>T 5586G>A  c.2475delC c.3319G>T c.5266dupC c.3710delT  2594delC 3438G>T 5382insC 3829delT  HGVS  BIC  c.8755delG c.6373delA c		
23199084	confirmed					23199084		sub		NM_007300.3:c.5569G>T	NM_007300.3:c.5800G>T		rs80356942		c.5569G>T				BRCA1	entrez	672			dna	c.123T>A	33251	33261	6384del2 (BIC: 6503delTT), c.3853dupA (BIC: 4081insA) and<<< c.5569G>T>>> (BIC: 5797G>T)).		
23199084	confirmed					23199084		sub		NM_000059.3:c.5569G>T	NM_000059.3:c.5795G>T		rs80358778		c.5569G>T				BRCA2	entrez	675			dna	c.123T>A	33251	33261	6384del2 (BIC: 6503delTT), c.3853dupA (BIC: 4081insA) and<<< c.5569G>T>>> (BIC: 5797G>T)).		
23199084	confirmed					23199084		dup		NM_007294.3:c.1292dupT|NM_007300.3:c.1292dupT	NM_007294.3:c.1523dupT|NM_007300.3:c.1523dupT		rs80357346|rs80357346		 c.1292dupT				BRCA1	entrez	672			dna	c.123dupA|c.123dupA	21531,40083	21542,40094	BRCA1 c.2193del5 (BIC: 2312del5), and<<< c.1292dupT>>> (BIC: 1411insT) mutations were also commonly found [92, 94]. In the south-west of Holland two founder mutations: 3.8-kb deletion of BRCA1 exon 13, al|538delAA  c.470_471delCT c.5153-1G>A  589_590delCT 5272-1G>A  c.5146_5149del4  374delTATG  c.212+3A>G c.2359dupG c.3661G>T c.2685_2686delAA c.2193del5<<< c.1292dupT>>> exon 13 deletion (3,8-kb) exon 22 deletion (510-bp) exon 17 deletion c.5266dupC c.181T>G c.4065_4068del4 c.2338C>T c.181T>G c.5266dupC  IVS5+3A>G 247		
23199084	confirmed					23199084		del		NM_007299.3:c.3604delA|NM_007297.3:c.3604delA	NM_007299.3:c.3797delA|NM_007297.3:c.3884delA		na		 3604delA|3604delA				BRCA1	entrez	672			dna	6174delT|6174delT	32805,41857	32814,41866	 majority (around 84%) of all BRCA1/2 mutations detected [130–138]. The most common BRCA1 mutations are c.4097-2A>G (BIC: 4216-2A>G), c.3485delA (BIC:<<< 3604delA>>>), c.3626delT (BIC: 3745delT), c.4327C>T (BIC: 4446C>T), c.2684del2 (BIC: 2803delAA) and c.5251C>T (BIC: 5370C>T).|075delGT  exons 1-13 deletion exon 13 duplication (ins6kbEx13) c.4097-2A>G c.3485delA c.3626delT c.4327C>T c.2684del2 c.5251C>T c.4096+3A>G  4216-2A>G<<< 3604delA>>> 3745delT 4446C>T 2803delAA 5370C>T IVS11+3A>G  c.771_775del5 c.7480C>T c.8327T>G c.9118-2A>G c.9117+1G>A  999del5 7708C>T 8555T>G 9346-2A>G 9345+1G>A		
23199084	confirmed					23199084		del		NM_000059.3:c.3604delA	NM_000059.3:c.3830delA		na		 3604delA|3604delA				BRCA2	entrez	675			dna	6174delT|6174delT	32805,41857	32814,41866	 majority (around 84%) of all BRCA1/2 mutations detected [130–138]. The most common BRCA1 mutations are c.4097-2A>G (BIC: 4216-2A>G), c.3485delA (BIC:<<< 3604delA>>>), c.3626delT (BIC: 3745delT), c.4327C>T (BIC: 4446C>T), c.2684del2 (BIC: 2803delAA) and c.5251C>T (BIC: 5370C>T).|075delGT  exons 1-13 deletion exon 13 duplication (ins6kbEx13) c.4097-2A>G c.3485delA c.3626delT c.4327C>T c.2684del2 c.5251C>T c.4096+3A>G  4216-2A>G<<< 3604delA>>> 3745delT 4446C>T 2803delAA 5370C>T IVS11+3A>G  c.771_775del5 c.7480C>T c.8327T>G c.9118-2A>G c.9117+1G>A  999del5 7708C>T 8555T>G 9346-2A>G 9345+1G>A		
23199084	confirmed					23199084		del		NM_007297.3:c.5149delC	NM_007297.3:c.5429delC		na		5149delC				BRCA1	entrez	672			dna	6174delT	16411	16420	be specific to the France, but the analysis of its haplotype is less conclusive and needs further confirmation [6]. The BRCA1 c.5030_5033delCTAA (BIC:<<< 5149delC>>>TAA) [76] and c.3839_3843delinsAGGC (BIC: 3958delCTCAGinsAGGC) [77] mutations were reported in at least three independent families from France. Well-d		
23199084	confirmed					23199084		del		NM_007294.3:c.1100delC|NM_007300.3:c.1100delC	NM_007294.3:c.1331delC|NM_007300.3:c.1331delC		na|na		1100delC				BRCA1	entrez	672			dna	6174delT	71341	71350	Syrjakoski K, Kuukasjarvi T, Auvinen A, Kallioniemi OP. CHEK2<<< 1100delC>>> is not a risk factor for male breast cancer population.		
23199084	notConfirmed							sub		c.5370C>T					5370C>T| 5370C>T				BRCA2	entrez	675			dna	859G>A|859G>A|859G>A|859G>A	26664,32918,41028,41893	26672,32926,41036,41901	04]. Greece In the Greek population four BRCA1 mutations (c.5526dupC, c.5212G>A (BIC: 5331G>A/G1738R), c.5251C>T (BIC:  EPMA Journal (2010) 1:397–412 <<< 5370C>T>>>/R1751X), c.5467G>A (BIC: 5586G>A), account for 54% of all mutations detected in BRCA1/2 genes and for 73% of the BRCA1 mutations positive families, w|>G (BIC: 4216-2A>G), c.3485delA (BIC: 3604delA), c.3626delT (BIC: 3745delT), c.4327C>T (BIC: 4446C>T), c.2684del2 (BIC: 2803delAA) and c.5251C>T (BIC:<<< 5370C>T>>>).|Finnish  Iceland British  Irish Polish  Latvian  BRCA1 mutation  BRCA2 mutation  HGVS  BIC  c.5266dupC c.5212G>A c.5251C>T c.5467G>A  5382insC 5331G>A<<< 5370C>T>>> 5586G>A  c.2475delC c.3319G>T c.5266dupC c.3710delT  2594delC 3438G>T 5382insC 3829delT  HGVS  BIC  c.8755delG c.6373delA c.1310_1013del4 c.6486_6489|3 duplication (ins6kbEx13) c.4097-2A>G c.3485delA c.3626delT c.4327C>T c.2684del2 c.5251C>T c.4096+3A>G  4216-2A>G 3604delA 3745delT 4446C>T 2803delAA<<< 5370C>T>>> IVS11+3A>G  c.771_775del5 c.7480C>T c.8327T>G c.9118-2A>G c.9117+1G>A  999del5 7708C>T 8555T>G 9346-2A>G 9345+1G>A  c.2681_2682delAA (Scotland)  2800		
23199084	confirmed					23199084		sub		NM_000059.3:c.8754+1_8754G>A	NM_000059.3:c.8980+1_8980G>A		rs397508006		c.8754+1G>A| c.8754+1G>A				BRCA2	entrez	675			dna	c.123+2A>T|c.123+2A>T	12851,39285	12863,39297	The most prevalent BRCA2 mutations are c.8363G>A (BIC: 8591G>A/W2788X),<<< c.8754+1G>A>>> (BIC: IVS211G>A) and c.3860delA (BIC: 4088delA), representing 9%, 7% and 6% of the BRCA2 mutation families respectively (Rappaport, personal communic|GVS  BIC  HGVS  BIC  c.68_69delAG c.5266dupC c.181T>G c.5266dupC c.1687C>T  185delAG 5382insC 300T>G 5382insC 1806C>T  c.5946delT  6174delT  c.8363G>A<<< c.8754+1G>A>>> c.3860delA  8591G>A IVS21-1G>A 4088delA  c.3016_3019del4 c.2676_2679del4 c.1687C>T c.181T>G c.5266dupC c.181T>A c.3228_3229delAG c.3285delA c.1380dup		
23199084	confirmed					23199084		sub		NM_007294.3:c.211A>G|NM_007300.3:c.211A>G|NM_007299.3:c.211A>G|NM_007298.3:c.211A>G	NM_007294.3:c.442A>G|NM_007300.3:c.442A>G|NM_007299.3:c.404A>G|NM_007298.3:c.229A>G		rs80357382|rs80357382|rs80357382|rs80357382		 c.211A>G|c.211A>G				BRCA1	entrez	672			dna	c.123T>A|c.123T>A|c.123T>A	17839,18367,39539	17848,18376,39548	and geographic distribution. A compilation of BRCA test results from different laboratories shows that five mutations in the BRCA1 gene (c.68_69delAG,<<< c.211A>G>>> (BIC: 330A>G), c.5117G>A (BIC: 5236G>A), c.5123C>A (BIC: 5242C>A), c.470_471delCT (BIC: 589_590delCT) account for 46.6% of BRCA1 mutations and four m|t al., [80] have reviewed the frequency of BRCA1 and BRCA2 recurrent mutations reported in seven geographic areas of Spain. The founder mutation BRCA1<<< c.211A>G>>>, that leads to aberrant splicing of the transcript, originates from North Western Spain (Galicia) and accounts up to 50% of all mutations in this region [81].| c.5266dupC c.181T>A c.3228_3229delAG c.3285delA c.1380dupA c.5062_5064del3 c.4964_4982del19 c.5062_5064delGTT c.3481_3491del11 c.5128G>T c.68_69delAG<<< c.211A>G>>> (Galicia) c.5117G>A c.5123C>A  3135del4 2795del4 1806C>T 300T>G 5382insC 300T>A 3347delAG 3404delA 1499insA 5181delGTT 5083del19 5181_5183delGTT 3600		
23199084	notConfirmed							del		c.8984G>None					 8984delG|8984delG				BRCA2	entrez	675			dna	6174delT|6174delT	27437,41208	27446,41217	The BRCA2 c.8755delG (BIC:<<< 8984delG>>>) mutation was reported in three unrelated families and could represent Cypriot founder mutation [107, 108]. Denmark BRCA1 and BRCA2 small scale mutat|.3319G>T c.5266dupC c.3710delT  2594delC 3438G>T 5382insC 3829delT  HGVS  BIC  c.8755delG c.6373delA c.1310_1013del4 c.6486_6489del4 c.3847_3848delGT <<< 8984delG>>> 6601delA 1538del4 6714del4 4075delGT  exons 3-16 deletion c.3171_3175dup c.2475delC c.1082_1092del11 c.1687C>T c.3626delT (Northern) c.1016dupA exon 		
23199084	confirmed					23199084		del		NM_000059.3:c.6275_6276delTT	NM_000059.3:c.6501_6502delTT		rs11571658		c.6275_6276delTT| c.6275_6276delTT				BRCA2	entrez	675			dna	c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT	20739,22092,34863,35007,40313,40352,42071	20756,22109,34880,35024,40330,40369,42088	r mutations (three BRCA1 c.212+3A> (BIC: IVS5+3A>G), c.2359dupG (BIC: 2478insG), c.3661G>T (BIC: 3780G>T) and three BRCA2 c.516+1G>A (BIC: IVS6+1G>A),<<< c.6275_6276delTT>>> (BIC: 6503_6504delTT), c.8904delC (BIC: 9132delC) alterations), which accounted for nearly 60% of all mutations identified. BRCA1 c.212+3A>G was prev|Together with another Dutch BRCA2 founder mutation<<< c.6275_6276delTT>>> (BIC: 6503delTT), c.5351dupA accounts for 62% of hereditary breast/ovarian families [94, 95]. Slightly outdated (as of year 2002) list of published a|f the total mutations detected, and almost one-quarter were accounted by just two founder mutations (BRCA1 c.2681_2682delAA (BIC: 2800delAA) and BRCA2<<< c.6275_6276delTT>>> (BIC: 6503delTT) [149].|BRCA2<<< c.6275_6276delTT>>> has been found elsewhere in the UK as well as in Dutch, Swedish, Danish and Belgian families (BIC database). In the North-west of England two reccure| c.5266dupC c.181T>G c.4065_4068del4 c.2338C>T c.181T>G c.5266dupC  IVS5+3A>G 2478insG 3780G>T 2804delAA 2312del5 1411insT  c.156_157insAlu c.516+1G>A<<< c.6275_6276delTT>>> c.8904delC c.5351dupA c.6275_6276delTT  384insAlu IVS6+1G>A 6503_6504delTT 9132delC 5579insA 6503delTT  c.1813dupA c.4478del4 c.9098dupA  2041insA 47|2338C>T c.181T>G c.5266dupC  IVS5+3A>G 2478insG 3780G>T 2804delAA 2312del5 1411insT  c.156_157insAlu c.516+1G>A c.6275_6276delTT c.8904delC c.5351dupA<<< c.6275_6276delTT>>>  384insAlu IVS6+1G>A 6503_6504delTT 9132delC 5579insA 6503delTT  c.1813dupA c.4478del4 c.9098dupA  2041insA 4706del4 9326insA  c.7913_7917del5 c.8537|75del5 c.7480C>T c.8327T>G c.9118-2A>G c.9117+1G>A  999del5 7708C>T 8555T>G 9346-2A>G 9345+1G>A  c.2681_2682delAA (Scotland)  2800delAA  c.771_775del5<<< c.6275_6276delTT>>> (Scotland)  999del5 6503delTT  c.4065_4068del4 (North-West) exon 13 duplication (ins6kbEx13) c.427G>T c.5266dupC c.181T>G c.4035delA c.4035delA c.526		
23199084	notConfirmed							del		c.3829T>None					3829delT| 3829delT				BRCA1	entrez	672			dna	6174delT|6174delT	27840,41115	27849,41124	The most common BRCA1 mutations were c.2475delC (BIC: 2594delC), c.3319G>T (BIC: 3438G>T), c.5266dupC and c.3710delT (BIC:<<< 3829delT>>>), which accounted 16%, 9%, 8% and 5% of BRCA1 positive families, respectively [109–111].|BIC  c.5266dupC c.5212G>A c.5251C>T c.5467G>A  5382insC 5331G>A 5370C>T 5586G>A  c.2475delC c.3319G>T c.5266dupC c.3710delT  2594delC 3438G>T 5382insC<<< 3829delT>>>  HGVS  BIC  c.8755delG c.6373delA c.1310_1013del4 c.6486_6489del4 c.3847_3848delGT  8984delG 6601delA 1538del4 6714del4 4075delGT  exons 3-16 deletio		
23199084	confirmed					23199084		sub		NM_007300.3:c.5331G>A	NM_007300.3:c.5562G>A		rs571834423		 5331G>A|5331G>A				BRCA1	entrez	672			dna	859G>A|859G>A	26599,41020	26607,41028	ients, one third carried BRCA2 mutations, including c.9098dupA [104]. Greece In the Greek population four BRCA1 mutations (c.5526dupC, c.5212G>A (BIC:<<< 5331G>A>>>/G1738R), c.5251C>T (BIC:  EPMA Journal (2010) 1:397–412  5370C>T/R1751X), c.5467G>A (BIC: 5586G>A), account for 54% of all mutations detected in BRCA|wegian  Finnish  Iceland British  Irish Polish  Latvian  BRCA1 mutation  BRCA2 mutation  HGVS  BIC  c.5266dupC c.5212G>A c.5251C>T c.5467G>A  5382insC<<< 5331G>A>>> 5370C>T 5586G>A  c.2475delC c.3319G>T c.5266dupC c.3710delT  2594delC 3438G>T 5382insC 3829delT  HGVS  BIC  c.8755delG c.6373delA c.1310_1013del4 c.6		
23199084	confirmed					23199084		sub		NM_000059.3:c.5331G>A	NM_000059.3:c.5557G>A		na		 5331G>A|5331G>A				BRCA2	entrez	675			dna	859G>A|859G>A	26599,41020	26607,41028	ients, one third carried BRCA2 mutations, including c.9098dupA [104]. Greece In the Greek population four BRCA1 mutations (c.5526dupC, c.5212G>A (BIC:<<< 5331G>A>>>/G1738R), c.5251C>T (BIC:  EPMA Journal (2010) 1:397–412  5370C>T/R1751X), c.5467G>A (BIC: 5586G>A), account for 54% of all mutations detected in BRCA|wegian  Finnish  Iceland British  Irish Polish  Latvian  BRCA1 mutation  BRCA2 mutation  HGVS  BIC  c.5266dupC c.5212G>A c.5251C>T c.5467G>A  5382insC<<< 5331G>A>>> 5370C>T 5586G>A  c.2475delC c.3319G>T c.5266dupC c.3710delT  2594delC 3438G>T 5382insC 3829delT  HGVS  BIC  c.8755delG c.6373delA c.1310_1013del4 c.6		
23199084	notConfirmed							sub		c.8555T>G					 8555T>G				BRCA2	entrez	675			dna	859G>A|859G>A	33136,41988	33144,41996	ost recurrent mutation in BRCA2 is the Icelandic founder mutation c.771_775del5 (BIC: 999del5), three other (c.7480C>T (BIC: 7708C>T), c.8327T>G (BIC:<<< 8555T>G>>>), c.9118-2A>G (BIC: 9346-2A>G) and following (c. 6384del2 (BIC: 6503delTT), c.3853dupA (BIC: 4081insA) and c.5569G>T (BIC: 5797G>T)).|096+3A>G  4216-2A>G 3604delA 3745delT 4446C>T 2803delAA 5370C>T IVS11+3A>G  c.771_775del5 c.7480C>T c.8327T>G c.9118-2A>G c.9117+1G>A  999del5 7708C>T<<< 8555T>G>>> 9346-2A>G 9345+1G>A  c.2681_2682delAA (Scotland)  2800delAA  c.771_775del5 c.6275_6276delTT (Scotland)  999del5 6503delTT  c.4065_4068del4 (North-Wes		
23199084	confirmed					23199084		dup		NM_007294.3:c.5266dupC	NM_007294.3:c.5497dupC		rs397509247		 c.5266dupC|c.5266dupC				BRCA1	entrez	672			dna	c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA	9214,9490,9881,10167,10520,11538,11895,13144,23467,23645,24058,24361,24474,24731,25955,26272,27705,27808,28748,32932,36179,36865,37564,37738,38440,38711,39168,39188,39389,40163,40218,40647,40969,41066,42190,42232,42493,42504,42524,44277,44546,44666	9225,9501,9892,10178,10531,11549,11906,13155,23478,23656,24069,24372,24485,24742,25966,26283,27716,27819,28759,32943,36190,36876,37575,37749,38451,38722,39179,39199,39400,40174,40229,40658,40980,41077,42201,42243,42504,42515,42535,44288,44557,44677	The most well characterized three founder mutations are two in BRCA1 gene c.68_69delAG (BIC: 185delAG) and<<< c.5266dupC>>> (BIC: 5382insC) and one in BRCA2 c.5946delT (BIC:  EPMA Journal (2010) 1:397–412  6174delT) [31–33].| these three founder mutations alone is now part of routine clinical practice for Ashkenazi Jewish individuals. These 3 mutations (BRCA1 c.68_69delAG,<<< c.5266dupC>>> and BRCA2 c.5946delT) account for 98–99% of identified mutations and are carried by about 2.6% (1/40) of the Ashkenazi Jewish population (1%, 0.13% and 1.52% respectively) [34–36].|ns and breast/ovarian cancer risk [37]. The average risk of breast cancer by the age of 70 years is similar for carriers of the BRCA1 c.68_69delAG and<<< c.5266dupC>>> mutations (64% and 67% respectively), however is much lower for the c.5946delT mutation (43%).|ovarian cancer lifetime risk is respectively of 14%, 33% and 20% in carriers, respectively [6, 37, 38]. It is worth noting that BRCA1 c.68_69delAG and<<< c.5266dupC>>> are not found exclusively in Ashkenazi patients.|es with frequencies similar to those in Ashkenazi populations [3], suggesting a common ancient ancestor or two independent mutational events [39]. The<<< c.5266dupC>>> mutation in BRCA1 exon 20 is the second most frequently reported mutation in the BIC database, being very prevalent in Central and Eastern Europe.|A common ancestor for<<< c.5266dupC>>> mutation families reported from Europe, Brazil and North America is evident [46, 56, 57]. Austria In Austria the ratio of BRCA1 mutations to BRCA2 mu|ion). There were initial reports for several apparently founder BRCA1 mutations in Austria [58, 59], although they  399  (c.181T>G (BIC: 300T>G/C61G),<<< c.5266dupC>>>, c.1687C>T (BIC: 1806C>T)) represent common mutations prevalent in other European countries.|, personal communication). Slovenia In Slovenia five highly recurrent specific mutations were identified: four in the BRCA1 gene (c.1687C>T, c.181T>G,<<< c.5266dupC>>>, c.181T> (BIC: 300T>A)) and one in the BRCA2 gene (c.7806-2A>G (BIC: IVS16-2A>G) [43, 61, 62].|Eighteen BRCA1 mutations, including the most common<<< c.5266dupC>>>, c.181T>G, c.4065_4068del4 (BIC: 4184del4) and c.2338C>T (BIC: 2457C>T), were found at least 3 times and comprised 66% of all BRCA1 mutations.|The 2 most common BRCA1<<< c.5266dupC>>> and c.181T>G mutations, also prevalent in other populations, accounted for 38% of BRCA1 mutations [4, 99].|98dupA (BIC: 9326insA) were associated with common alleles, suggesting a possible founder effect [99]. Czech Republic Five mutations (BRCA1: c.181T>G,<<< c.5266dupC>>>, c.3700_ 3704del5 (BIC: 3819del5), and BRCA2: c.7913_7917del5 (BIC: 8141del5) and c.8537_8538del2 (BIC: 8765delAG)) represented 52% of all mutations detected in one study population [52].|There is evident strong Slavic founder  402  effect, particularly for two BRCA1 mutations (c.181T>G and<<< c.5266dupC>>>) also regarded as founder mutations in Poland and some other Slavic countries [100].|The single BRCA1<<< c.5266dupC>>> mutation was detected in 51.4% of BRCA1 mutation positive women in one study from Prague area [51].|Three BRCA1 Czech founder mutations (c.181T>G, c.3700_3704del5, and<<< c.5266dupC>>>) account for approximately 9%, 13% and 44% of the BRCA1 mutations identified, respectively [51, 52]. BRCA1 mutations appears to be about 2 times more|/2 mutational spectrum in this population. Hungary In Hungarian patients from high-risk breast/ovarian cancer families, common BRCA1 founder mutations<<< c.5266dupC>>>, c.181T>G and c.68_69delAG accounted for 80% of all BRCA1 mutations and c.9098dupA (BIC: 9326insA) with c.5946delT accounted for 50% of all BRCA2 mutations [42, 103].|Breast cancer patients were more likely to carry the<<< c.5266dupC>>> mutation whereas ovarian patients were more likely to carry either the c.68_69delAG or the c.181T>G mutation [103].|Denmark BRCA1 and BRCA2 small scale mutations in Denmark are a mixture of Scandinavian founder mutations and other European mutations, including BRCA1<<< c.5266dupC>>>.|The most common BRCA1 mutations were c.2475delC (BIC: 2594delC), c.3319G>T (BIC: 3438G>T),<<< c.5266dupC>>> and c.3710delT (BIC: 3829delT), which accounted 16%, 9%, 8% and 5% of BRCA1 positive families, respectively [109–111].|Altogether 7 common BRCA1/2 mutations (excluding<<< c.5266dupC>>> ) accounts for around 35% of carriers [4]. LGRs in BRCA1 and BRCA2 are common in East Denmark and account for 9.2% (15/163) of the disease causing mutations.|The<<< c.5266dupC>>> is also found relatively frequently. The most recurrent mutation in BRCA2 is the Icelandic founder mutation c.771_775del5 (BIC: 999del5), three other|The BRCA1<<< c.5266dupC>>>, c.181T>G and c.4035delA accounted for about 56%, 25% and 10% of all BRCA1 mutations, respectively.|In North-Eastern Poland two common mutations <<<(c.5266dupC>>> and c.181T>G) accounted for more than half (up to 70%) of all BRCA-mutated families and no c.4035delA was identified [156], what is in accordance with other studies [157].|156] and its necessary to extend analysis, including LGR, among patients negative for BRCA1/2 founder mutations. Latvia In Latvia two BRCA1 mutations <<<(c.5266dupC>>> and c.4035delA) made up more than 80% of all mutations BRCA1 identified [50, 158].|The 4154delA mutation is the second most abundant BRCA1 gene mutation after the<<< c.5266dupC>>> in Latvia [50] and is especially common for patients of Baltic (Latvian and Lithuanian) origin.|In Poland 3 most common mutations <<<(c.5266dupC>>>, c.181T>G and c.4035delA (BIC: 4154delA) accounted for 91% (111/122) BRCA1 mutations  In Lithuania BRCA1 gene mutations are influenced by significant founder effect, which is similar to that reported from Latvian (Baltic) population [50].|BRCA1 c.4035delA and<<< c.5266dupC>>> attributes to 86% (53% and 33% respectively) of detected BRCA1 mutations [53, 54, 160].|n (North-East) French Spanish  Portuguese Belgian  Dutch  German  Czech  Hungarian  BRCA1 mutation  BRCA2 mutation  HGVS  BIC  HGVS  BIC  c.68_69delAG<<< c.5266dupC>>> c.181T>G c.5266dupC c.1687C>T  185delAG 5382insC 300T>G 5382insC 1806C>T  c.5946delT  6174delT  c.8363G>A c.8754+1G>A c.3860delA  8591G>A IVS21-1G>A |h Spanish  Portuguese Belgian  Dutch  German  Czech  Hungarian  BRCA1 mutation  BRCA2 mutation  HGVS  BIC  HGVS  BIC  c.68_69delAG c.5266dupC c.181T>G<<< c.5266dupC>>> c.1687C>T  185delAG 5382insC 300T>G 5382insC 1806C>T  c.5946delT  6174delT  c.8363G>A c.8754+1G>A c.3860delA  8591G>A IVS21-1G>A 4088delA  c.3016_301|2insC 1806C>T  c.5946delT  6174delT  c.8363G>A c.8754+1G>A c.3860delA  8591G>A IVS21-1G>A 4088delA  c.3016_3019del4 c.2676_2679del4 c.1687C>T c.181T>G<<< c.5266dupC>>> c.181T>A c.3228_3229delAG c.3285delA c.1380dupA c.5062_5064del3 c.4964_4982del19 c.5062_5064delGTT c.3481_3491del11 c.5128G>T c.68_69delAG c.211A>G (|74delTATG  c.212+3A>G c.2359dupG c.3661G>T c.2685_2686delAA c.2193del5 c.1292dupT exon 13 deletion (3,8-kb) exon 22 deletion (510-bp) exon 17 deletion<<< c.5266dupC>>> c.181T>G c.4065_4068del4 c.2338C>T c.181T>G c.5266dupC  IVS5+3A>G 2478insG 3780G>T 2804delAA 2312del5 1411insT  c.156_157insAlu c.516+1G>A c.6275_627|elAA c.2193del5 c.1292dupT exon 13 deletion (3,8-kb) exon 22 deletion (510-bp) exon 17 deletion c.5266dupC c.181T>G c.4065_4068del4 c.2338C>T c.181T>G<<< c.5266dupC>>>  IVS5+3A>G 2478insG 3780G>T 2804delAA 2312del5 1411insT  c.156_157insAlu c.516+1G>A c.6275_6276delTT c.8904delC c.5351dupA c.6275_6276delTT  384insAl|c.7913_7917del5 c.8537_8538del2  8141del5 8765delAG  c.9098dupA c.5946delT  9326insA 6174delT  c.3700_3704del5 exons 1–17 deletion exons 5–14 deletion<<< c.5266dupC>>> c.181T>G c.68_69delAG  5382insC 300T>G 4184del4 2457C>T 300T>G 5382insC 3819del5  5382insC 300T>G 185delAG  406  EPMA Journal (2010) 1:397–412  Table|ed) Population  Greek  Cypriot Danish  Swedish  Norwegian  Finnish  Iceland British  Irish Polish  Latvian  BRCA1 mutation  BRCA2 mutation  HGVS  BIC <<< c.5266dupC>>> c.5212G>A c.5251C>T c.5467G>A  5382insC 5331G>A 5370C>T 5586G>A  c.2475delC c.3319G>T c.5266dupC c.3710delT  2594delC 3438G>T 5382insC 3829delT  HGVS|  Latvian  BRCA1 mutation  BRCA2 mutation  HGVS  BIC  c.5266dupC c.5212G>A c.5251C>T c.5467G>A  5382insC 5331G>A 5370C>T 5586G>A  c.2475delC c.3319G>T<<< c.5266dupC>>> c.3710delT  2594delC 3438G>T 5382insC 3829delT  HGVS  BIC  c.8755delG c.6373delA c.1310_1013del4 c.6486_6489del4 c.3847_3848delGT  8984delG 6601delA |land)  2800delAA  c.771_775del5 c.6275_6276delTT (Scotland)  999del5 6503delTT  c.4065_4068del4 (North-West) exon 13 duplication (ins6kbEx13) c.427G>T<<< c.5266dupC>>> c.181T>G c.4035delA c.4035delA c.5266dupC  4184del4  c.1929delG (North-West)  2157delG  546G>T 5382insC 300T>G 4154delA 4154delA 5382insC  EPMA Journ|6delTT (Scotland)  999del5 6503delTT  c.4065_4068del4 (North-West) exon 13 duplication (ins6kbEx13) c.427G>T c.5266dupC c.181T>G c.4035delA c.4035delA<<< c.5266dupC>>>  4184del4  c.1929delG (North-West)  2157delG  546G>T 5382insC 300T>G 4154delA 4154delA 5382insC  EPMA Journal (2010) 1:397–412  407  Table 1 (continu|MA Journal (2010) 1:397–412  407  Table 1 (continued) Population  Lithuanian Belarusian Russian  BRCA1 mutation  BRCA2 mutation  HGVS  BIC  c.4035delA<<< c.5266dupC>>> c.5266dupC c.181T>G c.5266dupC  4154delA 5382insC 5382insC 300T>G 5382insC  HGVS  BIC  Apparently true founder mutations are written in italic.|(2010) 1:397–412  407  Table 1 (continued) Population  Lithuanian Belarusian Russian  BRCA1 mutation  BRCA2 mutation  HGVS  BIC  c.4035delA c.5266dupC<<< c.5266dupC>>> c.181T>G c.5266dupC  4154delA 5382insC 5382insC 300T>G 5382insC  HGVS  BIC  Apparently true founder mutations are written in italic.|7  Table 1 (continued) Population  Lithuanian Belarusian Russian  BRCA1 mutation  BRCA2 mutation  HGVS  BIC  c.4035delA c.5266dupC c.5266dupC c.181T>G<<< c.5266dupC>>>  4154delA 5382insC 5382insC 300T>G 5382insC  HGVS  BIC  Apparently true founder mutations are written in italic.|ing of this mutation in Lithuania. Estonia Newly published data from Estonia about BRCA1/2 mutations structure showed significant involvement of BRCA1<<< c.5266dupC>>> and to a lesser extent BRCA1 c.4035delA [162], what could be also expected projecting data from adjacent countries. Belarus Only one small study in W|untries. Belarus Only one small study in West Belarus for targeted BRCA1 mutations identified similar spectrum of 3 common mutations as in Poland, and<<< c.5266dupC>>> accounted here for 73% of all BRCA1 mutations [49].  Russia In Russia the most common BRCA1 gene mutation in c.5266dupC, comprising around 90% of all BRCA1 mutations [41, 163–167].|on mutations as in Poland, and c.5266dupC accounted here for 73% of all BRCA1 mutations [49].  Russia In Russia the most common BRCA1 gene mutation in<<< c.5266dupC>>>, comprising around 90% of all BRCA1 mutations [41, 163–167].		
23199084	confirmed					23199084		del		NM_000059.3:c.8755delG	NM_000059.3:c.8981delG		na		 c.8755delG|c.8755delG				BRCA2	entrez	675			dna	c.123delT|c.123delT	27420,41136	27431,41147	The BRCA2<<< c.8755delG>>> (BIC: 8984delG) mutation was reported in three unrelated families and could represent Cypriot founder mutation [107, 108]. Denmark BRCA1 and BRCA2 sm|2G>A c.5251C>T c.5467G>A  5382insC 5331G>A 5370C>T 5586G>A  c.2475delC c.3319G>T c.5266dupC c.3710delT  2594delC 3438G>T 5382insC 3829delT  HGVS  BIC <<< c.8755delG>>> c.6373delA c.1310_1013del4 c.6486_6489del4 c.3847_3848delGT  8984delG 6601delA 1538del4 6714del4 4075delGT  exons 3-16 deletion c.3171_3175dup c.2475		
23199084	notConfirmed							del		c.4075G>None					 4075delG|4075delG				BRCA1	entrez	672			dna	6174delT|6174delT|6174delT|6174delT	28300,31842,41244,41705	28309,31851,41253,41714	st common BRCA2 mutations were c.6373delA (BIC: 6601delA), c.1310_1013del4 (BIC: 1538del4), c.6486_6489del4 (BIC: 6714del4) and c.3847_3848delGT (BIC:<<< 4075delG>>>T), found in 11%, 10%, 9% and 5% of BRCA2 positive families, respectively [111].|3297G>T), c.4745delA (BIC: 4864delA), c.2351del7 (BIC: 2470del7), c.3084del11 (BIC: 3203del11) and BRCA2 c.2808del4 (BIC: 3036del4), c.3847delGT (BIC:<<< 4075delG>>>T)), account for about 60% BRCA1/2 carriers in Norway [128].|delC 3438G>T 5382insC 3829delT  HGVS  BIC  c.8755delG c.6373delA c.1310_1013del4 c.6486_6489del4 c.3847_3848delGT  8984delG 6601delA 1538del4 6714del4<<< 4075delG>>>T  exons 3-16 deletion c.3171_3175dup c.2475delC c.1082_1092del11 c.1687C>T c.3626delT (Northern) c.1016dupA exon 13 duplication (ins6kbEx13) c.1556de|sA  c.4258delG  4486delG  1675delA 3347delAG 816delGT 1135insA 3297G>T 4864delA 2470del7 3203del11 120A>C IVS17-2A>C  c.2808del4 c.3847delGT  3036del4<<< 4075delG>>>T  exons 1-13 deletion exon 13 duplication (ins6kbEx13) c.4097-2A>G c.3485delA c.3626delT c.4327C>T c.2684del2 c.5251C>T c.4096+3A>G  4216-2A>G 3604de		
23199084	confirmed					23199084		sub		NM_007294.3:c.1687C>T|NM_007300.3:c.1687C>T	NM_007294.3:c.1918C>T|NM_007300.3:c.1918C>T		rs80356898|rs80356898		 c.1687C>T|c.1687C>T				BRCA1	entrez	672			dna	c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A	11907,12145,13123,30173,30898,39199,39370,41318	11917,12155,13133,30183,30908,39209,39380,41328	were initial reports for several apparently founder BRCA1 mutations in Austria [58, 59], although they  399  (c.181T>G (BIC: 300T>G/C61G), c.5266dupC,<<< c.1687C>T>>> (BIC: 1806C>T)) represent common mutations prevalent in other European countries.|Of note,<<< c.1687C>T>>> is also frequent in Slovenia [43] and Sweden (BIC database).|spectively (Rappaport, personal communication). Slovenia In Slovenia five highly recurrent specific mutations were identified: four in the BRCA1 gene <<<(c.1687C>T>>>, c.181T>G, c.5266dupC, c.181T> (BIC: 300T>A)) and one in the BRCA2 gene (c.7806-2A>G (BIC: IVS16-2A>G) [43, 61, 62].|Another BRCA1 mutation,<<< c.1687C>T>>>, occurs primarily in southern Sweden as well as other European countries (BIC database).|n Sweden, six mutations, including the most common BRCA1 c.3171_3175dup, four other common Scandinavian BCRA1 mutations (c.1082_1092del11, c.2475delC,<<< c.1687C>T>>>, c.1016dupA (BIC: 1135insA)) and one BRCA2 mutation (c.4258delG) accounted for approximately 75% of all BRCA1/2 mutations [124].|Portuguese Belgian  Dutch  German  Czech  Hungarian  BRCA1 mutation  BRCA2 mutation  HGVS  BIC  HGVS  BIC  c.68_69delAG c.5266dupC c.181T>G c.5266dupC<<< c.1687C>T>>>  185delAG 5382insC 300T>G 5382insC 1806C>T  c.5946delT  6174delT  c.8363G>A c.8754+1G>A c.3860delA  8591G>A IVS21-1G>A 4088delA  c.3016_3019del4 c.26|5382insC 300T>G 5382insC 1806C>T  c.5946delT  6174delT  c.8363G>A c.8754+1G>A c.3860delA  8591G>A IVS21-1G>A 4088delA  c.3016_3019del4 c.2676_2679del4<<< c.1687C>T>>> c.181T>G c.5266dupC c.181T>A c.3228_3229delAG c.3285delA c.1380dupA c.5062_5064del3 c.4964_4982del19 c.5062_5064delGTT c.3481_3491del11 c.5128G>T c.6|13del4 c.6486_6489del4 c.3847_3848delGT  8984delG 6601delA 1538del4 6714del4 4075delGT  exons 3-16 deletion c.3171_3175dup c.2475delC c.1082_1092del11<<< c.1687C>T>>> c.3626delT (Northern) c.1016dupA exon 13 duplication (ins6kbEx13) c.1556delA c.3228delAG c.697delGT c.1016dupA c.3178G>T c.4745delA c.2351del7 c.3084		
23199084	confirmed					23199084		sub		NM_007297.3:c.4097-2_4097A>G	NM_007297.3:c.4377-2_4377A>G		na		 c.4097-2A>G|c.4097-2A>G				BRCA1	entrez	672			dna	c.123+2A>T|c.123+2A>T	32758,41769	32770,41781	BRCA1 and 7 in BRCA2 gene), and these represent majority (around 84%) of all BRCA1/2 mutations detected [130–138]. The most common BRCA1 mutations are<<< c.4097-2A>G>>> (BIC: 4216-2A>G), c.3485delA (BIC: 3604delA), c.3626delT (BIC: 3745delT), c.4327C>T (BIC: 4446C>T), c.2684del2 (BIC: 2803delAA) and c.5251C>T (BIC: 5370C>T).|297G>T 4864delA 2470del7 3203del11 120A>C IVS17-2A>C  c.2808del4 c.3847delGT  3036del4 4075delGT  exons 1-13 deletion exon 13 duplication (ins6kbEx13)<<< c.4097-2A>G>>> c.3485delA c.3626delT c.4327C>T c.2684del2 c.5251C>T c.4096+3A>G  4216-2A>G 3604delA 3745delT 4446C>T 2803delAA 5370C>T IVS11+3A>G  c.771_775del5 c.7		
23199084	confirmed					23199084		del		NM_000059.3:c.9310_9311delAA	NM_000059.3:c.9536_9537delAA		rs80359756		 c.9310_9311delAA|c.9310_9311delAA				BRCA2	entrez	675			dna	c.123_125delAT|c.123_125delAT	18128,39873	18145,39890	mutations and four mutations in BRCA2 (c.2808_2811del4 (BIC: 3036_3039del4), c.6629_6630delAA (BIC: c.6857delAA), c.9026_9030del5 (BIC: 92549258del5),<<< c.9310_9311delAA>>> (BIC: 9538delAA)) account for 56.6% of the BRCA2 mutations [79]. Diez et al., [80] have reviewed the frequency of BRCA1 and BRCA2 recurrent mutations|0A>G 5236G>A 5242C>A  c.7806-2A>G  IVS16-2A>G  c.8537_8538delAG(Sardinia)  8765delAG  c.2808_2811del4 (Castilla-Leon) c.6629_6630delAA c.9026_9030del5<<< c.9310_9311delAA>>>  3036_3039del4 c.6857delAA 9254-9258del5 9538delAA  c.470_471delCT c.5153-1G>A  589_590delCT 5272-1G>A  c.5146_5149del4  374delTATG  c.212+3A>G c.235		
23199084	confirmed					23199084		sub		NM_007298.3:c.3297G>T	NM_007298.3:c.3315G>T		na		3297G>T| 3297G>T				BRCA1	entrez	672			dna	859G>A|859G>A	31691,41617	31699,41625	le the fourth is from the southeast [127]. These four founder mutations together with other six most frequent BRCA1/2 mutations (BRCA1 c.3178G>T (BIC:<<< 3297G>T>>>), c.4745delA (BIC: 4864delA), c.2351del7 (BIC: 2470del7), c.3084del11 (BIC: 3203del11) and BRCA2 c.2808del4 (BIC: 3036del4), c.3847delGT (BIC: 4075delGT)), account for about 60% BRCA1/2 carriers in Norway [128].|del7 c.3084del11 c.1A>C c.5075-2A>C  3171ins5 2594delC 1201del11 1806C>T 3745delT 1135insA  c.4258delG  4486delG  1675delA 3347delAG 816delGT 1135insA<<< 3297G>T>>> 4864delA 2470del7 3203del11 120A>C IVS17-2A>C  c.2808del4 c.3847delGT  3036del4 4075delGT  exons 1-13 deletion exon 13 duplication (ins6kbEx13) c.409		
23199084	confirmed					23199084		sub		NM_007294.3:c.5128G>T|NM_007297.3:c.5128G>T	NM_007294.3:c.5359G>T|NM_007297.3:c.5408G>T		rs397509229|na		 c.5128G>T|c.5128G>T				BRCA1	entrez	672			dna	c.123T>A|c.123T>A|c.123T>A	15806,16234,39516	15816,16244,39526	The c.3481_3491del11 (BIC: 3600del11) in exon 11 accounts for 37% and the nonsense mutation<<< c.5128G>T>>> (BIC: 5247G>T/Gly1710X) in exon 18 for 15% of all BRCA1/2 mutations in that region (overall 52%) [4, 75]. The haplotype analysis of the families carr|The BRCA1 mutation<<< c.5128G>T>>> would appear to be specific to the France, but the analysis of its haplotype is less conclusive and needs further confirmation [6]. The BRCA1 c.5030_|del4 c.1687C>T c.181T>G c.5266dupC c.181T>A c.3228_3229delAG c.3285delA c.1380dupA c.5062_5064del3 c.4964_4982del19 c.5062_5064delGTT c.3481_3491del11<<< c.5128G>T>>> c.68_69delAG c.211A>G (Galicia) c.5117G>A c.5123C>A  3135del4 2795del4 1806C>T 300T>G 5382insC 300T>A 3347delAG 3404delA 1499insA 5181delGTT 5083del1		
23199084	confirmed					23199084		del		NM_007294.3:c.4035delA|NM_007300.3:c.4035delA|NM_007297.3:c.4035delA	NM_007294.3:c.4266delA|NM_007300.3:c.4266delA|NM_007297.3:c.4315delA		rs80357711|rs80357711|na		c.4035delA| c.4035delA				BRCA1	entrez	672			dna	c.123delT|c.123delT|c.123delT|c.123delT|c.123delT|c.123delT|c.123delT|c.123delT|c.123delT|c.123delT|c.123delT	36204,36967,37579,38465,38696,42210,42221,42482,43383,44317,44794	36215,36978,37590,38476,38707,42221,42232,42493,43394,44328,44805	The BRCA1 c.5266dupC, c.181T>G and<<< c.4035delA>>> accounted for about 56%, 25% and 10% of all BRCA1 mutations, respectively.|In North-Eastern Poland two common mutations (c.5266dupC and c.181T>G) accounted for more than half (up to 70%) of all BRCA-mutated families and no<<< c.4035delA>>> was identified [156], what is in accordance with other studies [157].|cessary to extend analysis, including LGR, among patients negative for BRCA1/2 founder mutations. Latvia In Latvia two BRCA1 mutations (c.5266dupC and<<< c.4035delA>>>) made up more than 80% of all mutations BRCA1 identified [50, 158].|In Poland 3 most common mutations (c.5266dupC, c.181T>G and<<< c.4035delA>>> (BIC: 4154delA) accounted for 91% (111/122) BRCA1 mutations  In Lithuania BRCA1 gene mutations are influenced by significant founder effect, which is similar to that reported from Latvian (Baltic) population [50].|BRCA1<<< c.4035delA>>> and c.5266dupC attributes to 86% (53% and 33% respectively) of detected BRCA1 mutations [53, 54, 160].|771_775del5 c.6275_6276delTT (Scotland)  999del5 6503delTT  c.4065_4068del4 (North-West) exon 13 duplication (ins6kbEx13) c.427G>T c.5266dupC c.181T>G<<< c.4035delA>>> c.4035delA c.5266dupC  4184del4  c.1929delG (North-West)  2157delG  546G>T 5382insC 300T>G 4154delA 4154delA 5382insC  EPMA Journal (2010) 1:397–412 | c.6275_6276delTT (Scotland)  999del5 6503delTT  c.4065_4068del4 (North-West) exon 13 duplication (ins6kbEx13) c.427G>T c.5266dupC c.181T>G c.4035delA<<< c.4035delA>>> c.5266dupC  4184del4  c.1929delG (North-West)  2157delG  546G>T 5382insC 300T>G 4154delA 4154delA 5382insC  EPMA Journal (2010) 1:397–412  407  Table|382insC  EPMA Journal (2010) 1:397–412  407  Table 1 (continued) Population  Lithuanian Belarusian Russian  BRCA1 mutation  BRCA2 mutation  HGVS  BIC <<< c.4035delA>>> c.5266dupC c.5266dupC c.181T>G c.5266dupC  4154delA 5382insC 5382insC 300T>G 5382insC  HGVS  BIC  Apparently true founder mutations are written in italic.|RCA1 amplicons by HRM analysis now is the innitial procedure for breast/ovarian cancer patients in our hospital. The most frequently observed is BRCA1<<< c.4035delA>>> mutation, which is more frequent in families of Baltic (Lithuanian) origin rather than Slavic [53, 54, 161], and was detected in 16.3% (7/43) of unre|ia Newly published data from Estonia about BRCA1/2 mutations structure showed significant involvement of BRCA1 c.5266dupC and to a lesser extent BRCA1<<< c.4035delA>>> [162], what could be also expected projecting data from adjacent countries. Belarus Only one small study in West Belarus for targeted BRCA1 mutations|Other less common mutations found in Western Russia are<<< c.4035delA>>>, c.181T>G, and c.68_69delAG.		
23199084	confirmed					23199084		sub		NM_007294.3:c.5117G>A|NM_007297.3:c.5117G>A	NM_007294.3:c.5348G>A|NM_007297.3:c.5397G>A		rs80356860|rs397509246		 c.5117G>A|c.5117G>A				BRCA1	entrez	672			dna	c.123T>A|c.123T>A	17863,39558	17873,39568	ion. A compilation of BRCA test results from different laboratories shows that five mutations in the BRCA1 gene (c.68_69delAG, c.211A>G (BIC: 330A>G),<<< c.5117G>A>>> (BIC: 5236G>A), c.5123C>A (BIC: 5242C>A), c.470_471delCT (BIC: 589_590delCT) account for 46.6% of BRCA1 mutations and four mutations in BRCA2 (c.2808|A c.3228_3229delAG c.3285delA c.1380dupA c.5062_5064del3 c.4964_4982del19 c.5062_5064delGTT c.3481_3491del11 c.5128G>T c.68_69delAG c.211A>G (Galicia)<<< c.5117G>A>>> c.5123C>A  3135del4 2795del4 1806C>T 300T>G 5382insC 300T>A 3347delAG 3404delA 1499insA 5181delGTT 5083del19 5181_5183delGTT 3600del11 5247G>T 185del		
23199084	confirmed					23199084		del		NM_000059.3:c.8537_8538delAG	NM_000059.3:c.8763_8764delAG		rs80359716		 c.8537_8538delAG|c.8537_8538delAG				BRCA2	entrez	675			dna	c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT	14432,17015,17312,39769	14449,17032,17329,39786	 of BRCA1/2 mutations to breast cancer predisposition has been reported for populations from the Northern part of the island [67], where founder BRCA2<<< c.8537_8538delAG>>> (BIC: 8765delAG) mutation comprises 28% for BRCA1/2 positive families [68, 69].|, c.962G>A (BIC: 1081G>A), c.2834_2836delinsC (BIC: 2953delGTA/insC) and 3 BRCA2 mutations (c.3170_3174del5 (BIC: 3398del5), c.5857G>T (BIC: 6085G>T),<<< c.8537_8538delAG>>> (BIC: 8765delAG)) are now routinely included in early onset breast/ovarian cancer screening assays and represent up to 84% of the total BRCA1/2 mutations in the FrenchCanadian population in Quebec [78].|Among these, the most common founder mutations are BRCA1 c.4327C>T and BRCA2<<< c.8537_8538delAG>>> and c.3170_3174del5, which are found in 1.7% of women affected by breast cancer diagnosed before age 41 and in 1.3% of women with ovarian cancer [6].|sC 300T>A 3347delAG 3404delA 1499insA 5181delGTT 5083del19 5181_5183delGTT 3600del11 5247G>T 185delAG 330A>G 5236G>A 5242C>A  c.7806-2A>G  IVS16-2A>G <<< c.8537_8538delAG>>>(Sardinia)  8765delAG  c.2808_2811del4 (Castilla-Leon) c.6629_6630delAA c.9026_9030del5 c.9310_9311delAA  3036_3039del4 c.6857delAA 9254-9258del5 9538		
23199084	confirmed					23199084		sub		NM_000059.3:c.8363G>A	NM_000059.3:c.8589G>A		rs80359080		c.8363G>A| c.8363G>A				BRCA2	entrez	675			dna	c.123T>A|c.123T>A	12818,39275	12828,39285	The most prevalent BRCA2 mutations are<<< c.8363G>A>>> (BIC: 8591G>A/W2788X), c.8754+1G>A (BIC: IVS211G>A) and c.3860delA (BIC: 4088delA), representing 9%, 7% and 6% of the BRCA2 mutation families respect|utation  HGVS  BIC  HGVS  BIC  c.68_69delAG c.5266dupC c.181T>G c.5266dupC c.1687C>T  185delAG 5382insC 300T>G 5382insC 1806C>T  c.5946delT  6174delT <<< c.8363G>A>>> c.8754+1G>A c.3860delA  8591G>A IVS21-1G>A 4088delA  c.3016_3019del4 c.2676_2679del4 c.1687C>T c.181T>G c.5266dupC c.181T>A c.3228_3229delAG c.3285de		
23199084	confirmed					23199084		sub		NM_000059.3:c.7480C>T	NM_000059.3:c.7706C>T		rs80358972		 c.7480C>T|c.7480C>T				BRCA2	entrez	675			dna	c.123T>A|c.123T>A|c.123T>A	33094,33400,41927	33104,33410,41937	is also found relatively frequently. The most recurrent mutation in BRCA2 is the Icelandic founder mutation c.771_775del5 (BIC: 999del5), three other <<<(c.7480C>T>>> (BIC: 7708C>T), c.8327T>G (BIC: 8555T>G), c.9118-2A>G (BIC: 9346-2A>G) and following (c. 6384del2 (BIC: 6503delTT), c.3853dupA (BIC: 4081insA) and c.5569G>T (BIC: 5797G>T)).|Some mutations are unique to the Finns, such as c.4096+3A>G (BIC: IVS11+3A>G) in BRCA1 and c.9117+1G>A (BIC: 9345+ 1G>A),<<< c.7480C>T>>>, c.8327T>G in BRCA2 genes. The mutation spectrum in Eastern part slightly differs from those observed in the Northern and Southern parts of the count|2A>G c.3485delA c.3626delT c.4327C>T c.2684del2 c.5251C>T c.4096+3A>G  4216-2A>G 3604delA 3745delT 4446C>T 2803delAA 5370C>T IVS11+3A>G  c.771_775del5<<< c.7480C>T>>> c.8327T>G c.9118-2A>G c.9117+1G>A  999del5 7708C>T 8555T>G 9346-2A>G 9345+1G>A  c.2681_2682delAA (Scotland)  2800delAA  c.771_775del5 c.6275_6276delT		
23199084	confirmed					23199084		sub		NM_007294.3:c.5857G>T	NM_007294.3:c.6088G>T		na		 c.5857G>T				BRCA1	entrez	672			dna	c.123T>A	16989	16999	0) 1:397–412  3875delGTCT), c.962G>A (BIC: 1081G>A), c.2834_2836delinsC (BIC: 2953delGTA/insC) and 3 BRCA2 mutations (c.3170_3174del5 (BIC: 3398del5),<<< c.5857G>T>>> (BIC: 6085G>T), c.8537_8538delAG (BIC: 8765delAG)) are now routinely included in early onset breast/ovarian cancer screening assays and represent up to 84% of the total BRCA1/2 mutations in the FrenchCanadian population in Quebec [78].		
23199084	confirmed					23199084		sub		NM_000059.3:c.5857G>T	NM_000059.3:c.6083G>T		rs80358814		 c.5857G>T				BRCA2	entrez	675			dna	c.123T>A	16989	16999	0) 1:397–412  3875delGTCT), c.962G>A (BIC: 1081G>A), c.2834_2836delinsC (BIC: 2953delGTA/insC) and 3 BRCA2 mutations (c.3170_3174del5 (BIC: 3398del5),<<< c.5857G>T>>> (BIC: 6085G>T), c.8537_8538delAG (BIC: 8765delAG)) are now routinely included in early onset breast/ovarian cancer screening assays and represent up to 84% of the total BRCA1/2 mutations in the FrenchCanadian population in Quebec [78].		
23199084	confirmed					23199084		del		NM_007294.3:c.2803delA|NM_007300.3:c.2803delA	NM_007294.3:c.3034delA|NM_007300.3:c.3034delA		na|na		2803delA| 2803delA				BRCA1	entrez	672			dna	6174delT|6174delT	32887,41883	32896,41892	n BRCA1 mutations are c.4097-2A>G (BIC: 4216-2A>G), c.3485delA (BIC: 3604delA), c.3626delT (BIC: 3745delT), c.4327C>T (BIC: 4446C>T), c.2684del2 (BIC:<<< 2803delA>>>A) and c.5251C>T (BIC: 5370C>T).|ion exon 13 duplication (ins6kbEx13) c.4097-2A>G c.3485delA c.3626delT c.4327C>T c.2684del2 c.5251C>T c.4096+3A>G  4216-2A>G 3604delA 3745delT 4446C>T<<< 2803delA>>>A 5370C>T IVS11+3A>G  c.771_775del5 c.7480C>T c.8327T>G c.9118-2A>G c.9117+1G>A  999del5 7708C>T 8555T>G 9346-2A>G 9345+1G>A  c.2681_2682delAA (Scotla		
23199084	confirmed					23199084		del		NM_007300.3:c.4843delC	NM_007300.3:c.5074delC		na		4843delC				BRCA1	entrez	672			dna	6174delT|6174delT	15092,58808	15101,58817	It was also recurrently found at least four times in Sicilia [70, 71]. Another BRCA1 c.4724delC (BIC:<<< 4843delC>>>) mutation could be a possible Sicilian founder mutation, although present evidence is scarce [71–73]. Using a number of independent approaches, Malac|Russo A et al.<<< 4843delC>>> of the BRCA1 gene is a possible founder mutation in Southern Italy (Sicily).		
23199084	confirmed					23199084		del		NM_000059.3:c.4843delC	NM_000059.3:c.5069delC		na		4843delC				BRCA2	entrez	675			dna	6174delT|6174delT	15092,58808	15101,58817	It was also recurrently found at least four times in Sicilia [70, 71]. Another BRCA1 c.4724delC (BIC:<<< 4843delC>>>) mutation could be a possible Sicilian founder mutation, although present evidence is scarce [71–73]. Using a number of independent approaches, Malac|Russo A et al.<<< 4843delC>>> of the BRCA1 gene is a possible founder mutation in Southern Italy (Sicily).		
23199084	notConfirmed							sub		c.2A>C					2A>C				BRCA1	entrez	672			dna	859G>A|859G>A|859G>A|859G>A	31949,31966,41497,41666	31954,31971,41502,41671	BRCA1 c.1A>C (BIC: 120A>C) and c.5075<<<-2A>C>>> (BIC: IVS17-2A>C) mutations are also locally frequent.|BRCA1 c.1A>C (BIC: 120A>C) and c.5075-2A>C (BIC: IVS17<<<-2A>C>>>) mutations are also locally frequent.|rn) c.1016dupA exon 13 duplication (ins6kbEx13) c.1556delA c.3228delAG c.697delGT c.1016dupA c.3178G>T c.4745delA c.2351del7 c.3084del11 c.1A>C c.5075<<<-2A>C>>>  3171ins5 2594delC 1201del11 1806C>T 3745delT 1135insA  c.4258delG  4486delG  1675delA 3347delAG 816delGT 1135insA 3297G>T 4864delA 2470del7 3203del1|4delC 1201del11 1806C>T 3745delT 1135insA  c.4258delG  4486delG  1675delA 3347delAG 816delGT 1135insA 3297G>T 4864delA 2470del7 3203del11 120A>C IVS17<<<-2A>C>>>  c.2808del4 c.3847delGT  3036del4 4075delGT  exons 1-13 deletion exon 13 duplication (ins6kbEx13) c.4097-2A>G c.3485delA c.3626delT c.4327C>T c.2684d		
23199084	confirmed					23199084		del		NM_007294.3:c.6601delA|NM_007300.3:c.6601delA	NM_007294.3:c.6832delA|NM_007300.3:c.6832delA		na|na		6601delA| 6601delA				BRCA1	entrez	672			dna	6174delT|6174delT	28197,41217	28206,41226	c.3319G>T BRCA1 mutation was also reported in Norway (http://www.legeforeningen.no/id/153250.0). The most common BRCA2 mutations were c.6373delA (BIC:<<< 6601delA>>>), c.1310_1013del4 (BIC: 1538del4), c.6486_6489del4 (BIC: 6714del4) and c.3847_3848delGT (BIC: 4075delGT), found in 11%, 10%, 9% and 5% of BRCA2 positive families, respectively [111].|c.5266dupC c.3710delT  2594delC 3438G>T 5382insC 3829delT  HGVS  BIC  c.8755delG c.6373delA c.1310_1013del4 c.6486_6489del4 c.3847_3848delGT  8984delG<<< 6601delA>>> 1538del4 6714del4 4075delGT  exons 3-16 deletion c.3171_3175dup c.2475delC c.1082_1092del11 c.1687C>T c.3626delT (Northern) c.1016dupA exon 13 duplic		
23199084	notConfirmed							sub		c.2A>G					2A>G				BRCA2	entrez	675			dna	859G>A|859G>A|859G>A|859G>A|859G>A|859G>A|859G>A|859G>A|859G>A|859G>A|859G>A|859G>A|859G>A	13213,13230,13363,32765,32781,33153,33169,39751,39763,41776,41852,41954,42001	13218,13235,13368,32770,32786,33158,33174,39756,39768,41781,41857,41959,42006	 specific mutations were identified: four in the BRCA1 gene (c.1687C>T, c.181T>G, c.5266dupC, c.181T> (BIC: 300T>A)) and one in the BRCA2 gene (c.7806<<<-2A>G>>> (BIC: IVS16-2A>G) [43, 61, 62].|ns were identified: four in the BRCA1 gene (c.1687C>T, c.181T>G, c.5266dupC, c.181T> (BIC: 300T>A)) and one in the BRCA2 gene (c.7806-2A>G (BIC: IVS16<<<-2A>G>>>) [43, 61, 62].|Respectively, they accounted for 26%, 18%, 13% and 11% of BRCA1 mutations and 56% of BRCA2 mutations. The c.7806<<<-2A>G>>> in the BRCA2 gene appears to be an unique founder mutation in the Slovenian population, found in 26% (10/38) of all BRCA1/2 mutations harboring families.|nd 7 in BRCA2 gene), and these represent majority (around 84%) of all BRCA1/2 mutations detected [130–138]. The most common BRCA1 mutations are c.4097<<<-2A>G>>> (BIC: 4216-2A>G), c.3485delA (BIC: 3604delA), c.3626delT (BIC: 3745delT), c.4327C>T (BIC: 4446C>T), c.2684del2 (BIC: 2803delAA) and c.5251C>T (BIC: 5370C>T).|ne), and these represent majority (around 84%) of all BRCA1/2 mutations detected [130–138]. The most common BRCA1 mutations are c.4097-2A>G (BIC: 4216<<<-2A>G>>>), c.3485delA (BIC: 3604delA), c.3626delT (BIC: 3745delT), c.4327C>T (BIC: 4446C>T), c.2684del2 (BIC: 2803delAA) and c.5251C>T (BIC: 5370C>T).|ation in BRCA2 is the Icelandic founder mutation c.771_775del5 (BIC: 999del5), three other (c.7480C>T (BIC: 7708C>T), c.8327T>G (BIC: 8555T>G), c.9118<<<-2A>G>>> (BIC: 9346-2A>G) and following (c. 6384del2 (BIC: 6503delTT), c.3853dupA (BIC: 4081insA) and c.5569G>T (BIC: 5797G>T)).|s the Icelandic founder mutation c.771_775del5 (BIC: 999del5), three other (c.7480C>T (BIC: 7708C>T), c.8327T>G (BIC: 8555T>G), c.9118-2A>G (BIC: 9346<<<-2A>G>>>) and following (c. 6384del2 (BIC: 6503delTT), c.3853dupA (BIC: 4081insA) and c.5569G>T (BIC: 5797G>T)).|6C>T 300T>G 5382insC 300T>A 3347delAG 3404delA 1499insA 5181delGTT 5083del19 5181_5183delGTT 3600del11 5247G>T 185delAG 330A>G 5236G>A 5242C>A  c.7806<<<-2A>G>>>  IVS16-2A>G  c.8537_8538delAG(Sardinia)  8765delAG  c.2808_2811del4 (Castilla-Leon) c.6629_6630delAA c.9026_9030del5 c.9310_9311delAA  3036_3039del4 |5382insC 300T>A 3347delAG 3404delA 1499insA 5181delGTT 5083del19 5181_5183delGTT 3600del11 5247G>T 185delAG 330A>G 5236G>A 5242C>A  c.7806-2A>G  IVS16<<<-2A>G>>>  c.8537_8538delAG(Sardinia)  8765delAG  c.2808_2811del4 (Castilla-Leon) c.6629_6630delAA c.9026_9030del5 c.9310_9311delAA  3036_3039del4 c.6857delAA |4864delA 2470del7 3203del11 120A>C IVS17-2A>C  c.2808del4 c.3847delGT  3036del4 4075delGT  exons 1-13 deletion exon 13 duplication (ins6kbEx13) c.4097<<<-2A>G>>> c.3485delA c.3626delT c.4327C>T c.2684del2 c.5251C>T c.4096+3A>G  4216-2A>G 3604delA 3745delT 4446C>T 2803delAA 5370C>T IVS11+3A>G  c.771_775del5 c.7|el4 4075delGT  exons 1-13 deletion exon 13 duplication (ins6kbEx13) c.4097-2A>G c.3485delA c.3626delT c.4327C>T c.2684del2 c.5251C>T c.4096+3A>G  4216<<<-2A>G>>> 3604delA 3745delT 4446C>T 2803delAA 5370C>T IVS11+3A>G  c.771_775del5 c.7480C>T c.8327T>G c.9118-2A>G c.9117+1G>A  999del5 7708C>T 8555T>G 9346-2A>G |c.4327C>T c.2684del2 c.5251C>T c.4096+3A>G  4216-2A>G 3604delA 3745delT 4446C>T 2803delAA 5370C>T IVS11+3A>G  c.771_775del5 c.7480C>T c.8327T>G c.9118<<<-2A>G>>> c.9117+1G>A  999del5 7708C>T 8555T>G 9346-2A>G 9345+1G>A  c.2681_2682delAA (Scotland)  2800delAA  c.771_775del5 c.6275_6276delTT (Scotland)  999del5 |6-2A>G 3604delA 3745delT 4446C>T 2803delAA 5370C>T IVS11+3A>G  c.771_775del5 c.7480C>T c.8327T>G c.9118-2A>G c.9117+1G>A  999del5 7708C>T 8555T>G 9346<<<-2A>G>>> 9345+1G>A  c.2681_2682delAA (Scotland)  2800delAA  c.771_775del5 c.6275_6276delTT (Scotland)  999del5 6503delTT  c.4065_4068del4 (North-West) exon 13		
23199084	confirmed					23199084		dup		NM_000059.3:c.5351dupA	NM_000059.3:c.5577dupA		rs80359509		 c.5351dupA|c.5351dupA				BRCA2	entrez	675			dna	c.123dupA|c.123dupA|c.123dupA	21793,22127,40341	21804,22138,40352	r mutations: 3.8-kb deletion of BRCA1 exon 13, also known as c.41861643_4357+2020del3835 (BIC: del exon 13del3835/  401  IVS12-1643del3835), and BRCA2<<< c.5351dupA>>> (BIC: 5579insA) were found in families from two different geographical areas, and were prevalent respectively in Catholic (West Braband clustering) and Protestant (South Beveland clustering) families, reflecting religious endogamy [95].|Together with another Dutch BRCA2 founder mutation c.6275_6276delTT (BIC: 6503delTT),<<< c.5351dupA>>> accounts for 62% of hereditary breast/ovarian families [94, 95]. Slightly outdated (as of year 2002) list of published and unpublished BRCA1/2 mutati|4068del4 c.2338C>T c.181T>G c.5266dupC  IVS5+3A>G 2478insG 3780G>T 2804delAA 2312del5 1411insT  c.156_157insAlu c.516+1G>A c.6275_6276delTT c.8904delC<<< c.5351dupA>>> c.6275_6276delTT  384insAlu IVS6+1G>A 6503_6504delTT 9132delC 5579insA 6503delTT  c.1813dupA c.4478del4 c.9098dupA  2041insA 4706del4 9326insA  c.791		
23199084	confirmed					23199084		dup		NM_007300.3:c.5526dupC	NM_007300.3:c.5757dupC		na		c.5526dupC				BRCA1	entrez	672			dna	c.123dupA|c.123dupA	26571,26960	26582,26971	arian male breast cancer patients, one third carried BRCA2 mutations, including c.9098dupA [104]. Greece In the Greek population four BRCA1 mutations <<<(c.5526dupC>>>, c.5212G>A (BIC: 5331G>A/G1738R), c.5251C>T (BIC:  EPMA Journal (2010) 1:397–412  5370C>T/R1751X), c.5467G>A (BIC: 5586G>A), account for 54% of all m| families, whereas the rest are unique or low-frequency mutations, reflecting the population’s genetic heterogeneity. The most frequent BRCA1 mutation<<< c.5526dupC>>> accounts for 31% of the BRCA1/2 mutations identified in Greek familial breast/ovarian cancer patients [45, 105]. Previously described as unclassified		
23199084	confirmed					23199084		del		NM_007294.3:c.470_471delCT|NM_007300.3:c.470_471delCT|NM_007299.3:c.470_471delCT|NM_007298.3:c.470_471delCT	NM_007294.3:c.701_702delCT|NM_007300.3:c.701_702delCT|NM_007299.3:c.663_664delCT|NM_007298.3:c.488_489delCT		rs80357887|rs80357887|rs80357887|rs80357887		 c.470_471delCT				BRCA1	entrez	672			dna	c.123_125delAT|c.123_125delAT	17915,39942	17930,39957	nt laboratories shows that five mutations in the BRCA1 gene (c.68_69delAG, c.211A>G (BIC: 330A>G), c.5117G>A (BIC: 5236G>A), c.5123C>A (BIC: 5242C>A),<<< c.470_471delCT>>> (BIC: 589_590delCT) account for 46.6% of BRCA1 mutations and four mutations in BRCA2 (c.2808_2811del4 (BIC: 3036_3039del4), c.6629_6630delAA (BIC: c.|nia)  8765delAG  c.2808_2811del4 (Castilla-Leon) c.6629_6630delAA c.9026_9030del5 c.9310_9311delAA  3036_3039del4 c.6857delAA 9254-9258del5 9538delAA <<< c.470_471delCT>>> c.5153-1G>A  589_590delCT 5272-1G>A  c.5146_5149del4  374delTATG  c.212+3A>G c.2359dupG c.3661G>T c.2685_2686delAA c.2193del5 c.1292dupT exon 13 dele		
23199084	notConfirmed							sub		c.4446C>T					4446C>T| 4446C>T				BRCA1	entrez	672			dna	859G>A|859G>A|859G>A	16779,32860,41875	16787,32868,41883	In this region 4 BRCA1 gene mutations (c.4327C>T (BIC:<<< 4446C>T>>>/Arg1443X), c.3756_3759del4 (BIC:  EPMA Journal (2010) 1:397–412  3875delGTCT), c.962G>A (BIC: 1081G>A), c.2834_2836delinsC (BIC: 2953delGTA/insC) and|d [130–138]. The most common BRCA1 mutations are c.4097-2A>G (BIC: 4216-2A>G), c.3485delA (BIC: 3604delA), c.3626delT (BIC: 3745delT), c.4327C>T (BIC:<<< 4446C>T>>>), c.2684del2 (BIC: 2803delAA) and c.5251C>T (BIC: 5370C>T).|13 deletion exon 13 duplication (ins6kbEx13) c.4097-2A>G c.3485delA c.3626delT c.4327C>T c.2684del2 c.5251C>T c.4096+3A>G  4216-2A>G 3604delA 3745delT<<< 4446C>T>>> 2803delAA 5370C>T IVS11+3A>G  c.771_775del5 c.7480C>T c.8327T>G c.9118-2A>G c.9117+1G>A  999del5 7708C>T 8555T>G 9346-2A>G 9345+1G>A  c.2681_2682delA		
23199084	confirmed					23199084		sub		NM_007294.3:c.962G>A|NM_007300.3:c.962G>A	NM_007294.3:c.1193G>A|NM_007300.3:c.1193G>A		rs80357292|rs80357292		c.962G>A				BRCA1	entrez	672			dna	c.123T>A	16866	16875	In this region 4 BRCA1 gene mutations (c.4327C>T (BIC: 4446C>T/Arg1443X), c.3756_3759del4 (BIC:  EPMA Journal (2010) 1:397–412  3875delGTCT),<<< c.962G>A>>> (BIC: 1081G>A), c.2834_2836delinsC (BIC: 2953delGTA/insC) and 3 BRCA2 mutations (c.3170_3174del5 (BIC: 3398del5), c.5857G>T (BIC: 6085G>T), c.8537_85		
23199084	confirmed					23199084		del		NM_007300.3:c.6373delA|NM_007297.3:c.6373delA	NM_007300.3:c.6604delA|NM_007297.3:c.6653delA		na|na		 c.6373delA|c.6373delA				BRCA1	entrez	672			dna	c.123delT|c.123delT|c.123delT	28180,28528,41147	28191,28539,41158	atabase) and the c.3319G>T BRCA1 mutation was also reported in Norway (http://www.legeforeningen.no/id/153250.0). The most common BRCA2 mutations were<<< c.6373delA>>> (BIC: 6601delA), c.1310_1013del4 (BIC: 1538del4), c.6486_6489del4 (BIC: 6714del4) and c.3847_3848delGT (BIC: 4075delGT), found in 11%, 10%, 9% and 5% of BRCA2 positive families, respectively [111].|Two of the recurrent BRCA2 mutations (c.1310_1313del4 and c.6486_ 6489del4) have also been observed in many other populations, whereas the<<< c.6373delA>>> BRCA2 mutation is less frequent.|C>T c.5467G>A  5382insC 5331G>A 5370C>T 5586G>A  c.2475delC c.3319G>T c.5266dupC c.3710delT  2594delC 3438G>T 5382insC 3829delT  HGVS  BIC  c.8755delG<<< c.6373delA>>> c.1310_1013del4 c.6486_6489del4 c.3847_3848delGT  8984delG 6601delA 1538del4 6714del4 4075delGT  exons 3-16 deletion c.3171_3175dup c.2475delC c.1082		
23199084	confirmed					23199084		del		NM_000059.3:c.6373delA	NM_000059.3:c.6599delA		rs80359578		 c.6373delA|c.6373delA				BRCA2	entrez	675			dna	c.123delT|c.123delT|c.123delT	28180,28528,41147	28191,28539,41158	atabase) and the c.3319G>T BRCA1 mutation was also reported in Norway (http://www.legeforeningen.no/id/153250.0). The most common BRCA2 mutations were<<< c.6373delA>>> (BIC: 6601delA), c.1310_1013del4 (BIC: 1538del4), c.6486_6489del4 (BIC: 6714del4) and c.3847_3848delGT (BIC: 4075delGT), found in 11%, 10%, 9% and 5% of BRCA2 positive families, respectively [111].|Two of the recurrent BRCA2 mutations (c.1310_1313del4 and c.6486_ 6489del4) have also been observed in many other populations, whereas the<<< c.6373delA>>> BRCA2 mutation is less frequent.|C>T c.5467G>A  5382insC 5331G>A 5370C>T 5586G>A  c.2475delC c.3319G>T c.5266dupC c.3710delT  2594delC 3438G>T 5382insC 3829delT  HGVS  BIC  c.8755delG<<< c.6373delA>>> c.1310_1013del4 c.6486_6489del4 c.3847_3848delGT  8984delG 6601delA 1538del4 6714del4 4075delGT  exons 3-16 deletion c.3171_3175dup c.2475delC c.1082		
23199084	confirmed					23199084		sub		NM_007294.3:c.181T>G|NM_007300.3:c.181T>G|NM_007299.3:c.181T>G|NM_007298.3:c.181T>G	NM_007294.3:c.412T>G|NM_007300.3:c.412T>G|NM_007299.3:c.374T>G|NM_007298.3:c.199T>G		rs28897672|rs28897672|rs28897672|rs28897672		c.181T>G| c.181T>G				BRCA1	entrez	672			dna	c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A	11866,13134,23479,23660,24048,24348,24700,25967,26143,26374,36191,36880,38159,38452,39179,39380,40174,40209,40658,42201,42515,42917,44806	11875,13143,23488,23669,24057,24357,24709,25976,26152,26383,36200,36889,38168,38461,39188,39389,40183,40218,40667,42210,42524,42926,44815	appaport, personal communication). There were initial reports for several apparently founder BRCA1 mutations in Austria [58, 59], although they  399  <<<(c.181T>G>>> (BIC: 300T>G/C61G), c.5266dupC, c.1687C>T (BIC: 1806C>T)) represent common mutations prevalent in other European countries.|(Rappaport, personal communication). Slovenia In Slovenia five highly recurrent specific mutations were identified: four in the BRCA1 gene (c.1687C>T,<<< c.181T>G>>>, c.5266dupC, c.181T> (BIC: 300T>A)) and one in the BRCA2 gene (c.7806-2A>G (BIC: IVS16-2A>G) [43, 61, 62].|Eighteen BRCA1 mutations, including the most common c.5266dupC,<<< c.181T>G>>>, c.4065_4068del4 (BIC: 4184del4) and c.2338C>T (BIC: 2457C>T), were found at least 3 times and comprised 66% of all BRCA1 mutations.|The 2 most common BRCA1 c.5266dupC and<<< c.181T>G>>> mutations, also prevalent in other populations, accounted for 38% of BRCA1 mutations [4, 99].|) and c.9098dupA (BIC: 9326insA) were associated with common alleles, suggesting a possible founder effect [99]. Czech Republic Five mutations (BRCA1:<<< c.181T>G>>>, c.5266dupC, c.3700_ 3704del5 (BIC: 3819del5), and BRCA2: c.7913_7917del5 (BIC: 8141del5) and c.8537_8538del2 (BIC: 8765delAG)) represented 52% of all mutations detected in one study population [52].|There is evident strong Slavic founder  402  effect, particularly for two BRCA1 mutations <<<(c.181T>G>>> and c.5266dupC) also regarded as founder mutations in Poland and some other Slavic countries [100].|Three BRCA1 Czech founder mutations <<<(c.181T>G>>>, c.3700_3704del5, and c.5266dupC) account for approximately 9%, 13% and 44% of the BRCA1 mutations identified, respectively [51, 52]. BRCA1 mutations|l spectrum in this population. Hungary In Hungarian patients from high-risk breast/ovarian cancer families, common BRCA1 founder mutations c.5266dupC,<<< c.181T>G>>> and c.68_69delAG accounted for 80% of all BRCA1 mutations and c.9098dupA (BIC: 9326insA) with c.5946delT accounted for 50% of all BRCA2 mutations [42, 103].|The BRCA1<<< c.181T>G>>> is the most frequent of founder mutations, representing 48% [103].|st cancer patients were more likely to carry the c.5266dupC mutation whereas ovarian patients were more likely to carry either the c.68_69delAG or the<<< c.181T>G>>> mutation [103].|The BRCA1 c.5266dupC,<<< c.181T>G>>> and c.4035delA accounted for about 56%, 25% and 10% of all BRCA1 mutations, respectively.|In North-Eastern Poland two common mutations (c.5266dupC and<<< c.181T>G>>>) accounted for more than half (up to 70%) of all BRCA-mutated families and no c.4035delA was identified [156], what is in accordance with other studies [157].|The BRCA1<<< c.181T>G>>> is the third recurrent mutation in Latvia, but is not very commonly found.|In Poland 3 most common mutations (c.5266dupC,<<< c.181T>G>>> and c.4035delA (BIC: 4154delA) accounted for 91% (111/122) BRCA1 mutations  In Lithuania BRCA1 gene mutations are influenced by significant founder effect, which is similar to that reported from Latvian (Baltic) population [50].|st) French Spanish  Portuguese Belgian  Dutch  German  Czech  Hungarian  BRCA1 mutation  BRCA2 mutation  HGVS  BIC  HGVS  BIC  c.68_69delAG c.5266dupC<<< c.181T>G>>> c.5266dupC c.1687C>T  185delAG 5382insC 300T>G 5382insC 1806C>T  c.5946delT  6174delT  c.8363G>A c.8754+1G>A c.3860delA  8591G>A IVS21-1G>A 4088delA |00T>G 5382insC 1806C>T  c.5946delT  6174delT  c.8363G>A c.8754+1G>A c.3860delA  8591G>A IVS21-1G>A 4088delA  c.3016_3019del4 c.2676_2679del4 c.1687C>T<<< c.181T>G>>> c.5266dupC c.181T>A c.3228_3229delAG c.3285delA c.1380dupA c.5062_5064del3 c.4964_4982del19 c.5062_5064delGTT c.3481_3491del11 c.5128G>T c.68_69delAG|c.212+3A>G c.2359dupG c.3661G>T c.2685_2686delAA c.2193del5 c.1292dupT exon 13 deletion (3,8-kb) exon 22 deletion (510-bp) exon 17 deletion c.5266dupC<<< c.181T>G>>> c.4065_4068del4 c.2338C>T c.181T>G c.5266dupC  IVS5+3A>G 2478insG 3780G>T 2804delAA 2312del5 1411insT  c.156_157insAlu c.516+1G>A c.6275_6276delTT c.|685_2686delAA c.2193del5 c.1292dupT exon 13 deletion (3,8-kb) exon 22 deletion (510-bp) exon 17 deletion c.5266dupC c.181T>G c.4065_4068del4 c.2338C>T<<< c.181T>G>>> c.5266dupC  IVS5+3A>G 2478insG 3780G>T 2804delAA 2312del5 1411insT  c.156_157insAlu c.516+1G>A c.6275_6276delTT c.8904delC c.5351dupA c.6275_6276delT|del5 c.8537_8538del2  8141del5 8765delAG  c.9098dupA c.5946delT  9326insA 6174delT  c.3700_3704del5 exons 1–17 deletion exons 5–14 deletion c.5266dupC<<< c.181T>G>>> c.68_69delAG  5382insC 300T>G 4184del4 2457C>T 300T>G 5382insC 3819del5  5382insC 300T>G 185delAG  406  EPMA Journal (2010) 1:397–412  Table 1 (conti|delAA  c.771_775del5 c.6275_6276delTT (Scotland)  999del5 6503delTT  c.4065_4068del4 (North-West) exon 13 duplication (ins6kbEx13) c.427G>T c.5266dupC<<< c.181T>G>>> c.4035delA c.4035delA c.5266dupC  4184del4  c.1929delG (North-West)  2157delG  546G>T 5382insC 300T>G 4154delA 4154delA 5382insC  EPMA Journal (2010)|7–412  407  Table 1 (continued) Population  Lithuanian Belarusian Russian  BRCA1 mutation  BRCA2 mutation  HGVS  BIC  c.4035delA c.5266dupC c.5266dupC<<< c.181T>G>>> c.5266dupC  4154delA 5382insC 5382insC 300T>G 5382insC  HGVS  BIC  Apparently true founder mutations are written in italic.|BRCA1 numbered by GeneBank U14680 reference sequence; BRCA2 numbered by GeneBank U43746 reference sequence  other mutations, BRCA1<<< c.181T>G>>> and recently proved to be pathogenious c.5258G>C (BIC: 5377G>C/R1753T) were also found in more than one family; together with two founder mutations t|Other less common mutations found in Western Russia are c.4035delA,<<< c.181T>G>>>, and c.68_69delAG.		
23199084	confirmed					23199084		sub		NM_007294.3:c.181T>A|NM_007300.3:c.181T>A|NM_007299.3:c.181T>A|NM_007298.3:c.181T>A	NM_007294.3:c.412T>A|NM_007300.3:c.412T>A|NM_007299.3:c.374T>A|NM_007298.3:c.199T>A		rs28897672|rs28897672|rs28897672|rs28897672		 c.181T>A				BRCA1	entrez	672			dna	c.123T>A	39400	39409	>T  c.5946delT  6174delT  c.8363G>A c.8754+1G>A c.3860delA  8591G>A IVS21-1G>A 4088delA  c.3016_3019del4 c.2676_2679del4 c.1687C>T c.181T>G c.5266dupC<<< c.181T>A>>> c.3228_3229delAG c.3285delA c.1380dupA c.5062_5064del3 c.4964_4982del19 c.5062_5064delGTT c.3481_3491del11 c.5128G>T c.68_69delAG c.211A>G (Galicia) 		
23199084	notConfirmed							sub		c.8591G>A					8591G>A| 8591G>A				BRCA2	entrez	675			dna	859G>A|859G>A	12834,39309	12842,39317	The most prevalent BRCA2 mutations are c.8363G>A (BIC:<<< 8591G>A>>>/W2788X), c.8754+1G>A (BIC: IVS211G>A) and c.3860delA (BIC: 4088delA), representing 9%, 7% and 6% of the BRCA2 mutation families respectively (Rappapo|8_69delAG c.5266dupC c.181T>G c.5266dupC c.1687C>T  185delAG 5382insC 300T>G 5382insC 1806C>T  c.5946delT  6174delT  c.8363G>A c.8754+1G>A c.3860delA <<< 8591G>A>>> IVS21-1G>A 4088delA  c.3016_3019del4 c.2676_2679del4 c.1687C>T c.181T>G c.5266dupC c.181T>A c.3228_3229delAG c.3285delA c.1380dupA c.5062_5064del3 c.		
23199084	confirmed					23199084		sub		NM_007294.3:c.5153-1_5153G>A|NM_007300.3:c.5153-1_5153G>A	NM_007294.3:c.5384-1_5384G>A|NM_007300.3:c.5384-1_5384G>A		rs80357239|na		 c.5153-1G>A|c.5153-1G>A				BRCA1	entrez	672			dna	c.123+2A>T|c.123+2A>T	19481,39957	19493,39969	ological mutation in the BIC database ranking with a presumable multiple different origins [85, 86].  EPMA Journal (2010) 1:397–412  Splicing mutation<<< c.5153-1G>A>>> (BIC: 5272-1G>A) of BRCA1 and frameshift mutation c.5146_5149del4 (BIC: 5374delTATG) of BRCA2 are also prevalent founder mutations in the Central Spa|  c.2808_2811del4 (Castilla-Leon) c.6629_6630delAA c.9026_9030del5 c.9310_9311delAA  3036_3039del4 c.6857delAA 9254-9258del5 9538delAA  c.470_471delCT<<< c.5153-1G>A>>>  589_590delCT 5272-1G>A  c.5146_5149del4  374delTATG  c.212+3A>G c.2359dupG c.3661G>T c.2685_2686delAA c.2193del5 c.1292dupT exon 13 deletion (3,8-kb		
23199084	confirmed					23199084		sub		NM_007294.3:c.427G>T|NM_007300.3:c.427G>T|NM_007299.3:c.427G>T|NM_007298.3:c.427G>T	NM_007294.3:c.658G>T|NM_007300.3:c.658G>T|NM_007299.3:c.620G>T|NM_007298.3:c.445G>T		rs80356991|rs80356991|rs80356991|rs80356991		c.427G>T| c.427G>T				BRCA1	entrez	672			dna	c.123T>A|c.123T>A	35865,42181	35874,42190	It is distributed mainly in English-speaking countries or in countries with historical links with Britain. Ireland A single BRCA1<<< c.427G>T>>> (BIC: 546G>T/E143X) mutation accounts for about 22% of all hereditary breast cancer patients from relatively homogenous Irish population and presumab|lAA (Scotland)  2800delAA  c.771_775del5 c.6275_6276delTT (Scotland)  999del5 6503delTT  c.4065_4068del4 (North-West) exon 13 duplication (ins6kbEx13)<<< c.427G>T>>> c.5266dupC c.181T>G c.4035delA c.4035delA c.5266dupC  4184del4  c.1929delG (North-West)  2157delG  546G>T 5382insC 300T>G 4154delA 4154delA 5382insC 		
23199084	confirmed					23199084		del		NM_007294.3:c.6857delA	NM_007294.3:c.7088delA		na		 c.6857delA|c.6857delA				BRCA1	entrez	672			dna	c.123delT|c.123delT	18077,39905	18088,39916	lCT (BIC: 589_590delCT) account for 46.6% of BRCA1 mutations and four mutations in BRCA2 (c.2808_2811del4 (BIC: 3036_3039del4), c.6629_6630delAA (BIC:<<< c.6857delA>>>A), c.9026_9030del5 (BIC: 92549258del5), c.9310_9311delAA (BIC: 9538delAA)) account for 56.6% of the BRCA2 mutations [79]. Diez et al., [80] have revi|G  IVS16-2A>G  c.8537_8538delAG(Sardinia)  8765delAG  c.2808_2811del4 (Castilla-Leon) c.6629_6630delAA c.9026_9030del5 c.9310_9311delAA  3036_3039del4<<< c.6857delA>>>A 9254-9258del5 9538delAA  c.470_471delCT c.5153-1G>A  589_590delCT 5272-1G>A  c.5146_5149del4  374delTATG  c.212+3A>G c.2359dupG c.3661G>T c.2685_268		
23199084	confirmed					23199084		del		NM_000059.3:c.6857delA	NM_000059.3:c.7083delA		na		 c.6857delA|c.6857delA				BRCA2	entrez	675			dna	c.123delT|c.123delT	18077,39905	18088,39916	lCT (BIC: 589_590delCT) account for 46.6% of BRCA1 mutations and four mutations in BRCA2 (c.2808_2811del4 (BIC: 3036_3039del4), c.6629_6630delAA (BIC:<<< c.6857delA>>>A), c.9026_9030del5 (BIC: 92549258del5), c.9310_9311delAA (BIC: 9538delAA)) account for 56.6% of the BRCA2 mutations [79]. Diez et al., [80] have revi|G  IVS16-2A>G  c.8537_8538delAG(Sardinia)  8765delAG  c.2808_2811del4 (Castilla-Leon) c.6629_6630delAA c.9026_9030del5 c.9310_9311delAA  3036_3039del4<<< c.6857delA>>>A 9254-9258del5 9538delAA  c.470_471delCT c.5153-1G>A  589_590delCT 5272-1G>A  c.5146_5149del4  374delTATG  c.212+3A>G c.2359dupG c.3661G>T c.2685_268		
23199084	notConfirmed							del		c.4154A>None					 4154delA|4154delA				BRCA1	entrez	672			dna	6174delT|6174delT|6174delT|6174delT|6174delT|6174delT|6174delT	37662,38482,42312,42321,42536,55376,74994	37671,38491,42321,42330,42545,55385,75003	The<<< 4154delA>>> mutation is the second most abundant BRCA1 gene mutation after the c.5266dupC in Latvia [50] and is especially common for patients of Baltic (Latvian and Lithuanian) origin.|In Poland 3 most common mutations (c.5266dupC, c.181T>G and c.4035delA (BIC:<<< 4154delA>>>) accounted for 91% (111/122) BRCA1 mutations  In Lithuania BRCA1 gene mutations are influenced by significant founder effect, which is similar to that reported from Latvian (Baltic) population [50].|cation (ins6kbEx13) c.427G>T c.5266dupC c.181T>G c.4035delA c.4035delA c.5266dupC  4184del4  c.1929delG (North-West)  2157delG  546G>T 5382insC 300T>G<<< 4154delA>>> 4154delA 5382insC  EPMA Journal (2010) 1:397–412  407  Table 1 (continued) Population  Lithuanian Belarusian Russian  BRCA1 mutation  BRCA2 mutation |ns6kbEx13) c.427G>T c.5266dupC c.181T>G c.4035delA c.4035delA c.5266dupC  4184del4  c.1929delG (North-West)  2157delG  546G>T 5382insC 300T>G 4154delA<<< 4154delA>>> 5382insC  EPMA Journal (2010) 1:397–412  407  Table 1 (continued) Population  Lithuanian Belarusian Russian  BRCA1 mutation  BRCA2 mutation  HGVS  BI|continued) Population  Lithuanian Belarusian Russian  BRCA1 mutation  BRCA2 mutation  HGVS  BIC  c.4035delA c.5266dupC c.5266dupC c.181T>G c.5266dupC <<< 4154delA>>> 5382insC 5382insC 300T>G 5382insC  HGVS  BIC  Apparently true founder mutations are written in italic.|High prevalence of two BRCA1 mutations,<<< 4154delA>>> and 5382insC, in Latvia.|The<<< 4154delA>>> mutation carriers in the BRCA1 gene share a common ancestry.		
23199084	confirmed					23199084		del		NM_000059.3:c.1929delG	NM_000059.3:c.2155delG		rs80359316		 c.1929delG|c.1929delG				BRCA2	entrez	675			dna	c.123delT|c.123delT	35219,42254	35230,42265	s in Dutch, Swedish, Danish and Belgian families (BIC database). In the North-west of England two reccurent mutations (BRCA1 c.4065_4068del4 and BRCA2<<< c.1929delG>>> (BIC: 2157delG) accounted for 16% of identified BRCA1 mutations in breast/ovarian cancer families and for 20% of BRCA2 positive male breast cancer fa|del5 6503delTT  c.4065_4068del4 (North-West) exon 13 duplication (ins6kbEx13) c.427G>T c.5266dupC c.181T>G c.4035delA c.4035delA c.5266dupC  4184del4 <<< c.1929delG>>> (North-West)  2157delG  546G>T 5382insC 300T>G 4154delA 4154delA 5382insC  EPMA Journal (2010) 1:397–412  407  Table 1 (continued) Population  Lithua		
23199084	confirmed					23199084		del		NM_007294.3:c.697delG|NM_007300.3:c.697delG|NM_007299.3:c.697delG|NM_007298.3:c.697delG|NM_007297.3:c.697delG	NM_007294.3:c.928delG|NM_007300.3:c.928delG|NM_007299.3:c.890delG|NM_007298.3:c.715delG|NM_007297.3:c.977delG		na|na|na|na|na		c.697delG| c.697delG				BRCA1	entrez	672			dna	c.123delT|c.123delT	31303,41417	31313,41427	ast cancer in this region [115, 125]. Norway Four Norwegian founder mutations in BRCA1 gene (c.1556delA (BIC: 1675delA), c.3228delAG (BIC: 3347delAG),<<< c.697delG>>>T (BIC: 816delGT) and c.1016dupA make up 68% of the BRCA1 mutation carriers [126, 127], and these have their own specific geographic distribution.|deletion c.3171_3175dup c.2475delC c.1082_1092del11 c.1687C>T c.3626delT (Northern) c.1016dupA exon 13 duplication (ins6kbEx13) c.1556delA c.3228delAG<<< c.697delG>>>T c.1016dupA c.3178G>T c.4745delA c.2351del7 c.3084del11 c.1A>C c.5075-2A>C  3171ins5 2594delC 1201del11 1806C>T 3745delT 1135insA  c.4258delG  4486de		
23199084	confirmed					23199084		sub		NM_000059.3:c.9117+1_9117G>A	NM_000059.3:c.9343+1_9343G>A		rs81002802		c.9117+1G>A| c.9117+1G>A				BRCA2	entrez	675			dna	c.123+2A>T|c.123+2A>T	33369,41959	33381,41971	Some mutations are unique to the Finns, such as c.4096+3A>G (BIC: IVS11+3A>G) in BRCA1 and<<< c.9117+1G>A>>> (BIC: 9345+ 1G>A), c.7480C>T, c.8327T>G in BRCA2 genes. The mutation spectrum in Eastern part slightly differs from those observed in the Northern an|7C>T c.2684del2 c.5251C>T c.4096+3A>G  4216-2A>G 3604delA 3745delT 4446C>T 2803delAA 5370C>T IVS11+3A>G  c.771_775del5 c.7480C>T c.8327T>G c.9118-2A>G<<< c.9117+1G>A>>>  999del5 7708C>T 8555T>G 9346-2A>G 9345+1G>A  c.2681_2682delAA (Scotland)  2800delAA  c.771_775del5 c.6275_6276delTT (Scotland)  999del5 6503delTT  c		
23199084	confirmed					23199084		sub		NM_007300.3:c.5247G>T	NM_007300.3:c.5478G>T		na		5247G>T| 5247G>T				BRCA1	entrez	672			dna	859G>A|859G>A	15822,39703	15830,39711	The c.3481_3491del11 (BIC: 3600del11) in exon 11 accounts for 37% and the nonsense mutation c.5128G>T (BIC:<<< 5247G>T>>>/Gly1710X) in exon 18 for 15% of all BRCA1/2 mutations in that region (overall 52%) [4, 75]. The haplotype analysis of the families carrying the mutat|icia) c.5117G>A c.5123C>A  3135del4 2795del4 1806C>T 300T>G 5382insC 300T>A 3347delAG 3404delA 1499insA 5181delGTT 5083del19 5181_5183delGTT 3600del11<<< 5247G>T>>> 185delAG 330A>G 5236G>A 5242C>A  c.7806-2A>G  IVS16-2A>G  c.8537_8538delAG(Sardinia)  8765delAG  c.2808_2811del4 (Castilla-Leon) c.6629_6630delAA c.9		
23199084	notConfirmed							sub		c.300T>A					 300T>A|300T>A				BRCA2	entrez	675			dna	859G>A|859G>A	13170,39621	13177,39628	 Slovenia In Slovenia five highly recurrent specific mutations were identified: four in the BRCA1 gene (c.1687C>T, c.181T>G, c.5266dupC, c.181T> (BIC:<<< 300T>A>>>)) and one in the BRCA2 gene (c.7806-2A>G (BIC: IVS16-2A>G) [43, 61, 62].|_4982del19 c.5062_5064delGTT c.3481_3491del11 c.5128G>T c.68_69delAG c.211A>G (Galicia) c.5117G>A c.5123C>A  3135del4 2795del4 1806C>T 300T>G 5382insC<<< 300T>A>>> 3347delAG 3404delA 1499insA 5181delGTT 5083del19 5181_5183delGTT 3600del11 5247G>T 185delAG 330A>G 5236G>A 5242C>A  c.7806-2A>G  IVS16-2A>G  c.8537_8		
23199084	confirmed					23199084		del		NM_007294.3:c.4745delA|NM_007297.3:c.4745delA	NM_007294.3:c.4976delA|NM_007297.3:c.5025delA		rs80357907|na		c.4745delA| c.4745delA				BRCA1	entrez	672			dna	c.123delT|c.123delT	31701,41449	31712,41460	rth is from the southeast [127]. These four founder mutations together with other six most frequent BRCA1/2 mutations (BRCA1 c.3178G>T (BIC: 3297G>T),<<< c.4745delA>>> (BIC: 4864delA), c.2351del7 (BIC: 2470del7), c.3084del11 (BIC: 3203del11) and BRCA2 c.2808del4 (BIC: 3036del4), c.3847delGT (BIC: 4075delGT)), account for about 60% BRCA1/2 carriers in Norway [128].|lC c.1082_1092del11 c.1687C>T c.3626delT (Northern) c.1016dupA exon 13 duplication (ins6kbEx13) c.1556delA c.3228delAG c.697delGT c.1016dupA c.3178G>T<<< c.4745delA>>> c.2351del7 c.3084del11 c.1A>C c.5075-2A>C  3171ins5 2594delC 1201del11 1806C>T 3745delT 1135insA  c.4258delG  4486delG  1675delA 3347delAG 816delGT 1		
23199084	confirmed					23199084		sub		NM_007297.3:c.5377G>C	NM_007297.3:c.5657G>C		na		5377G>C				BRCA1	entrez	672			dna	859G>A	42981	42989	sequence; BRCA2 numbered by GeneBank U43746 reference sequence  other mutations, BRCA1 c.181T>G and recently proved to be pathogenious c.5258G>C (BIC:<<< 5377G>C>>>/R1753T) were also found in more than one family; together with two founder mutations they comprise around 90% of BRCA1 gene mutations and around 85% of all BRCA1/2 mutations identified (Janavičius, unpublished data).		
23199084	confirmed					23199084		del		NM_007294.3:c.1556delA|NM_007300.3:c.1556delA|NM_007297.3:c.1556delA	NM_007294.3:c.1787delA|NM_007300.3:c.1787delA|NM_007297.3:c.1836delA		rs80357662|rs80357662|na		c.1556delA| c.1556delA				BRCA1	entrez	672			dna	c.123delT|c.123delT	31245,41394	31256,41405	more than 80% of excess number of ovarian cancer after breast cancer in this region [115, 125]. Norway Four Norwegian founder mutations in BRCA1 gene <<<(c.1556delA>>> (BIC: 1675delA), c.3228delAG (BIC: 3347delAG), c.697delGT (BIC: 816delGT) and c.1016dupA make up 68% of the BRCA1 mutation carriers [126, 127], and these have their own specific geographic distribution.| 4075delGT  exons 3-16 deletion c.3171_3175dup c.2475delC c.1082_1092del11 c.1687C>T c.3626delT (Northern) c.1016dupA exon 13 duplication (ins6kbEx13)<<< c.1556delA>>> c.3228delAG c.697delGT c.1016dupA c.3178G>T c.4745delA c.2351del7 c.3084del11 c.1A>C c.5075-2A>C  3171ins5 2594delC 1201del11 1806C>T 3745delT 1135in		
23199084	confirmed					23199084		sub		NM_007294.3:c.3178G>T|NM_007300.3:c.3178G>T|NM_007297.3:c.3178G>T	NM_007294.3:c.3409G>T|NM_007300.3:c.3409G>T|NM_007297.3:c.3458G>T		rs80357424|rs80357424|rs80357106		c.3178G>T| c.3178G>T				BRCA1	entrez	672			dna	c.123T>A|c.123T>A	31675,41439	31685,41449	the country, while the fourth is from the southeast [127]. These four founder mutations together with other six most frequent BRCA1/2 mutations (BRCA1<<< c.3178G>T>>> (BIC: 3297G>T), c.4745delA (BIC: 4864delA), c.2351del7 (BIC: 2470del7), c.3084del11 (BIC: 3203del11) and BRCA2 c.2808del4 (BIC: 3036del4), c.3847delGT (BIC: 4075delGT)), account for about 60% BRCA1/2 carriers in Norway [128].|p c.2475delC c.1082_1092del11 c.1687C>T c.3626delT (Northern) c.1016dupA exon 13 duplication (ins6kbEx13) c.1556delA c.3228delAG c.697delGT c.1016dupA<<< c.3178G>T>>> c.4745delA c.2351del7 c.3084del11 c.1A>C c.5075-2A>C  3171ins5 2594delC 1201del11 1806C>T 3745delT 1135insA  c.4258delG  4486delG  1675delA 3347delAG		
23199084	notConfirmed							sub		c.234T>G					 c.234T>G				BRCA1	entrez	672			dna	c.123T>A	29119	29128	 mutation, comprising 40% (6/15) of all BRCA1/2 families with LGRs [112].  EPMA Journal (2010) 1:397–412  Recently a pathogenic founder BRCA1 mutation<<< c.234T>G>>> (BIC: 2466T>G/Cys39Gly) was desribed in Greenland (Inuit population), an autonomous country within the Kingdom of Denmark, with a high carrier frequency (1.6%) in this population [113, 114].		
23199084	notConfirmed							sub		c.330A>G					 330A>G|330A>G				BRCA1	entrez	672			dna	859G>A|859G>A	17854,39720	17861,39727	distribution. A compilation of BRCA test results from different laboratories shows that five mutations in the BRCA1 gene (c.68_69delAG, c.211A>G (BIC:<<< 330A>G>>>), c.5117G>A (BIC: 5236G>A), c.5123C>A (BIC: 5242C>A), c.470_471delCT (BIC: 589_590delCT) account for 46.6% of BRCA1 mutations and four mutations in B|.5123C>A  3135del4 2795del4 1806C>T 300T>G 5382insC 300T>A 3347delAG 3404delA 1499insA 5181delGTT 5083del19 5181_5183delGTT 3600del11 5247G>T 185delAG<<< 330A>G>>> 5236G>A 5242C>A  c.7806-2A>G  IVS16-2A>G  c.8537_8538delAG(Sardinia)  8765delAG  c.2808_2811del4 (Castilla-Leon) c.6629_6630delAA c.9026_9030del5 c.9		
23199084	notConfirmed							sub		c.4096+3A>G					c.4096+3A>G| c.4096+3A>G				BRCA1	entrez	672			dna	c.123+2A>T|c.123+2A>T	33326,41834	33338,41846	Some mutations are unique to the Finns, such as<<< c.4096+3A>G>>> (BIC: IVS11+3A>G) in BRCA1 and c.9117+1G>A (BIC: 9345+ 1G>A), c.7480C>T, c.8327T>G in BRCA2 genes. The mutation spectrum in Eastern part slightly dif|c.3847delGT  3036del4 4075delGT  exons 1-13 deletion exon 13 duplication (ins6kbEx13) c.4097-2A>G c.3485delA c.3626delT c.4327C>T c.2684del2 c.5251C>T<<< c.4096+3A>G>>>  4216-2A>G 3604delA 3745delT 4446C>T 2803delAA 5370C>T IVS11+3A>G  c.771_775del5 c.7480C>T c.8327T>G c.9118-2A>G c.9117+1G>A  999del5 7708C>T 8555T>G		
23199084	notConfirmed							sub		c.7708C>T					7708C>T| 7708C>T				BRCA2	entrez	675			dna	859G>A|859G>A	33110,41980	33118,41988	latively frequently. The most recurrent mutation in BRCA2 is the Icelandic founder mutation c.771_775del5 (BIC: 999del5), three other (c.7480C>T (BIC:<<< 7708C>T>>>), c.8327T>G (BIC: 8555T>G), c.9118-2A>G (BIC: 9346-2A>G) and following (c. 6384del2 (BIC: 6503delTT), c.3853dupA (BIC: 4081insA) and c.5569G>T (BIC: 5797G>T)).|1C>T c.4096+3A>G  4216-2A>G 3604delA 3745delT 4446C>T 2803delAA 5370C>T IVS11+3A>G  c.771_775del5 c.7480C>T c.8327T>G c.9118-2A>G c.9117+1G>A  999del5<<< 7708C>T>>> 8555T>G 9346-2A>G 9345+1G>A  c.2681_2682delAA (Scotland)  2800delAA  c.771_775del5 c.6275_6276delTT (Scotland)  999del5 6503delTT  c.4065_4068del4 (N		
23199084	notConfirmed							sub		c.9118-2A>G					 c.9118-2A>G|c.9118-2A>G				BRCA2	entrez	675			dna	c.123+2A>T|c.123+2A>T	33146,41947	33158,41959	ent mutation in BRCA2 is the Icelandic founder mutation c.771_775del5 (BIC: 999del5), three other (c.7480C>T (BIC: 7708C>T), c.8327T>G (BIC: 8555T>G),<<< c.9118-2A>G>>> (BIC: 9346-2A>G) and following (c. 6384del2 (BIC: 6503delTT), c.3853dupA (BIC: 4081insA) and c.5569G>T (BIC: 5797G>T)).|26delT c.4327C>T c.2684del2 c.5251C>T c.4096+3A>G  4216-2A>G 3604delA 3745delT 4446C>T 2803delAA 5370C>T IVS11+3A>G  c.771_775del5 c.7480C>T c.8327T>G<<< c.9118-2A>G>>> c.9117+1G>A  999del5 7708C>T 8555T>G 9346-2A>G 9345+1G>A  c.2681_2682delAA (Scotland)  2800delAA  c.771_775del5 c.6275_6276delTT (Scotland)  999del5 		
23199084	confirmed					23199084		dup		NM_007294.3:c.2359dupG|NM_007300.3:c.2359dupG|NM_007299.3:c.2359dupG|NM_007297.3:c.2359dupG	NM_007294.3:c.2590dupG|NM_007300.3:c.2590dupG|NM_007299.3:c.2552dupG|NM_007297.3:c.2639dupG		rs397508964|rs397508964|na|na		c.2359dupG| c.2359dupG				BRCA1	entrez	672			dna	c.123dupA|c.123dupA|c.123dupA	20641,21031,40034	20652,21042,40045	[91] in a 49 BRCA1/2 positive families found six major recurrent founder mutations (three BRCA1 c.212+3A> (BIC: IVS5+3A>G),<<< c.2359dupG>>> (BIC: 2478insG), c.3661G>T (BIC: 3780G>T) and three BRCA2 c.516+1G>A (BIC: IVS6+1G>A), c.6275_6276delTT (BIC: 6503_6504delTT), c.8904delC (BIC: 9132d|BRCA1<<< c.2359dupG>>> and BRCA2 c.516+1G>A have not yet been reported in other populations. The Netherlands (Holland) Several founder mutations in BRCA1/2 have been identified in Holland [94], where significant regional and cultural differences exist.|1delAA  3036_3039del4 c.6857delAA 9254-9258del5 9538delAA  c.470_471delCT c.5153-1G>A  589_590delCT 5272-1G>A  c.5146_5149del4  374delTATG  c.212+3A>G<<< c.2359dupG>>> c.3661G>T c.2685_2686delAA c.2193del5 c.1292dupT exon 13 deletion (3,8-kb) exon 22 deletion (510-bp) exon 17 deletion c.5266dupC c.181T>G c.4065_4068		
23199084	confirmed					23199084		del		NM_007294.3:c.2475delC|NM_007300.3:c.2475delC|NM_007299.3:c.2475delC|NM_007298.3:c.2475delC	NM_007294.3:c.2706delC|NM_007300.3:c.2706delC|NM_007299.3:c.2668delC|NM_007298.3:c.2493delC		rs80357970|rs80357970|na|na		c.2475delC| c.2475delC				BRCA1	entrez	672			dna	c.123delT|c.123delT|c.123delT|c.123delT|c.123delT|c.123delT	27754,27942,29991,30886,41045,41290	27765,27953,30002,30897,41056,41301	The most common BRCA1 mutations were<<< c.2475delC>>> (BIC: 2594delC), c.3319G>T (BIC: 3438G>T), c.5266dupC and c.3710delT (BIC: 3829delT), which accounted 16%, 9%, 8% and 5% of BRCA1 positive families, respectively [109–111].|The<<< c.2475delC>>> BRCA1 mutation was also reported in Sweden, Norway and Western Europe (BIC database) and the c.3319G>T BRCA1 mutation was also reported in Norway (ht|Other common BRCA1 mutations in Sweden,<<< c.2475delC>>> and c.1082_1092del11 (BIC: 1201del11), have been detected primarily in families from southern Sweden [118–120], Denmark and Norway (BIC database).|n the Western Sweden, six mutations, including the most common BRCA1 c.3171_3175dup, four other common Scandinavian BCRA1 mutations (c.1082_1092del11,<<< c.2475delC>>>, c.1687C>T, c.1016dupA (BIC: 1135insA)) and one BRCA2 mutation (c.4258delG) accounted for approximately 75% of all BRCA1/2 mutations [124].|British  Irish Polish  Latvian  BRCA1 mutation  BRCA2 mutation  HGVS  BIC  c.5266dupC c.5212G>A c.5251C>T c.5467G>A  5382insC 5331G>A 5370C>T 5586G>A <<< c.2475delC>>> c.3319G>T c.5266dupC c.3710delT  2594delC 3438G>T 5382insC 3829delT  HGVS  BIC  c.8755delG c.6373delA c.1310_1013del4 c.6486_6489del4 c.3847_3848delG|755delG c.6373delA c.1310_1013del4 c.6486_6489del4 c.3847_3848delGT  8984delG 6601delA 1538del4 6714del4 4075delGT  exons 3-16 deletion c.3171_3175dup<<< c.2475delC>>> c.1082_1092del11 c.1687C>T c.3626delT (Northern) c.1016dupA exon 13 duplication (ins6kbEx13) c.1556delA c.3228delAG c.697delGT c.1016dupA c.3178G>T c		
23199084	confirmed					23199084		dup		NM_007294.3:c.1380dupA|NM_007300.3:c.1380dupA|NM_007297.3:c.1380dupA	NM_007294.3:c.1611dupA|NM_007300.3:c.1611dupA|NM_007297.3:c.1660dupA		rs397508863|rs397508863|na		c.1380dupA| c.1380dupA				BRCA1	entrez	672			dna	c.123dupA|c.123dupA|c.123dupA	13883,14116,39437	13894,14127,39448	as been demonstrated for few mutations [63–66]. Four distinct BRCA1 founder mutations (c.3228_ 3229delAG (BIC: 3347delAG), c.3285delA (BIC: 3404delA),<<< c.1380dupA>>> (BIC: 1499insA), c.5062_5064del3 (BIC: 5181delGTT) accounted for a large fraction (73%) of BRCA1-attributable hereditary breast/ ovarian cancer in fa|e fraction (73%) of BRCA1-attributable hereditary breast/ ovarian cancer in families originating from Tuscany (Central Italy) area [47, 66]. The BRCA1<<< c.1380dupA>>> mutation was reported in at least 14 families from Tuscany and originated here about 30 generations ago (∼750 years) [65].  400  In Sardinia, contrib|.8754+1G>A c.3860delA  8591G>A IVS21-1G>A 4088delA  c.3016_3019del4 c.2676_2679del4 c.1687C>T c.181T>G c.5266dupC c.181T>A c.3228_3229delAG c.3285delA<<< c.1380dupA>>> c.5062_5064del3 c.4964_4982del19 c.5062_5064delGTT c.3481_3491del11 c.5128G>T c.68_69delAG c.211A>G (Galicia) c.5117G>A c.5123C>A  3135del4 2795del4 		
23199084	notConfirmed							sub		c.7806-2A>G					c.7806-2A>G| c.7806-2A>G				BRCA2	entrez	675			dna	c.123+2A>T|c.123+2A>T|c.123+2A>T	13206,13356,39744	13218,13368,39756	current specific mutations were identified: four in the BRCA1 gene (c.1687C>T, c.181T>G, c.5266dupC, c.181T> (BIC: 300T>A)) and one in the BRCA2 gene <<<(c.7806-2A>G>>> (BIC: IVS16-2A>G) [43, 61, 62].|Respectively, they accounted for 26%, 18%, 13% and 11% of BRCA1 mutations and 56% of BRCA2 mutations. The<<< c.7806-2A>G>>> in the BRCA2 gene appears to be an unique founder mutation in the Slovenian population, found in 26% (10/38) of all BRCA1/2 mutations harboring families.|el4 1806C>T 300T>G 5382insC 300T>A 3347delAG 3404delA 1499insA 5181delGTT 5083del19 5181_5183delGTT 3600del11 5247G>T 185delAG 330A>G 5236G>A 5242C>A <<< c.7806-2A>G>>>  IVS16-2A>G  c.8537_8538delAG(Sardinia)  8765delAG  c.2808_2811del4 (Castilla-Leon) c.6629_6630delAA c.9026_9030del5 c.9310_9311delAA  3036_3039del4 		
23199084	notConfirmed							del		c.9538A>None					 9538delA|9538delA				BRCA2	entrez	675			dna	6174delT|6174delT	18151,39931	18160,39940	tions in BRCA2 (c.2808_2811del4 (BIC: 3036_3039del4), c.6629_6630delAA (BIC: c.6857delAA), c.9026_9030del5 (BIC: 92549258del5), c.9310_9311delAA (BIC:<<< 9538delA>>>A)) account for 56.6% of the BRCA2 mutations [79]. Diez et al., [80] have reviewed the frequency of BRCA1 and BRCA2 recurrent mutations reported in se|delAG(Sardinia)  8765delAG  c.2808_2811del4 (Castilla-Leon) c.6629_6630delAA c.9026_9030del5 c.9310_9311delAA  3036_3039del4 c.6857delAA 9254-9258del5<<< 9538delA>>>A  c.470_471delCT c.5153-1G>A  589_590delCT 5272-1G>A  c.5146_5149del4  374delTATG  c.212+3A>G c.2359dupG c.3661G>T c.2685_2686delAA c.2193del5 c.1292		
23199084	confirmed					23199084		del		NM_007299.3:c.1675delA|NM_007298.3:c.1675delA	NM_007299.3:c.1868delA|NM_007298.3:c.1693delA		rs80357117|rs80357117		1675delA| 1675delA				BRCA1	entrez	672			dna	6174delT|6174delT|6174delT	31262,41580,69306	31271,41589,69315	excess number of ovarian cancer after breast cancer in this region [115, 125]. Norway Four Norwegian founder mutations in BRCA1 gene (c.1556delA (BIC:<<< 1675delA>>>), c.3228delAG (BIC: 3347delAG), c.697delGT (BIC: 816delGT) and c.1016dupA make up 68% of the BRCA1 mutation carriers [126, 127], and these have their own specific geographic distribution.|.1016dupA c.3178G>T c.4745delA c.2351del7 c.3084del11 c.1A>C c.5075-2A>C  3171ins5 2594delC 1201del11 1806C>T 3745delT 1135insA  c.4258delG  4486delG <<< 1675delA>>> 3347delAG 816delGT 1135insA 3297G>T 4864delA 2470del7 3203del11 120A>C IVS17-2A>C  c.2808del4 c.3847delGT  3036del4 4075delGT  exons 1-13 deletion ex|Borg A, Dorum A, Heimdal K, Maehle L, Hovig E, Moller P. BRCA1<<< 1675delA>>> and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations.		
23199084	confirmed					23199084		sub		NM_007297.3:c.5242C>A	NM_007297.3:c.5522C>A		na		5242C>A| 5242C>A				BRCA1	entrez	672			dna	859G>A|859G>A	17905,39735	17913,39743	om different laboratories shows that five mutations in the BRCA1 gene (c.68_69delAG, c.211A>G (BIC: 330A>G), c.5117G>A (BIC: 5236G>A), c.5123C>A (BIC:<<< 5242C>A>>>), c.470_471delCT (BIC: 589_590delCT) account for 46.6% of BRCA1 mutations and four mutations in BRCA2 (c.2808_2811del4 (BIC: 3036_3039del4), c.6629_6|el4 2795del4 1806C>T 300T>G 5382insC 300T>A 3347delAG 3404delA 1499insA 5181delGTT 5083del19 5181_5183delGTT 3600del11 5247G>T 185delAG 330A>G 5236G>A<<< 5242C>A>>>  c.7806-2A>G  IVS16-2A>G  c.8537_8538delAG(Sardinia)  8765delAG  c.2808_2811del4 (Castilla-Leon) c.6629_6630delAA c.9026_9030del5 c.9310_9311delAA  3		
23199084	confirmed					23199084		del		NM_007294.3:c.5030_5033delCTAA	NM_007294.3:c.5261_5264delCTAA		rs80357862		c.5030_5033delCTAA				BRCA1	entrez	672			dna	c.123_125delAT	16386	16405	.5128G>T would appear to be specific to the France, but the analysis of its haplotype is less conclusive and needs further confirmation [6]. The BRCA1<<< c.5030_5033delCTAA>>> (BIC: 5149delCTAA) [76] and c.3839_3843delinsAGGC (BIC: 3958delCTCAGinsAGGC) [77] mutations were reported in at least three independent families from		
23199084	confirmed					23199084		sub		NM_007300.3:c.5236G>A	NM_007300.3:c.5467G>A		rs80357291		 5236G>A|5236G>A				BRCA1	entrez	672			dna	859G>A|859G>A	17879,39727	17887,39735	on of BRCA test results from different laboratories shows that five mutations in the BRCA1 gene (c.68_69delAG, c.211A>G (BIC: 330A>G), c.5117G>A (BIC:<<< 5236G>A>>>), c.5123C>A (BIC: 5242C>A), c.470_471delCT (BIC: 589_590delCT) account for 46.6% of BRCA1 mutations and four mutations in BRCA2 (c.2808_2811del4 (BIC|A  3135del4 2795del4 1806C>T 300T>G 5382insC 300T>A 3347delAG 3404delA 1499insA 5181delGTT 5083del19 5181_5183delGTT 3600del11 5247G>T 185delAG 330A>G<<< 5236G>A>>> 5242C>A  c.7806-2A>G  IVS16-2A>G  c.8537_8538delAG(Sardinia)  8765delAG  c.2808_2811del4 (Castilla-Leon) c.6629_6630delAA c.9026_9030del5 c.9310_9311		
23199084	confirmed					23199084		del		NM_000059.3:c.4258delG	NM_000059.3:c.4484delG		rs28897727		 c.4258delG|c.4258delG				BRCA2	entrez	675			dna	c.123delT|c.123delT|c.123delT	30641,30961,41558	30652,30972,41569	05ins6000(dup_ex13) mutation, is quite common in Sweden and is apparently specific to English-speaking and related countries [122]. One BRCA2 mutation<<< c.4258delG>>> (BIC: 4486delG) is found repeatedly in Swedish breast cancer families [120, 123]. In the Western Sweden, six mutations, including the most common BRC|_3175dup, four other common Scandinavian BCRA1 mutations (c.1082_1092del11, c.2475delC, c.1687C>T, c.1016dupA (BIC: 1135insA)) and one BRCA2 mutation <<<(c.4258delG>>>) accounted for approximately 75% of all BRCA1/2 mutations [124].|3228delAG c.697delGT c.1016dupA c.3178G>T c.4745delA c.2351del7 c.3084del11 c.1A>C c.5075-2A>C  3171ins5 2594delC 1201del11 1806C>T 3745delT 1135insA <<< c.4258delG>>>  4486delG  1675delA 3347delAG 816delGT 1135insA 3297G>T 4864delA 2470del7 3203del11 120A>C IVS17-2A>C  c.2808del4 c.3847delGT  3036del4 4075delGT  ex		
23199084	confirmed					23199084		del		NM_007297.3:c.4088delA	NM_007297.3:c.4368delA		na		4088delA| 4088delA				BRCA1	entrez	672			dna	6174delT|6174delT	12901,39328	12910,39337	The most prevalent BRCA2 mutations are c.8363G>A (BIC: 8591G>A/W2788X), c.8754+1G>A (BIC: IVS211G>A) and c.3860delA (BIC:<<< 4088delA>>>), representing 9%, 7% and 6% of the BRCA2 mutation families respectively (Rappaport, personal communication). Slovenia In Slovenia five highly recurr|C c.181T>G c.5266dupC c.1687C>T  185delAG 5382insC 300T>G 5382insC 1806C>T  c.5946delT  6174delT  c.8363G>A c.8754+1G>A c.3860delA  8591G>A IVS21-1G>A<<< 4088delA>>>  c.3016_3019del4 c.2676_2679del4 c.1687C>T c.181T>G c.5266dupC c.181T>A c.3228_3229delAG c.3285delA c.1380dupA c.5062_5064del3 c.4964_4982del19 c.506		
23199084	confirmed					23199084		del		NM_000059.3:c.4088delA	NM_000059.3:c.4314delA		na		4088delA| 4088delA				BRCA2	entrez	675			dna	6174delT|6174delT	12901,39328	12910,39337	The most prevalent BRCA2 mutations are c.8363G>A (BIC: 8591G>A/W2788X), c.8754+1G>A (BIC: IVS211G>A) and c.3860delA (BIC:<<< 4088delA>>>), representing 9%, 7% and 6% of the BRCA2 mutation families respectively (Rappaport, personal communication). Slovenia In Slovenia five highly recurr|C c.181T>G c.5266dupC c.1687C>T  185delAG 5382insC 300T>G 5382insC 1806C>T  c.5946delT  6174delT  c.8363G>A c.8754+1G>A c.3860delA  8591G>A IVS21-1G>A<<< 4088delA>>>  c.3016_3019del4 c.2676_2679del4 c.1687C>T c.181T>G c.5266dupC c.181T>A c.3228_3229delAG c.3285delA c.1380dupA c.5062_5064del3 c.4964_4982del19 c.506		
23199084	confirmed					23199084		del		NM_007294.3:c.3285delA|NM_007300.3:c.3285delA|NM_007299.3:c.3285delA|NM_007298.3:c.3285delA|NM_007297.3:c.3285delA	NM_007294.3:c.3516delA|NM_007300.3:c.3516delA|NM_007299.3:c.3478delA|NM_007298.3:c.3303delA|NM_007297.3:c.3565delA		rs397509051|rs397509051|na|na|rs80356843		 c.3285delA|c.3285delA				BRCA1	entrez	672			dna	c.123delT|c.123delT	13855,39426	13866,39437	nt regional founder effect has been demonstrated for few mutations [63–66]. Four distinct BRCA1 founder mutations (c.3228_ 3229delAG (BIC: 3347delAG),<<< c.3285delA>>> (BIC: 3404delA), c.1380dupA (BIC: 1499insA), c.5062_5064del3 (BIC: 5181delGTT) accounted for a large fraction (73%) of BRCA1-attributable hereditary |c.8363G>A c.8754+1G>A c.3860delA  8591G>A IVS21-1G>A 4088delA  c.3016_3019del4 c.2676_2679del4 c.1687C>T c.181T>G c.5266dupC c.181T>A c.3228_3229delAG<<< c.3285delA>>> c.1380dupA c.5062_5064del3 c.4964_4982del19 c.5062_5064delGTT c.3481_3491del11 c.5128G>T c.68_69delAG c.211A>G (Galicia) c.5117G>A c.5123C>A  3135del		
23199084	confirmed					23199084		del		NM_007294.3:c.2681_2682delAA|NM_007300.3:c.2681_2682delAA	NM_007294.3:c.2912_2913delAA|NM_007300.3:c.2912_2913delAA		rs80357971|rs80357971		c.2681_2682delAA| c.2681_2682delAA				BRCA1	entrez	672			dna	c.123_125delAT|c.123_125delAT|c.123_125delAT	34819,34914,42017	34836,34931,42034	ve in each gene) accounted for almost half of the total mutations detected, and almost one-quarter were accounted by just two founder mutations (BRCA1<<< c.2681_2682delAA>>> (BIC: 2800delAA) and BRCA2 c.6275_6276delTT (BIC: 6503delTT) [149].|The BRCA1<<< c.2681_2682delAA>>>, probably originated from the West-Central Scotland or Ireland [150].|3745delT 4446C>T 2803delAA 5370C>T IVS11+3A>G  c.771_775del5 c.7480C>T c.8327T>G c.9118-2A>G c.9117+1G>A  999del5 7708C>T 8555T>G 9346-2A>G 9345+1G>A <<< c.2681_2682delAA>>> (Scotland)  2800delAA  c.771_775del5 c.6275_6276delTT (Scotland)  999del5 6503delTT  c.4065_4068del4 (North-West) exon 13 duplication (ins6kbEx13) c.		
23199084	confirmed					23199084		sub		NM_000059.3:c.6085G>T	NM_000059.3:c.6311G>T		rs397507828		6085G>T				BRCA2	entrez	675			dna	859G>A	17005	17013	75delGTCT), c.962G>A (BIC: 1081G>A), c.2834_2836delinsC (BIC: 2953delGTA/insC) and 3 BRCA2 mutations (c.3170_3174del5 (BIC: 3398del5), c.5857G>T (BIC:<<< 6085G>T>>>), c.8537_8538delAG (BIC: 8765delAG)) are now routinely included in early onset breast/ovarian cancer screening assays and represent up to 84% of the total BRCA1/2 mutations in the FrenchCanadian population in Quebec [78].		
23199084	confirmed					23199084		sub		NM_000059.3:c.212+3_212A>G	NM_000059.3:c.438+3_438A>G		rs276174818		 c.212+3A>G|c.212+3A>G				BRCA2	entrez	675			dna	c.123+2A>T|c.123+2A>T	20886,40023	20897,40034	A), c.6275_6276delTT (BIC: 6503_6504delTT), c.8904delC (BIC: 9132delC) alterations), which accounted for nearly 60% of all mutations identified. BRCA1<<< c.212+3A>G>>> was previously reported as Belgian founder mutation [92, 93], later also found in a few German, Dutch and French families [91].| c.9310_9311delAA  3036_3039del4 c.6857delAA 9254-9258del5 9538delAA  c.470_471delCT c.5153-1G>A  589_590delCT 5272-1G>A  c.5146_5149del4  374delTATG <<< c.212+3A>G>>> c.2359dupG c.3661G>T c.2685_2686delAA c.2193del5 c.1292dupT exon 13 deletion (3,8-kb) exon 22 deletion (510-bp) exon 17 deletion c.5266dupC c.181T>G 		
23199084	confirmed					23199084		sub		NM_007294.3:c.5074G>A|NM_007297.3:c.5074G>A	NM_007294.3:c.5305G>A|NM_007297.3:c.5354G>A		rs80187739|rs80357283		c.5074G>A				BRCA1	entrez	672			dna	c.123T>A	34109	34119	e population, 8.5% of consecutive unselected breast cancer cases, 7.9% of ovarian cancer cases and 40% of male breast cancer cases [6, 146]. The BRCA1<<< c.5074G>A>>> (BIC: 5193G>A) is another founder mutation recently identified in Icelandic population, however it is extremely rare and contributes only to 1% of br		
23199084	confirmed					23199084		del		NM_007294.3:c.4864delA|NM_007300.3:c.4864delA	NM_007294.3:c.5095delA|NM_007300.3:c.5095delA		na|rs80357303		 4864delA|4864delA				BRCA1	entrez	672			dna	6174delT|6174delT	31718,41625	31727,41634	outheast [127]. These four founder mutations together with other six most frequent BRCA1/2 mutations (BRCA1 c.3178G>T (BIC: 3297G>T), c.4745delA (BIC:<<< 4864delA>>>), c.2351del7 (BIC: 2470del7), c.3084del11 (BIC: 3203del11) and BRCA2 c.2808del4 (BIC: 3036del4), c.3847delGT (BIC: 4075delGT)), account for about 60% BRCA1/2 carriers in Norway [128].|084del11 c.1A>C c.5075-2A>C  3171ins5 2594delC 1201del11 1806C>T 3745delT 1135insA  c.4258delG  4486delG  1675delA 3347delAG 816delGT 1135insA 3297G>T<<< 4864delA>>> 2470del7 3203del11 120A>C IVS17-2A>C  c.2808del4 c.3847delGT  3036del4 4075delGT  exons 1-13 deletion exon 13 duplication (ins6kbEx13) c.4097-2A>G c.		
23199084	confirmed					23199084		del		NM_000059.3:c.4864delA	NM_000059.3:c.5090delA		na		 4864delA|4864delA				BRCA2	entrez	675			dna	6174delT|6174delT	31718,41625	31727,41634	outheast [127]. These four founder mutations together with other six most frequent BRCA1/2 mutations (BRCA1 c.3178G>T (BIC: 3297G>T), c.4745delA (BIC:<<< 4864delA>>>), c.2351del7 (BIC: 2470del7), c.3084del11 (BIC: 3203del11) and BRCA2 c.2808del4 (BIC: 3036del4), c.3847delGT (BIC: 4075delGT)), account for about 60% BRCA1/2 carriers in Norway [128].|084del11 c.1A>C c.5075-2A>C  3171ins5 2594delC 1201del11 1806C>T 3745delT 1135insA  c.4258delG  4486delG  1675delA 3347delAG 816delGT 1135insA 3297G>T<<< 4864delA>>> 2470del7 3203del11 120A>C IVS17-2A>C  c.2808del4 c.3847delGT  3036del4 4075delGT  exons 1-13 deletion exon 13 duplication (ins6kbEx13) c.4097-2A>G c.		
23199084	confirmed					23199084		sub		NM_007294.3:c.546G>T|NM_007300.3:c.546G>T|NM_007299.3:c.546G>T|NM_007298.3:c.546G>T	NM_007294.3:c.777G>T|NM_007300.3:c.777G>T|NM_007299.3:c.739G>T|NM_007298.3:c.564G>T		na|na|na|na		546G>T| 546G>T				BRCA1	entrez	672			dna	859G>A|859G>A	35880,42289	35887,42296	It is distributed mainly in English-speaking countries or in countries with historical links with Britain. Ireland A single BRCA1 c.427G>T (BIC:<<< 546G>T>>>/E143X) mutation accounts for about 22% of all hereditary breast cancer patients from relatively homogenous Irish population and presumably is due to |rth-West) exon 13 duplication (ins6kbEx13) c.427G>T c.5266dupC c.181T>G c.4035delA c.4035delA c.5266dupC  4184del4  c.1929delG (North-West)  2157delG <<< 546G>T>>> 5382insC 300T>G 4154delA 4154delA 5382insC  EPMA Journal (2010) 1:397–412  407  Table 1 (continued) Population  Lithuanian Belarusian Russian  BRCA1 		
23199084	confirmed					23199084		sub		NM_007294.3:c.2338C>T|NM_007300.3:c.2338C>T|NM_007298.3:c.2338C>T	NM_007294.3:c.2569C>T|NM_007300.3:c.2569C>T|NM_007298.3:c.2356C>T		rs80356945|rs80356945|rs137892861		 c.2338C>T|c.2338C>T				BRCA1	entrez	672			dna	c.123T>A|c.123T>A	23525,40199	23535,40209	Eighteen BRCA1 mutations, including the most common c.5266dupC, c.181T>G, c.4065_4068del4 (BIC: 4184del4) and<<< c.2338C>T>>> (BIC: 2457C>T), were found at least 3 times and comprised 66% of all BRCA1 mutations.|661G>T c.2685_2686delAA c.2193del5 c.1292dupT exon 13 deletion (3,8-kb) exon 22 deletion (510-bp) exon 17 deletion c.5266dupC c.181T>G c.4065_4068del4<<< c.2338C>T>>> c.181T>G c.5266dupC  IVS5+3A>G 2478insG 3780G>T 2804delAA 2312del5 1411insT  c.156_157insAlu c.516+1G>A c.6275_6276delTT c.8904delC c.5351dupA c.6275		
23199084	confirmed					23199084		del		NM_007294.3:c.3860delA|NM_007300.3:c.3860delA	NM_007294.3:c.4091delA|NM_007300.3:c.4091delA		na|na		 c.3860delA|c.3860delA				BRCA1	entrez	672			dna	c.123delT|c.123delT	12884,39297	12895,39308	The most prevalent BRCA2 mutations are c.8363G>A (BIC: 8591G>A/W2788X), c.8754+1G>A (BIC: IVS211G>A) and<<< c.3860delA>>> (BIC: 4088delA), representing 9%, 7% and 6% of the BRCA2 mutation families respectively (Rappaport, personal communication). Slovenia In Slovenia fiv|VS  BIC  c.68_69delAG c.5266dupC c.181T>G c.5266dupC c.1687C>T  185delAG 5382insC 300T>G 5382insC 1806C>T  c.5946delT  6174delT  c.8363G>A c.8754+1G>A<<< c.3860delA>>>  8591G>A IVS21-1G>A 4088delA  c.3016_3019del4 c.2676_2679del4 c.1687C>T c.181T>G c.5266dupC c.181T>A c.3228_3229delAG c.3285delA c.1380dupA c.5062_50		
23199084	confirmed					23199084		del		NM_000059.3:c.3860delA	NM_000059.3:c.4086delA		rs80359411		 c.3860delA|c.3860delA				BRCA2	entrez	675			dna	c.123delT|c.123delT	12884,39297	12895,39308	The most prevalent BRCA2 mutations are c.8363G>A (BIC: 8591G>A/W2788X), c.8754+1G>A (BIC: IVS211G>A) and<<< c.3860delA>>> (BIC: 4088delA), representing 9%, 7% and 6% of the BRCA2 mutation families respectively (Rappaport, personal communication). Slovenia In Slovenia fiv|VS  BIC  c.68_69delAG c.5266dupC c.181T>G c.5266dupC c.1687C>T  185delAG 5382insC 300T>G 5382insC 1806C>T  c.5946delT  6174delT  c.8363G>A c.8754+1G>A<<< c.3860delA>>>  8591G>A IVS21-1G>A 4088delA  c.3016_3019del4 c.2676_2679del4 c.1687C>T c.181T>G c.5266dupC c.181T>A c.3228_3229delAG c.3285delA c.1380dupA c.5062_50		
23199084	confirmed					23199084		sub		NM_000059.3:c.8327T>G	NM_000059.3:c.8553T>G		rs397507977		c.8327T>G| c.8327T>G				BRCA2	entrez	675			dna	c.123T>A|c.123T>A|c.123T>A	33120,33411,41937	33130,33421,41947	requently. The most recurrent mutation in BRCA2 is the Icelandic founder mutation c.771_775del5 (BIC: 999del5), three other (c.7480C>T (BIC: 7708C>T),<<< c.8327T>G>>> (BIC: 8555T>G), c.9118-2A>G (BIC: 9346-2A>G) and following (c. 6384del2 (BIC: 6503delTT), c.3853dupA (BIC: 4081insA) and c.5569G>T (BIC: 5797G>T)).|Some mutations are unique to the Finns, such as c.4096+3A>G (BIC: IVS11+3A>G) in BRCA1 and c.9117+1G>A (BIC: 9345+ 1G>A), c.7480C>T,<<< c.8327T>G>>> in BRCA2 genes. The mutation spectrum in Eastern part slightly differs from those observed in the Northern and Southern parts of the country [139]. L|5delA c.3626delT c.4327C>T c.2684del2 c.5251C>T c.4096+3A>G  4216-2A>G 3604delA 3745delT 4446C>T 2803delAA 5370C>T IVS11+3A>G  c.771_775del5 c.7480C>T<<< c.8327T>G>>> c.9118-2A>G c.9117+1G>A  999del5 7708C>T 8555T>G 9346-2A>G 9345+1G>A  c.2681_2682delAA (Scotland)  2800delAA  c.771_775del5 c.6275_6276delTT (Scotlan		
23199084	confirmed					23199084		sub		NM_007294.3:c.3661G>T|NM_007300.3:c.3661G>T	NM_007294.3:c.3892G>T|NM_007300.3:c.3892G>T		rs80357310|rs80357310		 c.3661G>T				BRCA1	entrez	672			dna	c.123T>A|c.123T>A	20669,40045	20679,40055	91] in a 49 BRCA1/2 positive families found six major recurrent founder mutations (three BRCA1 c.212+3A> (BIC: IVS5+3A>G), c.2359dupG (BIC: 2478insG),<<< c.3661G>T>>> (BIC: 3780G>T) and three BRCA2 c.516+1G>A (BIC: IVS6+1G>A), c.6275_6276delTT (BIC: 6503_6504delTT), c.8904delC (BIC: 9132delC) alterations), which ac|6_3039del4 c.6857delAA 9254-9258del5 9538delAA  c.470_471delCT c.5153-1G>A  589_590delCT 5272-1G>A  c.5146_5149del4  374delTATG  c.212+3A>G c.2359dupG<<< c.3661G>T>>> c.2685_2686delAA c.2193del5 c.1292dupT exon 13 deletion (3,8-kb) exon 22 deletion (510-bp) exon 17 deletion c.5266dupC c.181T>G c.4065_4068del4 c.233		
23199084	notConfirmed							dup		c.9098A>AA					 c.9098dupA|c.9098dupA				BRCA1	entrez	672			dna	c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA	23903,26038,26500,40456,40549	23914,26049,26511,40467,40560	Seven distinct mutations accounted for 28% of BRCA2 mutations, and most frequent c.1813dupA (BIC: 2041insA), c.4478del4 (BIC: 4706del4) and<<< c.9098dupA>>> (BIC: 9326insA) were associated with common alleles, suggesting a possible founder effect [99]. Czech Republic Five mutations (BRCA1: c.181T>G, c.526|risk breast/ovarian cancer families, common BRCA1 founder mutations c.5266dupC, c.181T>G and c.68_69delAG accounted for 80% of all BRCA1 mutations and<<< c.9098dupA>>> (BIC: 9326insA) with c.5946delT accounted for 50% of all BRCA2 mutations [42, 103].|Among unselected Hungarian male breast cancer patients, one third carried BRCA2 mutations, including<<< c.9098dupA>>> [104]. Greece In the Greek population four BRCA1 mutations (c.5526dupC, c.5212G>A (BIC: 5331G>A/G1738R), c.5251C>T (BIC:  EPMA Journal (2010) 1:397–4|16+1G>A c.6275_6276delTT c.8904delC c.5351dupA c.6275_6276delTT  384insAlu IVS6+1G>A 6503_6504delTT 9132delC 5579insA 6503delTT  c.1813dupA c.4478del4<<< c.9098dupA>>>  2041insA 4706del4 9326insA  c.7913_7917del5 c.8537_8538del2  8141del5 8765delAG  c.9098dupA c.5946delT  9326insA 6174delT  c.3700_3704del5 exons 1–1|4delTT 9132delC 5579insA 6503delTT  c.1813dupA c.4478del4 c.9098dupA  2041insA 4706del4 9326insA  c.7913_7917del5 c.8537_8538del2  8141del5 8765delAG <<< c.9098dupA>>> c.5946delT  9326insA 6174delT  c.3700_3704del5 exons 1–17 deletion exons 5–14 deletion c.5266dupC c.181T>G c.68_69delAG  5382insC 300T>G 4184del4 245		
23199084	notConfirmed							del		c.9254A>None					9254delA				BRCA2	entrez	675			dna	6174delT	61306	61315	Haplotype analysis of the BRCA2<<< 9254delA>>>TCAT recurrent mutation in breast/ovarian cancer families from Spain.		
23199084	notConfirmed							sub		c.5797G>T					5797G>T				BRCA1	entrez	672			dna	859G>A	33267	33275	6384del2 (BIC: 6503delTT), c.3853dupA (BIC: 4081insA) and c.5569G>T (BIC:<<< 5797G>T>>>)).		
23199084	notConfirmed							del		c.2953G>None					2953delG				BRCA2	entrez	675			dna	6174delT	16916	16925	4327C>T (BIC: 4446C>T/Arg1443X), c.3756_3759del4 (BIC:  EPMA Journal (2010) 1:397–412  3875delGTCT), c.962G>A (BIC: 1081G>A), c.2834_2836delinsC (BIC:<<< 2953delG>>>TA/insC) and 3 BRCA2 mutations (c.3170_3174del5 (BIC: 3398del5), c.5857G>T (BIC: 6085G>T), c.8537_8538delAG (BIC: 8765delAG)) are now routinely includ		
23199084	notConfirmed							sub		c.3438G>T					3438G>T| 3438G>T				BRCA1	entrez	672			dna	859G>A|859G>A	27798,41098	27806,41106	The most common BRCA1 mutations were c.2475delC (BIC: 2594delC), c.3319G>T (BIC:<<< 3438G>T>>>), c.5266dupC and c.3710delT (BIC: 3829delT), which accounted 16%, 9%, 8% and 5% of BRCA1 positive families, respectively [109–111].| mutation  HGVS  BIC  c.5266dupC c.5212G>A c.5251C>T c.5467G>A  5382insC 5331G>A 5370C>T 5586G>A  c.2475delC c.3319G>T c.5266dupC c.3710delT  2594delC<<< 3438G>T>>> 5382insC 3829delT  HGVS  BIC  c.8755delG c.6373delA c.1310_1013del4 c.6486_6489del4 c.3847_3848delGT  8984delG 6601delA 1538del4 6714del4 4075delGT  		
23199084	notConfirmed							sub		c.1081G>A					1081G>A				BRCA2	entrez	675			dna	859G>A	16881	16889	s region 4 BRCA1 gene mutations (c.4327C>T (BIC: 4446C>T/Arg1443X), c.3756_3759del4 (BIC:  EPMA Journal (2010) 1:397–412  3875delGTCT), c.962G>A (BIC:<<< 1081G>A>>>), c.2834_2836delinsC (BIC: 2953delGTA/insC) and 3 BRCA2 mutations (c.3170_3174del5 (BIC: 3398del5), c.5857G>T (BIC: 6085G>T), c.8537_8538delAG (BIC: 		
23199084	confirmed					23199084		del		NM_000059.3:c.6629_6630delAA	NM_000059.3:c.6855_6856delAA		rs80359611		 c.6629_6630delAA|c.6629_6630delAA				BRCA2	entrez	675			dna	c.123_125delAT|c.123_125delAT	18054,39840	18071,39857	: 5242C>A), c.470_471delCT (BIC: 589_590delCT) account for 46.6% of BRCA1 mutations and four mutations in BRCA2 (c.2808_2811del4 (BIC: 3036_3039del4),<<< c.6629_6630delAA>>> (BIC: c.6857delAA), c.9026_9030del5 (BIC: 92549258del5), c.9310_9311delAA (BIC: 9538delAA)) account for 56.6% of the BRCA2 mutations [79]. Diez et al|GTT 3600del11 5247G>T 185delAG 330A>G 5236G>A 5242C>A  c.7806-2A>G  IVS16-2A>G  c.8537_8538delAG(Sardinia)  8765delAG  c.2808_2811del4 (Castilla-Leon)<<< c.6629_6630delAA>>> c.9026_9030del5 c.9310_9311delAA  3036_3039del4 c.6857delAA 9254-9258del5 9538delAA  c.470_471delCT c.5153-1G>A  589_590delCT 5272-1G>A  c.5146_5149d		
23199084	notConfirmed							del		c.2800A>None					 2800delA|2800delA				BRCA2	entrez	675			dna	6174delT|6174delT	34842,42046	34851,42055	ted for almost half of the total mutations detected, and almost one-quarter were accounted by just two founder mutations (BRCA1 c.2681_2682delAA (BIC:<<< 2800delA>>>A) and BRCA2 c.6275_6276delTT (BIC: 6503delTT) [149].|70C>T IVS11+3A>G  c.771_775del5 c.7480C>T c.8327T>G c.9118-2A>G c.9117+1G>A  999del5 7708C>T 8555T>G 9346-2A>G 9345+1G>A  c.2681_2682delAA (Scotland) <<< 2800delA>>>A  c.771_775del5 c.6275_6276delTT (Scotland)  999del5 6503delTT  c.4065_4068del4 (North-West) exon 13 duplication (ins6kbEx13) c.427G>T c.5266dupC c.1		
23199084	confirmed					23199084		del		NM_007297.3:c.6503delT	NM_007297.3:c.6783delT		na		6503delT| 6503delT				BRCA1	entrez	672			dna	6174delT|6174delT|6174delT|6174delT|6174delT	22115,33208,34886,40423,42108	22124,33217,34895,40432,42117	Together with another Dutch BRCA2 founder mutation c.6275_6276delTT (BIC:<<< 6503delT>>>T), c.5351dupA accounts for 62% of hereditary breast/ovarian families [94, 95]. Slightly outdated (as of year 2002) list of published and unpublished |6384del2 (BIC:<<< 6503delT>>>T), c.3853dupA (BIC: 4081insA) and c.5569G>T (BIC: 5797G>T)).|etected, and almost one-quarter were accounted by just two founder mutations (BRCA1 c.2681_2682delAA (BIC: 2800delAA) and BRCA2 c.6275_6276delTT (BIC:<<< 6503delT>>>T) [149].|el5 1411insT  c.156_157insAlu c.516+1G>A c.6275_6276delTT c.8904delC c.5351dupA c.6275_6276delTT  384insAlu IVS6+1G>A 6503_6504delTT 9132delC 5579insA<<< 6503delT>>>T  c.1813dupA c.4478del4 c.9098dupA  2041insA 4706del4 9326insA  c.7913_7917del5 c.8537_8538del2  8141del5 8765delAG  c.9098dupA c.5946delT  9326insA |G c.9117+1G>A  999del5 7708C>T 8555T>G 9346-2A>G 9345+1G>A  c.2681_2682delAA (Scotland)  2800delAA  c.771_775del5 c.6275_6276delTT (Scotland)  999del5<<< 6503delT>>>T  c.4065_4068del4 (North-West) exon 13 duplication (ins6kbEx13) c.427G>T c.5266dupC c.181T>G c.4035delA c.4035delA c.5266dupC  4184del4  c.1929delG (		
23199084	confirmed					23199084		del		NM_007300.3:c.4486delG|NM_007297.3:c.4486delG	NM_007300.3:c.4717delG|NM_007297.3:c.4766delG		na|na		4486delG| 4486delG				BRCA1	entrez	672			dna	6174delT|6174delT	30658,41570	30667,41579	3) mutation, is quite common in Sweden and is apparently specific to English-speaking and related countries [122]. One BRCA2 mutation c.4258delG (BIC:<<< 4486delG>>>) is found repeatedly in Swedish breast cancer families [120, 123]. In the Western Sweden, six mutations, including the most common BRCA1 c.3171_3175d|697delGT c.1016dupA c.3178G>T c.4745delA c.2351del7 c.3084del11 c.1A>C c.5075-2A>C  3171ins5 2594delC 1201del11 1806C>T 3745delT 1135insA  c.4258delG <<< 4486delG>>>  1675delA 3347delAG 816delGT 1135insA 3297G>T 4864delA 2470del7 3203del11 120A>C IVS17-2A>C  c.2808del4 c.3847delGT  3036del4 4075delGT  exons 1-13 d		
23199084	notConfirmed							del		c.3958C>None					 3958delC				BRCA1	entrez	672			dna	6174delT	16461	16470	 haplotype is less conclusive and needs further confirmation [6]. The BRCA1 c.5030_5033delCTAA (BIC: 5149delCTAA) [76] and c.3839_3843delinsAGGC (BIC:<<< 3958delC>>>TCAGinsAGGC) [77] mutations were reported in at least three independent families from France. Well-described founder mutations are identified in Frenc		
23199084	notConfirmed							sub		c.1806C>T					 1806C>T|1806C>T				BRCA1	entrez	672			dna	859G>A|859G>A|859G>A|859G>A	11923,39244,39597,41531	11931,39252,39605,41539	orts for several apparently founder BRCA1 mutations in Austria [58, 59], although they  399  (c.181T>G (BIC: 300T>G/C61G), c.5266dupC, c.1687C>T (BIC:<<< 1806C>T>>>)) represent common mutations prevalent in other European countries.|garian  BRCA1 mutation  BRCA2 mutation  HGVS  BIC  HGVS  BIC  c.68_69delAG c.5266dupC c.181T>G c.5266dupC c.1687C>T  185delAG 5382insC 300T>G 5382insC<<< 1806C>T>>>  c.5946delT  6174delT  c.8363G>A c.8754+1G>A c.3860delA  8591G>A IVS21-1G>A 4088delA  c.3016_3019del4 c.2676_2679del4 c.1687C>T c.181T>G c.5266dupC c|A c.5062_5064del3 c.4964_4982del19 c.5062_5064delGTT c.3481_3491del11 c.5128G>T c.68_69delAG c.211A>G (Galicia) c.5117G>A c.5123C>A  3135del4 2795del4<<< 1806C>T>>> 300T>G 5382insC 300T>A 3347delAG 3404delA 1499insA 5181delGTT 5083del19 5181_5183delGTT 3600del11 5247G>T 185delAG 330A>G 5236G>A 5242C>A  c.7806-2A>| (ins6kbEx13) c.1556delA c.3228delAG c.697delGT c.1016dupA c.3178G>T c.4745delA c.2351del7 c.3084del11 c.1A>C c.5075-2A>C  3171ins5 2594delC 1201del11<<< 1806C>T>>> 3745delT 1135insA  c.4258delG  4486delG  1675delA 3347delAG 816delGT 1135insA 3297G>T 4864delA 2470del7 3203del11 120A>C IVS17-2A>C  c.2808del4 c.384		
23199084	notConfirmed							del		c.5181G>None					 5181delG|5181delG				BRCA1	entrez	672			dna	6174delT|6174delT	13933,39656	13942,39665	ur distinct BRCA1 founder mutations (c.3228_ 3229delAG (BIC: 3347delAG), c.3285delA (BIC: 3404delA), c.1380dupA (BIC: 1499insA), c.5062_5064del3 (BIC:<<< 5181delG>>>TT) accounted for a large fraction (73%) of BRCA1-attributable hereditary breast/ ovarian cancer in families originating from Tuscany (Central Italy) |_3491del11 c.5128G>T c.68_69delAG c.211A>G (Galicia) c.5117G>A c.5123C>A  3135del4 2795del4 1806C>T 300T>G 5382insC 300T>A 3347delAG 3404delA 1499insA<<< 5181delG>>>TT 5083del19 5181_5183delGTT 3600del11 5247G>T 185delAG 330A>G 5236G>A 5242C>A  c.7806-2A>G  IVS16-2A>G  c.8537_8538delAG(Sardinia)  8765delAG  c.2808		
23199084	confirmed					23199084		sub		NM_000059.3:c.120A>C	NM_000059.3:c.346A>C		na		 120A>C|120A>C				BRCA2	entrez	675			dna	859G>A|859G>A	31930,41653	31937,41660	BRCA1 c.1A>C (BIC:<<< 120A>C>>>) and c.5075-2A>C (BIC: IVS17-2A>C) mutations are also locally frequent.| 3171ins5 2594delC 1201del11 1806C>T 3745delT 1135insA  c.4258delG  4486delG  1675delA 3347delAG 816delGT 1135insA 3297G>T 4864delA 2470del7 3203del11<<< 120A>C>>> IVS17-2A>C  c.2808del4 c.3847delGT  3036del4 4075delGT  exons 1-13 deletion exon 13 duplication (ins6kbEx13) c.4097-2A>G c.3485delA c.3626delT c.4327		
23199084	confirmed					23199084		del		NM_007294.3:c.4724delC|NM_007300.3:c.4724delC|NM_007297.3:c.4724delC	NM_007294.3:c.4955delC|NM_007300.3:c.4955delC|NM_007297.3:c.5004delC		rs80357052|na|na		c.4724delC				BRCA1	entrez	672			dna	c.123delT	15075	15086	It was also recurrently found at least four times in Sicilia [70, 71]. Another BRCA1<<< c.4724delC>>> (BIC: 4843delC) mutation could be a possible Sicilian founder mutation, although present evidence is scarce [71–73]. Using a number of independent ap		
23199084	confirmed					23199084		sub		NM_007294.3:c.5258G>C	NM_007294.3:c.5489G>C		rs397509246		c.5258G>C				BRCA1	entrez	672			dna	c.123T>A	42965	42975	14680 reference sequence; BRCA2 numbered by GeneBank U43746 reference sequence  other mutations, BRCA1 c.181T>G and recently proved to be pathogenious<<< c.5258G>C>>> (BIC: 5377G>C/R1753T) were also found in more than one family; together with two founder mutations they comprise around 90% of BRCA1 gene mutations and around 85% of all BRCA1/2 mutations identified (Janavičius, unpublished data).		
23199084	confirmed					23199084		sub		NM_007297.3:c.5586G>A	NM_007297.3:c.5866G>A		na		5586G>A| 5586G>A				BRCA1	entrez	672			dna	859G>A|859G>A	26697,41036	26705,41044	on four BRCA1 mutations (c.5526dupC, c.5212G>A (BIC: 5331G>A/G1738R), c.5251C>T (BIC:  EPMA Journal (2010) 1:397–412  5370C>T/R1751X), c.5467G>A (BIC:<<< 5586G>A>>>), account for 54% of all mutations detected in BRCA1/2 genes and for 73% of the BRCA1 mutations positive families, whereas the rest are unique or low| Iceland British  Irish Polish  Latvian  BRCA1 mutation  BRCA2 mutation  HGVS  BIC  c.5266dupC c.5212G>A c.5251C>T c.5467G>A  5382insC 5331G>A 5370C>T<<< 5586G>A>>>  c.2475delC c.3319G>T c.5266dupC c.3710delT  2594delC 3438G>T 5382insC 3829delT  HGVS  BIC  c.8755delG c.6373delA c.1310_1013del4 c.6486_6489del4 c.3		
23199084	confirmed					23199084		sub		NM_000059.3:c.5586G>A	NM_000059.3:c.5812G>A		na		5586G>A| 5586G>A				BRCA2	entrez	675			dna	859G>A|859G>A	26697,41036	26705,41044	on four BRCA1 mutations (c.5526dupC, c.5212G>A (BIC: 5331G>A/G1738R), c.5251C>T (BIC:  EPMA Journal (2010) 1:397–412  5370C>T/R1751X), c.5467G>A (BIC:<<< 5586G>A>>>), account for 54% of all mutations detected in BRCA1/2 genes and for 73% of the BRCA1 mutations positive families, whereas the rest are unique or low| Iceland British  Irish Polish  Latvian  BRCA1 mutation  BRCA2 mutation  HGVS  BIC  c.5266dupC c.5212G>A c.5251C>T c.5467G>A  5382insC 5331G>A 5370C>T<<< 5586G>A>>>  c.2475delC c.3319G>T c.5266dupC c.3710delT  2594delC 3438G>T 5382insC 3829delT  HGVS  BIC  c.8755delG c.6373delA c.1310_1013del4 c.6486_6489del4 c.3		
23199084	confirmed					23199084		del		NM_007294.3:c.68_69delAG|NM_007300.3:c.68_69delAG|NM_007299.3:c.68_69delAG|NM_007298.3:c.68_69delAG	NM_007294.3:c.299_300delAG|NM_007300.3:c.299_300delAG|NM_007299.3:c.261_262delAG|NM_007298.3:c.86_87delAG		rs386833395|rs386833395|rs386833395|rs386833395		c.68_69delAG| c.68_69delAG				BRCA1	entrez	672			dna	c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT|c.123_125delAT	9181,9476,9864,10150,10231,17825,18618,18897,25980,26354,37095,39155,39526,40667,44820	9194,9489,9877,10163,10244,17838,18631,18910,25993,26367,37108,39168,39539,40680,44833	The most well characterized three founder mutations are two in BRCA1 gene<<< c.68_69delAG>>> (BIC: 185delAG) and c.5266dupC (BIC: 5382insC) and one in BRCA2 c.5946delT (BIC:  EPMA Journal (2010) 1:397–412  6174delT) [31–33].| Screening for these three founder mutations alone is now part of routine clinical practice for Ashkenazi Jewish individuals. These 3 mutations (BRCA1<<< c.68_69delAG>>>, c.5266dupC and BRCA2 c.5946delT) account for 98–99% of identified mutations and are carried by about 2.6% (1/40) of the Ashkenazi Jewish population (1%, 0.13% and 1.52% respectively) [34–36].|articular mutations and breast/ovarian cancer risk [37]. The average risk of breast cancer by the age of 70 years is similar for carriers of the BRCA1<<< c.68_69delAG>>> and c.5266dupC mutations (64% and 67% respectively), however is much lower for the c.5946delT mutation (43%).|nding values for ovarian cancer lifetime risk is respectively of 14%, 33% and 20% in carriers, respectively [6, 37, 38]. It is worth noting that BRCA1<<< c.68_69delAG>>> and c.5266dupC are not found exclusively in Ashkenazi patients.|The<<< c.68_69delAG>>> mutation has been found in patients of Spanish ancestry (i.e.|r frequencies and geographic distribution. A compilation of BRCA test results from different laboratories shows that five mutations in the BRCA1 gene <<<(c.68_69delAG>>>, c.211A>G (BIC: 330A>G), c.5117G>A (BIC: 5236G>A), c.5123C>A (BIC: 5242C>A), c.470_471delCT (BIC: 589_590delCT) account for 46.6% of BRCA1 mutations |It was also found in French and British families of Spanish origin [82]. The BRCA1<<< c.68_69delAG>>> and BRCA2 c.9026_ 9030del5 mutations accounted for the 30.4% (7/23) of the BRCA1 mutations and for the 18.5% (5/27) of the BRCA2 positive families respectively and were specific only to the Mediterranean areas.|Indeed, haplotype studies indicated a common origin of<<< c.68_69delAG>>> mutation in Spanish (Sephardic Jewish) and Ashkenazi Jewish populations [83].| this population. Hungary In Hungarian patients from high-risk breast/ovarian cancer families, common BRCA1 founder mutations c.5266dupC, c.181T>G and<<< c.68_69delAG>>> accounted for 80% of all BRCA1 mutations and c.9098dupA (BIC: 9326insA) with c.5946delT accounted for 50% of all BRCA2 mutations [42, 103].|Breast cancer patients were more likely to carry the c.5266dupC mutation whereas ovarian patients were more likely to carry either the<<< c.68_69delAG>>> or the c.181T>G mutation [103].|By adding two other recurring BRCA1 mutations <<<(c.68_69delAG>>> and c.3700_3704del5), the vast majority (87%) of mutation-positive families will be encompassed.|abria) Italian (North-East) French Spanish  Portuguese Belgian  Dutch  German  Czech  Hungarian  BRCA1 mutation  BRCA2 mutation  HGVS  BIC  HGVS  BIC <<< c.68_69delAG>>> c.5266dupC c.181T>G c.5266dupC c.1687C>T  185delAG 5382insC 300T>G 5382insC 1806C>T  c.5946delT  6174delT  c.8363G>A c.8754+1G>A c.3860delA  8591G>A |7C>T c.181T>G c.5266dupC c.181T>A c.3228_3229delAG c.3285delA c.1380dupA c.5062_5064del3 c.4964_4982del19 c.5062_5064delGTT c.3481_3491del11 c.5128G>T<<< c.68_69delAG>>> c.211A>G (Galicia) c.5117G>A c.5123C>A  3135del4 2795del4 1806C>T 300T>G 5382insC 300T>A 3347delAG 3404delA 1499insA 5181delGTT 5083del19 5181_5183de|37_8538del2  8141del5 8765delAG  c.9098dupA c.5946delT  9326insA 6174delT  c.3700_3704del5 exons 1–17 deletion exons 5–14 deletion c.5266dupC c.181T>G<<< c.68_69delAG>>>  5382insC 300T>G 4184del4 2457C>T 300T>G 5382insC 3819del5  5382insC 300T>G 185delAG  406  EPMA Journal (2010) 1:397–412  Table 1 (continued) Populat|Other less common mutations found in Western Russia are c.4035delA, c.181T>G, and<<< c.68_69delAG>>>.		
23199084	confirmed					23199084		del		NM_007294.3:c.2685_2686delAA|NM_007300.3:c.2685_2686delAA|NM_007299.3:c.2685_2686delAA	NM_007294.3:c.2916_2917delAA|NM_007300.3:c.2916_2917delAA|NM_007299.3:c.2878_2879delAA		rs80357636|rs80357636|na		c.2685_2686delAA| c.2685_2686delAA				BRCA1	entrez	672			dna	c.123_125delAT|c.123_125delAT	21282,40055	21299,40072	The BRCA1<<< c.2685_2686delAA>>> (BIC: 2804delAA) founder mutation probably originated approximately 32 generations (∼200 years) ago, was also reported few times in Belgium and accounted for 24% of all BRCA1/ 2 mutations [92].| c.6857delAA 9254-9258del5 9538delAA  c.470_471delCT c.5153-1G>A  589_590delCT 5272-1G>A  c.5146_5149del4  374delTATG  c.212+3A>G c.2359dupG c.3661G>T<<< c.2685_2686delAA>>> c.2193del5 c.1292dupT exon 13 deletion (3,8-kb) exon 22 deletion (510-bp) exon 17 deletion c.5266dupC c.181T>G c.4065_4068del4 c.2338C>T c.181T>G c.5		
23199084	confirmed					23199084		del		NM_007294.3:c.3228delA|NM_007300.3:c.3228delA	NM_007294.3:c.3459delA|NM_007300.3:c.3459delA		rs397509048|rs397509048		c.3228delA| c.3228delA				BRCA1	entrez	672			dna	c.123delT|c.123delT	31273,41405	31284,41416	er of ovarian cancer after breast cancer in this region [115, 125]. Norway Four Norwegian founder mutations in BRCA1 gene (c.1556delA (BIC: 1675delA),<<< c.3228delA>>>G (BIC: 3347delAG), c.697delGT (BIC: 816delGT) and c.1016dupA make up 68% of the BRCA1 mutation carriers [126, 127], and these have their own specific geographic distribution.| exons 3-16 deletion c.3171_3175dup c.2475delC c.1082_1092del11 c.1687C>T c.3626delT (Northern) c.1016dupA exon 13 duplication (ins6kbEx13) c.1556delA<<< c.3228delA>>>G c.697delGT c.1016dupA c.3178G>T c.4745delA c.2351del7 c.3084del11 c.1A>C c.5075-2A>C  3171ins5 2594delC 1201del11 1806C>T 3745delT 1135insA  c.4258d		
23199084	confirmed					23199084		del		NM_000059.3:c.3228delA	NM_000059.3:c.3454delA		na		c.3228delA| c.3228delA				BRCA2	entrez	675			dna	c.123delT|c.123delT	31273,41405	31284,41416	er of ovarian cancer after breast cancer in this region [115, 125]. Norway Four Norwegian founder mutations in BRCA1 gene (c.1556delA (BIC: 1675delA),<<< c.3228delA>>>G (BIC: 3347delAG), c.697delGT (BIC: 816delGT) and c.1016dupA make up 68% of the BRCA1 mutation carriers [126, 127], and these have their own specific geographic distribution.| exons 3-16 deletion c.3171_3175dup c.2475delC c.1082_1092del11 c.1687C>T c.3626delT (Northern) c.1016dupA exon 13 duplication (ins6kbEx13) c.1556delA<<< c.3228delA>>>G c.697delGT c.1016dupA c.3178G>T c.4745delA c.2351del7 c.3084del11 c.1A>C c.5075-2A>C  3171ins5 2594delC 1201del11 1806C>T 3745delT 1135insA  c.4258d		
23199084	confirmed					23199084		del		NM_000059.3:c.8904delC	NM_000059.3:c.9130delC		rs41293519		 c.8904delC|c.8904delC				BRCA2	entrez	675			dna	c.123delT|c.123delT	20779,40330	20790,40341	 IVS5+3A>G), c.2359dupG (BIC: 2478insG), c.3661G>T (BIC: 3780G>T) and three BRCA2 c.516+1G>A (BIC: IVS6+1G>A), c.6275_6276delTT (BIC: 6503_6504delTT),<<< c.8904delC>>> (BIC: 9132delC) alterations), which accounted for nearly 60% of all mutations identified. BRCA1 c.212+3A>G was previously reported as Belgian founder mutation [92, 93], later also found in a few German, Dutch and French families [91].|T>G c.4065_4068del4 c.2338C>T c.181T>G c.5266dupC  IVS5+3A>G 2478insG 3780G>T 2804delAA 2312del5 1411insT  c.156_157insAlu c.516+1G>A c.6275_6276delTT<<< c.8904delC>>> c.5351dupA c.6275_6276delTT  384insAlu IVS6+1G>A 6503_6504delTT 9132delC 5579insA 6503delTT  c.1813dupA c.4478del4 c.9098dupA  2041insA 4706del4 9326		
23199084	notConfirmed							del		c.2594C>None					2594delC| 2594delC				BRCA1	entrez	672			dna	6174delT|6174delT|6174delT	27771,41089,41512	27780,41098,41521	The most common BRCA1 mutations were c.2475delC (BIC:<<< 2594delC>>>), c.3319G>T (BIC: 3438G>T), c.5266dupC and c.3710delT (BIC: 3829delT), which accounted 16%, 9%, 8% and 5% of BRCA1 positive families, respectively [109–111].|on  BRCA2 mutation  HGVS  BIC  c.5266dupC c.5212G>A c.5251C>T c.5467G>A  5382insC 5331G>A 5370C>T 5586G>A  c.2475delC c.3319G>T c.5266dupC c.3710delT <<< 2594delC>>> 3438G>T 5382insC 3829delT  HGVS  BIC  c.8755delG c.6373delA c.1310_1013del4 c.6486_6489del4 c.3847_3848delGT  8984delG 6601delA 1538del4 6714del4 407|exon 13 duplication (ins6kbEx13) c.1556delA c.3228delAG c.697delGT c.1016dupA c.3178G>T c.4745delA c.2351del7 c.3084del11 c.1A>C c.5075-2A>C  3171ins5<<< 2594delC>>> 1201del11 1806C>T 3745delT 1135insA  c.4258delG  4486delG  1675delA 3347delAG 816delGT 1135insA 3297G>T 4864delA 2470del7 3203del11 120A>C IVS17-2A>C		
23199084	confirmed					23199084		del		NM_000059.3:c.6174delT	NM_000059.3:c.6400delT		na		 6174delT|6174delT				BRCA2	entrez	675			dna	6174delT|6174delT|6174delT|6174delT|6174delT	9307,39265,40581,52304,53051	9316,39274,40590,52313,53060	ns are two in BRCA1 gene c.68_69delAG (BIC: 185delAG) and c.5266dupC (BIC: 5382insC) and one in BRCA2 c.5946delT (BIC:  EPMA Journal (2010) 1:397–412 <<< 6174delT>>>) [31–33].|n  BRCA2 mutation  HGVS  BIC  HGVS  BIC  c.68_69delAG c.5266dupC c.181T>G c.5266dupC c.1687C>T  185delAG 5382insC 300T>G 5382insC 1806C>T  c.5946delT <<< 6174delT>>>  c.8363G>A c.8754+1G>A c.3860delA  8591G>A IVS21-1G>A 4088delA  c.3016_3019del4 c.2676_2679del4 c.1687C>T c.181T>G c.5266dupC c.181T>A c.3228_3229del|TT  c.1813dupA c.4478del4 c.9098dupA  2041insA 4706del4 9326insA  c.7913_7917del5 c.8537_8538del2  8141del5 8765delAG  c.9098dupA c.5946delT  9326insA<<< 6174delT>>>  c.3700_3704del5 exons 1–17 deletion exons 5–14 deletion c.5266dupC c.181T>G c.68_69delAG  5382insC 300T>G 4184del4 2457C>T 300T>G 5382insC 3819del5 |Recurrent BRCA2<<< 6174delT>>> mutations in Ashkenazi Jewish women affected by breast cancer.|Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2<<< 6174delT>>> mutations: a combined analysis of 22 population based studies.		
23199084	confirmed					23199084		del		NM_007294.3:c.3626delT|NM_007300.3:c.3626delT	NM_007294.3:c.3857delT|NM_007300.3:c.3857delT		rs80357571|rs80357571		 c.3626delT|c.3626delT				BRCA1	entrez	672			dna	c.123delT|c.123delT|c.123delT|c.123delT	30299,32816,41328,41792	30310,32827,41339,41803	Yet another BRCA1 mutation<<< c.3626delT>>> (BIC: 3745delT) apparently originates in northern Sweden and Finland [121]. The 6-kb duplication of BRCA1 exon 13, aslo known as ins6kbEx13 (HGVS: c.|around 84%) of all BRCA1/2 mutations detected [130–138]. The most common BRCA1 mutations are c.4097-2A>G (BIC: 4216-2A>G), c.3485delA (BIC: 3604delA),<<< c.3626delT>>> (BIC: 3745delT), c.4327C>T (BIC: 4446C>T), c.2684del2 (BIC: 2803delAA) and c.5251C>T (BIC: 5370C>T).|486_6489del4 c.3847_3848delGT  8984delG 6601delA 1538del4 6714del4 4075delGT  exons 3-16 deletion c.3171_3175dup c.2475delC c.1082_1092del11 c.1687C>T<<< c.3626delT>>> (Northern) c.1016dupA exon 13 duplication (ins6kbEx13) c.1556delA c.3228delAG c.697delGT c.1016dupA c.3178G>T c.4745delA c.2351del7 c.3084del11 c.1A>|7 3203del11 120A>C IVS17-2A>C  c.2808del4 c.3847delGT  3036del4 4075delGT  exons 1-13 deletion exon 13 duplication (ins6kbEx13) c.4097-2A>G c.3485delA<<< c.3626delT>>> c.4327C>T c.2684del2 c.5251C>T c.4096+3A>G  4216-2A>G 3604delA 3745delT 4446C>T 2803delAA 5370C>T IVS11+3A>G  c.771_775del5 c.7480C>T c.8327T>G c.911		
23199084	confirmed					23199084		del		NM_007294.3:c.3228_3229delAG|NM_007300.3:c.3228_3229delAG	NM_007294.3:c.3459_3460delAG|NM_007300.3:c.3459_3460delAG		rs80357635|rs80357635		 c.3228_3229delAG				BRCA1	entrez	672			dna	c.123_125delAT	39409	39426	6delT  6174delT  c.8363G>A c.8754+1G>A c.3860delA  8591G>A IVS21-1G>A 4088delA  c.3016_3019del4 c.2676_2679del4 c.1687C>T c.181T>G c.5266dupC c.181T>A<<< c.3228_3229delAG>>> c.3285delA c.1380dupA c.5062_5064del3 c.4964_4982del19 c.5062_5064delGTT c.3481_3491del11 c.5128G>T c.68_69delAG c.211A>G (Galicia) c.5117G>A c.5123C		
23199084	confirmed					23199084		del		NM_000059.3:c.3228_3229delAG	NM_000059.3:c.3454_3455delAG		rs80359378		 c.3228_3229delAG				BRCA2	entrez	675			dna	c.123_125delAT	39409	39426	6delT  6174delT  c.8363G>A c.8754+1G>A c.3860delA  8591G>A IVS21-1G>A 4088delA  c.3016_3019del4 c.2676_2679del4 c.1687C>T c.181T>G c.5266dupC c.181T>A<<< c.3228_3229delAG>>> c.3285delA c.1380dupA c.5062_5064del3 c.4964_4982del19 c.5062_5064delGTT c.3481_3491del11 c.5128G>T c.68_69delAG c.211A>G (Galicia) c.5117G>A c.5123C		
23199084	confirmed					23199084		del		NM_007294.3:c.3404delA|NM_007300.3:c.3404delA|NM_007297.3:c.3404delA	NM_007294.3:c.3635delA|NM_007300.3:c.3635delA|NM_007297.3:c.3684delA		na|na|na		 3404delA				BRCA1	entrez	672			dna	6174delT|6174delT	13872,39638	13881,39647	er effect has been demonstrated for few mutations [63–66]. Four distinct BRCA1 founder mutations (c.3228_ 3229delAG (BIC: 3347delAG), c.3285delA (BIC:<<< 3404delA>>>), c.1380dupA (BIC: 1499insA), c.5062_5064del3 (BIC: 5181delGTT) accounted for a large fraction (73%) of BRCA1-attributable hereditary breast/ ovarian|_5064delGTT c.3481_3491del11 c.5128G>T c.68_69delAG c.211A>G (Galicia) c.5117G>A c.5123C>A  3135del4 2795del4 1806C>T 300T>G 5382insC 300T>A 3347delAG<<< 3404delA>>> 1499insA 5181delGTT 5083del19 5181_5183delGTT 3600del11 5247G>T 185delAG 330A>G 5236G>A 5242C>A  c.7806-2A>G  IVS16-2A>G  c.8537_8538delAG(Sardinia) 		
23199084	confirmed					23199084		del		NM_000059.3:c.3404delA	NM_000059.3:c.3630delA		na		 3404delA				BRCA2	entrez	675			dna	6174delT|6174delT	13872,39638	13881,39647	er effect has been demonstrated for few mutations [63–66]. Four distinct BRCA1 founder mutations (c.3228_ 3229delAG (BIC: 3347delAG), c.3285delA (BIC:<<< 3404delA>>>), c.1380dupA (BIC: 1499insA), c.5062_5064del3 (BIC: 5181delGTT) accounted for a large fraction (73%) of BRCA1-attributable hereditary breast/ ovarian|_5064delGTT c.3481_3491del11 c.5128G>T c.68_69delAG c.211A>G (Galicia) c.5117G>A c.5123C>A  3135del4 2795del4 1806C>T 300T>G 5382insC 300T>A 3347delAG<<< 3404delA>>> 1499insA 5181delGTT 5083del19 5181_5183delGTT 3600del11 5247G>T 185delAG 330A>G 5236G>A 5242C>A  c.7806-2A>G  IVS16-2A>G  c.8537_8538delAG(Sardinia) 		
23199084	confirmed					23199084		del		NM_007294.3:c.5062_5064delGTT	NM_007294.3:c.5293_5295delGTT		rs80358344		 c.5062_5064delGTT|c.5062_5064delGTT				BRCA1	entrez	672			dna	c.123_125delAT|c.123_125delAT|c.123_125delAT	15305,15485,39481	15323,15503,39499	[74] showed that previously reported BRCA1<<< c.5062_5064delGTT>>> (BIC: 5181_5183delGTT/1688Val) variant of unknown significance (VUS) actually is a deleterious mutation with high frequency in North-East Italy [74].|The founder<<< c.5062_5064delGTT>>> mutation accounts for 15% (9/61) of families with small BRCA1 mutations. France In France geographical clustering in North-Eastern part is evident for two recurrent BRCA1 mutations, suggesting a founder effect.|88delA  c.3016_3019del4 c.2676_2679del4 c.1687C>T c.181T>G c.5266dupC c.181T>A c.3228_3229delAG c.3285delA c.1380dupA c.5062_5064del3 c.4964_4982del19<<< c.5062_5064delGTT>>> c.3481_3491del11 c.5128G>T c.68_69delAG c.211A>G (Galicia) c.5117G>A c.5123C>A  3135del4 2795del4 1806C>T 300T>G 5382insC 300T>A 3347delAG 3404delA 1		
23199084	notConfirmed							del		c.8765A>None					8765delA| 8765delA				BRCA2	entrez	675			dna	6174delT|6174delT|6174delT|6174delT|6174delT	14455,17038,24173,39797,40538	14464,17047,24182,39806,40547	o breast cancer predisposition has been reported for populations from the Northern part of the island [67], where founder BRCA2 c.8537_8538delAG (BIC:<<< 8765delA>>>G) mutation comprises 28% for BRCA1/2 positive families [68, 69].|A), c.2834_2836delinsC (BIC: 2953delGTA/insC) and 3 BRCA2 mutations (c.3170_3174del5 (BIC: 3398del5), c.5857G>T (BIC: 6085G>T), c.8537_8538delAG (BIC:<<< 8765delA>>>G)) are now routinely included in early onset breast/ovarian cancer screening assays and represent up to 84% of the total BRCA1/2 mutations in the FrenchCanadian population in Quebec [78].|ic Five mutations (BRCA1: c.181T>G, c.5266dupC, c.3700_ 3704del5 (BIC: 3819del5), and BRCA2: c.7913_7917del5 (BIC: 8141del5) and c.8537_8538del2 (BIC:<<< 8765delA>>>G)) represented 52% of all mutations detected in one study population [52].| 1499insA 5181delGTT 5083del19 5181_5183delGTT 3600del11 5247G>T 185delAG 330A>G 5236G>A 5242C>A  c.7806-2A>G  IVS16-2A>G  c.8537_8538delAG(Sardinia) <<< 8765delA>>>G  c.2808_2811del4 (Castilla-Leon) c.6629_6630delAA c.9026_9030del5 c.9310_9311delAA  3036_3039del4 c.6857delAA 9254-9258del5 9538delAA  c.470_471delC|>A 6503_6504delTT 9132delC 5579insA 6503delTT  c.1813dupA c.4478del4 c.9098dupA  2041insA 4706del4 9326insA  c.7913_7917del5 c.8537_8538del2  8141del5<<< 8765delA>>>G  c.9098dupA c.5946delT  9326insA 6174delT  c.3700_3704del5 exons 1–17 deletion exons 5–14 deletion c.5266dupC c.181T>G c.68_69delAG  5382insC 300T>G		
23199084	confirmed					23199084		dup		NM_007297.3:c.1813dupA	NM_007297.3:c.2093dupA		na		 c.1813dupA|c.1813dupA				BRCA1	entrez	672			dna	c.123dupA|c.123dupA	23844,40434	23855,40445	Seven distinct mutations accounted for 28% of BRCA2 mutations, and most frequent<<< c.1813dupA>>> (BIC: 2041insA), c.4478del4 (BIC: 4706del4) and c.9098dupA (BIC: 9326insA) were associated with common alleles, suggesting a possible founder effect |T  c.156_157insAlu c.516+1G>A c.6275_6276delTT c.8904delC c.5351dupA c.6275_6276delTT  384insAlu IVS6+1G>A 6503_6504delTT 9132delC 5579insA 6503delTT <<< c.1813dupA>>> c.4478del4 c.9098dupA  2041insA 4706del4 9326insA  c.7913_7917del5 c.8537_8538del2  8141del5 8765delAG  c.9098dupA c.5946delT  9326insA 6174delT  c.3		
23199084	confirmed					23199084		dup		NM_000059.3:c.1813dupA	NM_000059.3:c.2039dupA		rs80359309		 c.1813dupA|c.1813dupA				BRCA2	entrez	675			dna	c.123dupA|c.123dupA	23844,40434	23855,40445	Seven distinct mutations accounted for 28% of BRCA2 mutations, and most frequent<<< c.1813dupA>>> (BIC: 2041insA), c.4478del4 (BIC: 4706del4) and c.9098dupA (BIC: 9326insA) were associated with common alleles, suggesting a possible founder effect |T  c.156_157insAlu c.516+1G>A c.6275_6276delTT c.8904delC c.5351dupA c.6275_6276delTT  384insAlu IVS6+1G>A 6503_6504delTT 9132delC 5579insA 6503delTT <<< c.1813dupA>>> c.4478del4 c.9098dupA  2041insA 4706del4 9326insA  c.7913_7917del5 c.8537_8538del2  8141del5 8765delAG  c.9098dupA c.5946delT  9326insA 6174delT  c.3		
23199084	confirmed					23199084		del		NM_000059.3:c.3847_3848delGT	NM_000059.3:c.4073_4074delGT		rs80359405		 c.3847_3848delGT|c.3847_3848delGT				BRCA2	entrez	675			dna	c.123_125delAT|c.123_125delAT	28277,41190	28294,41207	no/id/153250.0). The most common BRCA2 mutations were c.6373delA (BIC: 6601delA), c.1310_1013del4 (BIC: 1538del4), c.6486_6489del4 (BIC: 6714del4) and<<< c.3847_3848delGT>>> (BIC: 4075delGT), found in 11%, 10%, 9% and 5% of BRCA2 positive families, respectively [111].|6G>A  c.2475delC c.3319G>T c.5266dupC c.3710delT  2594delC 3438G>T 5382insC 3829delT  HGVS  BIC  c.8755delG c.6373delA c.1310_1013del4 c.6486_6489del4<<< c.3847_3848delGT>>>  8984delG 6601delA 1538del4 6714del4 4075delGT  exons 3-16 deletion c.3171_3175dup c.2475delC c.1082_1092del11 c.1687C>T c.3626delT (Northern) c.1016		
23199084	confirmed					23199084		del		NM_000059.3:c.3847delG	NM_000059.3:c.4073delG		rs397507691		c.3847delG| c.3847delG				BRCA2	entrez	675			dna	c.123delT|c.123delT	31824,41683	31835,41694	1 c.3178G>T (BIC: 3297G>T), c.4745delA (BIC: 4864delA), c.2351del7 (BIC: 2470del7), c.3084del11 (BIC: 3203del11) and BRCA2 c.2808del4 (BIC: 3036del4),<<< c.3847delG>>>T (BIC: 4075delGT)), account for about 60% BRCA1/2 carriers in Norway [128].|806C>T 3745delT 1135insA  c.4258delG  4486delG  1675delA 3347delAG 816delGT 1135insA 3297G>T 4864delA 2470del7 3203del11 120A>C IVS17-2A>C  c.2808del4<<< c.3847delG>>>T  3036del4 4075delGT  exons 1-13 deletion exon 13 duplication (ins6kbEx13) c.4097-2A>G c.3485delA c.3626delT c.4327C>T c.2684del2 c.5251C>T c.4096+3A		
23199084	confirmed					23199084		sub		NM_007294.3:c.2466T>G|NM_007300.3:c.2466T>G|NM_007299.3:c.2466T>G|NM_007297.3:c.2466T>G	NM_007294.3:c.2697T>G|NM_007300.3:c.2697T>G|NM_007299.3:c.2659T>G|NM_007297.3:c.2746T>G		na|na|na|na		2466T>G				BRCA1	entrez	672			dna	859G>A	29134	29142	rising 40% (6/15) of all BRCA1/2 families with LGRs [112].  EPMA Journal (2010) 1:397–412  Recently a pathogenic founder BRCA1 mutation c.234T>G (BIC:<<< 2466T>G>>>/Cys39Gly) was desribed in Greenland (Inuit population), an autonomous country within the Kingdom of Denmark, with a high carrier frequency (1.6%) in this population [113, 114].		
23199084	confirmed					23199084		sub		NM_000059.3:c.2466T>G	NM_000059.3:c.2692T>G		na		2466T>G				BRCA2	entrez	675			dna	859G>A	29134	29142	rising 40% (6/15) of all BRCA1/2 families with LGRs [112].  EPMA Journal (2010) 1:397–412  Recently a pathogenic founder BRCA1 mutation c.234T>G (BIC:<<< 2466T>G>>>/Cys39Gly) was desribed in Greenland (Inuit population), an autonomous country within the Kingdom of Denmark, with a high carrier frequency (1.6%) in this population [113, 114].		
23199084	confirmed					23199084		del		NM_007294.3:c.816delG|NM_007300.3:c.816delG	NM_007294.3:c.1047delG|NM_007300.3:c.1047delG		na|na		816delG| 816delG				BRCA1	entrez	672			dna	6174delT|6174delT	31320,41599	31328,41607	s region [115, 125]. Norway Four Norwegian founder mutations in BRCA1 gene (c.1556delA (BIC: 1675delA), c.3228delAG (BIC: 3347delAG), c.697delGT (BIC:<<< 816delG>>>T) and c.1016dupA make up 68% of the BRCA1 mutation carriers [126, 127], and these have their own specific geographic distribution.| c.4745delA c.2351del7 c.3084del11 c.1A>C c.5075-2A>C  3171ins5 2594delC 1201del11 1806C>T 3745delT 1135insA  c.4258delG  4486delG  1675delA 3347delAG<<< 816delG>>>T 1135insA 3297G>T 4864delA 2470del7 3203del11 120A>C IVS17-2A>C  c.2808del4 c.3847delGT  3036del4 4075delGT  exons 1-13 deletion exon 13 duplication 		
23199084	notConfirmed							dup		c.3853A>AA					c.3853dupA				BRCA1	entrez	672			dna	c.123dupA	33220	33231	6384del2 (BIC: 6503delTT),<<< c.3853dupA>>> (BIC: 4081insA) and c.5569G>T (BIC: 5797G>T)).		
23199084	confirmed					23199084		del		NM_007294.3:c.374delT|NM_007300.3:c.374delT|NM_007299.3:c.374delT|NM_007298.3:c.374delT	NM_007294.3:c.605delT|NM_007300.3:c.605delT|NM_007299.3:c.567delT|NM_007298.3:c.392delT		na|na|na|na		 374delT				BRCA1	entrez	672			dna	6174delT	40011	40019	026_9030del5 c.9310_9311delAA  3036_3039del4 c.6857delAA 9254-9258del5 9538delAA  c.470_471delCT c.5153-1G>A  589_590delCT 5272-1G>A  c.5146_5149del4 <<< 374delT>>>ATG  c.212+3A>G c.2359dupG c.3661G>T c.2685_2686delAA c.2193del5 c.1292dupT exon 13 deletion (3,8-kb) exon 22 deletion (510-bp) exon 17 deletion c.526		
23199084	confirmed					23199084		sub		NM_007294.3:c.5251C>T	NM_007294.3:c.5482C>T		rs80357123		c.5251C>T| c.5251C>T				BRCA1	entrez	672			dna	c.123T>A|c.123T>A|c.123T>A|c.123T>A	26616,32902,40990,41824	26626,32912,41000,41834	carried BRCA2 mutations, including c.9098dupA [104]. Greece In the Greek population four BRCA1 mutations (c.5526dupC, c.5212G>A (BIC: 5331G>A/G1738R),<<< c.5251C>T>>> (BIC:  EPMA Journal (2010) 1:397–412  5370C>T/R1751X), c.5467G>A (BIC: 5586G>A), account for 54% of all mutations detected in BRCA1/2 genes and for 7|ns are c.4097-2A>G (BIC: 4216-2A>G), c.3485delA (BIC: 3604delA), c.3626delT (BIC: 3745delT), c.4327C>T (BIC: 4446C>T), c.2684del2 (BIC: 2803delAA) and<<< c.5251C>T>>> (BIC: 5370C>T).|  Cypriot Danish  Swedish  Norwegian  Finnish  Iceland British  Irish Polish  Latvian  BRCA1 mutation  BRCA2 mutation  HGVS  BIC  c.5266dupC c.5212G>A<<< c.5251C>T>>> c.5467G>A  5382insC 5331G>A 5370C>T 5586G>A  c.2475delC c.3319G>T c.5266dupC c.3710delT  2594delC 3438G>T 5382insC 3829delT  HGVS  BIC  c.8755delG c.|.2808del4 c.3847delGT  3036del4 4075delGT  exons 1-13 deletion exon 13 duplication (ins6kbEx13) c.4097-2A>G c.3485delA c.3626delT c.4327C>T c.2684del2<<< c.5251C>T>>> c.4096+3A>G  4216-2A>G 3604delA 3745delT 4446C>T 2803delAA 5370C>T IVS11+3A>G  c.771_775del5 c.7480C>T c.8327T>G c.9118-2A>G c.9117+1G>A  999del5 770		
23199084	confirmed					23199084		sub		NM_000059.3:c.516+1_516G>A	NM_000059.3:c.742+1_742G>A		rs397507762		c.516+1G>A| c.516+1G>A				BRCA2	entrez	675			dna	c.123+2A>T|c.123+2A>T|c.123+2A>T	20710,21052,40302	20721,21063,40313	nd six major recurrent founder mutations (three BRCA1 c.212+3A> (BIC: IVS5+3A>G), c.2359dupG (BIC: 2478insG), c.3661G>T (BIC: 3780G>T) and three BRCA2<<< c.516+1G>A>>> (BIC: IVS6+1G>A), c.6275_6276delTT (BIC: 6503_6504delTT), c.8904delC (BIC: 9132delC) alterations), which accounted for nearly 60% of all mutations id|BRCA1 c.2359dupG and BRCA2<<< c.516+1G>A>>> have not yet been reported in other populations. The Netherlands (Holland) Several founder mutations in BRCA1/2 have been identified in Holland [94], where significant regional and cultural differences exist.|17 deletion c.5266dupC c.181T>G c.4065_4068del4 c.2338C>T c.181T>G c.5266dupC  IVS5+3A>G 2478insG 3780G>T 2804delAA 2312del5 1411insT  c.156_157insAlu<<< c.516+1G>A>>> c.6275_6276delTT c.8904delC c.5351dupA c.6275_6276delTT  384insAlu IVS6+1G>A 6503_6504delTT 9132delC 5579insA 6503delTT  c.1813dupA c.4478del4 c.9098		
23199084	notConfirmed							sub		c.300T>G					300T>G| 300T>G				BRCA1	entrez	672			dna	859G>A|859G>A|859G>A|859G>A|859G>A|859G>A|859G>A|859G>A	11881,39228,39605,40690,40714,40749,42305,42563	11888,39235,39612,40697,40721,40756,42312,42570	nal communication). There were initial reports for several apparently founder BRCA1 mutations in Austria [58, 59], although they  399  (c.181T>G (BIC:<<< 300T>G>>>/C61G), c.5266dupC, c.1687C>T (BIC: 1806C>T)) represent common mutations prevalent in other European countries.|rman  Czech  Hungarian  BRCA1 mutation  BRCA2 mutation  HGVS  BIC  HGVS  BIC  c.68_69delAG c.5266dupC c.181T>G c.5266dupC c.1687C>T  185delAG 5382insC<<< 300T>G>>> 5382insC 1806C>T  c.5946delT  6174delT  c.8363G>A c.8754+1G>A c.3860delA  8591G>A IVS21-1G>A 4088delA  c.3016_3019del4 c.2676_2679del4 c.1687C>T c.18|_5064del3 c.4964_4982del19 c.5062_5064delGTT c.3481_3491del11 c.5128G>T c.68_69delAG c.211A>G (Galicia) c.5117G>A c.5123C>A  3135del4 2795del4 1806C>T<<< 300T>G>>> 5382insC 300T>A 3347delAG 3404delA 1499insA 5181delGTT 5083del19 5181_5183delGTT 3600del11 5247G>T 185delAG 330A>G 5236G>A 5242C>A  c.7806-2A>G  IVS1|765delAG  c.9098dupA c.5946delT  9326insA 6174delT  c.3700_3704del5 exons 1–17 deletion exons 5–14 deletion c.5266dupC c.181T>G c.68_69delAG  5382insC<<< 300T>G>>> 4184del4 2457C>T 300T>G 5382insC 3819del5  5382insC 300T>G 185delAG  406  EPMA Journal (2010) 1:397–412  Table 1 (continued) Population  Greek  Cypri|946delT  9326insA 6174delT  c.3700_3704del5 exons 1–17 deletion exons 5–14 deletion c.5266dupC c.181T>G c.68_69delAG  5382insC 300T>G 4184del4 2457C>T<<< 300T>G>>> 5382insC 3819del5  5382insC 300T>G 185delAG  406  EPMA Journal (2010) 1:397–412  Table 1 (continued) Population  Greek  Cypriot Danish  Swedish  Norw|3704del5 exons 1–17 deletion exons 5–14 deletion c.5266dupC c.181T>G c.68_69delAG  5382insC 300T>G 4184del4 2457C>T 300T>G 5382insC 3819del5  5382insC<<< 300T>G>>> 185delAG  406  EPMA Journal (2010) 1:397–412  Table 1 (continued) Population  Greek  Cypriot Danish  Swedish  Norwegian  Finnish  Iceland British  Ir|3 duplication (ins6kbEx13) c.427G>T c.5266dupC c.181T>G c.4035delA c.4035delA c.5266dupC  4184del4  c.1929delG (North-West)  2157delG  546G>T 5382insC<<< 300T>G>>> 4154delA 4154delA 5382insC  EPMA Journal (2010) 1:397–412  407  Table 1 (continued) Population  Lithuanian Belarusian Russian  BRCA1 mutation  BRCA2 |uanian Belarusian Russian  BRCA1 mutation  BRCA2 mutation  HGVS  BIC  c.4035delA c.5266dupC c.5266dupC c.181T>G c.5266dupC  4154delA 5382insC 5382insC<<< 300T>G>>> 5382insC  HGVS  BIC  Apparently true founder mutations are written in italic.		
23199084	confirmed					23199084		del		NM_007297.3:c.5374delT	NM_007297.3:c.5654delT		na		5374delT| 5374delT				BRCA1	entrez	672			dna	6174delT|6174delT	19565,61451	19574,61460	rigins [85, 86].  EPMA Journal (2010) 1:397–412  Splicing mutation c.5153-1G>A (BIC: 5272-1G>A) of BRCA1 and frameshift mutation c.5146_5149del4 (BIC:<<< 5374delT>>>ATG) of BRCA2 are also prevalent founder mutations in the Central Spain region, accounting for 18.4% and 13.6% of BRCA1 and BRCA2 positive families, respectively [80, 85, 87].|BRCA1 5272-1G>A and BRCA2<<< 5374delT>>>ATG are founder mutations of high relevance for genetic counselling in breast/ovarian cancer families of Spanish origin.		
23199084	confirmed					23199084		del		NM_000059.3:c.5374delT	NM_000059.3:c.5600delT		na		5374delT| 5374delT				BRCA2	entrez	675			dna	6174delT|6174delT	19565,61451	19574,61460	rigins [85, 86].  EPMA Journal (2010) 1:397–412  Splicing mutation c.5153-1G>A (BIC: 5272-1G>A) of BRCA1 and frameshift mutation c.5146_5149del4 (BIC:<<< 5374delT>>>ATG) of BRCA2 are also prevalent founder mutations in the Central Spain region, accounting for 18.4% and 13.6% of BRCA1 and BRCA2 positive families, respectively [80, 85, 87].|BRCA1 5272-1G>A and BRCA2<<< 5374delT>>>ATG are founder mutations of high relevance for genetic counselling in breast/ovarian cancer families of Spanish origin.		
23199084	confirmed					23199084		dup		NM_007294.3:c.1016dupA|NM_007300.3:c.1016dupA	NM_007294.3:c.1247dupA|NM_007300.3:c.1247dupA		rs80357618|rs80357618		c.1016dupA| c.1016dupA				BRCA1	entrez	672			dna	c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA	30909,31334,32157,41350,41428	30920,31345,32168,41361,41439	ix mutations, including the most common BRCA1 c.3171_3175dup, four other common Scandinavian BCRA1 mutations (c.1082_1092del11, c.2475delC, c.1687C>T,<<< c.1016dupA>>> (BIC: 1135insA)) and one BRCA2 mutation (c.4258delG) accounted for approximately 75% of all BRCA1/2 mutations [124].| 125]. Norway Four Norwegian founder mutations in BRCA1 gene (c.1556delA (BIC: 1675delA), c.3228delAG (BIC: 3347delAG), c.697delGT (BIC: 816delGT) and<<< c.1016dupA>>> make up 68% of the BRCA1 mutation carriers [126, 127], and these have their own specific geographic distribution.|The large deletion of BRCA1 exons 1–13 is frequently found as well as exon 13 duplication (ins6kb13Ex) (http://www.inherited-cancer.com). The BRCA1<<< c.1016dupA>>> mutation has also been reported in other countries (Italy, Germany, French-Canada), however allelotyping results indicated an independent origin of this mutation.|48delGT  8984delG 6601delA 1538del4 6714del4 4075delGT  exons 3-16 deletion c.3171_3175dup c.2475delC c.1082_1092del11 c.1687C>T c.3626delT (Northern)<<< c.1016dupA>>> exon 13 duplication (ins6kbEx13) c.1556delA c.3228delAG c.697delGT c.1016dupA c.3178G>T c.4745delA c.2351del7 c.3084del11 c.1A>C c.5075-2A>C  3171ins|3171_3175dup c.2475delC c.1082_1092del11 c.1687C>T c.3626delT (Northern) c.1016dupA exon 13 duplication (ins6kbEx13) c.1556delA c.3228delAG c.697delGT<<< c.1016dupA>>> c.3178G>T c.4745delA c.2351del7 c.3084del11 c.1A>C c.5075-2A>C  3171ins5 2594delC 1201del11 1806C>T 3745delT 1135insA  c.4258delG  4486delG  1675delA		
23199084	confirmed					23199084		dup		NM_000059.3:c.1016dupA	NM_000059.3:c.1242dupA		na		c.1016dupA| c.1016dupA				BRCA2	entrez	675			dna	c.123dupA|c.123dupA|c.123dupA|c.123dupA|c.123dupA	30909,31334,32157,41350,41428	30920,31345,32168,41361,41439	ix mutations, including the most common BRCA1 c.3171_3175dup, four other common Scandinavian BCRA1 mutations (c.1082_1092del11, c.2475delC, c.1687C>T,<<< c.1016dupA>>> (BIC: 1135insA)) and one BRCA2 mutation (c.4258delG) accounted for approximately 75% of all BRCA1/2 mutations [124].| 125]. Norway Four Norwegian founder mutations in BRCA1 gene (c.1556delA (BIC: 1675delA), c.3228delAG (BIC: 3347delAG), c.697delGT (BIC: 816delGT) and<<< c.1016dupA>>> make up 68% of the BRCA1 mutation carriers [126, 127], and these have their own specific geographic distribution.|The large deletion of BRCA1 exons 1–13 is frequently found as well as exon 13 duplication (ins6kb13Ex) (http://www.inherited-cancer.com). The BRCA1<<< c.1016dupA>>> mutation has also been reported in other countries (Italy, Germany, French-Canada), however allelotyping results indicated an independent origin of this mutation.|48delGT  8984delG 6601delA 1538del4 6714del4 4075delGT  exons 3-16 deletion c.3171_3175dup c.2475delC c.1082_1092del11 c.1687C>T c.3626delT (Northern)<<< c.1016dupA>>> exon 13 duplication (ins6kbEx13) c.1556delA c.3228delAG c.697delGT c.1016dupA c.3178G>T c.4745delA c.2351del7 c.3084del11 c.1A>C c.5075-2A>C  3171ins|3171_3175dup c.2475delC c.1082_1092del11 c.1687C>T c.3626delT (Northern) c.1016dupA exon 13 duplication (ins6kbEx13) c.1556delA c.3228delAG c.697delGT<<< c.1016dupA>>> c.3178G>T c.4745delA c.2351del7 c.3084del11 c.1A>C c.5075-2A>C  3171ins5 2594delC 1201del11 1806C>T 3745delT 1135insA  c.4258delG  4486delG  1675delA		
23199084	confirmed					23199084		del		NM_007297.3:c.5946delT	NM_007297.3:c.6226delT		na		c.5946delT| c.5946delT				BRCA1	entrez	672			dna	c.123delT|c.123delT|c.123delT|c.123delT|c.123delT|c.123delT	9258,9511,9960,26070,39253,40560	9269,9522,9971,26081,39264,40571	The most well characterized three founder mutations are two in BRCA1 gene c.68_69delAG (BIC: 185delAG) and c.5266dupC (BIC: 5382insC) and one in BRCA2<<< c.5946delT>>> (BIC:  EPMA Journal (2010) 1:397–412  6174delT) [31–33].|mutations alone is now part of routine clinical practice for Ashkenazi Jewish individuals. These 3 mutations (BRCA1 c.68_69delAG, c.5266dupC and BRCA2<<< c.5946delT>>>) account for 98–99% of identified mutations and are carried by about 2.6% (1/40) of the Ashkenazi Jewish population (1%, 0.13% and 1.52% respectively) [34–36].|e age of 70 years is similar for carriers of the BRCA1 c.68_69delAG and c.5266dupC mutations (64% and 67% respectively), however is much lower for the<<< c.5946delT>>> mutation (43%).|ies, common BRCA1 founder mutations c.5266dupC, c.181T>G and c.68_69delAG accounted for 80% of all BRCA1 mutations and c.9098dupA (BIC: 9326insA) with<<< c.5946delT>>> accounted for 50% of all BRCA2 mutations [42, 103].|RCA1 mutation  BRCA2 mutation  HGVS  BIC  HGVS  BIC  c.68_69delAG c.5266dupC c.181T>G c.5266dupC c.1687C>T  185delAG 5382insC 300T>G 5382insC 1806C>T <<< c.5946delT>>>  6174delT  c.8363G>A c.8754+1G>A c.3860delA  8591G>A IVS21-1G>A 4088delA  c.3016_3019del4 c.2676_2679del4 c.1687C>T c.181T>G c.5266dupC c.181T>A c.32|delC 5579insA 6503delTT  c.1813dupA c.4478del4 c.9098dupA  2041insA 4706del4 9326insA  c.7913_7917del5 c.8537_8538del2  8141del5 8765delAG  c.9098dupA<<< c.5946delT>>>  9326insA 6174delT  c.3700_3704del5 exons 1–17 deletion exons 5–14 deletion c.5266dupC c.181T>G c.68_69delAG  5382insC 300T>G 4184del4 2457C>T 300T>G		
23199084	confirmed					23199084		del		NM_000059.3:c.5946delT	NM_000059.3:c.6172delT		rs80359550		c.5946delT| c.5946delT				BRCA2	entrez	675			dna	c.123delT|c.123delT|c.123delT|c.123delT|c.123delT|c.123delT	9258,9511,9960,26070,39253,40560	9269,9522,9971,26081,39264,40571	The most well characterized three founder mutations are two in BRCA1 gene c.68_69delAG (BIC: 185delAG) and c.5266dupC (BIC: 5382insC) and one in BRCA2<<< c.5946delT>>> (BIC:  EPMA Journal (2010) 1:397–412  6174delT) [31–33].|mutations alone is now part of routine clinical practice for Ashkenazi Jewish individuals. These 3 mutations (BRCA1 c.68_69delAG, c.5266dupC and BRCA2<<< c.5946delT>>>) account for 98–99% of identified mutations and are carried by about 2.6% (1/40) of the Ashkenazi Jewish population (1%, 0.13% and 1.52% respectively) [34–36].|e age of 70 years is similar for carriers of the BRCA1 c.68_69delAG and c.5266dupC mutations (64% and 67% respectively), however is much lower for the<<< c.5946delT>>> mutation (43%).|ies, common BRCA1 founder mutations c.5266dupC, c.181T>G and c.68_69delAG accounted for 80% of all BRCA1 mutations and c.9098dupA (BIC: 9326insA) with<<< c.5946delT>>> accounted for 50% of all BRCA2 mutations [42, 103].|RCA1 mutation  BRCA2 mutation  HGVS  BIC  HGVS  BIC  c.68_69delAG c.5266dupC c.181T>G c.5266dupC c.1687C>T  185delAG 5382insC 300T>G 5382insC 1806C>T <<< c.5946delT>>>  6174delT  c.8363G>A c.8754+1G>A c.3860delA  8591G>A IVS21-1G>A 4088delA  c.3016_3019del4 c.2676_2679del4 c.1687C>T c.181T>G c.5266dupC c.181T>A c.32|delC 5579insA 6503delTT  c.1813dupA c.4478del4 c.9098dupA  2041insA 4706del4 9326insA  c.7913_7917del5 c.8537_8538del2  8141del5 8765delAG  c.9098dupA<<< c.5946delT>>>  9326insA 6174delT  c.3700_3704del5 exons 1–17 deletion exons 5–14 deletion c.5266dupC c.181T>G c.68_69delAG  5382insC 300T>G 4184del4 2457C>T 300T>G		
23199084	notConfirmed							ins		c.156None>A					 c.156_157insA|c.156_157insA				BRCA2	entrez	675			dna	c.123_124insGC|c.123_124insGC	40286,62405	40300,62419	n (510-bp) exon 17 deletion c.5266dupC c.181T>G c.4065_4068del4 c.2338C>T c.181T>G c.5266dupC  IVS5+3A>G 2478insG 3780G>T 2804delAA 2312del5 1411insT <<< c.156_157insA>>>lu c.516+1G>A c.6275_6276delTT c.8904delC c.5351dupA c.6275_6276delTT  384insAlu IVS6+1G>A 6503_6504delTT 9132delC 5579insA 6503delTT  c.1813dupA c.44|The<<< c.156_157insA>>>lu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal.		
23199084	confirmed					23199084		sub		NM_007294.3:c.3319G>T|NM_007300.3:c.3319G>T|NM_007299.3:c.3319G>T	NM_007294.3:c.3550G>T|NM_007300.3:c.3550G>T|NM_007299.3:c.3512G>T		rs80357106|rs80357106|rs111791349		 c.3319G>T				BRCA1	entrez	672			dna	c.123T>A|c.123T>A|c.123T>A	27782,28046,41056	27792,28056,41066	The most common BRCA1 mutations were c.2475delC (BIC: 2594delC),<<< c.3319G>T>>> (BIC: 3438G>T), c.5266dupC and c.3710delT (BIC: 3829delT), which accounted 16%, 9%, 8% and 5% of BRCA1 positive families, respectively [109–111].|The c.2475delC BRCA1 mutation was also reported in Sweden, Norway and Western Europe (BIC database) and the<<< c.3319G>T>>> BRCA1 mutation was also reported in Norway (http://www.legeforeningen.no/id/153250.0). The most common BRCA2 mutations were c.6373delA (BIC: 6601delA|ish Polish  Latvian  BRCA1 mutation  BRCA2 mutation  HGVS  BIC  c.5266dupC c.5212G>A c.5251C>T c.5467G>A  5382insC 5331G>A 5370C>T 5586G>A  c.2475delC<<< c.3319G>T>>> c.5266dupC c.3710delT  2594delC 3438G>T 5382insC 3829delT  HGVS  BIC  c.8755delG c.6373delA c.1310_1013del4 c.6486_6489del4 c.3847_3848delGT  8984del		
23199084	confirmed					23199084		del		NM_007298.3:c.3229delA	NM_007298.3:c.3247delA		na		 3229delA				BRCA1	entrez	672			dna	6174delT	13827	13836	ated families, and significant regional founder effect has been demonstrated for few mutations [63–66]. Four distinct BRCA1 founder mutations (c.3228_<<< 3229delA>>>G (BIC: 3347delAG), c.3285delA (BIC: 3404delA), c.1380dupA (BIC: 1499insA), c.5062_5064del3 (BIC: 5181delGTT) accounted for a large fraction (73%) of 		
23199084	notConfirmed							del		c.3347A>None					 3347delA|3347delA				BRCA1	entrez	672			dna	6174delT|6174delT|6174delT|6174delT	13843,31291,39628,41589	13852,31300,39637,41598	nd significant regional founder effect has been demonstrated for few mutations [63–66]. Four distinct BRCA1 founder mutations (c.3228_ 3229delAG (BIC:<<< 3347delA>>>G), c.3285delA (BIC: 3404delA), c.1380dupA (BIC: 1499insA), c.5062_5064del3 (BIC: 5181delGTT) accounted for a large fraction (73%) of BRCA1-attributab|er after breast cancer in this region [115, 125]. Norway Four Norwegian founder mutations in BRCA1 gene (c.1556delA (BIC: 1675delA), c.3228delAG (BIC:<<< 3347delA>>>G), c.697delGT (BIC: 816delGT) and c.1016dupA make up 68% of the BRCA1 mutation carriers [126, 127], and these have their own specific geographic distribution.|l19 c.5062_5064delGTT c.3481_3491del11 c.5128G>T c.68_69delAG c.211A>G (Galicia) c.5117G>A c.5123C>A  3135del4 2795del4 1806C>T 300T>G 5382insC 300T>A<<< 3347delA>>>G 3404delA 1499insA 5181delGTT 5083del19 5181_5183delGTT 3600del11 5247G>T 185delAG 330A>G 5236G>A 5242C>A  c.7806-2A>G  IVS16-2A>G  c.8537_8538delAG(| c.3178G>T c.4745delA c.2351del7 c.3084del11 c.1A>C c.5075-2A>C  3171ins5 2594delC 1201del11 1806C>T 3745delT 1135insA  c.4258delG  4486delG  1675delA<<< 3347delA>>>G 816delGT 1135insA 3297G>T 4864delA 2470del7 3203del11 120A>C IVS17-2A>C  c.2808del4 c.3847delGT  3036del4 4075delGT  exons 1-13 deletion exon 13 dup		
23199084	confirmed					23199084		sub		NM_007294.3:c.5075-2_5075A>C|NM_007300.3:c.5075-2_5075A>C|NM_007297.3:c.5075-2_5075A>C	NM_007294.3:c.5306-2_5306A>C|NM_007300.3:c.5306-2_5306A>C|NM_007297.3:c.5355-2_5355A>C		na|na|na		 c.5075-2A>C				BRCA1	entrez	672			dna	c.123+2A>T|c.123+2A>T	31942,41490	31954,41502	BRCA1 c.1A>C (BIC: 120A>C) and<<< c.5075-2A>C>>> (BIC: IVS17-2A>C) mutations are also locally frequent.|(Northern) c.1016dupA exon 13 duplication (ins6kbEx13) c.1556delA c.3228delAG c.697delGT c.1016dupA c.3178G>T c.4745delA c.2351del7 c.3084del11 c.1A>C<<< c.5075-2A>C>>>  3171ins5 2594delC 1201del11 1806C>T 3745delT 1135insA  c.4258delG  4486delG  1675delA 3347delAG 816delGT 1135insA 3297G>T 4864delA 2470del7 3203del1		
23199084	confirmed					23199084		sub		NM_007294.3:c.4327C>T|NM_007300.3:c.4327C>T	NM_007294.3:c.4558C>T|NM_007300.3:c.4558C>T		rs41293455|rs41293455		 c.4327C>T|c.4327C>T				BRCA1	entrez	672			dna	c.123T>A|c.123T>A|c.123T>A|c.123T>A	16763,17292,32844,41803	16773,17302,32854,41813	In this region 4 BRCA1 gene mutations <<<(c.4327C>T>>> (BIC: 4446C>T/Arg1443X), c.3756_3759del4 (BIC:  EPMA Journal (2010) 1:397–412  3875delGTCT), c.962G>A (BIC: 1081G>A), c.2834_2836delinsC (BIC: 2953de|Among these, the most common founder mutations are BRCA1<<< c.4327C>T>>> and BRCA2 c.8537_8538delAG and c.3170_3174del5, which are found in 1.7% of women affected by breast cancer diagnosed before age 41 and in 1.3% of wom|utations detected [130–138]. The most common BRCA1 mutations are c.4097-2A>G (BIC: 4216-2A>G), c.3485delA (BIC: 3604delA), c.3626delT (BIC: 3745delT),<<< c.4327C>T>>> (BIC: 4446C>T), c.2684del2 (BIC: 2803delAA) and c.5251C>T (BIC: 5370C>T).| 120A>C IVS17-2A>C  c.2808del4 c.3847delGT  3036del4 4075delGT  exons 1-13 deletion exon 13 duplication (ins6kbEx13) c.4097-2A>G c.3485delA c.3626delT<<< c.4327C>T>>> c.2684del2 c.5251C>T c.4096+3A>G  4216-2A>G 3604delA 3745delT 4446C>T 2803delAA 5370C>T IVS11+3A>G  c.771_775del5 c.7480C>T c.8327T>G c.9118-2A>G c.9		
23199084	confirmed					23199084		del		NM_007294.3:c.2804delA|NM_007300.3:c.2804delA|NM_007298.3:c.2804delA	NM_007294.3:c.3035delA|NM_007300.3:c.3035delA|NM_007298.3:c.2822delA		na|na|na		 2804delA				BRCA1	entrez	672			dna	6174delT|6174delT	21305,40257	21314,40266	The BRCA1 c.2685_2686delAA (BIC:<<< 2804delA>>>A) founder mutation probably originated approximately 32 generations (∼200 years) ago, was also reported few times in Belgium and accounted for 24% of all BRCA1/ 2 mutations [92].|tion (3,8-kb) exon 22 deletion (510-bp) exon 17 deletion c.5266dupC c.181T>G c.4065_4068del4 c.2338C>T c.181T>G c.5266dupC  IVS5+3A>G 2478insG 3780G>T<<< 2804delA>>>A 2312del5 1411insT  c.156_157insAlu c.516+1G>A c.6275_6276delTT c.8904delC c.5351dupA c.6275_6276delTT  384insAlu IVS6+1G>A 6503_6504delTT 9132delC 5		
23199084	confirmed					23199084		del		NM_000059.3:c.2804delA	NM_000059.3:c.3030delA		na		 2804delA				BRCA2	entrez	675			dna	6174delT|6174delT	21305,40257	21314,40266	The BRCA1 c.2685_2686delAA (BIC:<<< 2804delA>>>A) founder mutation probably originated approximately 32 generations (∼200 years) ago, was also reported few times in Belgium and accounted for 24% of all BRCA1/ 2 mutations [92].|tion (3,8-kb) exon 22 deletion (510-bp) exon 17 deletion c.5266dupC c.181T>G c.4065_4068del4 c.2338C>T c.181T>G c.5266dupC  IVS5+3A>G 2478insG 3780G>T<<< 2804delA>>>A 2312del5 1411insT  c.156_157insAlu c.516+1G>A c.6275_6276delTT c.8904delC c.5351dupA c.6275_6276delTT  384insAlu IVS6+1G>A 6503_6504delTT 9132delC 5		
23199084	notConfirmed							del		c.3875G>None					 3875delG				BRCA2	entrez	675			dna	6174delT	16852	16861	In this region 4 BRCA1 gene mutations (c.4327C>T (BIC: 4446C>T/Arg1443X), c.3756_3759del4 (BIC:  EPMA Journal (2010) 1:397–412 <<< 3875delG>>>TCT), c.962G>A (BIC: 1081G>A), c.2834_2836delinsC (BIC: 2953delGTA/insC) and 3 BRCA2 mutations (c.3170_3174del5 (BIC: 3398del5), c.5857G>T (BIC: 6085G		
23199084	notConfirmed							del		c.2157G>None					 2157delG|2157delG				BRCA2	entrez	675			dna	6174delT|6174delT|6174delT	35236,42279,73719	35245,42288,73728	sh, Danish and Belgian families (BIC database). In the North-west of England two reccurent mutations (BRCA1 c.4065_4068del4 and BRCA2 c.1929delG (BIC:<<< 2157delG>>>) accounted for 16% of identified BRCA1 mutations in breast/ovarian cancer families and for 20% of BRCA2 positive male breast cancer families, respect|68del4 (North-West) exon 13 duplication (ins6kbEx13) c.427G>T c.5266dupC c.181T>G c.4035delA c.4035delA c.5266dupC  4184del4  c.1929delG (North-West) <<< 2157delG>>>  546G>T 5382insC 300T>G 4154delA 4154delA 5382insC  EPMA Journal (2010) 1:397–412  407  Table 1 (continued) Population  Lithuanian Belarusian Russian|alysis of two common  412  152.  153.  154. 155.  156.  157.  158.  159. 160.  161.  EPMA Journal (2010) 1:397–412 mutations, BRCA1 4184del4 and BRCA2<<< 2157delG>>>, in high risk northwest England breast/ovarian families.		
23199084	confirmed					23199084		del		NM_007297.3:c.4153delA	NM_007297.3:c.4433delA		rs80357157		4153delA				BRCA1	entrez	672			dna	6174delT|6174delT	55870,75275	55879,75284	High incidence of<<< 4153delA>>> BRCA1 gene mutations in Lithuanian breast- and breast-ovarian cancer families.|BRCA1<<< 4153delA>>> founder mutation in Russian ovarian cancer patients.		
23199084	confirmed					23199084		sub		NM_007294.3:c.5123C>A|NM_007297.3:c.5123C>A	NM_007294.3:c.5354C>A|NM_007297.3:c.5403C>A		rs28897696|na		 c.5123C>A|c.5123C>A				BRCA1	entrez	672			dna	c.123T>A|c.123T>A	17889,39568	17899,39578	 test results from different laboratories shows that five mutations in the BRCA1 gene (c.68_69delAG, c.211A>G (BIC: 330A>G), c.5117G>A (BIC: 5236G>A),<<< c.5123C>A>>> (BIC: 5242C>A), c.470_471delCT (BIC: 589_590delCT) account for 46.6% of BRCA1 mutations and four mutations in BRCA2 (c.2808_2811del4 (BIC: 3036_3039d|229delAG c.3285delA c.1380dupA c.5062_5064del3 c.4964_4982del19 c.5062_5064delGTT c.3481_3491del11 c.5128G>T c.68_69delAG c.211A>G (Galicia) c.5117G>A<<< c.5123C>A>>>  3135del4 2795del4 1806C>T 300T>G 5382insC 300T>A 3347delAG 3404delA 1499insA 5181delGTT 5083del19 5181_5183delGTT 3600del11 5247G>T 185delAG 330A>G 		
23199084	confirmed					23199084		sub		NM_000059.3:c.5123C>A	NM_000059.3:c.5349C>A		na		 c.5123C>A|c.5123C>A				BRCA2	entrez	675			dna	c.123T>A|c.123T>A	17889,39568	17899,39578	 test results from different laboratories shows that five mutations in the BRCA1 gene (c.68_69delAG, c.211A>G (BIC: 330A>G), c.5117G>A (BIC: 5236G>A),<<< c.5123C>A>>> (BIC: 5242C>A), c.470_471delCT (BIC: 589_590delCT) account for 46.6% of BRCA1 mutations and four mutations in BRCA2 (c.2808_2811del4 (BIC: 3036_3039d|229delAG c.3285delA c.1380dupA c.5062_5064del3 c.4964_4982del19 c.5062_5064delGTT c.3481_3491del11 c.5128G>T c.68_69delAG c.211A>G (Galicia) c.5117G>A<<< c.5123C>A>>>  3135del4 2795del4 1806C>T 300T>G 5382insC 300T>A 3347delAG 3404delA 1499insA 5181delGTT 5083del19 5181_5183delGTT 3600del11 5247G>T 185delAG 330A>G 		
23199084	notConfirmed							sub		c.3780G>T					3780G>T| 3780G>T				BRCA2	entrez	675			dna	859G>A|859G>A	20685,40249	20693,40257	1/2 positive families found six major recurrent founder mutations (three BRCA1 c.212+3A> (BIC: IVS5+3A>G), c.2359dupG (BIC: 2478insG), c.3661G>T (BIC:<<< 3780G>T>>>) and three BRCA2 c.516+1G>A (BIC: IVS6+1G>A), c.6275_6276delTT (BIC: 6503_6504delTT), c.8904delC (BIC: 9132delC) alterations), which accounted for ne| 13 deletion (3,8-kb) exon 22 deletion (510-bp) exon 17 deletion c.5266dupC c.181T>G c.4065_4068del4 c.2338C>T c.181T>G c.5266dupC  IVS5+3A>G 2478insG<<< 3780G>T>>> 2804delAA 2312del5 1411insT  c.156_157insAlu c.516+1G>A c.6275_6276delTT c.8904delC c.5351dupA c.6275_6276delTT  384insAlu IVS6+1G>A 6503_6504delTT 9		
23199084	confirmed					23199084		del		NM_007297.3:c.3745delT	NM_007297.3:c.4025delT		na		 3745delT|3745delT				BRCA1	entrez	672			dna	6174delT|6174delT|6174delT|6174delT	30316,32833,41539,41866	30325,32842,41548,41875	Yet another BRCA1 mutation c.3626delT (BIC:<<< 3745delT>>>) apparently originates in northern Sweden and Finland [121]. The 6-kb duplication of BRCA1 exon 13, aslo known as ins6kbEx13 (HGVS: c.4186-1787_4357+|l BRCA1/2 mutations detected [130–138]. The most common BRCA1 mutations are c.4097-2A>G (BIC: 4216-2A>G), c.3485delA (BIC: 3604delA), c.3626delT (BIC:<<< 3745delT>>>), c.4327C>T (BIC: 4446C>T), c.2684del2 (BIC: 2803delAA) and c.5251C>T (BIC: 5370C>T).|Ex13) c.1556delA c.3228delAG c.697delGT c.1016dupA c.3178G>T c.4745delA c.2351del7 c.3084del11 c.1A>C c.5075-2A>C  3171ins5 2594delC 1201del11 1806C>T<<< 3745delT>>> 1135insA  c.4258delG  4486delG  1675delA 3347delAG 816delGT 1135insA 3297G>T 4864delA 2470del7 3203del11 120A>C IVS17-2A>C  c.2808del4 c.3847delGT  3| exons 1-13 deletion exon 13 duplication (ins6kbEx13) c.4097-2A>G c.3485delA c.3626delT c.4327C>T c.2684del2 c.5251C>T c.4096+3A>G  4216-2A>G 3604delA<<< 3745delT>>> 4446C>T 2803delAA 5370C>T IVS11+3A>G  c.771_775del5 c.7480C>T c.8327T>G c.9118-2A>G c.9117+1G>A  999del5 7708C>T 8555T>G 9346-2A>G 9345+1G>A  c.2681_		
23199084	confirmed					23199084		del		NM_007294.3:c.3710delT|NM_007300.3:c.3710delT	NM_007294.3:c.3941delT|NM_007300.3:c.3941delT		rs80357564|rs80357564		c.3710delT| c.3710delT				BRCA1	entrez	672			dna	c.123delT|c.123delT	27823,41077	27834,41088	The most common BRCA1 mutations were c.2475delC (BIC: 2594delC), c.3319G>T (BIC: 3438G>T), c.5266dupC and<<< c.3710delT>>> (BIC: 3829delT), which accounted 16%, 9%, 8% and 5% of BRCA1 positive families, respectively [109–111].|BRCA1 mutation  BRCA2 mutation  HGVS  BIC  c.5266dupC c.5212G>A c.5251C>T c.5467G>A  5382insC 5331G>A 5370C>T 5586G>A  c.2475delC c.3319G>T c.5266dupC<<< c.3710delT>>>  2594delC 3438G>T 5382insC 3829delT  HGVS  BIC  c.8755delG c.6373delA c.1310_1013del4 c.6486_6489del4 c.3847_3848delGT  8984delG 6601delA 1538del4 67		
23199084	confirmed					23199084		del		NM_007294.3:c.3485delA|NM_007300.3:c.3485delA|NM_007299.3:c.3485delA|NM_007298.3:c.3485delA	NM_007294.3:c.3716delA|NM_007300.3:c.3716delA|NM_007299.3:c.3678delA|NM_007298.3:c.3503delA		rs80357509|rs80357509|na|na		c.3485delA| c.3485delA				BRCA1	entrez	672			dna	c.123delT|c.123delT	32788,41781	32799,41792	d these represent majority (around 84%) of all BRCA1/2 mutations detected [130–138]. The most common BRCA1 mutations are c.4097-2A>G (BIC: 4216-2A>G),<<< c.3485delA>>> (BIC: 3604delA), c.3626delT (BIC: 3745delT), c.4327C>T (BIC: 4446C>T), c.2684del2 (BIC: 2803delAA) and c.5251C>T (BIC: 5370C>T).|elA 2470del7 3203del11 120A>C IVS17-2A>C  c.2808del4 c.3847delGT  3036del4 4075delGT  exons 1-13 deletion exon 13 duplication (ins6kbEx13) c.4097-2A>G<<< c.3485delA>>> c.3626delT c.4327C>T c.2684del2 c.5251C>T c.4096+3A>G  4216-2A>G 3604delA 3745delT 4446C>T 2803delAA 5370C>T IVS11+3A>G  c.771_775del5 c.7480C>T c.83		
23199084	confirmed					23199084		sub		NM_007294.3:c.1A>C|NM_007300.3:c.1A>C|NM_007299.3:c.1A>C|NM_007298.3:c.1A>C|NM_007297.3:c.1A>C	NM_007294.3:c.232A>C|NM_007300.3:c.232A>C|NM_007299.3:c.194A>C|NM_007298.3:c.19A>C|NM_007297.3:c.281A>C		rs80357287|rs80357287|rs80357287|rs80357287|na		 c.1A>C|c.1A>C				BRCA1	entrez	672			dna	c.123T>A|c.123T>A	31917,41483	31924,41490	BRCA1<<< c.1A>C>>> (BIC: 120A>C) and c.5075-2A>C (BIC: IVS17-2A>C) mutations are also locally frequent.|26delT (Northern) c.1016dupA exon 13 duplication (ins6kbEx13) c.1556delA c.3228delAG c.697delGT c.1016dupA c.3178G>T c.4745delA c.2351del7 c.3084del11<<< c.1A>C>>> c.5075-2A>C  3171ins5 2594delC 1201del11 1806C>T 3745delT 1135insA  c.4258delG  4486delG  1675delA 3347delAG 816delGT 1135insA 3297G>T 4864delA 2470d		
23199084	confirmed					23199084		sub		NM_000059.3:c.1A>C	NM_000059.3:c.227A>C		na		 c.1A>C|c.1A>C				BRCA2	entrez	675			dna	c.123T>A|c.123T>A	31917,41483	31924,41490	BRCA1<<< c.1A>C>>> (BIC: 120A>C) and c.5075-2A>C (BIC: IVS17-2A>C) mutations are also locally frequent.|26delT (Northern) c.1016dupA exon 13 duplication (ins6kbEx13) c.1556delA c.3228delAG c.697delGT c.1016dupA c.3178G>T c.4745delA c.2351del7 c.3084del11<<< c.1A>C>>> c.5075-2A>C  3171ins5 2594delC 1201del11 1806C>T 3745delT 1135insA  c.4258delG  4486delG  1675delA 3347delAG 816delGT 1135insA 3297G>T 4864delA 2470d		
23199084	notConfirmed							del		c.9132C>None					 9132delC|9132delC				BRCA1	entrez	672			dna	6174delT|6174delT	20796,40405	20805,40414	59dupG (BIC: 2478insG), c.3661G>T (BIC: 3780G>T) and three BRCA2 c.516+1G>A (BIC: IVS6+1G>A), c.6275_6276delTT (BIC: 6503_6504delTT), c.8904delC (BIC:<<< 9132delC>>>) alterations), which accounted for nearly 60% of all mutations identified. BRCA1 c.212+3A>G was previously reported as Belgian founder mutation [92, 93], later also found in a few German, Dutch and French families [91].|>T 2804delAA 2312del5 1411insT  c.156_157insAlu c.516+1G>A c.6275_6276delTT c.8904delC c.5351dupA c.6275_6276delTT  384insAlu IVS6+1G>A 6503_6504delTT<<< 9132delC>>> 5579insA 6503delTT  c.1813dupA c.4478del4 c.9098dupA  2041insA 4706del4 9326insA  c.7913_7917del5 c.8537_8538del2  8141del5 8765delAG  c.9098dupA c.5		
23199084	confirmed					23199084		sub		NM_007294.3:c.5212G>A	NM_007294.3:c.5443G>A		rs80356937		 c.5212G>A				BRCA1	entrez	672			dna	c.123T>A|c.123T>A	26583,40980	26593,40990	reast cancer patients, one third carried BRCA2 mutations, including c.9098dupA [104]. Greece In the Greek population four BRCA1 mutations (c.5526dupC,<<< c.5212G>A>>> (BIC: 5331G>A/G1738R), c.5251C>T (BIC:  EPMA Journal (2010) 1:397–412  5370C>T/R1751X), c.5467G>A (BIC: 5586G>A), account for 54% of all mutations de|ion  Greek  Cypriot Danish  Swedish  Norwegian  Finnish  Iceland British  Irish Polish  Latvian  BRCA1 mutation  BRCA2 mutation  HGVS  BIC  c.5266dupC<<< c.5212G>A>>> c.5251C>T c.5467G>A  5382insC 5331G>A 5370C>T 5586G>A  c.2475delC c.3319G>T c.5266dupC c.3710delT  2594delC 3438G>T 5382insC 3829delT  HGVS  BIC  c.8		
23199084	confirmed					23199084		sub		NM_007294.3:c.5193G>A	NM_007294.3:c.5424G>A		na		5193G>A				BRCA1	entrez	672			dna	859G>A	34125	34133	5% of consecutive unselected breast cancer cases, 7.9% of ovarian cancer cases and 40% of male breast cancer cases [6, 146]. The BRCA1 c.5074G>A (BIC:<<< 5193G>A>>>) is another founder mutation recently identified in Icelandic population, however it is extremely rare and contributes only to 1% of breast/ovarian c		
23199084	notConfirmed							sub		c.1G>A					1G>A| 1G>A				BRCA1	entrez	672			dna	859G>A|859G>A|859G>A|859G>A|859G>A|859G>A|859G>A	19488,19504,33393,39323,39964,39988,61436	19493,19509,33398,39328,39969,39993,61441	l mutation in the BIC database ranking with a presumable multiple different origins [85, 86].  EPMA Journal (2010) 1:397–412  Splicing mutation c.5153<<<-1G>A>>> (BIC: 5272-1G>A) of BRCA1 and frameshift mutation c.5146_5149del4 (BIC: 5374delTATG) of BRCA2 are also prevalent founder mutations in the Central Spa|e BIC database ranking with a presumable multiple different origins [85, 86].  EPMA Journal (2010) 1:397–412  Splicing mutation c.5153-1G>A (BIC: 5272<<<-1G>A>>>) of BRCA1 and frameshift mutation c.5146_5149del4 (BIC: 5374delTATG) of BRCA2 are also prevalent founder mutations in the Central Spain region, accounting for 18.4% and 13.6% of BRCA1 and BRCA2 positive families, respectively [80, 85, 87].|Some mutations are unique to the Finns, such as c.4096+3A>G (BIC: IVS11+3A>G) in BRCA1 and c.9117+1G>A (BIC: 9345+<<< 1G>A>>>), c.7480C>T, c.8327T>G in BRCA2 genes. The mutation spectrum in Eastern part slightly differs from those observed in the Northern and Southern parts |66dupC c.181T>G c.5266dupC c.1687C>T  185delAG 5382insC 300T>G 5382insC 1806C>T  c.5946delT  6174delT  c.8363G>A c.8754+1G>A c.3860delA  8591G>A IVS21<<<-1G>A>>> 4088delA  c.3016_3019del4 c.2676_2679del4 c.1687C>T c.181T>G c.5266dupC c.181T>A c.3228_3229delAG c.3285delA c.1380dupA c.5062_5064del3 c.4964_4982de|8_2811del4 (Castilla-Leon) c.6629_6630delAA c.9026_9030del5 c.9310_9311delAA  3036_3039del4 c.6857delAA 9254-9258del5 9538delAA  c.470_471delCT c.5153<<<-1G>A>>>  589_590delCT 5272-1G>A  c.5146_5149del4  374delTATG  c.212+3A>G c.2359dupG c.3661G>T c.2685_2686delAA c.2193del5 c.1292dupT exon 13 deletion (3,8-kb|n) c.6629_6630delAA c.9026_9030del5 c.9310_9311delAA  3036_3039del4 c.6857delAA 9254-9258del5 9538delAA  c.470_471delCT c.5153-1G>A  589_590delCT 5272<<<-1G>A>>>  c.5146_5149del4  374delTATG  c.212+3A>G c.2359dupG c.3661G>T c.2685_2686delAA c.2193del5 c.1292dupT exon 13 deletion (3,8-kb) exon 22 deletion (510-|BRCA1 5272<<<-1G>A>>> and BRCA2 5374delTATG are founder mutations of high relevance for genetic counselling in breast/ovarian cancer families of Spanish origin.		
23199084	confirmed					23199084		del		NM_007297.3:c.185delA	NM_007297.3:c.465delA		na		 185delA|185delA				BRCA1	entrez	672			dna	6174delT|6174delT|6174delT|6174delT|6174delT|6174delT|6174delT	9200,39210,39711,40756,52064,53032,53516	9208,39218,39719,40764,52072,53040,53524	The most well characterized three founder mutations are two in BRCA1 gene c.68_69delAG (BIC:<<< 185delA>>>G) and c.5266dupC (BIC: 5382insC) and one in BRCA2 c.5946delT (BIC:  EPMA Journal (2010) 1:397–412  6174delT) [31–33].|Belgian  Dutch  German  Czech  Hungarian  BRCA1 mutation  BRCA2 mutation  HGVS  BIC  HGVS  BIC  c.68_69delAG c.5266dupC c.181T>G c.5266dupC c.1687C>T <<< 185delA>>>G 5382insC 300T>G 5382insC 1806C>T  c.5946delT  6174delT  c.8363G>A c.8754+1G>A c.3860delA  8591G>A IVS21-1G>A 4088delA  c.3016_3019del4 c.2676_2679de|5117G>A c.5123C>A  3135del4 2795del4 1806C>T 300T>G 5382insC 300T>A 3347delAG 3404delA 1499insA 5181delGTT 5083del19 5181_5183delGTT 3600del11 5247G>T<<< 185delA>>>G 330A>G 5236G>A 5242C>A  c.7806-2A>G  IVS16-2A>G  c.8537_8538delAG(Sardinia)  8765delAG  c.2808_2811del4 (Castilla-Leon) c.6629_6630delAA c.9026_9030|5 exons 1–17 deletion exons 5–14 deletion c.5266dupC c.181T>G c.68_69delAG  5382insC 300T>G 4184del4 2457C>T 300T>G 5382insC 3819del5  5382insC 300T>G<<< 185delA>>>G  406  EPMA Journal (2010) 1:397–412  Table 1 (continued) Population  Greek  Cypriot Danish  Swedish  Norwegian  Finnish  Iceland British  Irish Poli|Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation<<< 185delA>>>G in Ashkenazi Jewish families.|Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and<<< 185delA>>>G and BRCA2 6174delT mutations: a combined analysis of 22 population based studies.|Two distinct origins of a common BRCA1 mutation in breast-ovarian cancer families: a genetic study of 15<<< 185delA>>>G-mutation kindreds.		
23199084	confirmed					23199084		sub	NP_009225.1:p.Gly1710Stop	NM_007294.3:c.5128G>T	NM_007294.3:c.5359G>T		rs397509229		/Gly1710X				BRCA1	entrez	672			prot	Met1775Arg	15830	15839	The c.3481_3491del11 (BIC: 3600del11) in exon 11 accounts for 37% and the nonsense mutation c.5128G>T (BIC: 5247G>T<<</Gly1710X>>>) in exon 18 for 15% of all BRCA1/2 mutations in that region (overall 52%) [4, 75]. The haplotype analysis of the families carrying the mutation c.348		
23199084	confirmed					23199084		sub	NP_000050.2:p.Trp2788Stop	NM_000059.3:c.8364G>A|NM_000059.3:c.8363G>A	NM_000059.3:c.8590G>A|NM_000059.3:c.8589G>A		rs397507981|rs80359080		/W2788X				BRCA2	entrez	675			prot	M1775R	12842	12849	The most prevalent BRCA2 mutations are c.8363G>A (BIC: 8591G>A<<</W2788X>>>), c.8754+1G>A (BIC: IVS211G>A) and c.3860delA (BIC: 4088delA), representing 9%, 7% and 6% of the BRCA2 mutation families respectively (Rappaport, per		
23199084	confirmed					23199084		sub	NP_009225.1:p.Arg1443Stop|NP_009231.2:p.Arg1443Stop	NM_007294.3:c.4327C>T|NM_007300.3:c.4327C>T	NM_007294.3:c.4558C>T|NM_007300.3:c.4558C>T		rs41293455|rs41293455		/Arg1443X				BRCA1	entrez	672			prot	Met1775Arg	16787	16796	In this region 4 BRCA1 gene mutations (c.4327C>T (BIC: 4446C>T<<</Arg1443X>>>), c.3756_3759del4 (BIC:  EPMA Journal (2010) 1:397–412  3875delGTCT), c.962G>A (BIC: 1081G>A), c.2834_2836delinsC (BIC: 2953delGTA/insC) and 3 BRCA2 		
23199084	confirmed					23199084		sub	NP_009225.1:p.Arg1751Stop	NM_007294.3:c.5251C>T	NM_007294.3:c.5482C>T		rs80357123		/R1751X				BRCA1	entrez	672			prot	M1775R	26672	26679	ece In the Greek population four BRCA1 mutations (c.5526dupC, c.5212G>A (BIC: 5331G>A/G1738R), c.5251C>T (BIC:  EPMA Journal (2010) 1:397–412  5370C>T<<</R1751X>>>), c.5467G>A (BIC: 5586G>A), account for 54% of all mutations detected in BRCA1/2 genes and for 73% of the BRCA1 mutations positive families, whereas 		
23199084	confirmed					23199084		sub	NP_009230.2:p.Cys39Gly|NP_009225.1:p.Cys39Gly|NP_009229.2:p.Cys39Gly|NP_009231.2:p.Cys39Gly	NM_007299.3:c.115T>G|NM_007294.3:c.115T>G|NM_007298.3:c.115T>G|NM_007300.3:c.115T>G	NM_007299.3:c.308T>G|NM_007294.3:c.346T>G|NM_007298.3:c.133T>G|NM_007300.3:c.346T>G		rs80357164|rs80357164|rs80357164|rs80357164		/Cys39Gly				BRCA1	entrez	672			prot	Met1775Arg	29142	29151	0% (6/15) of all BRCA1/2 families with LGRs [112].  EPMA Journal (2010) 1:397–412  Recently a pathogenic founder BRCA1 mutation c.234T>G (BIC: 2466T>G<<</Cys39Gly>>>) was desribed in Greenland (Inuit population), an autonomous country within the Kingdom of Denmark, with a high carrier frequency (1.6%) in this population [113, 114].		
23199084	confirmed					23199084		sub	NP_009230.2:p.Arg71Gly|NP_009225.1:p.Arg71Gly|NP_009229.2:p.Arg71Gly|NP_009231.2:p.Arg71Gly	NM_007299.3:c.211A>G|NM_007294.3:c.211A>G|NM_007298.3:c.211A>G|NM_007300.3:c.211A>G	NM_007299.3:c.404A>G|NM_007294.3:c.442A>G|NM_007298.3:c.229A>G|NM_007300.3:c.442A>G		rs80357382|rs80357382|rs80357382|rs80357382		R71G				BRCA1	entrez	672			prot	M1775R	60789	60794	The<<< R71G>>> BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcript.		
23199084	confirmed					23199084		sub	NP_009230.2:p.Glu143Stop|NP_009225.1:p.Glu143Stop|NP_009229.2:p.Glu143Stop|NP_009231.2:p.Glu143Stop	NM_007299.3:c.427G>T|NM_007294.3:c.427G>T|NM_007298.3:c.427G>T|NM_007300.3:c.427G>T	NM_007299.3:c.620G>T|NM_007294.3:c.658G>T|NM_007298.3:c.445G>T|NM_007300.3:c.658G>T		rs80356991|rs80356991|rs80356991|rs80356991		/E143X				BRCA1	entrez	672			prot	M1775R	35887	35893	t is distributed mainly in English-speaking countries or in countries with historical links with Britain. Ireland A single BRCA1 c.427G>T (BIC: 546G>T<<</E143X>>>) mutation accounts for about 22% of all hereditary breast cancer patients from relatively homogenous Irish population and presumably is due to the fo		
23199084	confirmed					23199084		sub	NP_009225.1:p.Gly1738Arg	NM_007294.3:c.5212G>C|NM_007294.3:c.5212G>A	NM_007294.3:c.5443G>C|NM_007294.3:c.5443G>A		rs80356937|rs80356937		/G1738R|G1738R				BRCA1	entrez	672			prot	M1775R|M1775R|M1775R	26607,27144,65477	26614,27151,65484	ne third carried BRCA2 mutations, including c.9098dupA [104]. Greece In the Greek population four BRCA1 mutations (c.5526dupC, c.5212G>A (BIC: 5331G>A<<</G1738R>>>), c.5251C>T (BIC:  EPMA Journal (2010) 1:397–412  5370C>T/R1751X), c.5467G>A (BIC: 5586G>A), account for 54% of all mutations detected in BRCA1/2 gen|e BRCA1/2 mutations identified in Greek familial breast/ovarian cancer patients [45, 105]. Previously described as unclassified BRCA1 missense variant<<< G1738R>>> was proved to be pathogenic founder mutation in Greece and accounts for about 12% of all carriers with deleterious mutations in BRCA1/2 genes [106]. |2008;107:431–41. Anagnostopoulos T et al.<<< G1738R>>> is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history.		
23199084	confirmed					23199084		del	NP_009225.1:p.Val1688None	NM_007294.3:c.5064_5066delgtt	NM_007294.3:c.5293_5295delgtt		rs80358344		p.Val1688del				BRCA1	entrez	672			prot	p.Met1775del	59268	59281	BRCA1<<< p.Val1688del>>> is a deleterious mutation that recurs in breast and ovarian cancer families from Northeast Italy.		
23199084	confirmed					23199084		sub	NP_009230.2:p.Cys61Gly|NP_009225.1:p.Cys61Gly|NP_009229.2:p.Cys61Gly|NP_009231.2:p.Cys61Gly	NM_007299.3:c.181T>G|NM_007294.3:c.181T>G|NM_007298.3:c.181T>G|NM_007300.3:c.181T>G	NM_007299.3:c.374T>G|NM_007294.3:c.412T>G|NM_007298.3:c.199T>G|NM_007300.3:c.412T>G		rs28897672|rs28897672|rs28897672|rs28897672		/C61G				BRCA1	entrez	672			prot	M1775R	11888	11893	munication). There were initial reports for several apparently founder BRCA1 mutations in Austria [58, 59], although they  399  (c.181T>G (BIC: 300T>G<<</C61G>>>), c.5266dupC, c.1687C>T (BIC: 1806C>T)) represent common mutations prevalent in other European countries.		
23199084	confirmed					23199084		sub	NP_009225.1:p.Arg1753Thr	NM_007294.3:c.5258G>C	NM_007294.3:c.5489G>C		rs397509246		/R1753T				BRCA1	entrez	672			prot	M1775R	42989	42996	; BRCA2 numbered by GeneBank U43746 reference sequence  other mutations, BRCA1 c.181T>G and recently proved to be pathogenious c.5258G>C (BIC: 5377G>C<<</R1753T>>>) were also found in more than one family; together with two founder mutations they comprise around 90% of BRCA1 gene mutations and around 85% of all BRCA1/2 mutations identified (Janavičius, unpublished data).		
23199084	notConfirmed							sub		IVS21-1G>A					IVS21-1G>A				BRCA2	entrez	675			intron	IVS5+3A>G	39318	39328	 c.5266dupC c.181T>G c.5266dupC c.1687C>T  185delAG 5382insC 300T>G 5382insC 1806C>T  c.5946delT  6174delT  c.8363G>A c.8754+1G>A c.3860delA  8591G>A <<<IVS21-1G>A>>> 4088delA  c.3016_3019del4 c.2676_2679del4 c.1687C>T c.181T>G c.5266dupC c.181T>A c.3228_3229delAG c.3285delA c.1380dupA c.5062_5064del3 c.4964_4982de		
23199084	notConfirmed							sub		IVS5+3A>G					IVS5+3A>G				BRCA1	entrez	672			intron	IVS5+3A>G|IVS5+3A>G|IVS5+3A>G	20630,40231,63255	20639,40240,63264	[91] in a 49 BRCA1/2 positive families found six major recurrent founder mutations (three BRCA1 c.212+3A> (BIC: <<<IVS5+3A>G>>>), c.2359dupG (BIC: 2478insG), c.3661G>T (BIC: 3780G>T) and three BRCA2 c.516+1G>A (BIC: IVS6+1G>A), c.6275_6276delTT (BIC: 6503_6504delTT), c.8904del|l5 c.1292dupT exon 13 deletion (3,8-kb) exon 22 deletion (510-bp) exon 17 deletion c.5266dupC c.181T>G c.4065_4068del4 c.2338C>T c.181T>G c.5266dupC  <<<IVS5+3A>G>>> 2478insG 3780G>T 2804delAA 2312del5 1411insT  c.156_157insAlu c.516+1G>A c.6275_6276delTT c.8904delC c.5351dupA c.6275_6276delTT  384insAlu IVS6+1G>A|  101.  102.  103.  104.  105.  106.  107.  108.  109.  110.  111.  Belgian patient population and identification of a Belgian founder mutation BRCA1 <<<IVS5+3A>G>>>.		
23199084	notConfirmed							sub		IVS6+1G>A					IVS6+1G>A				BRCA2	entrez	675			intron	IVS5+3A>G|IVS5+3A>G	20728,40381	20737,40390	rent founder mutations (three BRCA1 c.212+3A> (BIC: IVS5+3A>G), c.2359dupG (BIC: 2478insG), c.3661G>T (BIC: 3780G>T) and three BRCA2 c.516+1G>A (BIC: <<<IVS6+1G>A>>>), c.6275_6276delTT (BIC: 6503_6504delTT), c.8904delC (BIC: 9132delC) alterations), which accounted for nearly 60% of all mutations identified. BRCA1 |IVS5+3A>G 2478insG 3780G>T 2804delAA 2312del5 1411insT  c.156_157insAlu c.516+1G>A c.6275_6276delTT c.8904delC c.5351dupA c.6275_6276delTT  384insAlu <<<IVS6+1G>A>>> 6503_6504delTT 9132delC 5579insA 6503delTT  c.1813dupA c.4478del4 c.9098dupA  2041insA 4706del4 9326insA  c.7913_7917del5 c.8537_8538del2  8141del5 8		
23199084	notConfirmed							sub		IVS11+3A>G					IVS11+3A>G				BRCA1	entrez	672			intron	IVS5+3A>G|IVS5+3A>G	33345,41902	33355,41912	Some mutations are unique to the Finns, such as c.4096+3A>G (BIC: <<<IVS11+3A>G>>>) in BRCA1 and c.9117+1G>A (BIC: 9345+ 1G>A), c.7480C>T, c.8327T>G in BRCA2 genes. The mutation spectrum in Eastern part slightly differs from those o|tion (ins6kbEx13) c.4097-2A>G c.3485delA c.3626delT c.4327C>T c.2684del2 c.5251C>T c.4096+3A>G  4216-2A>G 3604delA 3745delT 4446C>T 2803delAA 5370C>T <<<IVS11+3A>G>>>  c.771_775del5 c.7480C>T c.8327T>G c.9118-2A>G c.9117+1G>A  999del5 7708C>T 8555T>G 9346-2A>G 9345+1G>A  c.2681_2682delAA (Scotland)  2800delAA  c.77		
23199084	notConfirmed							sub		IVS17-2A>C					IVS17-2A>C				BRCA1	entrez	672			intron	IVS5+3A>G|IVS5+3A>G	31961,41661	31971,41671	BRCA1 c.1A>C (BIC: 120A>C) and c.5075-2A>C (BIC: <<<IVS17-2A>C>>>) mutations are also locally frequent.|5 2594delC 1201del11 1806C>T 3745delT 1135insA  c.4258delG  4486delG  1675delA 3347delAG 816delGT 1135insA 3297G>T 4864delA 2470del7 3203del11 120A>C <<<IVS17-2A>C>>>  c.2808del4 c.3847delGT  3036del4 4075delGT  exons 1-13 deletion exon 13 duplication (ins6kbEx13) c.4097-2A>G c.3485delA c.3626delT c.4327C>T c.2684d		
23199084	notConfirmed							sub		IVS16-2A>G					IVS16-2A>G				BRCA2	entrez	675			intron	IVS5+3A>G|IVS5+3A>G	13225,39758	13235,39768	tations were identified: four in the BRCA1 gene (c.1687C>T, c.181T>G, c.5266dupC, c.181T> (BIC: 300T>A)) and one in the BRCA2 gene (c.7806-2A>G (BIC: <<<IVS16-2A>G>>>) [43, 61, 62].|0T>G 5382insC 300T>A 3347delAG 3404delA 1499insA 5181delGTT 5083del19 5181_5183delGTT 3600del11 5247G>T 185delAG 330A>G 5236G>A 5242C>A  c.7806-2A>G  <<<IVS16-2A>G>>>  c.8537_8538delAG(Sardinia)  8765delAG  c.2808_2811del4 (Castilla-Leon) c.6629_6630delAA c.9026_9030del5 c.9310_9311delAA  3036_3039del4 c.6857delAA 		
23199084 All mutations found
30186769	confirmed					30186769		sub		NM_007294.3:c.2728C>T|NM_007300.3:c.2728C>T|NM_007297.3:c.2728C>T	NM_007294.3:c.2959C>T|NM_007300.3:c.2959C>T|NM_007297.3:c.3008C>T		rs397509004|rs397509004|rs80356973		c.2728C>T| c.2728C>T				BRCA1	entrez	672			dna	c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A	4850,15045,16850,18577,18981	4860,15055,16860,18587,18991	50 women) harbored one of the 3 mutations (19.7%); Of 76 fully sequenced cases (73 women), 6 (5 women) (7.9%) carried a pathogenic mutation: in BRCA1,<<< c.2728C>T>>> - p.(Gln910*); c.5407-?_(*1_?)del and c.5445G>A - p.(Trp1815*); in BRCA2, c.5351dup - p.(Asn1784Lysfs*3); c.7308del - p.(Asn2436Lysfs*33) and c.9026_9030del - p.(Tyr3009Serfs*7).|(A) BRCA1<<< c.2728C>T>>> - p.(Gln910*); (B) BRCA1 c.5407-?_(*1_?)del; (C) BRCA1: c.5445G>A-p.(Trp1815*); (D) BRCA2: c.5351dup - p.(Asn1784Lysfs*3); (E) BRCA2 c.7308del - p.(A|2)  11  4.2  4, Br (30-56); 1 Br & Fallopian tube (64); 1 Br/Ov (46)  5   Unique mutations (NGS)   Total  73        Gene: Mutation  5  6.8      BRCA1:<<< c.2728C>T>>> - p.(Gln910*)  1    Ov (55)  0   BRCA1: c.5407-?_(*1_?)del  1    Br (37)  0   BRCA1: c.5445G>A - p.(Trp1815*)  1    Br (47)    BRCA2: c.7308del - p.(|The description of the mutations are in Table ​Table4,4, as follows: BRCA1:<<< c.2728C>T>>> - p.(Gln910*), rs397509004, c.5407-?_(*1_?)del, c.5445G>A - p.(Trp1815*), rs397509284 and BRCA2: c.5351dup - p.(Asn1784Lysfs*3), rs80359508, c.7308de|es with a non-AJ founder mutation in BRCA1/2 from pedigrees drawn in Figure ​Figure22.  Mutation (HGVS nomenclature)  Description   --- ---   BRCA1:  <<< c.2728C>T>>> - p.(Gln910*) rs397509004  This is a rare mutation reported in ClinVar and we deposited in LOVD (Genomic Variant #0000206572).		
30186769	confirmed					30186769		sub		NM_000059.3:c.2728C>T	NM_000059.3:c.2954C>T		na		c.2728C>T| c.2728C>T				BRCA2	entrez	675			dna	c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A	4850,15045,16850,18577,18981	4860,15055,16860,18587,18991	50 women) harbored one of the 3 mutations (19.7%); Of 76 fully sequenced cases (73 women), 6 (5 women) (7.9%) carried a pathogenic mutation: in BRCA1,<<< c.2728C>T>>> - p.(Gln910*); c.5407-?_(*1_?)del and c.5445G>A - p.(Trp1815*); in BRCA2, c.5351dup - p.(Asn1784Lysfs*3); c.7308del - p.(Asn2436Lysfs*33) and c.9026_9030del - p.(Tyr3009Serfs*7).|(A) BRCA1<<< c.2728C>T>>> - p.(Gln910*); (B) BRCA1 c.5407-?_(*1_?)del; (C) BRCA1: c.5445G>A-p.(Trp1815*); (D) BRCA2: c.5351dup - p.(Asn1784Lysfs*3); (E) BRCA2 c.7308del - p.(A|2)  11  4.2  4, Br (30-56); 1 Br & Fallopian tube (64); 1 Br/Ov (46)  5   Unique mutations (NGS)   Total  73        Gene: Mutation  5  6.8      BRCA1:<<< c.2728C>T>>> - p.(Gln910*)  1    Ov (55)  0   BRCA1: c.5407-?_(*1_?)del  1    Br (37)  0   BRCA1: c.5445G>A - p.(Trp1815*)  1    Br (47)    BRCA2: c.7308del - p.(|The description of the mutations are in Table ​Table4,4, as follows: BRCA1:<<< c.2728C>T>>> - p.(Gln910*), rs397509004, c.5407-?_(*1_?)del, c.5445G>A - p.(Trp1815*), rs397509284 and BRCA2: c.5351dup - p.(Asn1784Lysfs*3), rs80359508, c.7308de|es with a non-AJ founder mutation in BRCA1/2 from pedigrees drawn in Figure ​Figure22.  Mutation (HGVS nomenclature)  Description   --- ---   BRCA1:  <<< c.2728C>T>>> - p.(Gln910*) rs397509004  This is a rare mutation reported in ClinVar and we deposited in LOVD (Genomic Variant #0000206572).		
30186769	notConfirmed							del		c.9254A>None					9254delA				BRCA2	entrez	675			dna	6174delT	31391	31400	Haplotype analysis of the BRCA2<<< 9254delA>>>TCAT recurrent mutation in breast/ovarian cancer families from Spain.		
30186769	confirmed					30186769		sub		NM_007294.3:c.5445G>A|NM_007300.3:c.5445G>A	NM_007294.3:c.5676G>A|NM_007300.3:c.5676G>A		rs397509284|rs397509275		c.5445G>A| c.5445G>A				BRCA1	entrez	672			dna	c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A	4898,15111,16945,18635,19549	4908,15121,16955,18645,19559	); Of 76 fully sequenced cases (73 women), 6 (5 women) (7.9%) carried a pathogenic mutation: in BRCA1, c.2728C>T - p.(Gln910*); c.5407-?_(*1_?)del and<<< c.5445G>A>>> - p.(Trp1815*); in BRCA2, c.5351dup - p.(Asn1784Lysfs*3); c.7308del - p.(Asn2436Lysfs*33) and c.9026_9030del - p.(Tyr3009Serfs*7).|(A) BRCA1 c.2728C>T - p.(Gln910*); (B) BRCA1 c.5407-?_(*1_?)del; (C) BRCA1:<<< c.5445G>A>>>-p.(Trp1815*); (D) BRCA2: c.5351dup - p.(Asn1784Lysfs*3); (E) BRCA2 c.7308del - p.(Asn2436Lysfs*33); (F) BRCA2 c.9026_9030del - p.(Tyr3009Serfs*7).  O|)   Total  73        Gene: Mutation  5  6.8      BRCA1: c.2728C>T - p.(Gln910*)  1    Ov (55)  0   BRCA1: c.5407-?_(*1_?)del  1    Br (37)  0   BRCA1:<<< c.5445G>A>>> - p.(Trp1815*)  1    Br (47)    BRCA2: c.7308del - p.(Asn2436Lysfs*33)  1    Br (38,45,47,52) & Ov (60, 64)  0   BRCA2: c.9026_9030del - p.(Tyr3009Se|The description of the mutations are in Table ​Table4,4, as follows: BRCA1: c.2728C>T - p.(Gln910*), rs397509004, c.5407-?_(*1_?)del,<<< c.5445G>A>>> - p.(Trp1815*), rs397509284 and BRCA2: c.5351dup - p.(Asn1784Lysfs*3), rs80359508, c.7308del - p.(Asn2436Lysfs*33), c.9026_9030del - p.(Tyr3009Serfs*|  BRCA1:  <<< c.5445G>A>>> - p.(Trp1815*) rs397509284  This mutation is deposited by different laboratories at least 5 times at the LOVD.		
30186769	confirmed					30186769		sub		NM_000059.3:c.7232A>C	NM_000059.3:c.7458A>C		rs80358950		c.7232A>C				BRCA2	entrez	675			dna	c.123T>A	21214	21224	     Open in a separate window  The following variant of uncertain significance (VUS) was detected in the samples analyzed by NGS: BRCA2:<<< c.7232A>C>>> - p.(Lys2411Thr), rs80358950 (we deposited at LOVD Genomic Variant #0000206714).  ## Discussion  The likelihood that AJ high risk individuals who do 		
30186769	confirmed					30186769		del		NM_000059.3:c.6174delT	NM_000059.3:c.6400delT		na		[6174delT				BRCA2	entrez	675			dna	6174delT	7296	7305	0 individuals is a carrier one of 3 recurrent mutations in BRCA1 [185delAG: c.68_69del (rs386833395) and 5382insC: c.5266dup (rs80357906)], and BRCA2 <<<[6174delT>>>: c.5946del (rs80359550)].		
30186769	confirmed					30186769		del		NM_007297.3:c.185delA	NM_007297.3:c.465delA		na		[185delA				BRCA1	entrez	672			dna	6174delT	7211	7219	In this ethnic group 1/40 individuals is a carrier one of 3 recurrent mutations in BRCA1 <<<[185delA>>>G: c.68_69del (rs386833395) and 5382insC: c.5266dup (rs80357906)], and BRCA2 [6174delT: c.5946del (rs80359550)].		
30186769	confirmed					30186769		sub		NM_007299.3:c.1906G>C|NM_007298.3:c.1906G>C	NM_007299.3:c.2099G>C|NM_007298.3:c.1924G>C		na|na		c.1906G>C				BRCA1	entrez	672			dna	c.123T>A|c.123T>A	17311,24524	17321,24534	n, number of probands; age@diag, age at diagnosis; Br, Breast Cancer; Ov, Ovarian Cancer.  (*) a patient was carrier of the mutation in the gene MSH2:<<< c.1906G>C>>> - p.(Ala636Pro), also of Ashkenazi origin (17).  ### Table 3  Analysis of mutations detected in male individuals.  Male patients mutation analysis  n|A case that exemplifies this point is the patient who co-harbored the MSH2<<< c.1906G>C>>> - p.(Ala636Pro) (17) and BRCA1 c.68_69del - p.(Glu23Valfs*17).		
30186769	confirmed					30186769		sub	NP_000050.2:p.Lys2411Thr	NM_000059.3:c.7232A>C	NM_000059.3:c.7458A>C		rs80358950		p.(Lys2411Thr|Lys2411Thr				BRCA2	entrez	675			prot	Met1775Arg|p.Met1775Arg	21229,21226	21240,21240	   Open in a separate window  The following variant of uncertain significance (VUS) was detected in the samples analyzed by NGS: BRCA2: c.7232A>C - p.<<<(Lys2411Thr>>>), rs80358950 (we deposited at LOVD Genomic Variant #0000206714).  ## Discussion  The likelihood that AJ high risk individuals who do not carry any of|      Open in a separate window  The following variant of uncertain significance (VUS) was detected in the samples analyzed by NGS: BRCA2: c.7232A>C -<<< p.(Lys2411Thr>>>), rs80358950 (we deposited at LOVD Genomic Variant #0000206714).  ## Discussion  The likelihood that AJ high risk individuals who do not carry any of		
30186769	confirmed					30186769		sub	NP_000050.2:p.Ser1982Arg	NM_000059.3:c.5946T>A|NM_000059.3:c.5944A>C|NM_000059.3:c.5946T>G	NM_000059.3:c.6172T>A|NM_000059.3:c.6170A>C|NM_000059.3:c.6172T>G		rs80359550|na|rs80359550		Ser1982Arg|p.(Ser1982Argfs*22				BRCA2	entrez	675			prot	Met1775Arg|Met1775Arg|p.Met1775Arg|p.Met1775Arg	16685,17719,16682,17716	16696,17730,16701,17735	, Ov (59, 77)  3 (*)   BRCA1: c.5266dup -p.(Gln1756Profs*74)  15  5.8  8, Br (28-46); 4, Ov (41-72); 2, Br/Ov (35,41; 37,45)  1   BRCA2: c.5946del -p.<<<(Ser1982Arg>>>fs*22)  11  4.2  4, Br (30-56); 1 Br & Fallopian tube (64); 1 Br/Ov (46)  5   Unique mutations (NGS)   Total  73        Gene: Mutation  5  6.8      BR|found  5  25.0    2   BRCA1: c.68_69del -p.(Glu23Valfs*17)  2    Br (75)  1   BRCA1: c.5266dup -p.(Gln1756Profs*74)  0    0  0   BRCA2: c.5946del - p.<<<(Ser1982Arg>>>fs*22)  3    Br (60); Br (59)  1   Non-Ashkenazi mutation (NGS):    0.0    0   Total  3        A mutation found  1  33.3      BRCA2: c.5351dup - p.(As|; 2, Ov (59, 77)  3 (*)   BRCA1: c.5266dup -p.(Gln1756Profs*74)  15  5.8  8, Br (28-46); 4, Ov (41-72); 2, Br/Ov (35,41; 37,45)  1   BRCA2: c.5946del <<<-p.(Ser1982Argfs*22>>>)  11  4.2  4, Br (30-56); 1 Br & Fallopian tube (64); 1 Br/Ov (46)  5   Unique mutations (NGS)   Total  73        Gene: Mutation  5  6.8      BRCA1: |on found  5  25.0    2   BRCA1: c.68_69del -p.(Glu23Valfs*17)  2    Br (75)  1   BRCA1: c.5266dup -p.(Gln1756Profs*74)  0    0  0   BRCA2: c.5946del -<<< p.(Ser1982Argfs*22>>>)  3    Br (60); Br (59)  1   Non-Ashkenazi mutation (NGS):    0.0    0   Total  3        A mutation found  1  33.3      BRCA2: c.5351dup - p.(Asn1784		
30186769	confirmed					30186769		sub	NP_000050.2:p.Asn1784Lys	NM_000059.3:c.5352C>G|NM_000059.3:c.5352C>A	NM_000059.3:c.5578C>G|NM_000059.3:c.5578C>A		rs398122531|rs398122531		p.(Asn1784Lysfs*3|Asn1784Lys				BRCA2	entrez	675			prot	Met1775Arg|Met1775Arg|Met1775Arg|Met1775Arg|Met1775Arg|Met1775Arg|p.Met1775Arg|p.Met1775Arg|p.Met1775Arg|p.Met1775Arg|p.Met1775Arg|p.Met1775Arg	4949,14370,15161,17877,18699,19885,4946,14367,15158,17874,18696,19882	4960,14381,15172,17888,18710,19896,4964,14385,15176,17892,18714,19900	en) (7.9%) carried a pathogenic mutation: in BRCA1, c.2728C>T - p.(Gln910*); c.5407-?_(*1_?)del and c.5445G>A - p.(Trp1815*); in BRCA2, c.5351dup - p.<<<(Asn1784Lys>>>fs*3); c.7308del - p.(Asn2436Lysfs*33) and c.9026_9030del - p.(Tyr3009Serfs*7).|J ethnicity, with two exceptions (Figure ​(Figure2):2): proband [B: BRCA1 c.5407-?_(*1_?)del] was half Sephardi, and proband [D: BRCA2: c.5351dup - p.<<<(Asn1784Lys>>>fs*3)] was half non-Jewish, although this side was not the side associated with inheritance of the syndrome.  An external file that holds a picture, i|(A) BRCA1 c.2728C>T - p.(Gln910*); (B) BRCA1 c.5407-?_(*1_?)del; (C) BRCA1: c.5445G>A-p.(Trp1815*); (D) BRCA2: c.5351dup - p.<<<(Asn1784Lys>>>fs*3); (E) BRCA2 c.7308del - p.(Asn2436Lysfs*33); (F) BRCA2 c.9026_9030del - p.(Tyr3009Serfs*7).  Overall, 61/279 genotyped cases (21.8%) harbored a BRCA1 mutation (n = 44) or a BRCA2 mutation (n = 17).|Argfs*22)  3    Br (60); Br (59)  1   Non-Ashkenazi mutation (NGS):    0.0    0   Total  3        A mutation found  1  33.3      BRCA2: c.5351dup - p.<<<(Asn1784Lys>>>fs*3)  1    Br (66)  0      Open in a separate window  n, number of probands; age@diag, age at diagnosis; Br, Breast Cancer.  Figure ​Figure22 depicts the pedigrees for the six families with a non AJ founder mutation.|Table4,4, as follows: BRCA1: c.2728C>T - p.(Gln910*), rs397509004, c.5407-?_(*1_?)del, c.5445G>A - p.(Trp1815*), rs397509284 and BRCA2: c.5351dup - p.<<<(Asn1784Lys>>>fs*3), rs80359508, c.7308del - p.(Asn2436Lysfs*33), c.9026_9030del - p.(Tyr3009Serfs*7), rs80359741.  ### Table 4  Families with a non-AJ founder muta|  BRCA2:   c.5351dup - p.<<<(Asn1784Lys>>>fs*3) rs80359508  We have detected this mutation 10 times and it is reported in LOVD at least 49 times (including 7 from our laboratory) (18).|women) (7.9%) carried a pathogenic mutation: in BRCA1, c.2728C>T - p.(Gln910*); c.5407-?_(*1_?)del and c.5445G>A - p.(Trp1815*); in BRCA2, c.5351dup -<<< p.(Asn1784Lysfs*3>>>); c.7308del - p.(Asn2436Lysfs*33) and c.9026_9030del - p.(Tyr3009Serfs*7).|r AJ ethnicity, with two exceptions (Figure ​(Figure2):2): proband [B: BRCA1 c.5407-?_(*1_?)del] was half Sephardi, and proband [D: BRCA2: c.5351dup -<<< p.(Asn1784Lysfs*3>>>)] was half non-Jewish, although this side was not the side associated with inheritance of the syndrome.  An external file that holds a picture, illus|(A) BRCA1 c.2728C>T - p.(Gln910*); (B) BRCA1 c.5407-?_(*1_?)del; (C) BRCA1: c.5445G>A-p.(Trp1815*); (D) BRCA2: c.5351dup -<<< p.(Asn1784Lysfs*3>>>); (E) BRCA2 c.7308del - p.(Asn2436Lysfs*33); (F) BRCA2 c.9026_9030del - p.(Tyr3009Serfs*7).  Overall, 61/279 genotyped cases (21.8%) harbored a BRCA1 mutation (n = 44) or a BRCA2 mutation (n = 17).|982Argfs*22)  3    Br (60); Br (59)  1   Non-Ashkenazi mutation (NGS):    0.0    0   Total  3        A mutation found  1  33.3      BRCA2: c.5351dup -<<< p.(Asn1784Lysfs*3>>>)  1    Br (66)  0      Open in a separate window  n, number of probands; age@diag, age at diagnosis; Br, Breast Cancer.  Figure ​Figure22 depicts the pedigrees for the six families with a non AJ founder mutation.|e ​Table4,4, as follows: BRCA1: c.2728C>T - p.(Gln910*), rs397509004, c.5407-?_(*1_?)del, c.5445G>A - p.(Trp1815*), rs397509284 and BRCA2: c.5351dup -<<< p.(Asn1784Lysfs*3>>>), rs80359508, c.7308del - p.(Asn2436Lysfs*33), c.9026_9030del - p.(Tyr3009Serfs*7), rs80359741.  ### Table 4  Families with a non-AJ founder mutation|  BRCA2:   c.5351dup -<<< p.(Asn1784Lysfs*3>>>) rs80359508  We have detected this mutation 10 times and it is reported in LOVD at least 49 times (including 7 from our laboratory) (18).		
30186769	confirmed					30186769		sub	NP_009230.2:p.Glu23Val|NP_009225.1:p.Glu23Val|NP_009229.2:p.Glu23Val|NP_009231.2:p.Glu23Val	NM_007299.3:c.68A>T|NM_007294.3:c.68A>T|NM_007298.3:c.68A>T|NM_007300.3:c.68A>T	NM_007299.3:c.261A>T|NM_007294.3:c.299A>T|NM_007298.3:c.86A>T|NM_007300.3:c.299A>T		na|na|na|na		Glu23Val| p.(Glu23Valfs*17|p.(Glu23Valfs*17				BRCA1	entrez	672			prot	Met1775Arg|Met1775Arg|Met1775Arg|p.Met1775Arg|p.Met1775Arg|p.Met1775Arg	16474,17612,24581,16471,17609,24578	16483,17621,24590,16488,17626,24595	 or age@diag)  Healthy   --- --- --- --- ---   Recurring Ashkenazi mutations   Total  259        Gene: Mutation  50  19.3    9   BRCA1: c.68_69del -p.<<<(Glu23Val>>>fs*17)  24  9.3  18, Br (30-72); 1 Br/Ov (46, 47); 2, Ov (59, 77)  3 (*)   BRCA1: c.5266dup -p.(Gln1756Profs*74)  15  5.8  8, Br (28-46); 4, Ov (41-72|alysis  n  (%)  age@diag  Healthy   --- --- --- --- ---   Ashkenazi mutation   Total  20        A mutation found  5  25.0    2   BRCA1: c.68_69del -p.<<<(Glu23Val>>>fs*17)  2    Br (75)  1   BRCA1: c.5266dup -p.(Gln1756Profs*74)  0    0  0   BRCA2: c.5946del - p.(Ser1982Argfs*22)  3    Br (60); Br (59)  1   Non-As|A case that exemplifies this point is the patient who co-harbored the MSH2 c.1906G>C - p.(Ala636Pro) (17) and BRCA1 c.68_69del - p.<<<(Glu23Val>>>fs*17).|nge or age@diag)  Healthy   --- --- --- --- ---   Recurring Ashkenazi mutations   Total  259        Gene: Mutation  50  19.3    9   BRCA1: c.68_69del <<<-p.(Glu23Valfs*17>>>)  24  9.3  18, Br (30-72); 1 Br/Ov (46, 47); 2, Ov (59, 77)  3 (*)   BRCA1: c.5266dup -p.(Gln1756Profs*74)  15  5.8  8, Br (28-46); 4, Ov (41-72); 2,| analysis  n  (%)  age@diag  Healthy   --- --- --- --- ---   Ashkenazi mutation   Total  20        A mutation found  5  25.0    2   BRCA1: c.68_69del <<<-p.(Glu23Valfs*17>>>)  2    Br (75)  1   BRCA1: c.5266dup -p.(Gln1756Profs*74)  0    0  0   BRCA2: c.5946del - p.(Ser1982Argfs*22)  3    Br (60); Br (59)  1   Non-Ashkena|A case that exemplifies this point is the patient who co-harbored the MSH2 c.1906G>C - p.(Ala636Pro) (17) and BRCA1 c.68_69del -<<< p.(Glu23Valfs*17>>>).		
30186769	confirmed					30186769		sub	NP_000050.2:p.Asn2436Lys	NM_000059.3:c.7308C>G|NM_000059.3:c.7308C>A	NM_000059.3:c.7534C>G|NM_000059.3:c.7534C>A		na|na		p.(Asn2436Lysfs*33|Asn2436Lys| p.(Asn2436Lysfs*33				BRCA2	entrez	675			prot	Met1775Arg|Met1775Arg|Met1775Arg|Met1775Arg|Met1775Arg|Met1775Arg|p.Met1775Arg|p.Met1775Arg|p.Met1775Arg|p.Met1775Arg|p.Met1775Arg|p.Met1775Arg	4981,15203,17009,18152,18743,20480,4978,15200,17006,18149,18740,20477	4992,15214,17020,18163,18754,20491,4997,15219,17025,18168,18759,20496	mutation: in BRCA1, c.2728C>T - p.(Gln910*); c.5407-?_(*1_?)del and c.5445G>A - p.(Trp1815*); in BRCA2, c.5351dup - p.(Asn1784Lysfs*3); c.7308del - p.<<<(Asn2436Lys>>>fs*33) and c.9026_9030del - p.(Tyr3009Serfs*7).|>T - p.(Gln910*); (B) BRCA1 c.5407-?_(*1_?)del; (C) BRCA1: c.5445G>A-p.(Trp1815*); (D) BRCA2: c.5351dup - p.(Asn1784Lysfs*3); (E) BRCA2 c.7308del - p.<<<(Asn2436Lys>>>fs*33); (F) BRCA2 c.9026_9030del - p.(Tyr3009Serfs*7).  Overall, 61/279 genotyped cases (21.8%) harbored a BRCA1 mutation (n = 44) or a BRCA2 mutation (n = 17).|T - p.(Gln910*)  1    Ov (55)  0   BRCA1: c.5407-?_(*1_?)del  1    Br (37)  0   BRCA1: c.5445G>A - p.(Trp1815*)  1    Br (47)    BRCA2: c.7308del - p.<<<(Asn2436Lys>>>fs*33)  1    Br (38,45,47,52) & Ov (60, 64)  0   BRCA2: c.9026_9030del - p.(Tyr3009Serfs*7)  1    Br (35)  0      Open in a separate window  n, number|Of the 6 mutations found, BRCA2 c.7308del - p.<<<(Asn2436Lys>>>fs*33) has not been previously reported and is therefore novel while the other 5 have been reported in non-Jewish populations.  Regarding the families|Gln910*), rs397509004, c.5407-?_(*1_?)del, c.5445G>A - p.(Trp1815*), rs397509284 and BRCA2: c.5351dup - p.(Asn1784Lysfs*3), rs80359508, c.7308del - p.<<<(Asn2436Lys>>>fs*33), c.9026_9030del - p.(Tyr3009Serfs*7), rs80359741.  ### Table 4  Families with a non-AJ founder mutation in BRCA1/2 from pedigrees drawn in Figu|  BRCA2:   c.7308del - p.<<<(Asn2436Lys>>>fs*33)  Novel, not reported in the databases and we deposited at LOVD (Genomic Variant #0000206927).|ic mutation: in BRCA1, c.2728C>T - p.(Gln910*); c.5407-?_(*1_?)del and c.5445G>A - p.(Trp1815*); in BRCA2, c.5351dup - p.(Asn1784Lysfs*3); c.7308del -<<< p.(Asn2436Lysfs*33>>>) and c.9026_9030del - p.(Tyr3009Serfs*7).|28C>T - p.(Gln910*); (B) BRCA1 c.5407-?_(*1_?)del; (C) BRCA1: c.5445G>A-p.(Trp1815*); (D) BRCA2: c.5351dup - p.(Asn1784Lysfs*3); (E) BRCA2 c.7308del -<<< p.(Asn2436Lysfs*33>>>); (F) BRCA2 c.9026_9030del - p.(Tyr3009Serfs*7).  Overall, 61/279 genotyped cases (21.8%) harbored a BRCA1 mutation (n = 44) or a BRCA2 mutation (n = 17).|8C>T - p.(Gln910*)  1    Ov (55)  0   BRCA1: c.5407-?_(*1_?)del  1    Br (37)  0   BRCA1: c.5445G>A - p.(Trp1815*)  1    Br (47)    BRCA2: c.7308del -<<< p.(Asn2436Lysfs*33>>>)  1    Br (38,45,47,52) & Ov (60, 64)  0   BRCA2: c.9026_9030del - p.(Tyr3009Serfs*7)  1    Br (35)  0      Open in a separate window  n, number of p|Of the 6 mutations found, BRCA2 c.7308del -<<< p.(Asn2436Lysfs*33>>>) has not been previously reported and is therefore novel while the other 5 have been reported in non-Jewish populations.  Regarding the families with|p.(Gln910*), rs397509004, c.5407-?_(*1_?)del, c.5445G>A - p.(Trp1815*), rs397509284 and BRCA2: c.5351dup - p.(Asn1784Lysfs*3), rs80359508, c.7308del -<<< p.(Asn2436Lysfs*33>>>), c.9026_9030del - p.(Tyr3009Serfs*7), rs80359741.  ### Table 4  Families with a non-AJ founder mutation in BRCA1/2 from pedigrees drawn in Figure ​F|  BRCA2:   c.7308del -<<< p.(Asn2436Lysfs*33>>>)  Novel, not reported in the databases and we deposited at LOVD (Genomic Variant #0000206927).		
30186769	confirmed					30186769		sub	NP_000050.2:p.Tyr3009Ser	NM_000059.3:c.9026A>C	NM_000059.3:c.9252A>C		na		 p.(Tyr3009Serfs*7|Tyr3009Ser|p.(Tyr3009Serfs*7				BRCA2	entrez	675			prot	Met1775Arg|Met1775Arg|Met1775Arg|Met1775Arg|Met1775Arg|p.Met1775Arg|p.Met1775Arg|p.Met1775Arg|p.Met1775Arg|p.Met1775Arg	5022,15251,17095,18781,20891,5019,15248,17092,18778,20888	5033,15262,17106,18792,20902,5037,15266,17110,18796,20906	*); c.5407-?_(*1_?)del and c.5445G>A - p.(Trp1815*); in BRCA2, c.5351dup - p.(Asn1784Lysfs*3); c.7308del - p.(Asn2436Lysfs*33) and c.9026_9030del - p.<<<(Tyr3009Ser>>>fs*7).|(C) BRCA1: c.5445G>A-p.(Trp1815*); (D) BRCA2: c.5351dup - p.(Asn1784Lysfs*3); (E) BRCA2 c.7308del - p.(Asn2436Lysfs*33); (F) BRCA2 c.9026_9030del - p.<<<(Tyr3009Ser>>>fs*7).  Overall, 61/279 genotyped cases (21.8%) harbored a BRCA1 mutation (n = 44) or a BRCA2 mutation (n = 17).| c.5445G>A - p.(Trp1815*)  1    Br (47)    BRCA2: c.7308del - p.(Asn2436Lysfs*33)  1    Br (38,45,47,52) & Ov (60, 64)  0   BRCA2: c.9026_9030del - p.<<<(Tyr3009Ser>>>fs*7)  1    Br (35)  0      Open in a separate window  n, number of probands; age@diag, age at diagnosis; Br, Breast Cancer; Ov, Ovarian Cancer.  (*) |del, c.5445G>A - p.(Trp1815*), rs397509284 and BRCA2: c.5351dup - p.(Asn1784Lysfs*3), rs80359508, c.7308del - p.(Asn2436Lysfs*33), c.9026_9030del - p.<<<(Tyr3009Ser>>>fs*7), rs80359741.  ### Table 4  Families with a non-AJ founder mutation in BRCA1/2 from pedigrees drawn in Figure ​Figure22.  Mutation (HGVS nomencla|  BRCA2:   c.9026_9030del - p.<<<(Tyr3009Ser>>>fs*7), rs80359741  This mutation was detected 3 times in our laboratory and at least 10 more times deposited at LOVD.|910*); c.5407-?_(*1_?)del and c.5445G>A - p.(Trp1815*); in BRCA2, c.5351dup - p.(Asn1784Lysfs*3); c.7308del - p.(Asn2436Lysfs*33) and c.9026_9030del -<<< p.(Tyr3009Serfs*7>>>).|l; (C) BRCA1: c.5445G>A-p.(Trp1815*); (D) BRCA2: c.5351dup - p.(Asn1784Lysfs*3); (E) BRCA2 c.7308del - p.(Asn2436Lysfs*33); (F) BRCA2 c.9026_9030del -<<< p.(Tyr3009Serfs*7>>>).  Overall, 61/279 genotyped cases (21.8%) harbored a BRCA1 mutation (n = 44) or a BRCA2 mutation (n = 17).|A1: c.5445G>A - p.(Trp1815*)  1    Br (47)    BRCA2: c.7308del - p.(Asn2436Lysfs*33)  1    Br (38,45,47,52) & Ov (60, 64)  0   BRCA2: c.9026_9030del -<<< p.(Tyr3009Serfs*7>>>)  1    Br (35)  0      Open in a separate window  n, number of probands; age@diag, age at diagnosis; Br, Breast Cancer; Ov, Ovarian Cancer.  (*) a pa|_?)del, c.5445G>A - p.(Trp1815*), rs397509284 and BRCA2: c.5351dup - p.(Asn1784Lysfs*3), rs80359508, c.7308del - p.(Asn2436Lysfs*33), c.9026_9030del -<<< p.(Tyr3009Serfs*7>>>), rs80359741.  ### Table 4  Families with a non-AJ founder mutation in BRCA1/2 from pedigrees drawn in Figure ​Figure22.  Mutation (HGVS nomenclature|  BRCA2:   c.9026_9030del -<<< p.(Tyr3009Serfs*7>>>), rs80359741  This mutation was detected 3 times in our laboratory and at least 10 more times deposited at LOVD.		
30186769	confirmed					30186769		sub	NP_009225.1:p.Gln1756Pro	NM_007294.3:c.5267A>C	NM_007294.3:c.5498A>C		na		p.(Gln1756Profs*74|Gln1756Pro				BRCA1	entrez	672			prot	Met1775Arg|Met1775Arg|p.Met1775Arg|p.Met1775Arg	16578,17667,16575,17664	16589,17678,16594,17683	utation  50  19.3    9   BRCA1: c.68_69del -p.(Glu23Valfs*17)  24  9.3  18, Br (30-72); 1 Br/Ov (46, 47); 2, Ov (59, 77)  3 (*)   BRCA1: c.5266dup -p.<<<(Gln1756Pro>>>fs*74)  15  5.8  8, Br (28-46); 4, Ov (41-72); 2, Br/Ov (35,41; 37,45)  1   BRCA2: c.5946del -p.(Ser1982Argfs*22)  11  4.2  4, Br (30-56); 1 Br & Fall|   Ashkenazi mutation   Total  20        A mutation found  5  25.0    2   BRCA1: c.68_69del -p.(Glu23Valfs*17)  2    Br (75)  1   BRCA1: c.5266dup -p.<<<(Gln1756Pro>>>fs*74)  0    0  0   BRCA2: c.5946del - p.(Ser1982Argfs*22)  3    Br (60); Br (59)  1   Non-Ashkenazi mutation (NGS):    0.0    0   Total  3        A m|: Mutation  50  19.3    9   BRCA1: c.68_69del -p.(Glu23Valfs*17)  24  9.3  18, Br (30-72); 1 Br/Ov (46, 47); 2, Ov (59, 77)  3 (*)   BRCA1: c.5266dup <<<-p.(Gln1756Profs*74>>>)  15  5.8  8, Br (28-46); 4, Ov (41-72); 2, Br/Ov (35,41; 37,45)  1   BRCA2: c.5946del -p.(Ser1982Argfs*22)  11  4.2  4, Br (30-56); 1 Br & Fallopian|---   Ashkenazi mutation   Total  20        A mutation found  5  25.0    2   BRCA1: c.68_69del -p.(Glu23Valfs*17)  2    Br (75)  1   BRCA1: c.5266dup <<<-p.(Gln1756Profs*74>>>)  0    0  0   BRCA2: c.5946del - p.(Ser1982Argfs*22)  3    Br (60); Br (59)  1   Non-Ashkenazi mutation (NGS):    0.0    0   Total  3        A mutati		
30186769	notConfirmed							sub		p.A636P					 p.(Ala636Pro|p.(Ala636Pro|Ala636Pro				BRCA1	entrez	672			prot	Met1775Arg|Met1775Arg|p.Met1775Arg|p.Met1775Arg	17326,24539,17323,24536	17336,24549,17336,24549	obands; age@diag, age at diagnosis; Br, Breast Cancer; Ov, Ovarian Cancer.  (*) a patient was carrier of the mutation in the gene MSH2: c.1906G>C - p.<<<(Ala636Pro>>>), also of Ashkenazi origin (17).  ### Table 3  Analysis of mutations detected in male individuals.  Male patients mutation analysis  n  (%)  age@diag|A case that exemplifies this point is the patient who co-harbored the MSH2 c.1906G>C - p.<<<(Ala636Pro>>>) (17) and BRCA1 c.68_69del - p.(Glu23Valfs*17).| probands; age@diag, age at diagnosis; Br, Breast Cancer; Ov, Ovarian Cancer.  (*) a patient was carrier of the mutation in the gene MSH2: c.1906G>C -<<< p.(Ala636Pro>>>), also of Ashkenazi origin (17).  ### Table 3  Analysis of mutations detected in male individuals.  Male patients mutation analysis  n  (%)  age@diag|A case that exemplifies this point is the patient who co-harbored the MSH2 c.1906G>C -<<< p.(Ala636Pro>>>) (17) and BRCA1 c.68_69del - p.(Glu23Valfs*17).		
30186769 All mutations found
30186769	confirmed					30186769		sub		NM_007294.3:c.2728C>T|NM_007300.3:c.2728C>T|NM_007297.3:c.2728C>T	NM_007294.3:c.2959C>T|NM_007300.3:c.2959C>T|NM_007297.3:c.3008C>T		rs397509004|rs397509004|rs80356973		c.2728C>T| c.2728C>T				BRCA1	entrez	672			dna	c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A	2472,13829,14335,15822,20067	2482,13839,14345,15832,20077	50 women) harbored one of the 3 mutations (19.7%); Of 76 fully sequenced cases (73 women), 6 (5 women) (7.9%) carried a pathogenic mutation: in BRCA1,<<< c.2728C>T>>> - p.(Gln910∗ ); c.5407-?_(∗ 1_?)del and c.5445G>A - p.(Trp1815∗ ); in BRCA2, c.5351dup - p.(Asn1784Lysfs∗ 3); c.7308del - p.(Asn2436Lysfs∗ 33) and c.9026_9030del - p.(Tyr3009Serfs∗ 7).|(A) BRCA1<<< c.2728C>T>>> - p.(Gln910*); (B) BRCA1 c.5407-?_(*1_?)del; (C) BRCA1: c.5445G>A-p.(Trp1815*); (D) BRCA2: c.5351dup - p.(Asn1784Lysfs*3); (E) BRCA2 c.7308del - p.(A|The description of the mutations are in Table 4, as follows: BRCA1:<<< c.2728C>T>>> - p.(Gln910∗ ), rs397509004, c.5407-?_(∗ 1_?)del, c.5445G>A - p.(Trp1815∗ ), rs397509284 and BRCA2: c.5351dup - p.(Asn1784Lysfs∗ 3), rs80359508, c.73|-p.(Ser1982Argfs*22)  11  4.2  4, Br (30-56); 1 Br & Fallopian tube (64); 1 Br/Ov (46)  5  Unique mutations (NGS) Total  73  Gene: Mutation  5  BRCA1:<<< c.2728C>T>>> - p.(Gln910*)  1  6.8 Ov (55)  0  BRCA1: c.5407-?_(*1_?)del  1  Br (37)  0  BRCA1: c.5445G>A - p.(Trp1815*)  1  Br (47)  BRCA2: c.7308del - p.(Asn243| al.  TABLE 4   Families with a non-AJ founder mutation in BRCA1/2 from pedigrees drawn in Figure 2. Mutation (HGVS nomenclature)  Description  BRCA1:<<< c.2728C>T>>> - p.(Gln910*) rs397509004  This is a rare mutation reported in ClinVar and we deposited in LOVD (Genomic Variant #0000206572).		
30186769	confirmed					30186769		sub		NM_000059.3:c.2728C>T	NM_000059.3:c.2954C>T		na		c.2728C>T| c.2728C>T				BRCA2	entrez	675			dna	c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A	2472,13829,14335,15822,20067	2482,13839,14345,15832,20077	50 women) harbored one of the 3 mutations (19.7%); Of 76 fully sequenced cases (73 women), 6 (5 women) (7.9%) carried a pathogenic mutation: in BRCA1,<<< c.2728C>T>>> - p.(Gln910∗ ); c.5407-?_(∗ 1_?)del and c.5445G>A - p.(Trp1815∗ ); in BRCA2, c.5351dup - p.(Asn1784Lysfs∗ 3); c.7308del - p.(Asn2436Lysfs∗ 33) and c.9026_9030del - p.(Tyr3009Serfs∗ 7).|(A) BRCA1<<< c.2728C>T>>> - p.(Gln910*); (B) BRCA1 c.5407-?_(*1_?)del; (C) BRCA1: c.5445G>A-p.(Trp1815*); (D) BRCA2: c.5351dup - p.(Asn1784Lysfs*3); (E) BRCA2 c.7308del - p.(A|The description of the mutations are in Table 4, as follows: BRCA1:<<< c.2728C>T>>> - p.(Gln910∗ ), rs397509004, c.5407-?_(∗ 1_?)del, c.5445G>A - p.(Trp1815∗ ), rs397509284 and BRCA2: c.5351dup - p.(Asn1784Lysfs∗ 3), rs80359508, c.73|-p.(Ser1982Argfs*22)  11  4.2  4, Br (30-56); 1 Br & Fallopian tube (64); 1 Br/Ov (46)  5  Unique mutations (NGS) Total  73  Gene: Mutation  5  BRCA1:<<< c.2728C>T>>> - p.(Gln910*)  1  6.8 Ov (55)  0  BRCA1: c.5407-?_(*1_?)del  1  Br (37)  0  BRCA1: c.5445G>A - p.(Trp1815*)  1  Br (47)  BRCA2: c.7308del - p.(Asn243| al.  TABLE 4   Families with a non-AJ founder mutation in BRCA1/2 from pedigrees drawn in Figure 2. Mutation (HGVS nomenclature)  Description  BRCA1:<<< c.2728C>T>>> - p.(Gln910*) rs397509004  This is a rare mutation reported in ClinVar and we deposited in LOVD (Genomic Variant #0000206572).		
30186769	notConfirmed							del		c.9254A>None					9254delA				BRCA2	entrez	675			dna	6174delT	28528	28537	Haplotype analysis of the BRCA2<<< 9254delA>>>TCAT recurrent mutation in breast/ovarian cancer families from Spain.		
30186769	confirmed					30186769		sub		NM_007294.3:c.5445G>A|NM_007300.3:c.5445G>A	NM_007294.3:c.5676G>A|NM_007300.3:c.5676G>A		rs397509284|rs397509275		c.5445G>A| c.5445G>A				BRCA1	entrez	672			dna	c.123T>A|c.123T>A|c.123T>A|c.123T>A|c.123T>A	2522,13895,14395,15915,20620	2532,13905,14405,15925,20630	 Of 76 fully sequenced cases (73 women), 6 (5 women) (7.9%) carried a pathogenic mutation: in BRCA1, c.2728C>T - p.(Gln910∗ ); c.5407-?_(∗ 1_?)del and<<< c.5445G>A>>> - p.(Trp1815∗ ); in BRCA2, c.5351dup - p.(Asn1784Lysfs∗ 3); c.7308del - p.(Asn2436Lysfs∗ 33) and c.9026_9030del - p.(Tyr3009Serfs∗ 7).|(A) BRCA1 c.2728C>T - p.(Gln910*); (B) BRCA1 c.5407-?_(*1_?)del; (C) BRCA1:<<< c.5445G>A>>>-p.(Trp1815*); (D) BRCA2: c.5351dup - p.(Asn1784Lysfs*3); (E) BRCA2 c.7308del - p.(Asn2436Lysfs*33); (F) BRCA2 c.9026_9030del - p.(Tyr3009Serfs*7).  D|The description of the mutations are in Table 4, as follows: BRCA1: c.2728C>T - p.(Gln910∗ ), rs397509004, c.5407-?_(∗ 1_?)del,<<< c.5445G>A>>> - p.(Trp1815∗ ), rs397509284 and BRCA2: c.5351dup - p.(Asn1784Lysfs∗ 3), rs80359508, c.7308del p.(Asn2436Lysfs∗ 33), c.9026_9030del - p.(Tyr3009Serfs|ique mutations (NGS) Total  73  Gene: Mutation  5  BRCA1: c.2728C>T - p.(Gln910*)  1  6.8 Ov (55)  0  BRCA1: c.5407-?_(*1_?)del  1  Br (37)  0  BRCA1:<<< c.5445G>A>>> - p.(Trp1815*)  1  Br (47)  BRCA2: c.7308del - p.(Asn2436Lysfs*33)  1  Br (38,45,47,52) & Ov (60, 64)  0  BRCA2: c.9026_9030del p.(Tyr3009Serfs*7)  1|As shown in Figure 2, this half Sephardi patient had family history of stomach and ovary cancer.  BRCA1:<<< c.5445G>A>>> - p.(Trp1815*) rs397509284  This mutation is deposited by different laboratories at least 5 times at the LOVD.		
30186769	confirmed					30186769		sub		NM_000059.3:c.7232A>C	NM_000059.3:c.7458A>C		rs80358950		c.7232A>C				BRCA2	entrez	675			dna	c.123T>A	22245	22255	 was associated to Spanish ascendancy (19).  The following variant of uncertain significance (VUS) was detected in the samples analyzed by NGS: BRCA2:<<< c.7232A>C>>> - p.(Lys2411Thr), rs80358950 (we deposited at LOVD Genomic Variant #0000206714).  PM, FJ, and DF analyzed the literature and evaluated statistics. Al		
30186769	confirmed					30186769		del		NM_000059.3:c.6174delT	NM_000059.3:c.6400delT		na		[6174delT				BRCA2	entrez	675			dna	6174delT	5511	5520	0 individuals is a carrier one of 3 recurrent mutations in BRCA1 [185delAG: c.68_69del (rs386833395) and 5382insC: c.5266dup (rs80357906)], and BRCA2 <<<[6174delT>>>: c.5946del (rs80359550)].		
30186769	confirmed					30186769		del		NM_007297.3:c.185delA	NM_007297.3:c.465delA		na		[185delA				BRCA1	entrez	672			dna	6174delT	5426	5434	In this ethnic group 1/40 individuals is a carrier one of 3 recurrent mutations in BRCA1 <<<[185delA>>>G: c.68_69del (rs386833395) and 5382insC: c.5266dup (rs80357906)], and BRCA2 [6174delT: c.5946del (rs80359550)].		
30186769	confirmed					30186769		sub		NM_007299.3:c.1906G>C|NM_007298.3:c.1906G>C	NM_007299.3:c.2099G>C|NM_007298.3:c.1924G>C		na|na		c.1906G>C				BRCA1	entrez	672			dna	c.123T>A|c.123T>A	16238,18200	16248,18210	 n, number of probands; age@diag, age at diagnosis; Br, Breast Cancer; Ov, Ovarian Cancer. (*) a patient was carrier of the mutation in the gene MSH2:<<< c.1906G>C>>> - p.(Ala636Pro), also of Ashkenazi origin (17).  comprehensive BRCA1/2 study and no other mutation would had been detected, the percentage obtained w|A case that exemplifies this point is the patient who co-harbored the MSH2<<< c.1906G>C>>> - p.(Ala636Pro) (17) and BRCA1 c.68_69del p.(Glu23Valfs∗ 17).		
30186769	confirmed					30186769		sub	NP_000050.2:p.Lys2411Thr	NM_000059.3:c.7232A>C	NM_000059.3:c.7458A>C		rs80358950		p.(Lys2411Thr|Lys2411Thr				BRCA2	entrez	675			prot	Met1775Arg|p.Met1775Arg	22260,22257	22271,22271	 to Spanish ascendancy (19).  The following variant of uncertain significance (VUS) was detected in the samples analyzed by NGS: BRCA2: c.7232A>C - p.<<<(Lys2411Thr>>>), rs80358950 (we deposited at LOVD Genomic Variant #0000206714).  PM, FJ, and DF analyzed the literature and evaluated statistics. All authors critic|ted to Spanish ascendancy (19).  The following variant of uncertain significance (VUS) was detected in the samples analyzed by NGS: BRCA2: c.7232A>C -<<< p.(Lys2411Thr>>>), rs80358950 (we deposited at LOVD Genomic Variant #0000206714).  PM, FJ, and DF analyzed the literature and evaluated statistics. All authors critic		
30186769	confirmed					30186769		sub	NP_000050.2:p.Ser1982Arg	NM_000059.3:c.5946T>A|NM_000059.3:c.5944A>C|NM_000059.3:c.5946T>G	NM_000059.3:c.6172T>A|NM_000059.3:c.6170A>C|NM_000059.3:c.6172T>G		rs80359550|na|rs80359550		Ser1982Arg|p.(Ser1982Argfs*22				BRCA2	entrez	675			prot	Met1775Arg|Met1775Arg|p.Met1775Arg|p.Met1775Arg	15675,18731,15672,18728	15686,18742,15691,18747	3Valfs*17)  24  9.3  9  BRCA1: c.5266dup -p.(Gln1756Profs*74)  15  5.8  8, Br (28-46); 4, Ov (41-72); 2, Br/Ov (35,41; 37,45)  1  BRCA2: c.5946del -p.<<<(Ser1982Arg>>>fs*22)  11  4.2  4, Br (30-56); 1 Br & Fallopian tube (64); 1 Br/Ov (46)  5  Unique mutations (NGS) Total  73  Gene: Mutation  5  BRCA1: c.2728C>T - p|tal  20  A mutation found  5  BRCA1: c.68_69del -p.(Glu23Valfs*17)  2  Br (75)  1  BRCA1: c.5266dup -p.(Gln1756Profs*74)  0  0  0  BRCA2: c.5946del p.<<<(Ser1982Arg>>>fs*22)  3  Br (60); Br (59)  1  Non-Ashkenazi mutation (NGS):  25.0  2  0.0  Total  3  A mutation found  1  BRCA2: c.5351dup p.(Asn1784Lysfs*3)  1  0 |lu23Valfs*17)  24  9.3  9  BRCA1: c.5266dup -p.(Gln1756Profs*74)  15  5.8  8, Br (28-46); 4, Ov (41-72); 2, Br/Ov (35,41; 37,45)  1  BRCA2: c.5946del <<<-p.(Ser1982Argfs*22>>>)  11  4.2  4, Br (30-56); 1 Br & Fallopian tube (64); 1 Br/Ov (46)  5  Unique mutations (NGS) Total  73  Gene: Mutation  5  BRCA1: c.2728C>T - p.(Gln| Total  20  A mutation found  5  BRCA1: c.68_69del -p.(Glu23Valfs*17)  2  Br (75)  1  BRCA1: c.5266dup -p.(Gln1756Profs*74)  0  0  0  BRCA2: c.5946del<<< p.(Ser1982Argfs*22>>>)  3  Br (60); Br (59)  1  Non-Ashkenazi mutation (NGS):  25.0  2  0.0  Total  3  A mutation found  1  BRCA2: c.5351dup p.(Asn1784Lysfs*3)  1  0  33.3		
30186769	confirmed					30186769		sub	NP_000050.2:p.Asn1784Lys	NM_000059.3:c.5352C>G|NM_000059.3:c.5352C>A	NM_000059.3:c.5578C>G|NM_000059.3:c.5578C>A		rs398122531|rs398122531		p.(Asn1784Lysfs*3|Asn1784Lys|p.(Asn1784Lysfs				BRCA2	entrez	675			prot	Met1775Arg|Met1775Arg|Met1775Arg|Met1775Arg|Met1775Arg|Met1775Arg|p.Met1775Arg|p.Met1775Arg|p.Met1775Arg|p.Met1775Arg|p.Met1775Arg|p.Met1775Arg	2574,11170,13945,14460,18869,20953,2571,11167,13942,14457,18866,20950	2585,11181,13956,14471,18880,20964,2587,11183,13960,14473,18884,20968	 (7.9%) carried a pathogenic mutation: in BRCA1, c.2728C>T - p.(Gln910∗ ); c.5407-?_(∗ 1_?)del and c.5445G>A - p.(Trp1815∗ ); in BRCA2, c.5351dup - p.<<<(Asn1784Lys>>>fs∗ 3); c.7308del - p.(Asn2436Lysfs∗ 33) and c.9026_9030del - p.(Tyr3009Serfs∗ 7).|by their AJ ethnicity, with two exceptions (Figure 2): proband [B: BRCA1 c.5407-?_(∗ 1_?)del] was half Sephardi, and proband [D: BRCA2: c.5351dup - p.<<<(Asn1784Lys>>>fs∗ 3)] was half non-Jewish, although this side was not the side associated with inheritance of the syndrome. Overall, 61/279 genotyped cases (21.8%) harbored a BRCA1 mutation (n = 44) or a BRCA2 mutation (n = 17).|(A) BRCA1 c.2728C>T - p.(Gln910*); (B) BRCA1 c.5407-?_(*1_?)del; (C) BRCA1: c.5445G>A-p.(Trp1815*); (D) BRCA2: c.5351dup - p.<<<(Asn1784Lys>>>fs*3); (E) BRCA2 c.7308del - p.(Asn2436Lysfs*33); (F) BRCA2 c.9026_9030del - p.(Tyr3009Serfs*7).  DISCUSSION  Regarding the families with a non-Ashken|ble 4, as follows: BRCA1: c.2728C>T - p.(Gln910∗ ), rs397509004, c.5407-?_(∗ 1_?)del, c.5445G>A - p.(Trp1815∗ ), rs397509284 and BRCA2: c.5351dup - p.<<<(Asn1784Lys>>>fs∗ 3), rs80359508, c.7308del p.(Asn2436Lysfs∗ 33), c.9026_9030del - p.(Tyr3009Serfs∗ 7), rs80359741.  Frontiers in Oncology   www.frontiersin.org  Th|c.5946del p.(Ser1982Argfs*22)  3  Br (60); Br (59)  1  Non-Ashkenazi mutation (NGS):  25.0  2  0.0  Total  3  A mutation found  1  BRCA2: c.5351dup p.<<<(Asn1784Lys>>>fs*3)  1  0  33.3 Br (66)  0  n, number of probands; age@diag, age at diagnosis; Br, Breast Cancer.  studies the rates were 4-5% of fully genotyped AJ cases.|ncer most frequently associated with BRCA1 mutations) at 47, was tested at 49 and had a sister who died of breast cancer at 46.  BRCA2: c.5351dup - p.<<<(Asn1784Lys>>>fs*3) rs80359508  We have detected this mutation 10 times and it is reported in LOVD at least 49 times (including 7 from our laboratory) (18).|en) (7.9%) carried a pathogenic mutation: in BRCA1, c.2728C>T - p.(Gln910∗ ); c.5407-?_(∗ 1_?)del and c.5445G>A - p.(Trp1815∗ ); in BRCA2, c.5351dup -<<< p.(Asn1784Lysfs>>>∗ 3); c.7308del - p.(Asn2436Lysfs∗ 33) and c.9026_9030del - p.(Tyr3009Serfs∗ 7).|ed by their AJ ethnicity, with two exceptions (Figure 2): proband [B: BRCA1 c.5407-?_(∗ 1_?)del] was half Sephardi, and proband [D: BRCA2: c.5351dup -<<< p.(Asn1784Lysfs>>>∗ 3)] was half non-Jewish, although this side was not the side associated with inheritance of the syndrome. Overall, 61/279 genotyped cases (21.8%) harbored a BRCA1 mutation (n = 44) or a BRCA2 mutation (n = 17).|(A) BRCA1 c.2728C>T - p.(Gln910*); (B) BRCA1 c.5407-?_(*1_?)del; (C) BRCA1: c.5445G>A-p.(Trp1815*); (D) BRCA2: c.5351dup -<<< p.(Asn1784Lysfs*3>>>); (E) BRCA2 c.7308del - p.(Asn2436Lysfs*33); (F) BRCA2 c.9026_9030del - p.(Tyr3009Serfs*7).  DISCUSSION  Regarding the families with a non-Ashkenazi | Table 4, as follows: BRCA1: c.2728C>T - p.(Gln910∗ ), rs397509004, c.5407-?_(∗ 1_?)del, c.5445G>A - p.(Trp1815∗ ), rs397509284 and BRCA2: c.5351dup -<<< p.(Asn1784Lysfs>>>∗ 3), rs80359508, c.7308del p.(Asn2436Lysfs∗ 33), c.9026_9030del - p.(Tyr3009Serfs∗ 7), rs80359741.  Frontiers in Oncology   www.frontiersin.org  The |2: c.5946del p.(Ser1982Argfs*22)  3  Br (60); Br (59)  1  Non-Ashkenazi mutation (NGS):  25.0  2  0.0  Total  3  A mutation found  1  BRCA2: c.5351dup<<< p.(Asn1784Lysfs*3>>>)  1  0  33.3 Br (66)  0  n, number of probands; age@diag, age at diagnosis; Br, Breast Cancer.  studies the rates were 4-5% of fully genotyped AJ cases.| cancer most frequently associated with BRCA1 mutations) at 47, was tested at 49 and had a sister who died of breast cancer at 46.  BRCA2: c.5351dup -<<< p.(Asn1784Lysfs*3>>>) rs80359508  We have detected this mutation 10 times and it is reported in LOVD at least 49 times (including 7 from our laboratory) (18).		
30186769	confirmed					30186769		sub	NP_009230.2:p.Glu23Val|NP_009225.1:p.Glu23Val|NP_009229.2:p.Glu23Val|NP_009231.2:p.Glu23Val	NM_007299.3:c.68A>T|NM_007294.3:c.68A>T|NM_007298.3:c.68A>T|NM_007300.3:c.68A>T	NM_007299.3:c.261A>T|NM_007294.3:c.299A>T|NM_007298.3:c.86A>T|NM_007300.3:c.299A>T		na|na|na|na		Glu23Val|p.(Glu23Valfs|p.(Glu23Valfs*17				BRCA1	entrez	672			prot	Met1775Arg|Met1775Arg|Met1775Arg|p.Met1775Arg|p.Met1775Arg|p.Met1775Arg	15520,18255,18632,15517,18252,18629	15529,18264,18641,15534,18266,18646	hy  18, Br (30-72); 1 Br/Ov (46, 47); 2, Ov (59, 77)  3 (*)  Recurring Ashkenazi mutations Total  259  Gene: Mutation  50  19.3  BRCA1: c.68_69del -p.<<<(Glu23Val>>>fs*17)  24  9.3  9  BRCA1: c.5266dup -p.(Gln1756Profs*74)  15  5.8  8, Br (28-46); 4, Ov (41-72); 2, Br/Ov (35,41; 37,45)  1  BRCA2: c.5946del -p.(Ser|A case that exemplifies this point is the patient who co-harbored the MSH2 c.1906G>C - p.(Ala636Pro) (17) and BRCA1 c.68_69del p.<<<(Glu23Val>>>fs∗ 17).|male individuals. Male patients mutation analysis  n  (%)  age@diag  Healthy  Ashkenazi mutation Total  20  A mutation found  5  BRCA1: c.68_69del -p.<<<(Glu23Val>>>fs*17)  2  Br (75)  1  BRCA1: c.5266dup -p.(Gln1756Profs*74)  0  0  0  BRCA2: c.5946del p.(Ser1982Argfs*22)  3  Br (60); Br (59)  1  Non-Ashkenazi mut|althy  18, Br (30-72); 1 Br/Ov (46, 47); 2, Ov (59, 77)  3 (*)  Recurring Ashkenazi mutations Total  259  Gene: Mutation  50  19.3  BRCA1: c.68_69del <<<-p.(Glu23Valfs*17>>>)  24  9.3  9  BRCA1: c.5266dup -p.(Gln1756Profs*74)  15  5.8  8, Br (28-46); 4, Ov (41-72); 2, Br/Ov (35,41; 37,45)  1  BRCA2: c.5946del -p.(Ser1982A|A case that exemplifies this point is the patient who co-harbored the MSH2 c.1906G>C - p.(Ala636Pro) (17) and BRCA1 c.68_69del<<< p.(Glu23Valfs>>>∗ 17).|in male individuals. Male patients mutation analysis  n  (%)  age@diag  Healthy  Ashkenazi mutation Total  20  A mutation found  5  BRCA1: c.68_69del <<<-p.(Glu23Valfs*17>>>)  2  Br (75)  1  BRCA1: c.5266dup -p.(Gln1756Profs*74)  0  0  0  BRCA2: c.5946del p.(Ser1982Argfs*22)  3  Br (60); Br (59)  1  Non-Ashkenazi mutation		
30186769	confirmed					30186769		sub	NP_000050.2:p.Asn2436Lys	NM_000059.3:c.7308C>G|NM_000059.3:c.7308C>A	NM_000059.3:c.7534C>G|NM_000059.3:c.7534C>A		na|na		p.(Asn2436Lysfs*33|p.(Asn2436Lysfs|Asn2436Lys				BRCA2	entrez	675			prot	Met1775Arg|Met1775Arg|Met1775Arg|Met1775Arg|Met1775Arg|Met1775Arg|p.Met1775Arg|p.Met1775Arg|p.Met1775Arg|p.Met1775Arg|p.Met1775Arg|p.Met1775Arg	2607,12303,13987,14503,15975,21545,2604,12300,13984,14500,15972,21542	2618,12314,13998,14514,15986,21556,2620,12316,14003,14516,15991,21561	tion: in BRCA1, c.2728C>T - p.(Gln910∗ ); c.5407-?_(∗ 1_?)del and c.5445G>A - p.(Trp1815∗ ); in BRCA2, c.5351dup - p.(Asn1784Lysfs∗ 3); c.7308del - p.<<<(Asn2436Lys>>>fs∗ 33) and c.9026_9030del - p.(Tyr3009Serfs∗ 7).|Of the 6 mutations found, BRCA2 c.7308del - p.<<<(Asn2436Lys>>>fs∗ 33) has not been previously reported and is therefore novel while the other 5 have been reported in non-Jewish populations.  RESULTS Participant’s|>T - p.(Gln910*); (B) BRCA1 c.5407-?_(*1_?)del; (C) BRCA1: c.5445G>A-p.(Trp1815*); (D) BRCA2: c.5351dup - p.(Asn1784Lysfs*3); (E) BRCA2 c.7308del - p.<<<(Asn2436Lys>>>fs*33); (F) BRCA2 c.9026_9030del - p.(Tyr3009Serfs*7).  DISCUSSION  Regarding the families with a non-Ashkenazi mutation, the particular details of th|n910∗ ), rs397509004, c.5407-?_(∗ 1_?)del, c.5445G>A - p.(Trp1815∗ ), rs397509284 and BRCA2: c.5351dup - p.(Asn1784Lysfs∗ 3), rs80359508, c.7308del p.<<<(Asn2436Lys>>>fs∗ 33), c.9026_9030del - p.(Tyr3009Serfs∗ 7), rs80359741.  Frontiers in Oncology   www.frontiersin.org  The likelihood that AJ high risk individuals |2728C>T - p.(Gln910*)  1  6.8 Ov (55)  0  BRCA1: c.5407-?_(*1_?)del  1  Br (37)  0  BRCA1: c.5445G>A - p.(Trp1815*)  1  Br (47)  BRCA2: c.7308del - p.<<<(Asn2436Lys>>>fs*33)  1  Br (38,45,47,52) & Ov (60, 64)  0  BRCA2: c.9026_9030del p.(Tyr3009Serfs*7)  1  Br (35)  0  n, number of probands; age@diag, age at diagnos|ish side could be phenocopies, and for this reason the prevalence for BRCA2 non AJ was also calculated non including this case.  BRCA2: c.7308del - p.<<<(Asn2436Lys>>>fs*33)  Novel, not reported in the databases and we deposited at LOVD (Genomic Variant #0000206927).|utation: in BRCA1, c.2728C>T - p.(Gln910∗ ); c.5407-?_(∗ 1_?)del and c.5445G>A - p.(Trp1815∗ ); in BRCA2, c.5351dup - p.(Asn1784Lysfs∗ 3); c.7308del -<<< p.(Asn2436Lysfs>>>∗ 33) and c.9026_9030del - p.(Tyr3009Serfs∗ 7).|Of the 6 mutations found, BRCA2 c.7308del -<<< p.(Asn2436Lysfs>>>∗ 33) has not been previously reported and is therefore novel while the other 5 have been reported in non-Jewish populations.  RESULTS Participant’s C|28C>T - p.(Gln910*); (B) BRCA1 c.5407-?_(*1_?)del; (C) BRCA1: c.5445G>A-p.(Trp1815*); (D) BRCA2: c.5351dup - p.(Asn1784Lysfs*3); (E) BRCA2 c.7308del -<<< p.(Asn2436Lysfs*33>>>); (F) BRCA2 c.9026_9030del - p.(Tyr3009Serfs*7).  DISCUSSION  Regarding the families with a non-Ashkenazi mutation, the particular details of the fam|(Gln910∗ ), rs397509004, c.5407-?_(∗ 1_?)del, c.5445G>A - p.(Trp1815∗ ), rs397509284 and BRCA2: c.5351dup - p.(Asn1784Lysfs∗ 3), rs80359508, c.7308del<<< p.(Asn2436Lysfs>>>∗ 33), c.9026_9030del - p.(Tyr3009Serfs∗ 7), rs80359741.  Frontiers in Oncology   www.frontiersin.org  The likelihood that AJ high risk individuals wh| c.2728C>T - p.(Gln910*)  1  6.8 Ov (55)  0  BRCA1: c.5407-?_(*1_?)del  1  Br (37)  0  BRCA1: c.5445G>A - p.(Trp1815*)  1  Br (47)  BRCA2: c.7308del -<<< p.(Asn2436Lysfs*33>>>)  1  Br (38,45,47,52) & Ov (60, 64)  0  BRCA2: c.9026_9030del p.(Tyr3009Serfs*7)  1  Br (35)  0  n, number of probands; age@diag, age at diagnosis; B|Jewish side could be phenocopies, and for this reason the prevalence for BRCA2 non AJ was also calculated non including this case.  BRCA2: c.7308del -<<< p.(Asn2436Lysfs*33>>>)  Novel, not reported in the databases and we deposited at LOVD (Genomic Variant #0000206927).		
30186769	confirmed					30186769		sub	NP_000050.2:p.Tyr3009Ser	NM_000059.3:c.9026A>C	NM_000059.3:c.9252A>C		na		p.(Tyr3009Serfs|Tyr3009Ser|p.(Tyr3009Serfs*7				BRCA2	entrez	675			prot	Met1775Arg|Met1775Arg|Met1775Arg|Met1775Arg|Met1775Arg|p.Met1775Arg|p.Met1775Arg|p.Met1775Arg|p.Met1775Arg|p.Met1775Arg	2649,14035,14542,16056,21953,2646,14032,14539,16053,21950	2660,14046,14553,16067,21964,2662,14050,14555,16071,21968	c.5407-?_(∗ 1_?)del and c.5445G>A - p.(Trp1815∗ ); in BRCA2, c.5351dup - p.(Asn1784Lysfs∗ 3); c.7308del - p.(Asn2436Lysfs∗ 33) and c.9026_9030del - p.<<<(Tyr3009Ser>>>fs∗ 7).|(C) BRCA1: c.5445G>A-p.(Trp1815*); (D) BRCA2: c.5351dup - p.(Asn1784Lysfs*3); (E) BRCA2 c.7308del - p.(Asn2436Lysfs*33); (F) BRCA2 c.9026_9030del - p.<<<(Tyr3009Ser>>>fs*7).  DISCUSSION  Regarding the families with a non-Ashkenazi mutation, the particular details of the family history of cancers related to BRCA was strong for the 6 probands, as shown in the pedigrees drawn in Figure 2.|el, c.5445G>A - p.(Trp1815∗ ), rs397509284 and BRCA2: c.5351dup - p.(Asn1784Lysfs∗ 3), rs80359508, c.7308del p.(Asn2436Lysfs∗ 33), c.9026_9030del - p.<<<(Tyr3009Ser>>>fs∗ 7), rs80359741.  Frontiers in Oncology   www.frontiersin.org  The likelihood that AJ high risk individuals who do not carry any of the predominant|0  BRCA1: c.5445G>A - p.(Trp1815*)  1  Br (47)  BRCA2: c.7308del - p.(Asn2436Lysfs*33)  1  Br (38,45,47,52) & Ov (60, 64)  0  BRCA2: c.9026_9030del p.<<<(Tyr3009Ser>>>fs*7)  1  Br (35)  0  n, number of probands; age@diag, age at diagnosis; Br, Breast Cancer; Ov, Ovarian Cancer. (*) a patient was carrier of the mutat|Two relatives were tested, a niece of 38 was found to be a non-carrier and a nephew at 41 an unaffected carrier.  BRCA2: c.9026_9030del - p.<<<(Tyr3009Ser>>>fs*7), rs80359741  This mutation was detected 3 times in our laboratory and at least 10 more times deposited at LOVD.|); c.5407-?_(∗ 1_?)del and c.5445G>A - p.(Trp1815∗ ); in BRCA2, c.5351dup - p.(Asn1784Lysfs∗ 3); c.7308del - p.(Asn2436Lysfs∗ 33) and c.9026_9030del -<<< p.(Tyr3009Serfs>>>∗ 7).|l; (C) BRCA1: c.5445G>A-p.(Trp1815*); (D) BRCA2: c.5351dup - p.(Asn1784Lysfs*3); (E) BRCA2 c.7308del - p.(Asn2436Lysfs*33); (F) BRCA2 c.9026_9030del -<<< p.(Tyr3009Serfs*7>>>).  DISCUSSION  Regarding the families with a non-Ashkenazi mutation, the particular details of the family history of cancers related to BRCA was strong for the 6 probands, as shown in the pedigrees drawn in Figure 2.|?)del, c.5445G>A - p.(Trp1815∗ ), rs397509284 and BRCA2: c.5351dup - p.(Asn1784Lysfs∗ 3), rs80359508, c.7308del p.(Asn2436Lysfs∗ 33), c.9026_9030del -<<< p.(Tyr3009Serfs>>>∗ 7), rs80359741.  Frontiers in Oncology   www.frontiersin.org  The likelihood that AJ high risk individuals who do not carry any of the predominant A|)  0  BRCA1: c.5445G>A - p.(Trp1815*)  1  Br (47)  BRCA2: c.7308del - p.(Asn2436Lysfs*33)  1  Br (38,45,47,52) & Ov (60, 64)  0  BRCA2: c.9026_9030del<<< p.(Tyr3009Serfs*7>>>)  1  Br (35)  0  n, number of probands; age@diag, age at diagnosis; Br, Breast Cancer; Ov, Ovarian Cancer. (*) a patient was carrier of the mutation |Two relatives were tested, a niece of 38 was found to be a non-carrier and a nephew at 41 an unaffected carrier.  BRCA2: c.9026_9030del -<<< p.(Tyr3009Serfs*7>>>), rs80359741  This mutation was detected 3 times in our laboratory and at least 10 more times deposited at LOVD.		
30186769	confirmed					30186769		sub	NP_009225.1:p.Gln1756Pro	NM_007294.3:c.5267A>C	NM_007294.3:c.5498A>C		na		p.(Gln1756Profs*74|Gln1756Pro				BRCA1	entrez	672			prot	Met1775Arg|Met1775Arg|p.Met1775Arg|p.Met1775Arg	15569,18684,15566,18681	15580,18695,15585,18700	77)  3 (*)  Recurring Ashkenazi mutations Total  259  Gene: Mutation  50  19.3  BRCA1: c.68_69del -p.(Glu23Valfs*17)  24  9.3  9  BRCA1: c.5266dup -p.<<<(Gln1756Pro>>>fs*74)  15  5.8  8, Br (28-46); 4, Ov (41-72); 2, Br/Ov (35,41; 37,45)  1  BRCA2: c.5946del -p.(Ser1982Argfs*22)  11  4.2  4, Br (30-56); 1 Br & Fallo|  (%)  age@diag  Healthy  Ashkenazi mutation Total  20  A mutation found  5  BRCA1: c.68_69del -p.(Glu23Valfs*17)  2  Br (75)  1  BRCA1: c.5266dup -p.<<<(Gln1756Pro>>>fs*74)  0  0  0  BRCA2: c.5946del p.(Ser1982Argfs*22)  3  Br (60); Br (59)  1  Non-Ashkenazi mutation (NGS):  25.0  2  0.0  Total  3  A mutation found|9, 77)  3 (*)  Recurring Ashkenazi mutations Total  259  Gene: Mutation  50  19.3  BRCA1: c.68_69del -p.(Glu23Valfs*17)  24  9.3  9  BRCA1: c.5266dup <<<-p.(Gln1756Profs*74>>>)  15  5.8  8, Br (28-46); 4, Ov (41-72); 2, Br/Ov (35,41; 37,45)  1  BRCA2: c.5946del -p.(Ser1982Argfs*22)  11  4.2  4, Br (30-56); 1 Br & Fallopian |  n  (%)  age@diag  Healthy  Ashkenazi mutation Total  20  A mutation found  5  BRCA1: c.68_69del -p.(Glu23Valfs*17)  2  Br (75)  1  BRCA1: c.5266dup <<<-p.(Gln1756Profs*74>>>)  0  0  0  BRCA2: c.5946del p.(Ser1982Argfs*22)  3  Br (60); Br (59)  1  Non-Ashkenazi mutation (NGS):  25.0  2  0.0  Total  3  A mutation found  1  		
30186769	notConfirmed							sub		p.A636P					p.(Ala636Pro|Ala636Pro				BRCA1	entrez	672			prot	Met1775Arg|Met1775Arg|p.Met1775Arg|p.Met1775Arg	16253,18215,16250,18212	16263,18225,16263,18225	robands; age@diag, age at diagnosis; Br, Breast Cancer; Ov, Ovarian Cancer. (*) a patient was carrier of the mutation in the gene MSH2: c.1906G>C - p.<<<(Ala636Pro>>>), also of Ashkenazi origin (17).  comprehensive BRCA1/2 study and no other mutation would had been detected, the percentage obtained would still have|A case that exemplifies this point is the patient who co-harbored the MSH2 c.1906G>C - p.<<<(Ala636Pro>>>) (17) and BRCA1 c.68_69del p.(Glu23Valfs∗ 17).|f probands; age@diag, age at diagnosis; Br, Breast Cancer; Ov, Ovarian Cancer. (*) a patient was carrier of the mutation in the gene MSH2: c.1906G>C -<<< p.(Ala636Pro>>>), also of Ashkenazi origin (17).  comprehensive BRCA1/2 study and no other mutation would had been detected, the percentage obtained would still have|A case that exemplifies this point is the patient who co-harbored the MSH2 c.1906G>C -<<< p.(Ala636Pro>>>) (17) and BRCA1 c.68_69del p.(Glu23Valfs∗ 17).		
30186769 All mutations found
0 total mutations in db file
2 documents processed, 0 db mutations for these, 0 genome positions, 895 mutations output, 0 hits
